<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t7hasb5l26e2 st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0" tabindex="0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="270_PDFsam_Medical Laboratory Science - J Ochei-1.pdf">270_PDFsam_Medical Laboratory Science - J Ochei-1.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">12.1MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> 270_PDFsam_Medical Laboratory Science - J Ochei-1.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>Scanned by CamScanner</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section">Section<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><img src="assets/images/image-20251218-9634720c.jpeg" alt="img-0.jpeg"></p>
<hr>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="haematology">Haematology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haematology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chapter 1</p>
<p>Introduction</p>
<p>The word "Haematology" literally means 'study of blood'. In a clinical set-up, a haematology laboratory is concerned with the abnormalities of the constituents of blood, namely the plasma and the blood cells. The laboratory tests performed include enumeration of different types of cells, relative distribution of various categories and their chemical, functional and structural abnormalities. Haematological tests are also required as a part of patient's admission report because many diseases show signs and symptoms of haematological nature. These tests are commonly referred to as Complete Blood Count (CBC) and include estimation of haemoglobin, enumeration of red and white blood cells, differential count (i.e. classification of white blood cells), morphological abnormalities of red cells, and platelets.</p>
<p>Since the equilibrium of blood is affected by many factors, haematological tests are useful in assessing the degree of diseases or disorders of haematological or non-haematological origin. Thus, haematological tests can help in the diagnosis of nutritional, metabolic, hereditary, hormonal, neoplastic, drug-induced, inflammatory or infectious disease states.</p>
<p>Blood absorbs oxygen in the lungs, nutrients in the gastro-intestinal system and supplies the tissues with these essential substances. The blood also collects harmful wastes produced as end products of metabolism and transports them to the organs of excretion.</p>
<p>An average healthy adult has blood equivalent to 7–8 % of the body weight. In quantity it is about 6 litres. Blood is mainly composed of plasma, a fluid in which red blood cells (RBC) or erythrocytes, white blood cells (WBC) or leucocytes and platelets or thrombocytes are suspended. The plasma, occupying 55 % of the total volume of blood, contains 90 % water, the remaining 10 % being proteins, carbohydrates, lipids, hormones, enzymes, vitamins and salts. The majority of cells suspended in plasma are erythrocytes. The leucocytes are much fewer in number than the erythrocytes, while the platelets are associated with blood coagulation mechanism. The erythrocytes contain a high concentration of haemoglobin, a red coloured pigment which acts as the oxygen carrier. Leucocytes exist in different forms, each having a physiological function in the defence mechanism.</p>
<p>Various haematological investigations and their reference values are listed in Table 1.1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="collection-of-blood">COLLECTION OF BLOOD<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#collection-of-blood" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Inside the body (in vivo), blood is in a liquid form. But outside the body (in vitro), it clots within a few minutes. If left undisturbed in a tube, this clot begins to retract or shrink, and a pale yellow fluid, called serum, separates from the clot, appearing in the upper part of the tube. During this process of coagulation or clotting, certain factors or constituents in the blood are used up and most of the cells (white, red and platelets) are trapped in the clot.</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p>Table 1.1 Haematology reference values</p>
<table><thead><tr><th></th><th>Conventional Units</th><th>Multiplication factor</th><th>SI Units</th></tr></thead><tbody><tr><td>Haemoglobin (Hb)</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>13.0–18.0 g/dl</td><td>10</td><td>130–180 g/L</td></tr><tr><td>Female</td><td>12.0–16.0 g/dl</td><td>10</td><td>120–160 g/L</td></tr><tr><td>Total red cell count</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>4.5–5.9 × 10^{6}/μl</td><td>10^{6}</td><td>4.5–5.9 × 10^{12}/L</td></tr><tr><td></td><td>(4.5–5.9 million/mm^{3})</td><td></td><td></td></tr><tr><td>Female</td><td>4.1–5.1 × 10^{6}/μl</td><td>10^{6}</td><td>4.1–5.1 × 10^{12}/L</td></tr><tr><td>Haematocrit (PCV)</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>40–52%</td><td>0.01</td><td>0.4–0.52 L/L</td></tr><tr><td>Female</td><td>37–47%</td><td>0.01</td><td>0.37–0.47 L/L</td></tr><tr><td>Red cell indices</td><td></td><td></td><td></td></tr><tr><td>Mean corpuscular volume (MCV)</td><td>80–100 μm^{3}</td><td>1</td><td>80–100 fl</td></tr><tr><td>Mean corpuscular hemoglobin (MCH)</td><td>27–32 pg</td><td>1</td><td>27–32 pg</td></tr><tr><td>Mean corpuscular haemoglobin concentration (MCHC)</td><td>32–36%</td><td>0.01</td><td>0.32–0.36</td></tr><tr><td>Total leucocyte count (TLC)</td><td>4.5–11.0 × 10^{3}/μl</td><td>10^{6}</td><td>4.5–11.0 × 10^{9}/L</td></tr><tr><td></td><td>(4,500–11,000/mm^{3})</td><td></td><td></td></tr><tr><td>Differential count (DLC)</td><td>Percentage Absolute count</td><td>Fraction</td><td>Absolute count</td></tr><tr><td>Neutrophils</td><td>40–72%</td><td>0.4–0.72</td><td>1.8–7.8 × 10^{9}/L</td></tr><tr><td>Band forms</td><td>2–4</td><td>0.02–0.04</td><td>0–0.7 × 10^{9}/L</td></tr><tr><td>Eosinophils</td><td>1–6%</td><td>0.01–0.06</td><td>0.0.5–0.45 × 10^{9}/L</td></tr><tr><td>Basophils</td><td>0–0.5%</td><td>0–0.005</td><td>0–0.2 × 10^{9}/L</td></tr><tr><td>Lymphocytes</td><td>20–45%</td><td>0.2–0.45</td><td>1.0–4.5 × 10^{9}/L</td></tr><tr><td>Monocytes</td><td>2–8%</td><td>0.02–0.08</td><td>0.1–0.8 × 10^{9}/L</td></tr><tr><td>Platelet count</td><td>150,000–400,000/μl</td><td>10^{6}</td><td>150–400 × 10^{9}/L</td></tr><tr><td>Reticulocyte count</td><td>0.2–2%</td><td></td><td></td></tr><tr><td></td><td>20,000–100,000/μl</td><td>10^{6}</td><td>20–100 × 10^{9}/L</td></tr><tr><td>Erythrocyte sedimentation rate (ESR), Westergren</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>&lt; 10 mm/h</td><td></td><td></td></tr><tr><td>Female</td><td>&lt; 20 mm/h</td><td></td><td></td></tr><tr><td>Haemoglobin F (HbF)</td><td>&lt; 2%</td><td>0.01</td><td>0.02</td></tr><tr><td>Bleeding Time</td><td>2–8 min*</td><td></td><td></td></tr><tr><td>Clotting time</td><td>5–10 min*</td><td></td><td></td></tr><tr><td>Activated partial thromboplastin time (APTT)</td><td>25–35s*</td><td></td><td></td></tr><tr><td>Prothrombin time</td><td>10–13s*</td><td></td><td></td></tr><tr><td>Thrombin time</td><td>17–25s*</td><td></td><td></td></tr></tbody></table>
<ul>
<li>The results vary with the method and reagent used.</li>
</ul>
<p>Scanned by CamScanner</p>
<p>Introduction 261</p>
<p>Such a blood sample is totally unsuitable for haematological investigations. Therefore, it is necessary to prevent coagulation of blood by using anticoagulants. If the anticoagulated, well mixed blood is centrifuged, it separates into 3 main layers (Fig. 1.1). The bottom layer consists of packed red cells which normally makes up for about 40–47 % of the total blood volume. A thin whitish layer appears on top of this layer and normally makes up about 1 % of the volume. This layer is called ‘buffy coat’ and contains leucocytes and platelets. The uppermost liquid layer makes up about 52–57 % of the total volume. This pale yellow fluid is the plasma. In a normal, healthy individual, these three constituents are in a state of equilibrium in relation to the demand and supply of the body functions. This state of equilibrium is known as homeostasis. Blood samples for haematological study are usually obtained either by finger puncture (capillary blood) or venipuncture (venous blood).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="collection-of-capillary-blood">Collection of Capillary Blood<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#collection-of-capillary-blood" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Capillary blood can be used with satisfactory results for differential blood counts, for enumeration of cells and for estimation of haemoglobin. The capillary blood can be obtained from the tip of the finger from adults, and from the heel or the large toe from infants. However, the use of capillary blood should be avoided as far as possible because of the high risk of sampling error and of infection. Repeat testing is usually restricted because of the smallness of the quantity of blood collected. Capillary blood should be used only when the venous blood is not advisable, for example, in new-born infants, burn cases, amputees or in patients whose veins prove to be difficult to locate.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Select an appropriate site for puncture. The ball of the middle finger is usually satisfactory. Clean the area vigorously with 75 % alcohol and allow it to dry. This disinfects the skin and promotes circulation. For skin puncture, various types of disposable lancets are available. Use of non-disposable lancets is not recommended because of the risk of cross-infections. Make a firm, quick stab with the lancet simultaneously applying a little pressure. This ensures a free flow of blood. Wipe away the first one or two drops of blood using a dry cotton swab. Carefully draw blood into an appropriate pipette (e.g. haemoglobin, RBC or WBC pipette) by applying gentle suction through the mouth-end of the rubber tubing attached to the pipette. Draw blood exactly up to the mark, avoid air bubbles. Wipe the outer surface of the pipette and deliver the blood into an appropriate diluent by blowing slowly. Mix to prevent coagulation.</p>
<p><img src="assets/images/image-20251218-b9158f79.jpeg" alt="img-1.jpeg">
Fig. 1.1 Layers of anticoagulated blood after centrifugation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="collection-of-venous-blood">Collection of Venous Blood<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#collection-of-venous-blood" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The most commonly used sites for venipuncture are the veins inside the bend of the elbow (the antecubital fossa). The three main veins in this area are the cephalic, median cubital and median basilica veins. Other sites, such as the veins in the wrist or ankle may be used if necessary.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Apply a tourniquet to the upper arm sufficiently tightly to restrict the venous flow and make the veins stand out. The patient should be asked to keep the arm straight and clench the fist.</p>
<p>Scanned by CamScanner</p>
<p>262 Haematology</p>
<p>Usually the veins are obvious by this time. It is advisable to feel the veins so that the most suitable one can be selected. A little tapping or gently massaging the arm from the wrist to the elbow helps in dilation of the veins. Swab the selected vein and site with 75 % alcohol and allow it to dry.</p>
<p>Prepare the syringe and appropriate containers. Usually a 21 gauge needle is appropriate for very fine veins, 22 or 23 gauge needles may be used only if necessary. Using the left thumb, press just below the puncture site to anchor the vein. Insert the needle smoothly with the bevel facing upwards, at an angle of 20° to 30° to surface of the arm, and in a direct line with the vein. When the needle has entered the vein, blood is withdrawn into the syringe and tourniquet released. When a sufficient quantity of blood is collected, loosen the tourniquet, place a wad of cotton wool at the puncture site and withdraw the needle gently. The puncture sight should be kept pressed to stop the flow of blood. Ask the patient to release the clenched fist. Detach the needle and discard in an appropriate disposal container. Dispense the blood in the sample tubes as required. Mix the blood to be anticoagulated. Apply a strip dressing at the puncture site.</p>
<p><strong>Note</strong></p>
<ol>
<li>
<p>Infection may be transmitted from patient to staff during the blood collection procedure. Viral agents are the greatest hazard and sometimes potentially lethal. All skin lesions on the hands of the collecting staff must be covered with waterproof dressing and gloves should be worn. All swabs, used by ringes and needles should be secured in suitable containers and disposed off by incineration. Working surfaces should be disinfected frequently as they may get contaminated by droplets.</p>
</li>
<li>
<p>It is advisable to use disposable syringes and needles to avoid the risk of cross infection due to improper sterilisation.</p>
</li>
<li>
<p>In recent years, instead of traditional needle and syringe, some laboratories use vacuum tube system (Fig. 1.2). This uses a double ended needle in a plastic holder. One end of the needle is inserted into the patient's vein and the other is pushed into the rubber stopper of a vacuum tube. The blood will then flow into the tube. Such vacuum tube systems are commercially available.</p>
</li>
</ol>
<p>Table 1.2 compares the capillary and venous collection of blood samples.</p>
<p><img src="assets/images/image-20251218-3e0d09ae.jpeg" alt="img-2.jpeg">
Fig. 1.2 Vacuum tube system for blood collection</p>
<p>Scanned by CamScanner</p>
<p>Introduction 263</p>
<p>Table 1.2 Comparison of blood collection procedures</p>
<table><thead><tr><th></th><th>Capillary</th><th>Venous</th></tr></thead><tbody><tr><td>Site</td><td>Digit, earlobe, toe</td><td>Arm, wrist, hand, groin</td></tr><tr><td>Volume</td><td>Up to 0.5 ml</td><td>Up to 60 ml</td></tr><tr><td>Equipment</td><td>Minimal. Lancet, sample container, pippette or glass capillary.</td><td>Syringe and needle or vacuum system. Sample containers,</td></tr><tr><td>Disadvantages</td><td>Repeat testing restricted. Additional tests often not possible. Sample may only represent 0.002% of total blood volume. Local stasis may produce false results.</td><td>Artefact may be introduced by the anticoagulant.</td></tr><tr><td>Advantages</td><td>Cheap, quick, relatively easy. Direct measurement of sample.</td><td>More representative sample, suitable for majority of investigations. Repeat or additional tests possible.</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="use-of-anticoagulants">USE OF ANTICOAGULANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#use-of-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Many haematological tests require unclotted blood specimens. Such a blood sample can be obtained by collecting it into a tube containing an anticoagulant. There are various types of anticoagulants used for this purpose, each having its advantages and disadvantages. A suitable anticoagulant should be selected according to the investigations required.</p>
<p>Table 1.3 summarises the use of three anticoagulants most commonly used in Haematology.</p>
<p>Table 1.3 Anticoagulants commonly used in Haematology</p>
<table><thead><tr><th>Property</th><th>EDTA^{1}</th><th>Trisodium citrate</th><th>Trisodium citrate</th><th>Heparin</th></tr></thead><tbody><tr><td>Colour Code (BSS)</td><td>Pink</td><td>Purple</td><td>Purple and white</td><td>Orange</td></tr><tr><td>Substance</td><td>Di-or tripotassium EDTA</td><td>32.0 g/L Trisodium citrate solution</td><td>30.8 g/L Trisodium citrate solution</td><td>Lithium heparin Dried or fluid</td></tr><tr><td>Amount</td><td>1.5 mg/ml</td><td>1 volume to 9 volumes blood</td><td>1 volume to 4 volumes blood</td><td>10–50 units (1–5 mg/ml)</td></tr><tr><td>Mode of action</td><td>Stoichiometric chelation of Ca^{2+}</td><td>Binds Ca^{2+} in loose ionic complex</td><td></td><td>Anti-Xa and IIa factors</td></tr><tr><td>Uses</td><td>Routine cellular haematology</td><td>Studies of haemostasis</td><td>Westergren ESR^{2}</td><td>Osmotic fragility Cell culture</td></tr><tr><td>Advantages</td><td>Preserves morphology of RBC and WBC. No platelet clumping</td><td>Coagulation factors stable. Platelet function retained.</td><td>Reference method recommendation.</td><td>Ca^{2+} still present</td></tr><tr><td>Disadvantages</td><td>Not suitable for coagulation studies. Useless for platelet function</td><td>Not suitable for cell counting due to dilution</td><td></td><td>Unsuitable for blood films, WBC and platelet counting and coagulation studies.</td></tr></tbody></table>
<ol>
<li>EDTA = Ethylenediamine tetraacetic acid.</li>
<li>ESR = Erythrocyte sedimentation rate.</li>
</ol>
<p>Scanned by CamScanner</p>
<p>264 Haematology</p>
<p><strong>Note</strong>
It is necessary to mix the blood and the anticoagulant by gently inverting the container several times as soon as the blood is added into it.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="defibrinated-blood">Defibrinated Blood<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#defibrinated-blood" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If blood is continuously agitated in the presence of objects such as glass beads or paper clips during coagulation. Fibrin, which is the end product of coagulation process, collects around these objects and is separated from the blood sample together with platelets. Most of the red cells and white cells remain suspended in the serum. This prevents the removal of calcium. This procedure is adopted when the use of anticoagulant is contraindicated e.g. for complement activity.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 2</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="haemopoiesis-production-of-blood-cells">Haemopoiesis (Production of Blood Cells)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemopoiesis-production-of-blood-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>During the foetal life, production of blood cells occurs in various body tissues, but mainly in the liver and the bone marrow. Shortly after birth, under normal conditions, the marrow is the only tissue that continues to produce red cells, granulocytes, monocytes and platelets. Until about 5 years of age, the marrow in all the bones is red and cellular. However, this red marrow is gradually replaced by yellow inactive bone marrow and by the age of 18 to 20 years the active red marrow remains only in the sternum, the ribs, the vertebrae, the skull, the pelvic bones and the proximal ends of long bones.</p>
<p>Lymphocytes also originate in the bone marrow, but the lymphoid tissue (lymph nodes, spleen, thymus, etc.) has a prime function in their maturation. These formed elements of blood go through a series of developmental steps consisting of duplication, differentiation and maturation in the marrow or the lymphoid tissue. They are released in the circulating peripheral blood only when they are sufficiently developed or mature.</p>
<p>All these blood cells have a predetermined life span. The plasma components, mainly proteins, also have a fixed rate of turnover, which is often expressed as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>T</mi><mn>50</mn></msub></mrow><annotation encoding="application/x-tex">T_{50}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, i.e., the time during which half the substance is removed from the circulation and replaced. The loss of cells through the normal process of aging, physiological consumption and sometimes by loss from the body, is normally compensated for by proliferation, maturation and release of new cells. This process is referred to as haemopoiesis. The constituents of the blood are in a state of balance between loss, regeneration and replacement. This state of equilibrium is known as homeostasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="main-cell-lines">MAIN CELL LINES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#main-cell-lines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the marrow, a common pluripotential or multipotential stem cell, after a number of cell divisions and differentiation steps, gives rise to three main cell lines.</p>
<ul>
<li>(a) Erythroid series</li>
<li>(b) Granulocytic, monocytic, as well as lymphocytic series</li>
<li>(c) Megakaryocytic series</li>
</ul>
<p>The mechanism by which the multipotential stem cells are induced to become stem cells (progenitor cells) for the various cell lines is not clearly understood. The stem cells have the capability of self-renewal and of responding to various stimuli and hormonal messages with increased production of one or the other cell line when the need arises. There are very few pluripotential stem cells in the body. Their number is regulated and kept constant by a feedback mechanism and in a healthy indi</p>
<p>Scanned by CamScanner</p>
<p>266 Haematology</p>
<p>vidual, they are capable of supplying the blood cells according to requirements.</p>
<p>The development of a mature blood cell from a pluripotential cell takes place in three phases.</p>
<ol>
<li>
<p><strong>Differentiation phase</strong> On receiving a stimulus, the pluripotential stem cell divides by mitosis to produce two daughter cells. One of these cells retains the properties of the pluripotential cell while the other starts development to produce a blood cell as directed by the stimulus. This cell is called the blast cell of that particular cell line, e.g., myeloblast of the leucocyte series.</p>
</li>
<li>
<p><strong>Proliferation phase.</strong> In this phase, the blast cell divides and re-divides to produce a large number of immature cells. With each division, the cell progresses towards maturity, while still increasing in number.</p>
</li>
<li>
<p><strong>Maturation phase</strong> During this phase, each cell starts developing characteristic properties which will be necessary to perform its assigned physiological function. When the blood cells are almost mature, they are released in the peripheral blood circulation.</p>
</li>
</ol>
<p>Figure 2.1 shows a summary of haemopoiesis.</p>
<p><img src="assets/images/image-20251218-11e8da79.jpeg" alt="img-3.jpeg"></p>
<p>Fig. 2.1 Haemopoiesis</p>
<p>Scanned by CamScanner</p>
<p>Haemopoiesis (Production of Blood Cells) 267</p>
<p><strong>Note</strong>
Production of platelets is different from that of the red and the white blood cells. The process is known as endomitosis or endoreduplication where the nuclear division is not accompanied by cell division. As a result, the developing cell, megakaryocyte, continues to increase in size.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="erythropoiesis">ERYTHROPOIESIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythropoiesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The production of red cells is regulated by the kidneys with the help of a hormone, erythropoietin. When the oxygen tension is reduced, it stimulates the pluripotential stem cell to undergo mitosis and differentiation into a blast cell called pronormoblast or proerythroblast.</p>
<ol>
<li>
<p><strong>Pronormoblast</strong> The earliest recognisable erythroid cell in the marrow is the pronormoblast. It is a large round or oval cell, 15–17 microns in diameter. The nucleus is large and occupies most of the cell. It has a delicate membrane of fine chromatin, and 1 to 3 nucleoli are clearly visible. The cytoplasm stains blue and may show small, thick, rounded projections at the periphery. The pronormoblast divides by mitosis to produce basophilic normoblast.</p>
</li>
<li>
<p><strong>Basophilic (early) normoblast</strong> This cell has an average diameter of 13–17 microns. The nucleus is slightly smaller than that of the pronormoblast and nucleoli may not be visible. The cytoplasm stains deep blue due to the increase in the concentration of ribonucleic acid (RNA) in the cytoplasm. The early normoblast divides by mitotic division.</p>
</li>
<li>
<p><strong>Polychromatic (intermediate) normoblast</strong> It is smaller in size, the average diameter being 11 to 15 microns. The nucleus is also reduced considerably in size and shows a dense clumping of chromatin. The cytoplasm changes colour to purple and then to grayish-pink due to gradual disappearance of RNA and formation of haemoglobin. The cell divides by mitosis only in early stage.</p>
</li>
<li>
<p><strong>Orthochromatic (late) normoblast</strong> The diameter of this cell is about 8 to 10 microns. The nucleus is very small in size and starts slowly to disappear from the cytoplasm. The cytoplasm stains pinkish as the RNA is scanty and haemoglobinisation is nearly complete.</p>
</li>
<li>
<p><strong>Reticulocyte</strong> This cell has an average diameter of 8 microns. It is an immature erythrocyte. The nucleus has completely disappeared at this stage and some remnants of ribosomes are still present, giving the cell a bluish tinge. The ribosomes may be seen as a reticular structure in the cytoplasm when stained supra-vitally with brilliant cresyl blue. The reticulocyte may be released into the peripheral blood.</p>
</li>
<li>
<p><strong>Erythrocyte</strong> After 24 to 48 hours in the peripheral blood, the reticulocyte matures into an adult red cell. A normal red blood cell (RBC) is a biconcave disc, with an average diameter of 7.3 microns, thicker at the edges and thinner at the centre. It is non-nucleated and contains haemoglobin. The whole sequence of maturation from the pronormoblast to a mature RBC takes about 3–5 days; and each RBC has a total life span of approximately 120 days. There are about 5 million erythrocytes per mm³ (5 × 10⁶/μl) of peripheral blood in a healthy individual. Figure 2.2 shows the process of maturation of erythrocytes.</p>
</li>
</ol>
<p><strong>Note</strong>
All the cells described above are according to their appearance when stained with a Romanowsky stain, e.g., Leishman stain.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="function-of-red-blood-cells">Function of Red Blood Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#function-of-red-blood-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The main function of the RBC is to carry oxygen to the cells of the body. Haemoglobin within each RBC acts as the oxygen carrier. The concentration of haemoglobin in blood is thus an indication of its capacity to carry oxygen, on which all cells are absolutely dependent for life and energy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="elimination-of-red-blood-cells">Elimination of Red Blood Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#elimination-of-red-blood-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>At the end of its life span of 120 days, the worn-out RBC is removed from circulation by the reticulo-</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p><img src="assets/images/image-20251218-85f580ce.jpeg" alt="img-4.jpeg">
Fig. 2.2 Maturation of erythrocytes</p>
<p>endothelial system (RES) by a process called phagocytosis. The RES cells are located in sinusoids (small blood vessels) in the liver, spleen, bone marrow, lymph nodes, etc. The old RBCs show some changes on their surface which are recognised by the phagocytes in the RES and removed by engulfing and digesting them. All the re-usable components, such as protein and iron are recovered and re-circulated, while non-reusable components are eliminated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="leucopoiesis">LEUCOPOIESIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#leucopoiesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Under normal conditions, five types of mature white blood cells (WBCs) or leucocytes are found in the peripheral blood. Three of these types contain granules in their cytoplasm, and are therefore called granulocytes. Depending on the nature of the granules, they are called neutrophils, eosinophils and basophils. The other two types of cells, called agranulocytes, are monocytes and lymphocytes.</p>
<p>Out of these cells, granulocytes and monocytes are formed in the bone marrow from a pluripotential cell by differentiation, proliferation and maturation. Lymphocytes, however, have a very complex method of maturation and this process takes place in the reticulo-endothelial system. The blood granulocytes and monocytes, on the</p>
<p>other hand, are controlled by a feedback system similar to that of RBCs. There are colony stimulating factors (CSFs) or leucopoietins which stimulate and produce colonies of a particular white cell line.</p>
<p>There are certain criteria for identifying the cells: (1) size of the cell, (2) ratio of size of nucleus to that of the cytoplasm, (3) appearance of nuclear membrane, (4) presence of nucleoli, (5) staining reaction of the cytoplasm, (6) presence of cytoplasmic granules, and (7) the type, size and distribution of granules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="development-of-granulocyte-series-myeloid-series">Development of Granulocyte Series (Myeloid series)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#development-of-granulocyte-series-myeloid-series" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The description of blood and bone marrow cells stained with a Romanowsky stain can be summarised as follows:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-pluripotential-stem-cell">1. Pluripotential stem cell<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-pluripotential-stem-cell" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Size Usually 25–40 microns, having an irregular margin with blunt protoplasmic projections.</p>
<p>Nucleus Round, large with finely reticulated purple-red stained nuclear chromatin. Nucleus to cytoplasm ratio is 1:1.</p>
<p>Nucleoli 1–4, pale blue, well defined and irregular in shape.</p>
<p>Cytoplasm Bluish, non granular, less deeply stained near the nucleus.</p>
<p>Scanned by CamScanner</p>
<p>Haemopoiesis (Production of Blood Cells) 269</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-myeloblast">2 Myeloblast<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-myeloblast" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><em>Size</em> 10–18 microns in diameter, ovoid.</p>
<p><em>Nucleus</em> Occupies most of the cell, round or slightly ovoid, nucleus to cytoplasm ratio approximately 6:1. It has a smooth, thin nuclear membrane with fine, reticular, evenly distributed, purplish nuclear chromatin.</p>
<p><em>Nucleoli</em> 2 or more, distinct, ovoid, pale blue.</p>
<p><em>Cytoplasm</em> Very thin, blue basophilic rim though less basophilic than pronormoblast.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-promyelocyte">3. Promyelocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-promyelocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><em>Size</em> 12–20 microns, round or oval.</p>
<p><em>Nucleus</em> Ovoid, large; with slightly coarse clumping, light purple chromatin. The nucleus to cytoplasm ratio is 5:1.</p>
<p><em>Nucleoli</em> 2 or more, less distinct than in the blast cell, ovoid and pale blue.</p>
<p><em>Cytoplasm</em> Light purple, basophilic with few relatively large dark blue granules occasionally overlapping the nucleus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-myelocyte">4. Myelocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-myelocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><em>Size</em> 12–18 microns. Round or oval.</p>
<p><em>Nucleus</em> Round or oval, indistinct with more coarse clumping of purple chromatin. The nucleus to cytoplasm ratio is approximately 2:1.</p>
<p><em>Nucleoli</em> Usually absent.</p>
<p><em>Cytoplasm</em> Bluish pink with early undifferentiating azurophilic granules, more numerous and smaller than in promyelocyte. They may start differentiating into secondary specific granules such as chunky orange red (eosinophilic), blue black (basophilic), or lilac (neutrophilic) granules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-metamyelocyte">5. Metamyelocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-metamyelocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><em>Size</em> 10–18 microns, round or oval, slightly smaller than the myelocyte. It can be differentiated from the myelocyte by the shape of the nucleus.</p>
<p><em>Nucleus</em> Indented and kidney shaped. The nucleus to cytoplasm ratio is approximately 1.5:1. The nuclear chromatin is dark, purplish and coarse or in strands.</p>
<p><em>Cytoplasm</em> Abundant, pinkish blue and filled with numerous small granules (neutrophilic, eosinophilic or basophilic).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="6-stab-cell-band-cell">6. Stab cell (Band cell)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6-stab-cell-band-cell" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><em>Size</em> 10–16 microns, round or oval.</p>
<p><em>Nucleus</em> Sausage or horse shoe shape with occasional areas of constriction. The nucleus to cytoplasm ratio is approximately 1:2. Nuclear chromatin is coarse and deep purple blue.</p>
<p><em>Nucleoli</em> Absent.</p>
<p><em>Cytoplasm</em> A large amount is present, and it is pale blue or pink, with fine lilac (neutrophilic), large chunky orange (eosinophilic) or coarse blue black (basophilic) granules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="7-polymorphonuclear-granulocytes-neutrophil-eosinophil-and-basophil">7. Polymorphonuclear granulocytes (Neutrophil, Eosinophil and Basophil)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#7-polymorphonuclear-granulocytes-neutrophil-eosinophil-and-basophil" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><em>Size</em> 10–15 microns.</p>
<p><em>Nucleus</em> The nucleus in a younger cell consists of 2 purplish lobes separated by a strand of chromatin. The older cells have 3 or more lobes separated by very thin chromatin strands. The nucleus cytoplasm ratio is approximately 3:1.</p>
<p><em>Nucleoli</em> Absent.</p>
<p><em>Cytoplasm</em> Light pink to blue. The neutrophil has many small violet pink granules, the eosinophil has large bright orange granules and the basophil has large coarse blue black granules which completely fill the cytoplasm and obscure the nucleus.</p>
<p>&gt; <strong>Note:</strong> Stages 1–4 is the proliferation phase of development while stages 5–7 is the differentiation and maturation phase (Fig. 2.1).</p>
<p>Figure 2.3 shows stages of maturation of a granulocyte.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="development-of-the-lymphocyte-series">Development of The Lymphocyte Series<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#development-of-the-lymphocyte-series" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-lymphoblast">1. Lymphoblast<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-lymphoblast" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Present in bone marrow on occasions but in extremely small numbers; it is difficult to differentiate it from myeloblast.</p>
<p><em>Size</em> 10–18 microns.</p>
<p><em>Nucleus</em> Occupies most of the cell, round or oval. The chromatin is dark purple and aggregates along the nuclear membrane. It is coarser than in myeloblast. The nucleus to cytoplasm ratio is 6:1.</p>
<p><em>Nucleoli</em> 1–2, indistinct light blue.</p>
<p><em>Cytoplasm</em> Deep blue with no granules, most cells show paler perinuclear area.</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p><img src="assets/images/image-20251218-b12c1602.jpeg" alt="img-5.jpeg">
Fig. 2.3 Maturation of granulocytes (e.g. neutrophils)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-prolymphocyte">2. Prolymphocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-prolymphocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Size 9–17 microns.</p>
<p>Nucleus Ovoid, occasionally indented border. Chromatin is coarser, darker and more aggregated than in the lymphoblast. The nucleus to cytoplasm ratio is 4.5:1.</p>
<p>Nucleolus One, bluish.</p>
<p>Cytoplasm More than in the lymphoblast, with light to dark blue colour, occasionally with azurophilic granules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-lymphocyte">3. Lymphocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-lymphocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Size Two types: large, 8–16 microns and small, 7–9 microns.</p>
<p>Nucleus Usually round in shape and frequently eccentrically located. Chromatin is dark purple blue, very coarse and clumped. The nucleus to cytoplasm ratio is 1.5:1 in large lymphocyte and 1.25:1 in small lymphocyte. The nuclear membrane is sharply defined.</p>
<p>Nucleoli Absent.</p>
<p>Cytoplasm Light blue and varies from only a ring around the nucleus in small lymphocytes to relatively abundant in large lymphocytes. Occasional azurophilic granules may be seen in large lymphocytes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="development-of-the-monocyte-series">Development of The Monocyte Series<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#development-of-the-monocyte-series" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-monoblast">1. Monoblast<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-monoblast" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Size 12–20 microns.</p>
<p>Nucleus Large, round or ovoid. Light purple pink reticular chromatin, very fine with a distinct nuclear membrane. The nucleus to cytoplasm ratio is about 2:1.</p>
<p>Nucleoli 1–2.</p>
<p>Cytoplasm Light blue without granules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-promonocyte">2. Promonocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-promonocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Size 12–18 microns.</p>
<p>Nucleus Large lobulated, kidney shaped with fine, light purple, thread like (reticular) chromatin. The nucleus to cytoplasm ratio is approximately 2.5:1.</p>
<p>Nucleoli 0–1.</p>
<p>Cytoplasm Grey blue with large and small lilac azurophilic dust-like granules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="3-monocyte">3. Monocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-monocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This is the largest of normally occurring peripheral blood cells.</p>
<p>Size 12–16 microns.</p>
<p>Nucleus Oval, kidney or horse shoe shaped. Fine, lacy delicate chromatin stained light purple pink. Nucleus to cytoplasm ratio is approximately 2.5:1.</p>
<p>Nucleoli Absent.</p>
<p>Cytoplasm Abundant, slate grey with many fine lilac coloured granules and vacuoles.</p>
<p>&gt; <strong>Note</strong>
&gt; The monocyte can be differentiated from metamyelocyte and prolymphocyte by the lighter staining nucleus and fine lilac granules.</p>
<p>Scanned by CamScanner</p>
<p>Haemopoiesis (Production of Blood Cells) 271</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="development-of-the-plasmocyte-series">Development of the Plasmocyte Series<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#development-of-the-plasmocyte-series" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Plasmocyte is formed by transformation of antibody producing lymphocyte (B-lymphocyte). When stimulated by an antigen, the B-lymphocyte transforms into a plasmoblast which proliferates and matures to form a plasmocyte or plasma cell. These plasma cells produce antibody which is specifically directed against the stimulating antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-plasmoblast">1. Plasmoblast<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-plasmoblast" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Normally not present in blood and only rarely seen in normal bone marrow.</p>
<p><strong>Size</strong> 14–24 microns.</p>
<p><strong>Nucleus</strong> Eccentrically placed, somewhat egg-shaped, usually in the narrower pole of the cell. The chromatin is reticulated, purplish and coarse. The nucleus to cytoplasm ratio is about 1–2:1.</p>
<p><strong>Nucleoli</strong> 1–3 large nucleoli.</p>
<p><strong>Cytoplasm</strong> Relatively abundant, deeply basophilic with occasional areas of light staining.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-proplasmocyte">2. Proplasmocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-proplasmocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Size</strong> 14–22 microns.</p>
<p><strong>Nucleus</strong> Eccentric, oval shaped, with peripheral coarse chromatin. The nucleus to cytoplasm ratio is 2:1.</p>
<p><strong>Nucleoli</strong> 1–2 and large.</p>
<p><strong>Cytoplasm</strong> Abundant, light blue with lighter perinuclear halo.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-plasmocyte-plasma-cell">3. Plasmocyte (Plasma cell)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-plasmocyte-plasma-cell" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Egg shaped, narrower at one end than the other.</p>
<p><strong>Size</strong> 8–18 microns.</p>
<p><strong>Nucleus</strong> Ovoid, eccentrically located usually in the narrower end of the cell. The chromatin is purplish and extremely coarse giving a cart-wheel appearance. The nucleus to cytoplasm ratio is approximately 1:2.</p>
<p><strong>Nucleoli</strong> Absent</p>
<p><strong>Cytoplasm</strong> Deep blue with pale peri-nuclear halo near one side of the nucleus. Vacuoles may be present near the cell border.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="development-of-thrombocytes-platelets">Development of Thrombocytes (Platelets)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#development-of-thrombocytes-platelets" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Thrombocytes or platelets are formed by budding from the cytoplasm of megakaryocytes in the bone marrow and occasionally in the lungs. About 3000 to 4000 platelets are produced from a single megakaryocyte.</p>
<p>The cytological characteristics of platelets and their progenitors are as follows:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-megakaryoblast">1. Megakaryoblast<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-megakaryoblast" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Size</strong> 16 to 25 microns.</p>
<p><strong>Nucleus</strong> It is lobulated with one or two diploid nucleoli, dark purple or blue finely reticulated chromatin. The nucleus to cytoplasm ratio is approximately 9:1.</p>
<p><strong>Nucleoli</strong> Indistinct 2–5.</p>
<p><strong>Cytoplasm</strong> Scanty, greyish blue in colour with occasional vacuole.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-promegakaryocyte-basophilic-megakaryocyte">2. Promegakaryocyte (Basophilic megakaryocyte)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-promegakaryocyte-basophilic-megakaryocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Size</strong> 20–45 microns.</p>
<p><strong>Nucleus</strong> Coarse, lobulated with purplish chromatin network. The nucleus to cytoplasm ratio is approximately 9:2.</p>
<p><strong>Nucleoli</strong> Indistinct 1 or 2.</p>
<p><strong>Cytoplasm</strong> Slightly polychromatic (purplish pink), with occasional fine azurophilic granules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="3-megakaryocyte">3. Megakaryocyte<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-megakaryocyte" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This is the largest of all the blood cells with pleomorphic uninuclear structure, occasionally with multilobular pattern.</p>
<p><strong>Size</strong> 30–90 microns.</p>
<p><strong>Nucleus</strong> Red purple, coarse clumped chromatin with multi lobulated pattern. The nucleus to cytoplasm ratio varies because the nucleus may occupy most of the cell in some cases or may be eccentric with abundant cytoplasm in others.</p>
<p><strong>Nucleoli</strong> Varies from 0–1 but very indistinct.</p>
<p><strong>Cytoplasm</strong> Usually abundant, light purple blue filled with fine purple granules. It frequently shows irregular pseudopodal projections representing platelets in the process of transformation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="4-thrombocytes-platelets">4. Thrombocytes (platelets)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-thrombocytes-platelets" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Size</strong> 2–4 microns.</p>
<p><strong>Nucleus</strong> None.</p>
<p><strong>Nucleoli</strong> None.</p>
<p><strong>Cytoplasm</strong> Pale blue with pink-red azurophilic granules.</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="functions-of-white-blood-cells">FUNCTIONS OF WHITE BLOOD CELLS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-white-blood-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="granulocyte-function">Granulocyte Function<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#granulocyte-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A large number of white cells, especially of the granulocyte or myeloid series, are held in the marrow as a 'reserve pool'. A normal bone marrow contains more myeloid cells than erythroid cells in the ratio <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>:</mo><mn>1</mn><mo>−</mo><mn>12</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">2:1-12:1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span>. The largest population is that of neutrophils and metamyelocytes. When released into the peripheral blood, granulocytes spend about 10 hours in the circulating blood. From circulation, they move into the tissues where they perform their phagocytic function. They clear the body of unwanted particulate material such as dead or injured tissue cells; and also engulf and destroy foreign bodies such as bacteria. They have a comparatively short life-span of about 4-5 days in the tissues before they are destroyed during defensive action or are removed because they are worn-out. At any given time, normally, the number of granulocytes in the circulating blood is equal to that of granulocytes in tissues; and this is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mo>×</mo><msup><mn>10</mn><mn>9</mn></msup><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">5 - 10 \times 10^{9} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">9</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> (5,000 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">/</mi><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>3</mn></msup></mrow><annotation encoding="application/x-tex">10,000 / \mathrm{mm}^{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000/</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span></span></span></span></span></span></span></span></span>).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="monocyte-function">Monocyte Function<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monocyte-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Like granulocytes, monocytes also act as phagocytes and scavengers. They are released from the marrow into the circulating blood. They remain in blood for about 20-40 hours and enter the tissues. In tissues, they are called macrophages. Their life span in tissues may be as long as several months or even years. They may assume specific functions in different tissues such as skin, liver and intestines.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="lymphocyte-function">Lymphocyte Function<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lymphocyte-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The immunologically competent cells or immunocytes comprise the lymphocytes, their precursors and plasma cells. These cells assist the phagocytes in the defence of the body against infection. Unlike the phagocytic function, the protection by lymphocytes is specific.</p>
<p>The immune response depends on two types of lymphocytes, B-cells and T-cells. In man, B-cells are derived from the bone marrow. After stimulation by antigens, B-cells proliferate, transform and mature into plasma cells which secrete specific immunoglobulin antibody.</p>
<p>The T-lymphocyte is derived from the thymus gland and is concerned with cell-mediated immunity (CMI). It is a very complex process involving the cells surrounding the antigenic material and destroying it. The T-lymphocytes have various sub-populations, each with a specific immune function, e.g., helper T cells (<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>), suppressor T-cells (<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>8</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{8}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">8</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>), memory cells, etc. They have a very long life span, possibly up to 20 years.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="functions-of-platelets">FUNCTIONS OF PLATELETS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-platelets" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the circulating blood, platelets are an essential part of blood coagulating mechanism. They act as plugs around the opening of a wound and release certain factors that are necessary for the formation of a blood clot to prevent blood loss. The platelets also maintain the integrity of the blood vessels by plugging the gaps in the endothelial lining.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 3</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-complete-blood-count-cbc">The Complete Blood Count (CBC)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-complete-blood-count-cbc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The investigations included under the title 'complete blood count (CBC)' may vary in different laboratory set-ups, but generally include the following:</p>
<ol>
<li>Estimation of haemoglobin (Hb).</li>
<li>Total red cell count.</li>
<li>Packed cell volume (PCV).</li>
<li>Red cell indices.</li>
<li>Total white cell count.</li>
<li>Peripheral blood smear examination including the differential leucocyte count (DLC). In some cases, other tests may also be included;</li>
<li>Total eosinophil count.</li>
<li>Platelet count.</li>
<li>Reticulocyte count (see Chapter 6).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="haemoglobin-hb">HAEMOGLOBIN (Hb)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemoglobin-hb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="structure">Structure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#structure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>There are about 2–3 million Hb molecules in a red cell, each having a molecular weight of 64,458.</p>
<p>Haemoglobin is a chromoprotein consisting of a globin molecule attached to 4 red coloured haem molecules (Fig. 3.1). The globin molecule consists of two alpha and two beta polypeptide chains. Haem is a metal complex containing an iron atom in the centre of a porphyrin structure. Haemoglobin is formed in the developing erythrocyte in the bone marrow. The life span of haemoglobin is the same as the life span of the red cell that accommodates it, that is, about 120 days. In the adult, the concentration of haemoglobin in the blood is 14–16 grams per 100 ml. A healthy adult loses and produces 6.25 g of haemoglobin per day. A litre of normal blood is capable of carrying 200 ml of oxygen and 1.0 gram of haemoglobin combines with 1.34 ml of oxygen. Oxidisation converts haem into haematin. The iron content of each haemoglobin molecule is 3.4 nanograms.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="synthesis-of-haemoglobin">Synthesis of Haemoglobin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#synthesis-of-haemoglobin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Haem synthesis occurs largely in the mitochondria by a series of biochemical reactions.</p>
<ol>
<li>Glycine + succinyl coenzyme A is condensed by delta amino laevulinic acid (ALA) synthetase in the presence of pyridoxal phosphate (Vit B₆). This leads to the formation of protoporphyrin.</li>
</ol>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>Glycine</mtext><mo>+</mo><msub><mtext>Vit.&nbsp;B</mtext><mn>6</mn></msub><mo>+</mo><mtext>Succinyl&nbsp;CoA</mtext><munderover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mtext>synthetase</mtext></mpadded><mpadded width="+0.6em" lspace="0.3em"><mtext>ALA</mtext></mpadded></munderover><mtext>Protoporphyrin</mtext></mrow><annotation encoding="application/x-tex">\text{Glycine} + \text{Vit. B}_6 + \text{Succinyl CoA} \xrightarrow[\text{synthetase}]{\text{ALA}} \text{Protoporphyrin}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">Glycine</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord text"><span class="mord">Vit.&nbsp;B</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">6</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.8445em; vertical-align: -0.7442em;"></span><span class="mord text"><span class="mord">Succinyl&nbsp;CoA</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.1003em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">ALA</span></span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span><span style="top: -2.0919em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">synthetase</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.7442em;"><span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">Protoporphyrin</span></span></span></span></span></span></div>
<ol start="2">
<li>Protoporphyrin combines with iron to form haem.</li>
</ol>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>Fe</mtext><mo>+</mo><mtext>Protoporphyrin</mtext><mo>⟶</mo><mtext>Haem</mtext></mrow><annotation encoding="application/x-tex">\text{Fe} + \text{Protoporphyrin} \longrightarrow \text{Haem}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord text"><span class="mord">Fe</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">Protoporphyrin</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">⟶</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord text"><span class="mord">Haem</span></span></span></span></span></span></div>
<ol start="3">
<li>Each molecule of haem combines with the globin chains on polyribosomes.</li>
<li>Tetramer of 4 globin chains, each with its own haem group, makes up a haemoglobin molecule (Fig. 3.1).</li>
</ol>
<p>Scanned by CamScanner</p>
<p>274 Haematology</p>
<p><img src="assets/images/image-20251218-a5cf5c28.jpeg" alt="img-6.jpeg">
Fig. 3.1 Structure of Haemoglobin</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="degradation-of-haemoglobin">Degradation of Haemoglobin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#degradation-of-haemoglobin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When the red cell completes its life span, at the end of about 120 days, it is removed by the macrophages of the reticuloendothelial system. The haemoglobin is released, broken down, the useful portion is recirculated and the rest is excreted.</p>
<p>The degradation of haemoglobin begins in the reticuloendothelial cell. The protein fraction is separated and broken down to amino acids which enter the common metabolic pool. Iron is separated and stored as ferritin and haemosiderin for reutilisation in the synthesis of haemoglobin and other haem proteins. The porphyrin portion is converted into biliverdin in reticuloendothelial cells and enters the blood as free bilirubin. In the liver it is conjugated and excreted in bile. In the intestine, bilirubin is converted into faecal urobilinogen by the action of intestinal bacteria. Some faecal urobilinogen is reabsorbed and carried back to the liver to be excreted into bile. Some escapes the liver and is excreted in the urine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="forms-of-haemoglobin">Forms of Haemoglobin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#forms-of-haemoglobin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Depending on the content and sequence of amino acids in the globin chains, different forms of haemoglobin may occur in the red cells.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="haemoglobin-a-hba">Haemoglobin A (HbA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemoglobin-a-hba" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is the main adult haemoglobin (97 %) and contains 2 alpha and 2 beta globin chains. Another form of adult haemoglobin, HbA₂, contains 2 alpha chains paired with 2 delta chains. HbA₂ is present in normal adults in small amounts (2–4 %).</p>
<p><strong>Haemoglobin F (HbF)</strong> HbF is the major form of haemoglobin during intrauterine life and at birth. In HbF, 2 alpha chains are paired with 2 gamma chains. HbF is slowly replaced by HbA and at the</p>
<p>Scanned by CamScanner</p>
<p>The Complete Blood Count (CBC) 275</p>
<p>end of the first year, the HbF concentration is reduced to 1–2 % from 70–90 % at birth. A normal adult may have 1–2 % HbF in blood.</p>
<p>HbF combines more readily with oxygen than HbA, thus helping the foetus in acquiring oxygen in placental circulation. It also differs from HbA in that, it resists denaturation with alkali, unlike HbA which is easily denatured.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complexes-of-haemoglobin">Complexes of Haemoglobin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complexes-of-haemoglobin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Certain complexes of haemoglobin may be formed if it is acted upon by other chemicals. Such complexes may drastically reduce its capacity to react with oxygen, thus leading to hypoxia or cyanosis. Such forms include:</p>
<p><strong>Carboxyhaemoglobin (HbCO)</strong> This is produced when haemoglobin combines with carbon monoxide. Haemoglobin has a much greater affinity for carbon monoxide than for oxygen and combines readily with it. It is found in higher concentrations in the blood of smokers.</p>
<p><strong>Methaemoglobin (HI)</strong> The formation of methaemoglobin results from its reaction with certain drugs such as phenacetin or sulphonamides. In this form, iron is oxidised from the ferrous to the ferric state and is therefore incapable of reacting with oxygen.</p>
<p><strong>Sulphhaemoglobin (SHb)</strong> SHb is formed irreversibly by the action of certain drugs and chemicals such as sulphonamides. Once formed, it remains for the life of the carrier RBC and is not capable of oxygen transport.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="structurally-abnormal-haemoglobins-and-related-disorders">Structurally Abnormal Haemoglobins and Related Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#structurally-abnormal-haemoglobins-and-related-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The term abnormal haemoglobin is reserved for abnormalities in the globin molecules of haemoglobin. These consist of formation of abnormal alpha or beta peptide chains because one or more of the constituent amino acids has been substituted by another. Abnormal haemoglobins formed in this way are designated as haemoglobin C, D, E, G, H, I, J, K and S. These can be differentiated by techniques of electrophoresis and chromatography.</p>
<p>Abnormal haemoglobins are associated with congenital and hereditary defects (inborn errors). The disorders produced by abnormal haemoglobin are called haemoglobinopathies. For instance, possession of haemoglobin S (HbS) makes the red cell sickle shaped in reduced oxygen tension. In thalassaemia, the abnormal gene interferes with the formation of adult haemoglobin (HbA).</p>
<p><strong>Sickle cell anaemia</strong> In haemoglobin S, one of the amino acids in the beta-chain of HbA is substituted. This is due to inheritance of a defective beta-gene. If only one parent passes this gene to the off-spring, it is heterozygous and the condition is called sickle-cell trait. The blood of such a person will contain both HbA and HbS. If the defective gene is inherited from both the parents, the off-spring is homozygous and will produce only HbS. This is called sickle-cell disease, and is a very serious condition.</p>
<p><strong>Thalassaemia</strong> Thalassaemia is a condition in which there is suppression of either alpha or beta globin chains. In beta-thalassaemia, there is a reduced number of beta-chains produced. Hence the patient’s blood may contain HbA₂ (2 alpha + 2 delta chains in globin molecules) and HbF (2 alpha + 2 gamma chains). In alpha-thalassaemia, however, levels of HbA, HbA₂ and HbF are equally suppressed because all contain alpha chains, which are suppressed. In such cases HbH is formed with all beta-chains in the globin molecules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="estimation-of-haemoglobin">ESTIMATION OF HAEMOGLOBIN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#estimation-of-haemoglobin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The purpose of estimating haemoglobin is to determine the oxygen carrying capacity of blood. The results help in detecting diseases which cause deficiency or excess of haemoglobin. Haemoglobin estimation also helps in citing changes in the haemoglobin concentration before and after operation and blood transfusion. Several techniques have been used to determine haemoglobin in the form of oxyhaemoglobin, carboxyhaemoglobin, cyanmethaemoglobin, acid and alkaline haematin, based on their oxygen carrying capacity, iron content or colour.</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p>Haemoglobin is expressed as grams per litre, grams per 100 ml or grams per decilitre (dl) of blood. A major problem in accurate measurement of haemoglobin content is the non availability of a suitable standard. Some visual methods, such as Sahli's, use artificial standard. However, in 1966, the International Committee for Standardisation in Haematology (ICSH) recommended cyanmethaemoglobin, prepared according to strict specifications, as a suitable standard. Cyanmethaemoglobin is very stable and the standard is available commercially.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-acid-haematin-method-sahli">1. Acid Haematin Method (Sahli)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-acid-haematin-method-sahli" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is a visual method of haemoglobin estimation, and is not very accurate. Visual methods are now used only in the areas of the world where electricity is not available.</p>
<p><strong>Principle</strong> Haemoglobin is converted into acid haematin by the action of hydrochloric acid. The brown colour of the compound is matched visually against a brown glass standard in a comparator.</p>
<p><strong>Specimen</strong> The sample may be venous blood collected in EDTA or oxalate anticoagulant; or blood obtained by capillary puncture.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="apparatus-and-reagent">Apparatus and reagent<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#apparatus-and-reagent" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Sahli graduated tube and haemoglobinometer consisting of the comparator with glass standards. One side of the tube gives the reading in grams of Hb/100 ml blood while the other side gives it as percentage (14.6 g = 100%).</p>
</li>
<li>
<p>0.1 N Hydrochloric acid.</p>
</li>
<li>
<p>Haemoglobin pipette marked at 20 cu.mm (μl) or 0.02 ml.</p>
</li>
</ol>
<p><strong>Technique</strong> Fill the graduated tube up to the mark 20 with 0.1 N HCl. Fill haemoglobin pipette exactly up to the 20 cu.mm mark with well mixed blood by gentle controlled sucking, holding the pipette horizontal. Wipe off the blood on the outside of the pipette with a piece of gauze. Empty the pipette into the acid in the tube gently without causing bubbles. Rinse the pipette 2–3 times by drawing in and discharging the fluid. Mix the acid haematin solution in the tube and allow to stand for 5–10 minutes. Place the tube in the Sahli comparator and start adding 0.1 N HCl or distilled water drop by drop. Mix between each addition, continue till the colour matches that of the standard. Read the volume of solution in the graduated tube, and express as grams/100 ml (g/dl) or as percentage.</p>
<p>&gt; <strong>Note</strong>
&gt; Care should be taken to clean the haemoglobin pipette with distilled water by sucking in and discharging water several times. It should be dried with acetone or alcohol before reuse.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-cyanmethaemoglobin-method">2. Cyanmethaemoglobin Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-cyanmethaemoglobin-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is a colorimetric method, and therefore, more accurate than Sahli's. A commercial cyanmethaemoglobin standard is used for comparison.</p>
<p><strong>Principle</strong> The haemoglobin is treated with a reagent containing potassium ferricyanide, potassium cyanide and potassium dihydrogen phosphate. The ferricyanide forms methaemoglobin which is converted to cyanmethaemoglobin by the cyanide. All forms of haemoglobin except sulfhaemoglobin are converted to cyanmethaemoglobin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-drabkin-s-solution">1. Drabkin's solution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-drabkin-s-solution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<table><thead><tr><th>Potassium cyanide</th><th>500 mg</th></tr></thead><tbody><tr><td>Potassium ferricyanide</td><td>200 mg</td></tr><tr><td>Potassium dihydrogen phosphate</td><td>140 mg</td></tr><tr><td>Distilled water</td><td>1 litre</td></tr><tr><td>pH</td><td>7.0–7.4</td></tr></tbody></table>
<p>Store in a dark bottle. The solution keeps for several months.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-cyanmethaemoglobin-standard">2. Cyanmethaemoglobin standard<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-cyanmethaemoglobin-standard" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>It is available commercially in sealed ampoules. The concentration is indicated on the label and is usually about 60 mg per 100 ml.</p>
<p><strong>Technique</strong> Add 0.02 ml (20 μl) of blood to 5 ml of Drabkin's solution in a test tube (1:250 dilution).</p>
<p>Mix well and allow to stand for 10 minutes. Read the absorbance colorimetrically at 540 nanometers (green filter) with Drabkin's solution as blank. Read the absorbance of the standard in the same way.</p>
<p>Scanned by CamScanner</p>
<p>The Complete Blood Count (CBC) 277</p>
<p>Calculation Grams of haemoglobin per 100 ml of blood.</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.16em" columnalign="left" columnspacing="1em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mfrac><mtext>Reading&nbsp;of&nbsp;test</mtext><mtext>Reading&nbsp;of&nbsp;standard</mtext></mfrac><mo>×</mo><mtext>Dilution&nbsp;factor</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>×</mo><mfrac><mtext>Concentration&nbsp;of&nbsp;standard&nbsp;in&nbsp;mg/100&nbsp;ml</mtext><mn>1000</mn></mfrac></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mfrac><mtext>Reading&nbsp;of&nbsp;test</mtext><mtext>Reading&nbsp;of&nbsp;standard</mtext></mfrac><mo>×</mo><mn>250</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>×</mo><mfrac><mtext>Concentration&nbsp;of&nbsp;standard</mtext><mn>1000</mn></mfrac></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mfrac><mtext>Reading&nbsp;of&nbsp;test</mtext><mtext>Reading&nbsp;of&nbsp;standard</mtext></mfrac><mo>×</mo><mfrac><mtext>Concentration&nbsp;of&nbsp;standard</mtext><mn>4</mn></mfrac></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{array}{l}
= \frac{\text{Reading of test}}{\text{Reading of standard}} \times \text{Dilution factor} \\
\times \frac{\text{Concentration of standard in mg/100 ml}}{1000} \\
= \frac{\text{Reading of test}}{\text{Reading of standard}} \times 250 \\
\times \frac{\text{Concentration of standard}}{1000} \\
= \frac{\text{Reading of test}}{\text{Reading of standard}} \times \frac{\text{Concentration of standard}}{4} \\
\end{array}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 6.8501em; vertical-align: -3.175em;"></span><span class="mord"><span class="mtable"><span class="arraycolsep" style="width: 0.5em;"></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 3.675em;"><span style="top: -5.7528em;"><span class="pstrut" style="height: 3.01em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.9322em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Reading&nbsp;of&nbsp;standard</span></span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.4461em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Reading&nbsp;of&nbsp;test</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.4811em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">Dilution&nbsp;factor</span></span></span></span><span style="top: -4.2617em;"><span class="pstrut" style="height: 3.01em;"></span><span class="mord"><span class="mord">×</span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.01em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1000</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.485em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Concentration&nbsp;of&nbsp;standard&nbsp;in&nbsp;mg/100&nbsp;ml</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span><span style="top: -2.9695em;"><span class="pstrut" style="height: 3.01em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.9322em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Reading&nbsp;of&nbsp;standard</span></span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.4461em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Reading&nbsp;of&nbsp;test</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.4811em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">250</span></span></span><span style="top: -1.6083em;"><span class="pstrut" style="height: 3.01em;"></span><span class="mord"><span class="mord">×</span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8801em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1000</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Concentration&nbsp;of&nbsp;standard</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span><span style="top: -0.3161em;"><span class="pstrut" style="height: 3.01em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.9322em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Reading&nbsp;of&nbsp;standard</span></span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.4461em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Reading&nbsp;of&nbsp;test</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.4811em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8801em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Concentration&nbsp;of&nbsp;standard</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 3.175em;"><span></span></span></span></span></span><span class="arraycolsep" style="width: 0.5em;"></span></span></span></span></span></span></span></div>
<p>Alternatively, a calibration curve may be prepared by diluting the standard 1:2, 1:3 and 1:4; and the concentration plotted against the absorbance. The concentration of the haemoglobin in the blood can then be measured from its absorbance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="haemocytometry-counting-of-cells-in-blood">HAEMOCYTOMETRY (COUNTING OF CELLS IN BLOOD)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemocytometry-counting-of-cells-in-blood" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Counting of blood cells, such as red blood cells (RBCs), white blood cells (WBCs) and platelets is a fundamental measurement in a haematology laboratory. These cells can be counted either manually by microscopy or with the help of automated electronic devices.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="manual-cell-counts">MANUAL CELL COUNTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#manual-cell-counts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The manual method of counting involves:</p>
<ol>
<li>Dilution of blood in an appropriate diluting fluid</li>
<li>Use of a haemocytometer to count the number of cells per unit volume of blood. e.g. One cubic millimetre (mm³, μl) or one litre (L)</li>
</ol>
<p><strong>Note</strong> One cubic millimetre is equal to 1 microlitre (1μl). One litre is equal to 10⁶ microlitres.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dilution-of-blood-for-cell-counts-using-thoma-pipettes">Dilution of Blood for Cell Counts Using Thoma Pipettes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dilution-of-blood-for-cell-counts-using-thoma-pipettes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A Thoma pipette (Fig. 3.2) consists of a graduated capillary tube divided into 10 parts marked 0.5 at the fifth mark and 1.0 at the tenth mark. The capillary tube opens into a mixing bulb containing a glass bead which facilitate mixing of the blood and the diluent. There is another short capillary tube</p>
<p><img src="assets/images/image-20251218-b4896428.jpeg" alt="img-7.jpeg">
Fig. 3.2 Thoma red cell and white cell counting pipettes</p>
<p>Scanned by CamScanner</p>
<p>278 Haematology</p>
<p>above the bulb marked 11.0 on the white cell pipette and 101.0 on the red cell pipette. In the Thoma white cell pipette, if blood is collected up to the 0.5 mark and diluted up to the 11.0 mark, the resulting dilution within the bulb is 1:20. The red cell pipette allows a ten times greater dilution than the white cell pipette and when 0.5 units is measured and diluted up to 101.0 mark, the dilution is 1:200. Each Thoma pipette is provided with an aspirating tube.</p>
<p><strong>Note</strong> While making dilutions, it must be remembered that 1.0 unit in the stem of the pipette contains only the diluent and therefore, must not be used for counting cells. Discarding first 3-5 drops removes this fluid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="techniques">Techniques<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#techniques" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Using an appropriate (RBC or WBC) Thoma pipette, aspirate well mixed blood into the capillary tube of the pipette to slightly above the 0.5 mark.</li>
<li>Wipe off the outside of the pipette with a gauze and adjust the blood level exactly to 0.5 mark by tapping the tip of the pipette with a gloved finger or using any other non absorbent material. Use of absorbent material such as guaze should be avoided as it will absorb only the liquid portion of blood, thus increasing actual concentration of cells in blood.</li>
<li>Hold the pipette in a horizontal position to maintain the blood level at 0.5 mark and place the tip of the pipette into the diluting fluid. Using a constant suction, draw the fluid into the pipette while twirling the pipette between the fingers. Continue aspirating slowly till the mixture reaches the top mark (11.0 in WBC pipette or 101.0 in RBC pipette) above the bulb.</li>
<li>Remove the pipette from the diluting fluid and still holding in horizontally, remove the aspiration tube. Hold the pipette with the thumb and third finger at either end and shake vigorously at right angles to the long axis of the pipette. The glass bead in the pipette helps in mixing the suspension.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dilution-of-blood-for-cell-counts-using-a-self-filling-self-measuring-dilution-pipette-unoppette">Dilution of Blood for Cell Counts Using a Self Filling, Self Measuring Dilution Pipette (Unoppette)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dilution-of-blood-for-cell-counts-using-a-self-filling-self-measuring-dilution-pipette-unoppette" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The unoppette cell diluting system consists of a straight, thin-walled capillary tube, fitted into a plastic holder. It is also provided with a plastic reservoir containing a premeasured volume of diluent. The capillary tube is enclosed in a plastic shield (Fig. 3.3). Special unoppette systems are available for leucocyte counts, red cell counts, platelet counts and eosinophil counts. Each uses the respective diluting fluid to obtain an appropriate dilution.</p>
<p><img src="assets/images/image-20251218-73195442.jpeg" alt="img-8.jpeg">
Fig. 3.3 Disposable self filling pipette system with diluent reservoir</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Open the diluent reservoir by forcing the blunt end of the plastic shield into the reservoir cap.</li>
<li>Draw the blood into the capillary pipette either from an EDTA-anticoagulated blood</li>
</ol>
<p>Scanned by CamScanner</p>
<p>The Complete Blood Count (CBC) 279</p>
<p>or from a finger prick. The blood will fill the pipette by capillary action to a fixed volume.</p>
<ol start="3">
<li>Wipe the exterior of the pipette with a guaze and introduce the blood into the reservoir. Squeezing the reservoir helps to release the blood into the diluting fluid.</li>
<li>Mix the diluted blood in the reservoir.</li>
<li>Before charging the counting chamber, remove the capillary tube from the reservoir and reattach it in a reversed position. Squeeze the reservoir gently to force a few drops of diluted blood out through the capillary to fill the counting chamber.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="use-of-counting-chamber-haemocytometer-for-cell-counting">USE OF COUNTING CHAMBER (HAEMOCYTOMETER) FOR CELL COUNTING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#use-of-counting-chamber-haemocytometer-for-cell-counting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A haemocytometer consists of a counting chamber, a coverglass for the counting chamber and the diluting pipettes. Many types of counting chambers are available. Improved Neubauer and Fuchs Rosenthal are the two most commonly used chambers in laboratories.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="improved-neubauer-counting-chamber">Improved Neubauer counting chamber<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#improved-neubauer-counting-chamber" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The improved Neubauer counting chamber consists of a thick rectangular glass slide with an 'H' shaped trough, forming two counting areas (Fig. 3.4(a)). Beyond the two vertical arms of the trough are two raised shoulders which support the specially made thick, optically flat coverglass. The space between the coverglass and surface of the counting area (i.e. the depth) is exactly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">0.1\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span> if the coverglass is correctly applied (Fig. 3.4(b)). Each counting area is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>×</mo><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">3\times 3\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span>. This produces a total counting volume of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">u</mi><mi mathvariant="normal">.</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">0.9\mathrm{cu.mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.9</span><span class="mord"><span class="mord mathrm">cu.mm</span></span></span></span></span></span>.</p>
<p>When the ruled area is viewed under the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>×</mo></mrow><annotation encoding="application/x-tex">10 \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mord">×</span></span></span></span></span> objective of the microscope, it shows 5 squares each having <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">1\mathrm{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span> area (Fig. 3.5). These <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">1\mathrm{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span> sections in the four corners are divided into 16 equal squares. The square in the centre of the ruled</p>
<p><img src="assets/images/image-20251218-48186ab4.jpeg" alt="img-9.jpeg"></p>
<p><img src="assets/images/image-20251218-8fb39216.jpeg" alt="img-10.jpeg">
Fig. 3.4 (a) Counting chamber front view (b) Counting chamber side view</p>
<p>Scanned by CamScanner</p>
<p>280 Haematology</p>
<p>area is divided into 25 equal squares. In turn, each of these <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>25</mn><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">1/25\mathrm{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">1/25</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span> squares are further divided into 16 portions, each having an area <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>400</mn><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">1/400\mathrm{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">1/400</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span>. The area can be selected according to the cell type to be counted. Figure 3.6 shows the various areas and their dimensions.</p>
<p><img src="assets/images/image-20251218-8cac6f70.jpeg" alt="img-11.jpeg">
Fig. 3.5 Improved Neubauer ruling</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fuchs-rosenthal-counting-chamber">Fuchs-Rosenthal Counting Chamber<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fuchs-rosenthal-counting-chamber" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are two types of Fuchs Rosenthal chambers available. The older type has 16 squares, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">1\mathrm{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span> each, bounded by triple lines (Fig. 3.7). Each of these squares is further subdivided into 16 squares. Thus the smallest square has an area <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>16</mn><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">1/16\mathrm{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">1/16</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span>. The depth of the chamber is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">0.2\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.2</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span>.</p>
<p>The other type of Fuchs-Rosenthal chamber has a total ruled area of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9</mn><msup><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">9\mathrm{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">9</span><span class="mord"><span class="mord"><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span> which is divided into 9 squares. The depth is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">0.2\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.2</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span>. Fuchs-Rosenthal chamber is more commonly used for counting cells in cerebrospinal fluid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="charging-the-counting-chamber-for-cell-counts">Charging the Counting Chamber for cell Counts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#charging-the-counting-chamber-for-cell-counts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The counting chamber should be set up correctly so that the depth of the counting chamber is uniform. To facilitate this, moisten the raised shoulders of the chamber and slide the coverslip onto the shoulders with both thumbs. If correctly placed, the coverslip should not fall off even after inverting the counting chamber and should show rainbow colours (Newton’s rings).</p>
<p>To fill up the chamber, care must be taken that the diluted blood does not overflow into the ‘H’ shaped trough around the counting surface. Fill the</p>
<p><img src="assets/images/image-20251218-c4ca7e1e.jpeg" alt="img-12.jpeg">
Fig. 3.6 Counting areas (magnified) of improved Neubauer chamber</p>
<p>Scanned by CamScanner</p>
<p>The Complete Blood Count (CBC) 281</p>
<p><img src="assets/images/image-20251218-3414688a.jpeg" alt="img-13.jpeg">
Fig. 3.7 Fuchs-Rosenthal counting chamber</p>
<p>counting area by touching a drop of well mixed diluted blood to the edge of the coverglass and the fluid is drawn in by capillary action. It is necessary to charge both the counting areas. Before counting, allow the cells to settle in a moist chamber. A simple moist chamber can be prepared by placing a wet cotton pad or filter paper in a petri dish.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="counting-of-cells">Counting of Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#counting-of-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>While counting the cells in the squares include those that touch the lines on the left side or on top of the squares, and exclude those that touch the lines on the right side and at the bottom of the square (Fig. 3.8). For squares outlined with a triple set of lines, the central line denotes the boundary of the square. This system of counting avoids the chances of a cell being counted twice or of being omitted.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="red-cell-count-manual-method">RED CELL COUNT (MANUAL METHOD)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#red-cell-count-manual-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> Whole blood is diluted appropriately using an isotonic diluent to avoid lysis of red cells. The number of red cells in a known volume and of known dilution is counted using a counting chamber.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="diluting-fluid-formal-citrate">Diluting fluid (Formal citrate)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diluting-fluid-formal-citrate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<table><thead><tr><th>Sodium citrate</th><th>3.0 g</th></tr></thead><tbody><tr><td>Formaldehyde</td><td>1.0 ml</td></tr><tr><td>Distilled water</td><td>99.0 ml</td></tr></tbody></table>
<p>Alternatively, 0.85 % sodium chloride may be used.</p>
<p><strong>Specimen</strong> Whole blood, anticoagulated with EDTA. Capillary blood can be used if it is diluted immediately after collection.</p>
<p><img src="assets/images/image-20251218-99958096.jpeg" alt="img-14.jpeg">
Fig. 3.8 Method of counting cells in a ruled area</p>
<p>Scanned by CamScanner</p>
<p>282 Haematology</p>
<p>Technique Prepare 1:200 dilution of the blood in the diluting fluid in a Thoma pipette or using Unopette system, as described earlier. Alternatively, add 0.02 ml of blood to 3.98 ml of diluting fluid.</p>
<p>Charge the improved Neubauer counting chamber carefully with the well mixed diluted blood. If Thoma pipette is used, remember to discard first 3-5 drops before charging the chamber. Allow the cells to settle in a moist chamber for 3 to 5 minutes.</p>
<p>Locate the ruled area of the counting chamber under <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>×</mo></mrow><annotation encoding="application/x-tex">10 \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mord">×</span></span></span></span></span> objective of the microscope. Check that the cells are evenly distributed.</p>
<p>Using <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>×</mo></mrow><annotation encoding="application/x-tex">40 \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mord">×</span></span></span></span></span> objective, count the total number of red cells in five groups of 16 small squares in the central ruled area (areas A, B, C, D and E in Fig. 3.5), which is equal to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">/</mi><mn>400</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">80/400 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80/400</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> i.e. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><msup><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">0.2 \mathrm{~mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">0.2</span><span class="mord"><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>Calculation Total red cell count/cu.mm</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.16em" columnalign="left" columnspacing="1em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mtext>Number&nbsp;of&nbsp;cell&nbsp;counted</mtext><mo>×</mo><mfrac><mn>1</mn><mtext>Area&nbsp;counted&nbsp;(mm)</mtext></mfrac></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>×</mo><mfrac><mn>1</mn><mtext>Depth&nbsp;(mm)</mtext></mfrac><mo>×</mo><mtext>Dilution</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mtext>Number&nbsp;of&nbsp;cells&nbsp;counted</mtext><mo>×</mo><mfrac><mn>1</mn><mn>0.2</mn></mfrac><mo>×</mo><mfrac><mn>1</mn><mn>0.1</mn></mfrac><mo>×</mo><mn>200</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mtext>Number&nbsp;of&nbsp;cells&nbsp;counted</mtext><mo>×</mo><mn>10</mn><mo separator="true">,</mo><mn>000</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{array}{l}
= \text{Number of cell counted} \times \frac{1}{\text{Area counted (mm)}} \\
\times \frac{1}{\text{Depth (mm)}} \times \text{Dilution} \\
= \text{Number of cells counted} \times \frac{1}{0.2} \times \frac{1}{0.1} \times 200 \\
= \text{Number of cells counted} \times 10,000 \\
\end{array}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 5.1353em; vertical-align: -2.3177em;"></span><span class="mord"><span class="mtable"><span class="arraycolsep" style="width: 0.5em;"></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.8177em;"><span style="top: -4.9726em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;cell&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Area&nbsp;counted&nbsp;(mm)</span></span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.52em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span><span style="top: -3.6074em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">×</span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Depth&nbsp;(mm)</span></span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.52em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">Dilution</span></span></span></span><span style="top: -2.2423em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;cells&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">0.2</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">0.1</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">200</span></span></span><span style="top: -1.0423em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;cells&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 2.3177em;"><span></span></span></span></span></span><span class="arraycolsep" style="width: 0.5em;"></span></span></span></span></span></span></span></div>
<p>Normal Range</p>
<p>Men: 4.5-5.9 million/cu.mm (4.5-5.9 × 10¹²/L)</p>
<p>Women: 4.1-5.1 million/cu.mm (4.1-5.1 × 10¹²/L)</p>
<p>At birth: 4.0 to 5.6 million/cu.mm (4.0-5.6 × 10¹²/L)</p>
<p><strong>Note</strong>: If the patient is very anaemic or if less than 400 cells have been counted, the dilution of blood should be decreased to 1/100 by filling the pipettes with blood to the 1.0 mark instead of the 0.5 mark.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hematocrit-or-packed-cell-volume-pcv">HEMATOCRIT OR PACKED CELL VOLUME (PCV)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hematocrit-or-packed-cell-volume-pcv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The PCV or Hematocrit is a percentage of the total volume of whole blood occupied by packed red blood cells, when a known volume of whole blood is centrifuged at a constant speed for a constant period of time. Value thus obtained is used in the determination of the red cell indices: mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC) and the mean corpuscular volume (MCV).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="93870cf0">1. Method Using Wintrobe’s Tube for PCV<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#93870cf0" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h4 level="4" id="apparatus">Apparatus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#apparatus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h4></div>
<ol>
<li>Wintrobe’s hematocrit/ESR tube (Fig. 3.9)</li>
<li>Centrifuge</li>
</ol>
<p><img src="assets/images/image-20251218-4134e2bf.jpeg" alt="img-15.jpeg">
Fig. 3.9 Wintrobe’s haematocrit/ESR tube with stand</p>
<p>Scanned by CamScanner</p>
<p>The Complete Blood Count (CBC) 283</p>
<p>Specimen Venous blood anticoagulated with EDTA, oxalate or heparin.</p>
<p>Technique With a long stemmed pasteur pipette fill the hematocrit tube up to the top mark, i.e., 100 mm, avoiding air bubbles. Centrifuge at 3000 r.p.m. for 30 minutes. The bottom of the tube thus contains packed red cells and on top it has a small buffy layer, consisting of the white blood cells and the platelets and a column of plasma above it. Without shaking the tube read the volume of packed red cells on the tube, expressed as a percentage of the whole blood. If the height of the blood column is not exactly 100 mm, a simple calculation can be made to correct this:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">%</mi><mo>=</mo><mfrac><mtext>Packed&nbsp;RBC&nbsp;column&nbsp;height</mtext><mtext>Total&nbsp;blood&nbsp;column&nbsp;height</mtext></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\mathrm{PCV}\% = \frac{\text{Packed RBC column height}}{\text{Total blood column height}} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">PCV</span></span><span class="mord">%</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Total&nbsp;blood&nbsp;column&nbsp;height</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Packed&nbsp;RBC&nbsp;column&nbsp;height</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-microhaematocrit-method">2. Microhaematocrit Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-microhaematocrit-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>For this method, instead of Wintrobe’s tubes, special non-graduated glass capillary tubes are used. These tubes are 7 cm in length and 1 mm in internal diameter. They can be purchased pre-coated internally with dried heparin for capillary blood. Plain capillaries (without heparin) can be used for anticoagulated blood specimen. (Plain capillary tubes may be coated with heparin by filling them with 1:1000 dilution of heparin and drying at 56°C).</p>
<p>Fill the capillary tube two-thirds full either with well mixed venous blood or directly from a capillary puncture. Seal one end of the capillary tube with modelling clay (plasticine). The filled tubes are then placed in the microhaematocrit centrifuge and spun at 12,000 g for 5 minutes. Place the spun tube into a specially designed scale, and read the PCV as a percentage. Alternatively, PCV can be calculated as for the Wintrobe’s method.</p>
<p><strong>Normal range</strong></p>
<p>Men: 40–52 % (0.4–0.52 L/L)</p>
<p>Women: 37–47 % (0.37–0.47 L/L)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="red-blood-cell-indices">RED BLOOD CELL INDICES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#red-blood-cell-indices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The purpose of determining the haematological indices is to corroborate and correlate the fundamental results obtained in the routine complete blood count, i.e., haematocrit, RBC count and haemoglobin determination. In this way, the types of anaemia may be objectively classified and red cell variation may be specifically studied.</p>
<p>As the results are dependent upon the accuracy of various estimations, the red cell count, which has the greatest potential for error, must be performed with care.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-the-mean-corpuscular-haemoglobin-mch">1. The Mean Corpuscular Haemoglobin (MCH)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-the-mean-corpuscular-haemoglobin-mch" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This indicates the weight of haemoglobin in a single red blood cell and is expressed in picograms (pg) (1 pg = 10⁻¹² g).</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">H</mi></mrow><mo>=</mo><mfrac><mrow><mtext>Haemoglobin&nbsp;(g&nbsp;per&nbsp;100&nbsp;ml)</mtext><mo>×</mo><mn>10</mn></mrow><mtext>RBC&nbsp;count&nbsp;million&nbsp;per&nbsp;cu.mm</mtext></mfrac></mrow><annotation encoding="application/x-tex">\mathrm{MCH} = \frac{\text{Haemoglobin (g per 100 ml)} \times 10}{\text{RBC count million per cu.mm}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">MCH</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.3074em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">RBC&nbsp;count&nbsp;million&nbsp;per&nbsp;cu.mm</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Haemoglobin&nbsp;(g&nbsp;per&nbsp;100&nbsp;ml)</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>or</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mtext>Haemoglobin&nbsp;(g/L)</mtext><mtext>RBC&nbsp;(10¹²/L)</mtext></mfrac></mrow><annotation encoding="application/x-tex">\frac{\text{Haemoglobin (g/L)}}{\text{RBC (10¹²/L)}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.363em; vertical-align: -0.936em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">RBC&nbsp;(10¹²/L)</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Haemoglobin&nbsp;(g/L)</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>Normal range is 27 to 32 pg. per cell</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-mean-corpuscular-haemoglobin-concentration-mchc">2. Mean Corpuscular Haemoglobin Concentration (MCHC)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-mean-corpuscular-haemoglobin-concentration-mchc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This denotes the haemoglobin concentration per 100 ml of packed red blood cells and is related to the colour of the red cells. This is expressed as percentage of packed cells.</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi></mrow><mo>=</mo><mfrac><mtext>Haemoglobin&nbsp;(g/dl)</mtext><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">%</mi></mrow></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\mathrm{MCHC} = \frac{\text{Haemoglobin (g/dl)}}{\mathrm{PCV}\%} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">MCHC</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.1686em; vertical-align: -0.7416em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">PCV</span></span><span class="mord">%</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Haemoglobin&nbsp;(g/dl)</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.7416em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p>or</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mtext>Haemoglobin&nbsp;(g/L)</mtext><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi><mo stretchy="false">(</mo><mi mathvariant="normal">L</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi><mo stretchy="false">)</mo></mrow><mo>×</mo><mn>10</mn></mrow></mfrac></mrow><annotation encoding="application/x-tex">\frac{\text{Haemoglobin (g/L)}}{\mathrm{PCV (L/L)} \times 10}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.363em; vertical-align: -0.936em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">PCV</span><span class="mopen">(</span><span class="mord mathrm">L/L</span><span class="mclose">)</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Haemoglobin&nbsp;(g/L)</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>The normal range is 32 to 36 %. A decreased MCHC indicates iron deficiency and macrocytic anaemia and increased MCHC usually indicates spherocytosis.</p>
<p>Scanned by CamScanner</p>
<p>284 Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-the-mean-corpuscular-volume-mcv">3. The Mean Corpuscular Volume (MCV)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-the-mean-corpuscular-volume-mcv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is expressed as the volume in cubic microns or femto litres of an average red blood cell.</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi></mrow><mo>=</mo><mfrac><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi></mrow><mi mathvariant="normal">%</mi><mo>×</mo><mn>10</mn></mrow><mtext>Red&nbsp;blood&nbsp;cells&nbsp;in&nbsp;millions&nbsp;per&nbsp;cu.&nbsp;mm</mtext></mfrac></mrow><annotation encoding="application/x-tex">\mathrm{MCV} = \frac{\mathrm{PCV}\% \times 10}{\text{Red blood cells in millions per cu. mm}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">MCV</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.3074em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Red&nbsp;blood&nbsp;cells&nbsp;in&nbsp;millions&nbsp;per&nbsp;cu.&nbsp;mm</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">PCV</span></span><span class="mord">%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>Or</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi></mrow><mrow><mo fence="true">(</mo><mi mathvariant="normal">L</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi><mo fence="true">)</mo></mrow><mo>×</mo><mn>1000</mn></mrow><mrow><mrow><mi mathvariant="normal">R</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">C</mi></mrow><mrow><mo fence="true">(</mo><msup><mn>10</mn><mn>12</mn></msup><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi><mo fence="true">)</mo></mrow></mrow></mfrac></mrow><annotation encoding="application/x-tex">\frac{\mathrm{PCV} \left( \mathrm{L}/\mathrm{L} \right) \times 1000}{\mathrm{RBC} \left( 10^{12}/\mathrm{L} \right)}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.363em; vertical-align: -0.936em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">RBC</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7401em;"><span style="top: -2.989em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathrm">L</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">PCV</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord mathrm">L</span><span class="mord">/</span><span class="mord mathrm">L</span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">1000</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p><strong>Normal Range</strong> 80–100 cubic microns (femto litres, fL).</p>
<p>MCV above 100 cubic microns indicates macrocytosis and below 80 cubic microns indicates microcytosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="erythrocyte-sedimentation-rate-esr">ERYTHROCYTE SEDIMENTATION RATE (ESR)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythrocyte-sedimentation-rate-esr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>ESR, though not a part of Complete Blood Count, is usually requested with it. The basic principle of the ESR is based on the fact that blood is essentially a suspension of formed elements such as red and white corpuscles in plasma. Therefore, when whole blood is mixed with an anticoagulant and placed in a perpendicular tube, the red blood cells sink to the bottom because they are heavier than the plasma in which they are suspended. The speed at which the red blood cells in normal blood settle is relatively slow. However, in many diseases, e.g., inflammatory or degenerative cell diseases, changes occur in physicochemical properties of plasma. These changes include alterations in the positive charges of the plasma colloids, increase in plasma fibrinogen, variation in the concentration of plasma protein fractions and in the ratio of the various plasma protein fractions to one another.</p>
<p>Changes may also occur in the erythrocyte surface. Change in the surface electric charge of the red blood cells causes the erythrocytes to aggregate, clump, or to form rouleaux. The large clumps of cells thus formed fall at a faster rate. The changes in the proportion of the soluble constituents of plasma such as increased fibrinogen or globulin also results in increased rate of erythrocyte fall.</p>
<p>Sequentially, there are 3 stages in erythrocyte sedimentation.</p>
<ol>
<li>The initial period of a few minutes, during which rouleaux formation occurs.</li>
<li>A period of approximately 30 to 100 minutes, depending on the tube length during which sedimentation occurs at a fairly constant rate.</li>
<li>A period of slower rate of fall during which packing of the sedimented red cell column occurs.</li>
</ol>
<p>For these reasons, the sedimentation rate must be set up within 2 to 6 hours of blood collection.</p>
<p>There are two main methods of performing the ESR, viz., Wintrobe’s and Westergren’s methods.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="be3001cf">1. Wintrobe’s Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#be3001cf" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="requirements">Requirements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#requirements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Wintrobe haematocrit tube</strong> This tube is 11 cms in length with an internal diameter of 2.5 mm. It is graduated from the bottom in mm divisions over a 10 cms scale (Fig. 3.9). When filled, the tube contains 0.7 ml of blood.</p>
<p><strong>Specimen</strong> 5 ml of venous blood after overnight fast is withdrawn and immediately mixed in a tube containing 6 mgs of dried ammonium oxalate and 4 mgs of dried potassium oxalate.</p>
<p><strong>Technique</strong> Using a pasteur pipette with a long stem, fill the haemocrit tube to the 10 mark with well mixed blood. Forming of air bubbles in the tube should be avoided. Fix the tube in the stand, ensuring that the tube is vertical. Take readings preferably at 15 minute intervals for one hour in order to get an indication of the sedimentation rate. Note the level of red cells from 0 at the top.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="normal-range">Normal range<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#normal-range" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>At the end of one hour</p>
<p>Men: 0 to 9 mm.</p>
<p>Women: 0 to 20 mm.</p>
<p>Scanned by CamScanner</p>
<p>The Complete Blood Count (CBC) 285</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-westergren-method">2. Westergren Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-westergren-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="requirements">Requirements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#requirements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li><strong>Westergren ESR tube</strong> This tube looks similar to a one ml pipette. It is 300 mm long with an internal diameter of 2.5 mm. It is graduated from the base over a 200 mm scale in mm divisions. (Fig 3.10)</li>
</ol>
<p><img src="assets/images/image-20251218-d16e63aa.jpeg" alt="img-16.jpeg">
Fig. 3.10 Westergren's ESR pipette with stand</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-sodium-citrate-3-8-w-v">2. Sodium citrate 3.8 % (W/V)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-sodium-citrate-3-8-w-v" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Specimen</strong> Add 0.5 ml of 3.8 % sodium citrate in a small test tube. Collect 2 ml of venous blood after overnight fasting and mix with the sodium citrate.</p>
<p><strong>Technique</strong> Aspirate the blood into the Westergren tube to the top mark (0). The tube is then stood vertically in a stop rack with spring clips that hold the lower end of the pipette tightly against a rubber mat in a vertical position. Leave for one hour. Note the readings as for Wintrobe’s method.</p>
<p><strong>Normal Range</strong> At the end of one hour.
Men: 3 to 5 mm
Women: 4 to 7 mm</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="97019132">♦ WHITE CELL COUNT (TOTAL, TLC) (MANUAL METHOD)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#97019132" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Principle</strong> Whole blood is diluted appropriately using a diluent which haemolyses red cells, leaving all the nucleated cells intact. The number of white cells in a known volume and known dilution are counted using a counting chamber.</p>
<p><strong>Diluting fluid</strong> Acetic acid, 2 % (v/v), tinged with gentian violet.</p>
<p><strong>Specimen</strong> Whole blood, anticoagulated with EDTA. Capillary blood can be used if it is diluted immediately after collection.</p>
<p><strong>Technique</strong> Prepare 1:20 dilution of the blood in the diluting fluid in a Thoma pipette or using Unopette system, as described earlier.</p>
<p>Alternatively, add 0.02 ml of blood to 0.38 ml of diluting fluid.</p>
<p>Charge the improved Neubauer counting chamber with the well-mixed diluted blood. Thoma pipette is used, remember to discard first 3–5 drops before charging the chamber.</p>
<p>Allow the cells to settle in a moist chamber for 3–5 minutes.</p>
<p>Using 10 × objective of the microscope, locate the four large corner squares (areas 1, 2, 3 and 4 in Fig. 3.5). The area of these squares is 4 mm². Check that the cells are evenly distributed.</p>
<p>Count the total number of white cells in the four large corner squares in the same pattern as described for the red cell count (Fig. 3.8).</p>
<p>Scanned by CamScanner</p>
<p>286 Haematology</p>
<p><strong>Calculation</strong> Total white cell count/cu.mm (or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi></mrow><annotation encoding="application/x-tex">\mu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">μ</span></span></span></span></span>l)</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mi>a</mi><mi>m</mi><mi>p</mi><mo separator="true">;</mo><mo>=</mo><mtext>Number&nbsp;of&nbsp;cells&nbsp;counted</mtext><mo>×</mo><mfrac><mn>1</mn><mrow><msup><mtext>area&nbsp;counted&nbsp;(mm</mtext><mn>2</mn></msup><mtext>)</mtext></mrow></mfrac></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mi>a</mi><mi>m</mi><mi>p</mi><mo separator="true">;</mo><mspace width="1em"></mspace><mo>×</mo><mfrac><mn>1</mn><mtext>depth&nbsp;(mm)</mtext></mfrac><mo>×</mo><mtext>dilution</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mi>a</mi><mi>m</mi><mi>p</mi><mo separator="true">;</mo><mo>=</mo><mtext>Number&nbsp;of&nbsp;cells&nbsp;counted</mtext><mo>×</mo><mfrac><mn>1</mn><mn>4</mn></mfrac><mo>×</mo><mfrac><mn>1</mn><mn>0.1</mn></mfrac><mo>×</mo><mn>20</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mi>a</mi><mi>m</mi><mi>p</mi><mo separator="true">;</mo><mo>=</mo><mtext>Number&nbsp;of&nbsp;cells&nbsp;counted</mtext><mo>×</mo><mn>50</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned}
&amp;amp; = \text{Number of cells counted} \times \frac{1}{\text{area counted (mm}^2\text{)}} \\
&amp;amp; \quad \times \frac{1}{\text{depth (mm)}} \times \text{dilution} \\
&amp;amp; = \text{Number of cells counted} \times \frac{1}{4} \times \frac{1}{0.1} \times 20 \\
&amp;amp; = \text{Number of cells counted} \times 50
\end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 9.0803em; vertical-align: -4.2902em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 4.7902em;"><span style="top: -6.7902em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"></span></span><span style="top: -4.0747em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"></span></span><span style="top: -1.5173em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"></span></span><span style="top: 0.3087em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 4.2902em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 4.7902em;"><span style="top: -6.7902em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"><span class="mord"></span><span class="mord mathnormal">am</span><span class="mord mathnormal">p</span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;cells&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.156em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord text"><span class="mord">area&nbsp;counted&nbsp;(mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.954em;"><span style="top: -3.2029em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span><span class="mord text"><span class="mord">)</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.094em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span><span style="top: -4.0747em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"><span class="mord"></span><span class="mord mathnormal">am</span><span class="mord mathnormal">p</span><span class="mpunct">;</span><span class="mspace" style="margin-right: 1em;"></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">×</span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">depth&nbsp;(mm)</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">dilution</span></span></span></span><span style="top: -1.5173em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"><span class="mord"></span><span class="mord mathnormal">am</span><span class="mord mathnormal">p</span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;cells&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">4</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">0.1</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">20</span></span></span><span style="top: 0.3087em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"><span class="mord"></span><span class="mord mathnormal">am</span><span class="mord mathnormal">p</span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;cells&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">50</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 4.2902em;"><span></span></span></span></span></span></span></span></span></span></span></span></div>
<p><strong>Normal range</strong></p>
<p>Adults: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo separator="true">,</mo><mn>500</mn><mo>−</mo><mn>11</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">/</mi><mtext>cu.mm&nbsp;</mtext><mo stretchy="false">(</mo><mn>4.5</mn><mo>−</mo><mn>11.0</mn><mo>×</mo><msup><mn>10</mn><mn>9</mn></msup><mi mathvariant="normal">/</mi><mtext>L</mtext><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">4,500 - 11,000/\text{cu.mm} \ (4.5 - 11.0 \times 10^9/\text{L})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">500</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000/</span><span class="mord text"><span class="mord">cu.mm</span></span><span class="mspace">&nbsp;</span><span class="mopen">(</span><span class="mord">4.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">11.0</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">9</span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord text"><span class="mord">L</span></span><span class="mclose">)</span></span></span></span></span></p>
<p>Neonates: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo separator="true">,</mo><mn>000</mn><mo>−</mo><mn>25</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">/</mi><mtext>cu.mm&nbsp;</mtext><mo stretchy="false">(</mo><mn>10.0</mn><mo>−</mo><mn>25.0</mn><mo>×</mo><msup><mn>10</mn><mn>9</mn></msup><mi mathvariant="normal">/</mi><mtext>L</mtext><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">10,000 - 25,000/\text{cu.mm} \ (10.0 - 25.0 \times 10^9/\text{L})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000/</span><span class="mord text"><span class="mord">cu.mm</span></span><span class="mspace">&nbsp;</span><span class="mopen">(</span><span class="mord">10.0</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25.0</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">9</span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord text"><span class="mord">L</span></span><span class="mclose">)</span></span></span></span></span></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="total-eosinophil-count-tec">TOTAL EOSINOPHIL COUNT (TEC)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#total-eosinophil-count-tec" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> Whole blood is diluted appropriately using a diluent which lyses the red cells and stains granules in the eosinophils, but does not stain the other leucocytes. The total number of eosinophils in a known volume of known dilution are counted using a counting chamber.</p>
<p><strong>Diluting fluid</strong></p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> Aqueous eosin Y 5 ml
Acetone 5 ml
Distilled water 90 ml</p>
<p><strong>Specimen</strong> Whole blood, anticoagulated with EDTA. Capillary blood can be used if it is diluted immediately after collection.</p>
<p><strong>Technique</strong></p>
<p>Prepare 1:20 dilution of the blood in the diluting fluid in the Thoma pipette.</p>
<p>Alternatively, add <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.02</mn><mtext>&nbsp;ml</mtext></mrow><annotation encoding="application/x-tex">0.02\ \text{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">0.02</span><span class="mspace">&nbsp;</span><span class="mord text"><span class="mord">ml</span></span></span></span></span></span> of blood to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.38</mn><mtext>&nbsp;ml</mtext></mrow><annotation encoding="application/x-tex">0.38\ \text{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">0.38</span><span class="mspace">&nbsp;</span><span class="mord text"><span class="mord">ml</span></span></span></span></span></span> of the diluting fluid. Charge the improved Neubauer counting chamber with the well mixed diluted blood. If Thoma pipette is used, discard first few drops before charging the chamber.</p>
<p>Allow the cells to settle in a moist chamber for 3 to 5 minutes.</p>
<p>Locate the ruled area of the counting chamber under <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>×</mo></mrow><annotation encoding="application/x-tex">10 \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mord">×</span></span></span></span></span> objective.</p>
<p>Identify the eosinophils by their bright red stained granules. Count the number of eosinophils in the four large corner squares (<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mtext>&nbsp;</mtext><msup><mtext>mm</mtext><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">4\ \text{mm}^2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">4</span><span class="mspace">&nbsp;</span><span class="mord"><span class="mord text"><span class="mord">mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span>) under <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>×</mo></mrow><annotation encoding="application/x-tex">50 \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mord">×</span></span></span></span></span> objective.</p>
<p><strong>Calculation</strong></p>
<p>Total eosinophil count./cu.mm (or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi></mrow><annotation encoding="application/x-tex">\mu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">μ</span></span></span></span></span>l)</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mi>a</mi><mi>m</mi><mi>p</mi><mo separator="true">;</mo><mo>=</mo><mtext>Number&nbsp;of&nbsp;eosinophils&nbsp;counted</mtext><mo>×</mo><mfrac><mn>1</mn><mrow><msup><mtext>area&nbsp;counted&nbsp;(mm</mtext><mn>2</mn></msup><mtext>)</mtext></mrow></mfrac><mo>×</mo><mfrac><mn>1</mn><mtext>depth&nbsp;(mm)</mtext></mfrac><mo>×</mo><mtext>dilution</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mi>a</mi><mi>m</mi><mi>p</mi><mo separator="true">;</mo><mo>=</mo><mtext>Number&nbsp;of&nbsp;eosinophil&nbsp;counted</mtext><mo>×</mo><mfrac><mn>1</mn><mn>4</mn></mfrac><mo>×</mo><mfrac><mn>1</mn><mn>0.1</mn></mfrac><mo>×</mo><mn>20</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mi>a</mi><mi>m</mi><mi>p</mi><mo separator="true">;</mo><mo>=</mo><mtext>Number&nbsp;of&nbsp;eosinophils&nbsp;counted</mtext><mo>×</mo><mn>50</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned}
&amp;amp; = \text{Number of eosinophils counted} \times \frac{1}{\text{area counted (mm}^2\text{)}} \times \frac{1}{\text{depth (mm)}} \times \text{dilution} \\
&amp;amp; = \text{Number of eosinophil counted} \times \frac{1}{4} \times \frac{1}{0.1} \times 20 \\
&amp;amp; = \text{Number of eosinophils counted} \times 50
\end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 6.5229em; vertical-align: -3.0114em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 3.5114em;"><span style="top: -5.5114em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"></span></span><span style="top: -2.796em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"></span></span><span style="top: -0.97em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 3.0114em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 3.5114em;"><span style="top: -5.5114em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"><span class="mord"></span><span class="mord mathnormal">am</span><span class="mord mathnormal">p</span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;eosinophils&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.156em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord text"><span class="mord">area&nbsp;counted&nbsp;(mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.954em;"><span style="top: -3.2029em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span><span class="mord text"><span class="mord">)</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.094em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">depth&nbsp;(mm)</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">dilution</span></span></span></span><span style="top: -2.796em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"><span class="mord"></span><span class="mord mathnormal">am</span><span class="mord mathnormal">p</span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;eosinophil&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">4</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">0.1</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">20</span></span></span><span style="top: -0.97em;"><span class="pstrut" style="height: 3.3214em;"></span><span class="mord"><span class="mord"></span><span class="mord mathnormal">am</span><span class="mord mathnormal">p</span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;eosinophils&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">50</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 3.0114em;"><span></span></span></span></span></span></span></span></span></span></span></span></div>
<p><strong>Normal range</strong> Adults: 50–450 cu.mm (0.05 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.45</mn><mo>×</mo><msup><mn>10</mn><mn>9</mn></msup><mi mathvariant="normal">/</mi><mtext>L</mtext></mrow><annotation encoding="application/x-tex">0.45 \times 10^9/\text{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.45</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">9</span></span></span></span></span></span></span></span><span class="mord">/</span><span class="mord text"><span class="mord">L</span></span></span></span></span></span>)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="platelet-count-manual-method">PLATELET COUNT (Manual Method)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#platelet-count-manual-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> Platelets are difficult to count because</p>
<ol>
<li>They agglutinate, fragment and break down readily and quickly.</li>
<li>Because of their small size they are hard to differentiate from debris.</li>
<li>They adhere to glass.</li>
<li>Platelets are not evenly distributed throughout the blood and have a tendency to clump together.</li>
</ol>
<p>The diluent used haemolyses the red cells leaving the white cells and the platelets intact.</p>
<p>Blood specimen is collected taking care that the platelets do not clump. Whole blood is diluted appropriately using a diluent which haemolyses red cells. The platelets are then counted in a counting chamber.</p>
<p><strong>Specimen</strong> Venous blood should be collected in a tube containing EDTA as an anti-coagulant (<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mtext>&nbsp;mg/ml</mtext></mrow><annotation encoding="application/x-tex">2\ \text{mg/ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mspace">&nbsp;</span><span class="mord text"><span class="mord">mg/ml</span></span></span></span></span></span> of blood). The EDTA also prevents clumping of platelets. Blood collected by finger prick should not be used because platelets are probably lost at the site of skin puncture.</p>
<p>Scanned by CamScanner</p>
<p>The Complete Blood Count (CBC) 287</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diluting-fluids">Diluting fluids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diluting-fluids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Formal citrate fluid: Prepare 31.3 g per litre solution of trisodium citrate. Add 1 ml of formalin to 99 ml of the citrate solution.</li>
<li>Ammonium oxalate: 10 g per litre (1 %). Prepare freshly just before use.</li>
</ol>
<p><strong>Technique</strong> Prepare 1:200 dilution of the blood using the diluting fluid in a Thoma pipette. Alternatively, add 0.02ml of blood to 3.98ml of diluting fluid. Charge the improved Neubauer counting chamber with the well mixed diluted blood. Allow the platelets to settle in a moist chamber for 3 to 5 minutes.</p>
<p>Locate the ruled area of the counting chamber under 10 × objective. Reduce the illumination by closing the iris diaphragm. Platelets appear as highly refractile particles. A phase contrast microscope is more useful for platelet count.</p>
<p>Count the total number of platelets using a high power (40 ×) objective in the four large corner squares (4 mm²).</p>
<p><strong>Calculation</strong> Total number of platelets/cu.mm (or μl)</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.16em" columnalign="left" columnspacing="1em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mtext>Number&nbsp;of&nbsp;platelets&nbsp;counted</mtext><mo>×</mo><mfrac><mn>1</mn><mrow><msup><mtext>area&nbsp;counted&nbsp;(mm</mtext><mn>2</mn></msup><mtext>)</mtext></mrow></mfrac><mo>×</mo><mfrac><mn>1</mn><mtext>depth&nbsp;(mm)</mtext></mfrac><mo>×</mo><mtext>dilution</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mtext>Number&nbsp;of&nbsp;platelets&nbsp;counted</mtext><mo>×</mo><mfrac><mn>1</mn><mn>4</mn></mfrac><mo>×</mo><mfrac><mn>1</mn><mn>0.1</mn></mfrac><mo>×</mo><mn>200</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mtext>Number&nbsp;of&nbsp;platelets&nbsp;counted</mtext><mo>×</mo><mn>500</mn></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{array}{l}
= \text{Number of platelets counted} \times \frac{1}{\text{area counted (mm}^2\text{)}} \times \frac{1}{\text{depth (mm)}} \times \text{dilution} \\
= \text{Number of platelets counted} \times \frac{1}{4} \times \frac{1}{0.1} \times 200 \\
= \text{Number of platelets counted} \times 500 \\
\end{array}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3.8354em; vertical-align: -1.6677em;"></span><span class="mord"><span class="mtable"><span class="arraycolsep" style="width: 0.5em;"></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.1677em;"><span style="top: -4.3226em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;platelets&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.5898em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">area&nbsp;counted&nbsp;(mm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8575em;"><span style="top: -2.8971em; margin-right: 0.0714em;"><span class="pstrut" style="height: 2.5em;"></span><span class="sizing reset-size3 size1 mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span><span class="mord text mtight"><span class="mord mtight">)</span></span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.5852em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">depth&nbsp;(mm)</span></span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.52em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">dilution</span></span></span></span><span style="top: -2.8923em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;platelets&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">0.1</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">200</span></span></span><span style="top: -1.6923em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;platelets&nbsp;counted</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">500</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.6677em;"><span></span></span></span></span></span><span class="arraycolsep" style="width: 0.5em;"></span></span></span></span></span></span></span></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="normal-range">Normal Range<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#normal-range" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>150,000 to 400,000 cu.mm (150 – 400 × 10⁹/L)
Table 3.1 shows normal values for CBC.</p>
<p>Table 3.1 Normal values for CBC</p>
<table><thead><tr><th>Normal values</th><th>Men</th><th>Women</th></tr></thead><tbody><tr><td>White cell count × 10⁹/L</td><td>4.5–11</td><td>4.5–11</td></tr><tr><td>Red cell count × 10¹²/L</td><td>4.9–5.9</td><td>4.1–5.1</td></tr><tr><td>Haemoglobin g/L</td><td>130–180</td><td>120–160</td></tr><tr><td>Packed cell volume (haematocrit L/L)</td><td>0.40–0.52</td><td>0.37–0.47</td></tr><tr><td>Mean cell volume (MCV) fl/cell</td><td>80–100</td><td>80–100</td></tr><tr><td>Mean cell haemoglobin (MCH) pg/cell</td><td>27–32</td><td>27–32</td></tr><tr><td>Mean cell haemoglobin concentration (MCHC)%</td><td>32–36</td><td>32–36</td></tr><tr><td>Platelet count × Reticulocytes 10⁹/L</td><td>150–400</td><td>150–400</td></tr><tr><td>Erythrocyte sedimentation rate mm/hr (Wintrobe)</td><td>&lt; 10</td><td>&lt; 20</td></tr><tr><td>(Westergren)</td><td>3–5</td><td>4–7</td></tr><tr><td>Reticulocytes %</td><td>0.2–2.0</td><td>0.2–2.0</td></tr><tr><td>10⁹/L</td><td>20–100</td><td>20–100</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Chapter 4</p>
<p><img src="assets/images/image-20251218-6b531bed.jpeg" alt="img-17.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="examination-of-peripheral-blood-smear">Examination of Peripheral Blood Smear<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#examination-of-peripheral-blood-smear" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Microscopic examination of the peripheral blood is performed by preparing, staining and examining a thin film of blood. It provides valuable information on the status of blood cells and presence of parasitic elements. The blood film is the only permanent record of haematological investigations. Therefore, a well-made, well-stained smear is essential. It is a common practice to prepare at least two blood films from each specimen, one stained, and the other kept in reserve, to be stained if and when necessary.</p>
<p>Capillary blood is ideal for preparing a blood smear. A drop of blood is transferred to a slide or touch the slide to the site of fingerprick during blood flow. If venous blood is used, EDTA is the anticoagulant of choice because it retains the morphological features of blood cells and also prevents clumping of platelets.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparation-of-blood-smear">PREPARATION OF BLOOD SMEAR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparation-of-blood-smear" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>For the correct interpretation of a blood film, the film must be prepared in a technically correct manner so that the cells are evenly distributed throughout the smear. An ideal blood film</p>
<ol>
<li>
<p>should be smooth and not interrupted by ridges and holes.</p>
</li>
<li>
<p>it should cover 1/2 to 3/4th of the area of the slide.</p>
</li>
<li>
<p>it should be thickest at the origin or the 'head' (thick end), and gradually thin out forming a 'tail' (feather edge) without a defined border at the end. (Fig. 4.1)</p>
</li>
</ol>
<p><img src="assets/images/image-20251218-7ca69925.jpeg" alt="img-18.jpeg">
Fig. 4.1 Preparation of a blood film</p>
<p>Preparation of a good blood smear is learnt by practice. The thickness and the length of the film will depend on the angle of the spreader, the size of the drop of blood and the speed at which the spreader is pushed forward.</p>
<p>It is essential to use a clean slide. A glass slide cleaned with alcohol and wiped dry gives the best results. A spreader, e.g. a margin-free slide with ground glass edges, should be used to make the film.</p>
<p>Scanned by CamScanner</p>
<p>Examination of Peripheral Blood Smear 289</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Place a small drop of EDTA anticoagulated blood, about 2 mm in diameter, about 1 cm from one end of the slide. If blood is collected from a finger-prick, wipe away the first drop and place the second drop of blood on the slide by touching it with the slide.</p>
<p>Place the slide on a flat surface. Hold it down firmly at the opposite end with the thumb and the forefinger.</p>
<p>Quickly, place the spreader just in front of the drop of blood at 45° angle. Draw it back slightly to touch the drop of blood and to allow the blood to spread along the contact line. Push the spreader forward smoothly and rapidly, maintaining the contact between the slide and the spreader (Fig. 4.1).</p>
<p>The smear formed should be about 3–4 cm long, slightly thicker at the base or head and thin at the tail end without ragged tails. If the patient is anaemic, the spreader should be held more erect (at 60°), and blood spread more quickly to obtain a thicker smear. Even distribution of cells in the smear plays an important role in obtaining accurate results. Allow the smear to dry in air. Label the slide with patient’s identification at the thick end with a lead pencil.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="staining-the-blood-smear">STAINING THE BLOOD SMEAR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staining-the-blood-smear" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>After preparation, the blood smear should be stained as soon as possible, otherwise it should be fixed by dipping in methanol for 1–2 seconds, air-dried and stored until it is ready to be stained.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="romanowsky-stains">Romanowsky Stains<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#romanowsky-stains" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Affinity of a cell or its constituents for a particular stain depends on its chemical nature and the pH of the medium. In an appropriate pH (e.g. 6.8) the acidic structures take up basic dyes (which are therefore, called basophilic) and the basic structures stain with acidic dyes (therefore, called acidophilic). The Romanowsky stains contain methylene blue (a basic dye), eosin (an acidic dye) and polychrome methylene blue or methylene azure. Using this stain, the acidic cell components such as nuclear DNA and cytoplasmic RNA are stained bluish purple with polychrome methylene blue, while basic components such as haemoglobin and granules in eosinophils are stained orange to pink with eosin. Various types of Romanowsky stain which are in common use are Wright, Leishman or Giemsa stains.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-leishman-stain">1. Leishman Stain<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-leishman-stain" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Preparation Solution 1</strong></p>
<table><thead><tr><th>Methylene blue</th><th>1 g</th></tr></thead><tbody><tr><td>Sodium carbonate</td><td></td></tr><tr><td>(0.5 % aqueous solution)</td><td>100 ml.</td></tr><tr><td>Eosin (0.1 % aqueous solution)</td><td>100 ml.</td></tr><tr><td>Methyl alcohol</td><td>100 ml</td></tr></tbody></table>
<p>Dissolve methylene blue in the sodium carbonate solution. Heat at 65°C for 12 hours, cool and allow the mixture to stand for 10 days. Add equal volume (100 ml) of eosin solution, mix well and allow to stand for 6 to 12 hours. Filter and collect the precipitate. Wash the precipitate with several changes of distilled water until no more colour is extracted. Dry the precipitate at 37°C. Grind to powder in a mortar.</p>
<p>Weigh 0.15 g of the powder and grind it in a mortar with methyl alcohol. Pour off the supernatant into a volumetric flask and add more methanol until all the powder is dissolved. Make up the volume up to 100 ml with methanol. Store in a dark tightly stoppered bottle and allow to stand for 24 hours before use.</p>
<p>&gt; <strong>Note:</strong> The Leishman stain is also commercially available in powder and liquid forms.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="solution-2-buffer-solution-ph-6-8">Solution 2 Buffer solution (pH 6.8)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#solution-2-buffer-solution-ph-6-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Disodium hydrogen phosphate (anhydrous) M/15 solution: Dissolve 9.47 g of the powder per litre of distilled water.</p>
<p>(b) Potassium di-hydrogen phosphate (anhydrous) M/15 solution. Dissolve 9.08 g per litre of distilled water.</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p>To prepare the buffer, mix 49.6 ml of solution (a) and 50.4 ml of solution (b). Check the pH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="staining-technique">Staining technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staining-technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Prepare a thin smear as described earlier. Dry the smear in air.
(ii) Cover the smear completely with Leishman stain.
(iii) Stain for 1 to 2 minutes.
(iv) Dilute the stain with twice its volume of the buffer solution. The slide will almost be completely flooded.
(v) Stain for 10 minutes.
(vi) Wash the slide with the buffer solution. Use tap water if not too acidic or alkaline.
(viii) Drain and dry in air by keeping it in a slanting position.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-giemsa-stain">2. Giemsa stain<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-giemsa-stain" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="solution-1">Solution 1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#solution-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<table><thead><tr><th>Azure II eosin</th><th>3 g</th></tr></thead><tbody><tr><td>Azur II</td><td>0.8 g</td></tr><tr><td>Glycerol</td><td>200 ml</td></tr><tr><td>Methyl alcohol</td><td>300 ml</td></tr></tbody></table>
<p>Grind the two dyes together in a mortar. Mix the alcohol with glycerol in a 1 litre flask. Sprinkle the ground dye carefully over the surface of the alcohol-glycerol mixture and allow it to stand for 24 hours. Stir the mixture at intervals after 24 hours to ensure that all the dye is passed into solution. Store in a tightly stoppered dark bottle.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="solution-2">Solution 2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#solution-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Buffer solution pH 7.0</p>
<p>M/15 disodium hydrogen phosphate (9.47 g per litre) 61.1 ml.</p>
<p>M/15 potassium dihydrogen phosphate (9.08 g per litre) 38.9 ml.</p>
<p>Mix the two solutions</p>
<p>Check the pH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="staining-technique">Staining technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staining-technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Prepare a thin blood film, dry in air and fix in methyl alcohol for 3 minutes.
(ii) Dilute one volume of solution 1 with nine volumes of solution 2.
(iii) Flood the slide with the stain and allow to act for 10-15 minutes.
(iv) Wash and differentiate with the buffer solution.</p>
<p>(v) Drain, dry in air and examine microscopically.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="microscopic-examination-of-the-blood-film">MICROSCOPIC EXAMINATION OF THE BLOOD FILM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#microscopic-examination-of-the-blood-film" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If the blood film has been properly stained, it should appear light purple to the naked eye. A thorough examination of the blood smear should include the following steps:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="67e4e4fd">A. Examination of the Blood Smear Under the Low Power (10×) Objective<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#67e4e4fd" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The purpose of this examination is</p>
<ul>
<li>To evaluate the quality of the blood film.</li>
<li>To estimate roughly the red cell and the white cell counts.</li>
</ul>
<ol>
<li>Evaluation of the quality of the blood film A good quality blood smear should show evenly distributed red and white blood cells. Although the smear will appear thick at the origin, the latter part of the smear should show the cells spread evenly without clumping or overlapping each other. The white cells should not accumulate along the sides or at the tail end. The low power scanning is helpful in selecting the 'counting area' where the cells are clearly separated and well distributed (Fig 4.2).</li>
</ol>
<p><img src="assets/images/image-20251218-542037af.jpeg" alt="img-19.jpeg">
Fig. 4.2 Counting areas of a blood film and pathway for differential count</p>
<ol start="2">
<li>Rough estimation of cell counts Under the low power (10×) objective, the RBCs appear as small, round, reddish orange bodies and are the major cell type. Scattered among the RBCs are the white cells. The white cells are nucleated and their</li>
</ol>
<p>Scanned by CamScanner</p>
<p>Examination of Peripheral Blood Smear 291</p>
<p>nuclei stain in shades of purple and the cytoplasm stain in different colours, depending on the type of cell. In an area where the cells are evenly spread in a single layer, 5 white blood cells in a low power field are roughly equal to 1000 red cells/cu.mm (1 × 10⁹ cells/L). At least five low power fields should be counted to average the estimate of white cell count.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="6658bf94">B. Examination of the Blood Film Under Oil Immersion (100 × )Lens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6658bf94" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It should include:</p>
<ol>
<li>(a) The differential count of leucocytes.
(b) Detection of abnormalities in leucocytes.</li>
<li>Morphological alterations in red blood cells.</li>
<li>Evaluation of platelet count and morphology.</li>
<li>Detection of blood parasites.</li>
</ol>
<p>These are described in detail in the following sections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="aff39670">◆ THE DIFFERENTIAL COUNT OF LEUCOCYTES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aff39670" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The differential count means identification and counting of various types of white blood cells and expressing the number of each type per 100 white cells. For this purpose at least 100, preferably 200, white cells should be counted continuously and the number of each category of white cells should be noted.</p>
<p>There are five types of white cells observed in a normal peripheral blood smear (Fig. 4.3). For identification, they can be grouped into two broad categories;</p>
<ol>
<li>Granulocytes which include neutrophils, eosinophils and basophils. Depending on the staining reaction of the granules.</li>
<li>Agranulocytes are lymphocytes and monocytes. Monocytes do contain granules in their cytoplasm, but they are very fine and may not be obvious.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-granulocytes">1. Granulocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-granulocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Neutrophils (Polymorphonuclear neutrophil or PMN): This is the most numerous white cell type in the normal blood smear. The cell measures 10–14 microns and contains a lobular nucleus, which is an elongated nucleus constricted at one to four places, forming lobes connected by thin strands of chromatin. The nuclear chromatin stains</p>
<p><img src="assets/images/image-20251218-fadefef4.jpeg" alt="img-20.jpeg">
Fig. 4.3 Cells in peripheral blood</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p>deep reddish purple. Nucleoli are absent. The cytoplasm is abundant, light pink in colour, and contains a large number of fine neutrophilic granules which are also light pink in colour. A few darker azurophilic granules may be present. The normal range of neutrophils is 40–72 % (1800–7800/μl).</p>
<p>A normal blood smear may contain a few (up to 3 %) band cells which are neutrophils in a slightly premature stage in which the band shaped long nucleus is not yet divided into lobes.</p>
<p><strong>Function of neutrophils</strong> Neutrophils capture and destroy invading organisms and other foreign toxic materials as soon as they enter the body. They show amoeboid motility. They migrate into the tissues via the bloodstream, and are attracted to the organisms by a process called chemotaxis. The organisms and other materials are then removed from the blood or tissue by phagocytosis.</p>
<p>The organisms and other foreign bodies are phagocytosed (engulfed) and removed from the blood and tissue. This action is shown as phagocytosis.</p>
<p><strong>Eosinophils</strong> These cells contain granules which have affinity for the acidic dye, eosin, in the Romanowsky stains. The eosinophils are slightly larger than the neutrophils. They usually contain a bilobed nucleus in a typical "spectacle arrangement". Nucleoli are absent. The cytoplasm is not clearly visible as it is filled with large, distinct acidophilic granules, stained orange red with eosin. The percentage of eosinophils in normal blood is 1–6 % (50–450/μl).</p>
<p><strong>Functions of eosinophils</strong> Eosinophils have a phagocytic function which is aimed mainly at antigen-antibody complexes. They also counteract the effect of histamine and help in wound repair.</p>
<p><strong>Basophils</strong> The polymorphonuclear basophil is slightly smaller than the neutrophil, the average diameter being 10 microns. The nucleus may have two or more lobes and stains deep purple blue. Sometimes the segmentation of the nucleus is incomplete. The cytoplasm is slightly basophilic and contains large granules which stain purple or black due to their strongly basophilic nature. The nucleus may be obscured by the granules. The normal range is 0–0.5 % (0–200/μl).</p>
<p><strong>Functions of basophils</strong> The basophilic granules contain heparin and histamine. Basophils gather around inflammatory lesions and release histamine. They are less phagocytic in function than the other granulocytes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-agranulocytes">2. Agranulocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-agranulocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Monocytes</strong> Monocytes are the largest of the normal leucocytes in peripheral blood, measuring 16–20 microns in diameter. The nucleus is fairly large, oval or lobular, but most frequently, kidney shaped. The nucleus stains unevenly giving it a stringy appearance. The cytoplasm is abundant and stains greyish-blue due to its mildly basophilic nature. A few extremely fine azurophilic granules called 'azure dust' may be seen in the cytoplasm. Vacuoles may also be seen. Normal blood contains 2–8 % monocytes (100–800/μl).</p>
<p><strong>Functions of monocytes</strong> The monocytes are phagocytic in function and are capable of ingesting a large number of bacteria.</p>
<p><strong>Lymphocytes</strong> Lymphocytes in the peripheral blood appear in two forms, small lymphocytes (7–10 microns) and large lymphocytes (12–15 microns).</p>
<p>The small lymphocyte, being the more mature form, is more frequently seen in adult blood. The nucleus is usually round with condensed chromatin and stains deep purple. Nucleoli are generally not seen. The cytoplasm appears as a dark blue band around the nucleus and azure dust is usually absent.</p>
<p>The large lymphocyte has a slightly larger nucleus and more abundant cytoplasm. The nucleus stains lightly as compared to that of the small lymphocyte. The cytoplasm is pale blue in colour. The lymphocyte count of normal blood may range between 20–45 % (1000–4500/μl).</p>
<p><strong>Functions of lymphocytes</strong> There are two subpopulations of lymphocytes, T-cells and B-cells, which are morphologically indistinguishable in the peripheral blood smear. Other special tests using different markers are necessary for their identification.</p>
<p>Both T and B lymphocytes are immunocompetant cells which act to direct and effect the</p>
<p>Scanned by CamScanner</p>
<p>Examination of Peripheral Blood Smear 293</p>
<p>immune defense system of the body. The cells migrate to various sites in the body to await antigenic stimulus. When activated, they respond to antigenic challenges. B-lymphocytes produce antibodies whereas T-lymphocytes are responsible for the cell mediated immunity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reporting-the-differential-leucocyte-count">Reporting the Differential Leucocyte Count<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reporting-the-differential-leucocyte-count" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After counting 100 white cells, the number of cells belonging to each of the above five categories should be reported as the percentage of that type of cell.</p>
<table><thead><tr><th>Differential count</th><th>Normal Range</th><th></th></tr></thead><tbody><tr><td>Neutrophils</td><td>40–72 %</td><td>(1800–7800/μl)</td></tr><tr><td>Eosinophils</td><td>1–6 %</td><td>(50–450/μl)</td></tr><tr><td>Basophils</td><td>0–0.5 %</td><td>(0–200/μl)</td></tr><tr><td>Lymphocytes</td><td>20–45 %</td><td>(1000–4500/μl)</td></tr><tr><td>Monocytes</td><td>2–8 %</td><td>(100–800/μl)</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-of-the-variations-abnormalities-in-leucocytes">INTERPRETATION OF THE VARIATIONS/ABNORMALITIES IN LEUCOCYTES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-of-the-variations-abnormalities-in-leucocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-quantitative-changes">A. Quantitative Changes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-quantitative-changes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Neutrophil leucocytosis</strong> This denotes an increase in the number of neutrophils and is also called neutrophilia. Neutrophilia is seen in acute infections, toxic conditions, acute haemorrhage, postoperative conditions, malignancies, etc. In severe cases, it is associated with appearance of earlier stages of maturation of myeloid cells in the peripheral blood. This is called shift to the left. Prominent granulation is also seen and is called toxic change.</p>
<p><strong>Neutropenia</strong> It is the reduction in neutrophils and occurs in aplastic anaemia, treatment with certain drugs, and in certain conditions such as bacterial, viral and parasitic infections.</p>
<p><strong>Eosinophilia</strong> Increased eosinophil count may be seen in allergic reactions, parasitic infestations, asthma, some skin disorders, Hodgkin’s disease and some leukaemias.</p>
<p><strong>Basophilia</strong> Increase in basophils is not very frequently seen. It may occur in chronic myeloid leukaemia, chronic haemolytic anaemia, after splenectomy and irradiation.</p>
<p><strong>Lymphocytosis</strong> It is seen characteristically in certain acute infections such as infectious mononucleosis, pertusis (whooping cough), mumps, rubella (German measles). It also occurs in chronic infections like tuberculosis, brucellosis, infectious hepatitis and in fungal infections.</p>
<p><strong>Lymphopenia</strong> It may result as an effect of treatment with some drugs, and is also seen in acquired immune deficiency syndrome (AIDS).</p>
<p><strong>Monocytosis</strong> Increase in monocytes may occur in infectious mononucleosis, malaria and some viral infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-qualitative-or-morphological-changes">B. Qualitative (or morphological) Changes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-qualitative-or-morphological-changes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Most alterations in leucocyte morphology can be classified into three categories:</p>
<ol>
<li>
<p><strong>Toxic or reactive changes</strong> These are generally associated with bacterial infection or a toxic reaction.</p>
</li>
<li>
<p><strong>Anomalous changes</strong> Deviation from the normal (anomaly) or irregularity can be congenital or acquired.</p>
</li>
<li>
<p><strong>Malignant changes</strong> In leukaemia, there is an abnormal, uncontrolled proliferation of one or more of the various haemopoietic cells. They progressively displace normal cellular elements. The affected cells may show morphological variations.</p>
</li>
<li>
<p><strong>Toxic or reactive changes in leucocytes</strong>
<strong>Hypersegmentation of nucleus:</strong> Neutrophils with five or more lobes in the nucleus are typically seen in anaemias due to vitamin B₁₂ and folic acid deficiency (megaloblastic or pernicious anaemia). The neutrophils are larger than normal in size.</p>
</li>
</ol>
<p><strong>Cytoplasmic vacuolation</strong> indicates toxic change and may be followed by phagocytosis. The granules in the cytoplasm may be reduced in number.</p>
<p>Scanned by CamScanner</p>
<p>294 Haematology</p>
<p>Note: A specimen anticoagulated with EDTA may also show cytoplasmic vacuoles.</p>
<p>Toxic granulation: Toxic granules appear as deeply basophilic blue-black granules in the cytoplasm of neutrophils. The granules are larger in size than the normal neutrophilic granules. The toxic granules may be seen in conditions such as acute bacterial infection, burns and drug poisoning.</p>
<p>Dohle bodies are seen in the cytoplasm of neutrophils as small, oval, light blue staining areas. The cytoplasmic RNA from the earlier stages of development may not be completely removed and appears as Dohle bodies. They may be seen in conditions such as infections, administration of toxic drugs, burn cases and pregnancy.</p>
<p>Basket cells or smudge cells: These are damaged white cells showing degenerating nuclei without any cytoplasm. A few basket cells may be seen in a normal smear. However, they may be seen in large numbers in some leukaemias.</p>
<p>Turk cells: These cells are similar to plasmacytes, but stain more deeply. They are found to be associated with viral infections.</p>
<p>Reactive lymphocytes: These lymphocytes are seen in viral infections, particularly in infectious mononucleosis. The alterations from the normal form are due to an immune response to a stimulus. The nucleus may become loose and delicate, and is called reticular nucleus; or it may show heavy clumps of chromatin. The cytoplasm increases in volume, and shows amoeboid characteristics.</p>
<p>Barr Bodies: A Barr body is a knob-like extension of the nuclear chromatin observed in some neutrophils in normal females. It is considered to be a sex chromatin (inactivated x-chromosome).</p>
<p>Auer Bodies or Auer Rods are found only in the cytoplasm of myeloblasts or promyelocytes in acute myeloid leukaemia. They appear as rod-shaped, slender bodies, staining reddish-purple. They are only seen in the cells of myeloid series and are never seen in the lymphoid cells. Their presence in a leucocyte precursor, therefore, excludes lymphocytic leukaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-anomalies-in-leucocytes">2. Anomalies in leucocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-anomalies-in-leucocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pelger-Huet anomaly can be inherited or acquired. In this anomaly, the nuclei of the granulocytes fail to segment. The nucleus may be seen as a band form, ring form of two lobes joined by a short filament. The nuclear chromatin is quite densely clumped. This condition may not have any clinical significance.</p>
<p>May-Hegglin anomaly: In this type of anomaly, the neutrophils show spindle shaped inclusion bodies which stain grey-blue with Romanowsky group of stains. This disorder is hereditary and the patients have no clinical symptoms.</p>
<p>Alder-Reilly anomaly: This anomaly is expressed as heavy granulation in all granulocytes and sometimes also in monocytes and lymphocytes. The anomaly is inherited.</p>
<p>Table 4.1 shows some causes of toxic changes and anomalies in leucocytes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-malignant-or-leukaemic-changes">3. Malignant or leukaemic changes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-malignant-or-leukaemic-changes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Leukaemia is a disease of unknown aetiology with predisposing factors such as heredity, chemicals, radiation and viruses. Leukaemia is characterised by uncontrolled and abnormal formation of cells of one or more of the blood cell series.</p>
<p>Leukaemia is classified on the basis of the clinical course as acute and chronic. Acute leukaemia has a sudden onset and the disease progresses rapidly. Death is either due to haemorrhage or infection. Chronic leukaemia has a gradual onset and the symptoms may not be obvious for a long time. The patient usually survives for a much longer time from 3–30 years. The cause of death may be unrelated to the disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="morphological-classification-of-leukaemia">Morphological Classification of Leukaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#morphological-classification-of-leukaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Leukaemia can be diagnosed from haematological investigations such as the complete blood count (especially WBC, RBC and platelet counts), examination of the peripheral blood smear and examination of the bone marrow smear.</p>
<p>Leukaemia can be classified according to the cell type involved:</p>
<p>Scanned by CamScanner</p>
<p>Examination of Peripheral Blood Smear 295</p>
<p>Table 4.1 Causes of toxic changes and anomalies in leucocytes</p>
<table><thead><tr><th>Abnormalities</th><th>Description</th><th>Associated disorders</th></tr></thead><tbody><tr><td>Atypical lymphocytes</td><td>Lymphocytes usually larger than normal, with cytoplasm which often stains blue.</td><td>Infectious mononucleosis and viral infections, toxoplasmosis, drug reactions, post-transfusion syndrome.</td></tr><tr><td>Auer rods</td><td>Rodlike (sometimes round) red inclusions in blast cells.</td><td>Acute myeloid leukaemia (especially promyelocyte type).</td></tr><tr><td>Dohle bodies</td><td>Small blue cytoplasmic inclusions in neutrophils.</td><td>Infectious and inflammatory diseases, burns, myeloproliferative disorders.</td></tr><tr><td>Lupus erythematosus (LE) cell</td><td>Neutrophils with a homogeneous pink inclusion</td><td>Lupus erythematosus and collagen diseases, drug reactions.</td></tr><tr><td>May-Hegglin anomaly</td><td>Basophilic cytoplasmic inclusions in white cells.</td><td>May-Hegglin syndrome with thrombocytopenia.</td></tr><tr><td>Pelger-Huet anomaly</td><td>Neutrophils with bilobed non-segmented nucleus. Coarse chromatin.</td><td>Hereditary myeloid leukaemia</td></tr><tr><td>Plasma-Turk cells</td><td>Plasma cells in blood.</td><td>Severe bacterial, viral or protozoal infections, multiple myeloma and plasma cell leukaemia, drug reactions.</td></tr><tr><td>“Shift to left”</td><td>Presence of metamyelocytes and earlier granulocytic forms.</td><td>Infections, tissue necrosis, diabetic ketoacidosis, leukaemoid reactions, chronic granulocytic leukaemia, myeloproliferative disorders.</td></tr><tr><td>“Shift to right”</td><td>Hypersegmented neutrophils (5 or more lobes).</td><td>Megaloblastic anaemias, iron deficiency, uraemia.</td></tr><tr><td>Smudge or basket</td><td>Disintegrated lymphocyte.</td><td>Chronic lymphocytic leukaemia, normal babies.</td></tr><tr><td>Toxic granulation</td><td>Coarse purple granules.</td><td>Infectious and inflammatory diseases.</td></tr></tbody></table>
<ol>
<li>Myeloid (or non lymphocytic)</li>
<li>Lymphocytic</li>
<li>Monocytic</li>
<li>Erythroid</li>
<li>Plasma cell.</li>
</ol>
<p>Each of the above types can be acute or chronic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="characteristics-of-myeloid-leukaemia">Characteristics of myeloid leukaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#characteristics-of-myeloid-leukaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) There is marked leucocytosis. The cell count may range between 20,000–100,000 / cu.mm (20 to 100 × 10⁹/L) in acute myeloid leukaemia (AML); and as high as 800,000/cu.mm (800 × 10⁹/L) in chronic myeloid leukaemia (CML).</p>
<p>Sometimes in AML, the total leucocyte count may fall below 2,000/cu.mm. This is known as aleukaemic leukaemia.</p>
<p>(ii) In AML, about 30–90 % blast cells may be seen in the peripheral blood smear. Generally, more than 60 % blast cells indicates AML. On the other hand, CML will show about 1–10 % blast cells in the peripheral blood and contains all granulocyte developmental stages including mature forms.</p>
<p>(iii) An increased percentage of basophils (3–20 %), and sometimes eosinophils may be observed in CML, whereas in AML it is difficult to find mature forms of granulocytes.</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p>(iv) Severe anaemia is a characteristic feature of AML due to decreased production of red cells. The red blood cells are generally normocytic and normochromic. CML is associated with a moderate degree of anaemia with mild anisocytosis and poikilocytosis.</p>
<p>(v) Thrombocytopenia (low platelet count) is very characteristic of acute leukaemia while platelet count is generally within the normal limits in chronic leukaemia. Therefore, in AML, bleeding time is prolonged, and clot retraction is poor.</p>
<p>(vi) Bone marrow is hypercellular showing hyperplasia of the myeloid series. In AML, the majority are blast cells while in CML all stages of myeloid maturation are also present. In both cases, red cell series is suppressed. Megakaryocytes are suppressed in AML and are unaffected in CML.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="characteristics-of-lymphocytic-leukaemia">Characteristics of Lymphocytic Leukaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#characteristics-of-lymphocytic-leukaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) There is an increase in total white cell count usually to about 200,000 to 250,000/cu.mm. (200 × 10⁹/L to 250 × 10⁹/L)</p>
<p>(ii) In acute lymphocytic leukaemia (ALL), a large number of lymphoblasts (70 to 90%) can be seen, while in chronic lymphocytic leukaemia (CLL), the percentage may be about 10%.</p>
<p>&gt; <strong>Note</strong>
&gt; It is difficult to differentiate between a myeloblast and a lymphoblast on the basis of morphology. Therefore, cytochemical and histochemical staining techniques (e.g. leucocyte alkaline phosphatase activity, esterase activity, periodic-acid-schiff (PAS) reaction) are used to identify abnormal precursors in blood with more accuracy.</p>
<p>(iii) There is normocytic, normochromic anaemia in both ALL and CLL.</p>
<p>(iv) The platelet count is normal or slightly reduced in later stages.</p>
<p>(v) Bone marrow is hypercellular with increase in the cells of lymphoid series while other cell types are suppressed.</p>
<p>Table 4.2 shows cytochemical methods for differentiation between AML and ALL.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="monocytic-leukaemia">Monocytic leukaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monocytic-leukaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The monocytic leukaemia has characteristics similar to those of myeloid leukaemia except that the predominant cell type is the precursor of monocyte, the monoblast.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="acute-erythroid-leukaemia">Acute erythroid leukaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acute-erythroid-leukaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Increased production of red cell precursors leads to acute erythroid leukaemia. The cells are usually megaloblastic and appear in the peripheral blood, bone marrow and sometimes, in the tissues. Sooner or later, these appearances change into acute myeloid leukaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="plasma-cell-leukaemia">Plasma cell leukaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#plasma-cell-leukaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This is a very rare condition where plasma cells are present in large numbers in the peripheral blood.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="morphological-variations-abnromalities-in-erythrocytes">MORPHOLOGICAL VARIATIONS/ ABNROMALITIES IN ERYTHROCYTES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#morphological-variations-abnromalities-in-erythrocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Alterations in the morphology of erythrocytes are associated with many diseases. The most significant of these conditions is anaemia, in which the oxygen carrying capacity of blood is decreased. The causes of anaemia are varied, and most of them are expressed as changes in RBC morphology. Therefore, morphological examination of red cells is very helpful in evaluating and determining the cause of anaemia.</p>
<p>Normal red blood cells stained with a Romanowsky stain are nearly uniform in size, shape and colour. Each cell appears as a pink disk, about 7 microns in diameter, with a rim of haemoglobin and a clear central area called central pallor. The central pallor generally occupies less than one-third of the cell. The red cells having normal size and normal colour are said to be normocytic and normochromic. Blood disorders may also be indicated by changes in the shape of red cells or by the presence of inclusions. Figure 4.4 shows some red cell abnormalities and inclusions.</p>
<p>During the examination of the peripheral blood smear, the following characteristics in the red cell morphology should be observed and reported:</p>
<ol>
<li>Colour (Haemoglobin content)</li>
<li>Size</li>
<li>Shape</li>
<li>Inclusions</li>
</ol>
<p>Scanned by CamScanner</p>
<p>Examination of Peripheral Blood Smear 297</p>
<p>Table 4.2 Differentiation between acute myeloid and lymphoblastic leukaemia</p>
<table><thead><tr><th>Properties</th><th>Acute Myeloid Leukaemias (AML)</th><th></th><th>Acute lymphoblastic leukaemias (ALL)</th><th></th></tr></thead><tbody><tr><td>Associated cells</td><td>Recognisable granulocyte precursors may be seen (myeloblast, promyelocyte, myelocyte and metamyelocyte</td><td></td><td>Recognisable lymphocytic precursors may be seen (lymphoblast, prolymphoblast)</td><td></td></tr><tr><td>Neucleoli in blast cells</td><td>Multiple</td><td></td><td>Single</td><td></td></tr><tr><td>Glycogen in cytoplasm (PAS stain)</td><td>Fine granules (+)</td><td></td><td>Coarse granules (++)</td><td></td></tr><tr><td>Peroxidase and Sudan Black B stains</td><td>Positive (++)</td><td></td><td>Negative</td><td></td></tr><tr><td>Auer rods in cytoplasm</td><td>Present in some cells</td><td></td><td>Absent</td><td></td></tr><tr><td>Acid phosphatase reaction</td><td>Negative</td><td></td><td>Positive (Lumps)</td><td></td></tr><tr><td>Age</td><td>Mainly adults</td><td></td><td>Mainly children</td><td></td></tr></tbody></table>
<ol start="5">
<li>Distribution pattern</li>
<li>Nucleated red cells</li>
<li>Artefacts.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-variation-in-colour">1. Variation in Colour<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-variation-in-colour" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A red cell showing a normal staining reaction is described as normochromic and represents a haemoglobin content within the normal range.</p>
<p>Hypochromic cells stain very pale and show an increased area of central pallor. Hypochromasia is a result of reduced haemoglobin content, most commonly observed in iron-deficiency anaemia.</p>
<p>Hyperchromic cells are not seen very commonly. These cells stain deeply appearing oversaturated with haemoglobin. Such cells are observed in spherocytosis.</p>
<p>Polychromatic cells show a mixed staining reaction and appear blue-orange in colour. They contain residual ribonucleic acid (RNA) which is basophilic, in addition to haemoglobin. These are slightly premature cells, just released in circulation from the bone marrow. A normal blood smear may show 1–2% polychromatic cells. They are called reticulocytes. They are slightly larger in size than normal red cells. When stained with a supra-vital</p>
<p>Scanned by CamScanner</p>
<p>298 Haematology</p>
<p><img src="assets/images/image-20251218-9e59e934.jpeg" alt="img-21.jpeg"></p>
<p>Normal blood film: Normocytic, normochromic</p>
<ol>
<li>Variation in size: Anisocytosis</li>
</ol>
<p><img src="assets/images/image-20251218-9b3cf1e7.jpeg" alt="img-22.jpeg"></p>
<p>Macrocytic: Cells on average larger</p>
<p><img src="assets/images/image-20251218-c2f88f18.jpeg" alt="img-23.jpeg"></p>
<p>Macrocytic: Cells on average smaller</p>
<p><img src="assets/images/image-20251218-f585ab7a.jpeg" alt="img-24.jpeg"></p>
<p>Macrocytic: Cells on average smaller</p>
<ol start="2">
<li>Irregularities in shape: Poikilocytosis</li>
</ol>
<p><img src="assets/images/image-20251218-0390a960.jpeg" alt="img-25.jpeg"></p>
<p><img src="assets/images/image-20251218-4774ab69.jpeg" alt="img-26.jpeg"></p>
<p>Burr cells: Due to altered plasma composition-e.g. uraemia</p>
<p><img src="assets/images/image-20251218-adcd1557.jpeg" alt="img-27.jpeg"></p>
<p>Schistocytes: Fragments of red cells damaged in blood flow, e.g. through abnormal blood vessels</p>
<p>Scanned by CamScanner</p>
<p>Examination of Peripheral Blood Smear 299</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-variation-in-colour">3. Variation in colour<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-variation-in-colour" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><img src="assets/images/image-20251218-e31b87ee.jpeg" alt="img-28.jpeg">
Hypochromia: Ring staining of cells due to poor haemoglobinisation</p>
<p><img src="assets/images/image-20251218-2a48a076.jpeg" alt="img-29.jpeg">
Spherocytosis: Small dense red cells due to cell membrane abnormalities. Cells show increased osmotic fragility. (Loss of biconcavity)</p>
<p><img src="assets/images/image-20251218-11f10343.jpeg" alt="img-30.jpeg">
Target cells: Cells showing central area of density with surrounding pallor. (Thin cells with central bulge)</p>
<p><img src="assets/images/image-20251218-d425953a.jpeg" alt="img-31.jpeg">
Sickle cells: Severe distortion of red cells due to aggregation of abnormal haemoglobin molecules in reduced state</p>
<p>These changes are associated with haemoglobinopathies</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-red-cell-inclusion">4. Red cell inclusion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-red-cell-inclusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>|  Stain used: | Howell-Jolly bodies:
Fragments of nuclear Chromatin (1-2 μm)
Romanowski stain (Leishman, Giemsa) | Pappenheimer bodies:
Small fragments containing iron
Prussian blue stain | Heinz bodies:
Denatured globin
Supravital stain (Brilliant cresyl blue) | Punctate basophilia
Romanowski stain  |
| --- | --- | --- | --- | --- |
|  Clinical condition: | Macrocytic anaemias | Especially after spelenctomy | Chemical poisoning | Lead poisoning  |</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-nucleated-red-cells">5. Nucleated red cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-nucleated-red-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Normoblast: In anaemias, especially after severe haemorrhage or haemolysis</p>
<p>Magaloblast: In pernicious anaemia and folic acid deficiency</p>
<p>Scanned by CamScanner</p>
<p>300 Haematology</p>
<p>stain such as brilliant cresyl blue, these cells show a reticulum of RNA. An increase in the number of these cells in the peripheral blood indicates increased red cell production by the bone marrow and may be seen in conditions such as haemolytic anaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-variation-in-size">2. Variation in Size<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-variation-in-size" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Variation in size, called anisocytosis, is a common and important erythrocyte morphological feature. The term describes any large variation in size of a normal erythrocyte. A red cell within the normal range of diameter is called a normocyte.</p>
<p><strong>Macrocytosis</strong> It is a condition in which red blood cells have a diameter greater than 7.8 microns and MCV usually greater than 100 cu microns (femtolitres, fL). Macrocytic cells are characteristically seen in megaloblastic anaemia due to Vit B₁₂ or folic acid deficiencies, or in haemolytic anaemia.</p>
<p><strong>Microcytosis</strong> It is a condition in which red blood cells have a diameter less than 6.5 microns and MCV less than 80 cu microns (fL). Microcytic cells frequently have less haemoglobin than normal cells and are seen in iron deficiency anaemia, spherocytic anaemia, lead poisoning and thalassaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-variation-in-shape">3. Variation in Shape<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-variation-in-shape" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A normal red cell is a circular, biconcave disc. Any alteration in this shape should be observed.</p>
<p><strong>Poikilocytosis</strong> The term describes a condition in which there are major variations in the shape of the erythrocyte. The most common of these variations is a tear drop shape. They are found in various anaemias and haemolytic states.</p>
<p><strong>Spherocyte</strong> It is a red cell whose average thickness has increased, usually with a reduced diameter. The spherical shape results when a normal cell volume is enclosed within a reduced surface area. When seen in a blood smear, it is a small, deeply staining cell with no red cell central pallor. A spherocyte has a 14 day life span as compared to 120 days of a normal blood cell. It commonly shows increased osmotic fragility. Spherocytes are found in congenital and acquired haemolytic anaemias.</p>
<p><strong>Elliptocytes</strong> These are red blood cells which are oval or egg-shaped, sometimes almost cylindrical. They do not show the central pallor. Large elliptocytes may be seen in megaloblastic anaemia. Elliptocytosis may be acquired or inherited.</p>
<p><strong>Target cells</strong> These cells have a central area of haemoglobin within the area of central pallor, making them look like targets. This is a result of having excessive cell membrane, compared to the amount of haemoglobin. They occur in various types of anaemias, liver disease and after splenectomy.</p>
<p><strong>Sickle cells</strong> These elongated erythrocytes with crescentic shapes and occasionally U, S, or L shapes are formed after exposure to reduced oxygen tension. This variation occurs if the red blood cell contains the abnormal haemoglobin S. This is a hereditary disorder, which may appear in two forms: the sickle cell trait or sickle cell disease.</p>
<p><strong>Burr cells</strong> These erythrocytes have a focal crenation producing irregular contractions resulting in long spine-like processes, irregularly distributed over the cell surface. They have been observed in renal insufficiency and thrombocytopenia.</p>
<p><strong>Schistocytes</strong> These are fragmented portions of red cells which appear in various shapes, e.g., helmet cells. Their presence indicates a very serious pathological condition e.g. mechanical fracture of cells during circulation in conditions such as a defective heart valve and glomerular filtration. They may also form due to toxic or metabolic injury as in malignancies. They are frequently seen in blood smears of severely burnt patients, and in some haemolytic anaemias.</p>
<p><strong>Acanthocytes</strong> These cells show irregular margins with pointed projections. The cause of this variation is not clearly understood, but may be due to abnormality in the phospholipid content of the red cell membrane.</p>
<p>Table 4.3 shows causes of variations in shape, size and colour of red cells.</p>
<p>Scanned by CamScanner</p>
<p>Examination of Peripheral Blood Smear 301</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-abnormal-inclusions-in-red-blood-cells">4. Abnormal Inclusions in Red Blood Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-abnormal-inclusions-in-red-blood-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A normal red cell does not contain any inclusion. Various types of inclusions may be seen in RBCs which may indicate disorders or disease conditions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="basophilic-stippling">Basophilic stippling<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#basophilic-stippling" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The red cells may show fine or coarse dark blue granules dispersed throughout the cell. This is known as basophilic stippling and results from the precipitation of ribosomal RNA. The stippling may occur due to abnormal red cell formation in the bone marrow and is seen in heavy metal poisoning (lead, mercury or bismuth), thalassaemia and megaloblastic anaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="howell-jolly-bodies">Howell-Jolly bodies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#howell-jolly-bodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>These are round, dense purple granules less than 1 micron in size, appearing eccentrically located in some red cells. If present, not more than two Howell-Jolly bodies are seen in a single red cell. They are the remnants of the nuclear material and indicate incomplete expulsion of the nucleus from the red cell through the spleen. Therefore, the Howell-Jolly bodies may appear in the peripheral blood after splenectomy, and also in megaloblastic anaemia and some haemolytic anaemias.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="heinz-bodies">Heinz bodies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heinz-bodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Heinz bodies are oxidised denatured haemoglobin. They can be demonstrated only by supravital staining with brilliant cresyl blue. Heinz bodies may appear in the peripheral blood smear after removal of the spleen, or in haemolytic anaemias such as that due to G6PD deficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="siderocytes">Siderocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#siderocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The red cells containing small, dense, blue-purple granules are called siderocytes. They resemble Howell-Jolly bodies in appearance, but they are granules of free iron, uncombined with haemoglobin, instead of fragments of DNA. The iron-granules inside siderocytes are known as Pappenheimer bodies. A special stain for iron, such as Prussian blue, can distinguish these granules from Howell-Jolly bodies. They are seen in peripheral blood after the removal of spleen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="cabot-s-rings">Cabot's rings<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cabot-s-rings" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>These are rare inclusions appearing as threadlike strands in the form of a ring or figure of 8, reddish-violet in colour. Their origin is not clearly understood, but may be the result of an abnormality in mitosis. They appear in cases of megaloblastic anaemia or lead poisoning. They can be differentiated from the malarial ring forms by their large size and absence of red chromatin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="parasites">Parasites<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#parasites" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Various stages of the malarial parasites may be seen in the red cells of patients suffering from malaria. Their appearance depends on the developmental stage (e.g. ring form, amoeboid trophozoite, schizont, gametocyte) and the infecting species of the genus <em>Plasmodium</em>, e.g., <em>Plasmodium vivax</em>, <em>Plasmodium falciparum</em>. Other parasites such as trypanosomes and microfilariae may also be seen in a peripheral blood smear. Blood parasites are discussed in greater details in Parasitology in Microbiology Section.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-alterations-in-the-distribution-pattern-of-red-cells">5. Alterations in the Distribution Pattern of Red Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-alterations-in-the-distribution-pattern-of-red-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="rouleaux-formation">Rouleaux Formation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rouleaux-formation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Sometimes red cells stick together in row looking like stacks of coins. This is called rouleaux formation. They may appear in the thick portion of the smear of healthy individuals. However, their presence in the thinner ‘examination area’ of the smear indicates increased levels of plasma globulin or fibrinogen e.g. in multiple myeloma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="agglutination">Agglutination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#agglutination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Agglutination is irregular clumping. If agglutination is observed in blood samples stored in the refrigerator, it may be due to the presence of cold agglutinins, which are autoantibodies indicating an auto-immune haemolytic state or anaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="6-nucleated-red-cells-in-the-peripheral-blood-erythroblastic-reaction">6. Nucleated red Cells in the Peripheral Blood (Erythroblastic Reaction)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6-nucleated-red-cells-in-the-peripheral-blood-erythroblastic-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The peripheral blood of a healthy individual does not show the presence of nucleated red cells. Their appearance in the peripheral blood indicates intense stimulation of the bone marrow releasing red cell precursors in the peripheral blood. This occurs in acute blood loss, megaloblastic and haemolytic anaemias and malignancies. Normoblasts (erythroblasts) in various stages of development may be seen depending on the severity of the stimulus.</p>
<p>Scanned by CamScanner</p>
<p>302 Haematology</p>
<p>Table 4.3 Causes of variations in shape, size and colour of red cells</p>
<table><thead><tr><th>Abnormality</th><th>Description</th><th>Probable causes</th></tr></thead><tbody><tr><td>Acanthocytes</td><td>Small cells, almost spherical, with multiple thorny projections</td><td>Abnormality in red cell membrane.</td></tr><tr><td>Anisocytosis</td><td>Unequal variation in size</td><td>A non-specific feature but more pronounced in severe anaemia</td></tr><tr><td>Crenated cells</td><td>Cell with multiple evenly spread blunt projections</td><td>Artefact, old age, thyroid deficiency, delay in making film.</td></tr><tr><td>Elliptocytosis</td><td>Thin, elongated cells</td><td>Iron deficiency, megaloblastic anaemia, hereditary elliptocytosis</td></tr><tr><td>Hypochromia</td><td>Pale cells (MCH &lt; 27pg)</td><td>Anaemias</td></tr><tr><td>Macrocytosis</td><td>Large cells (MCV &gt; 100fl)</td><td>Megaloblastic anaemias, liver disease, recticulocytosis, newborn, alcoholism</td></tr><tr><td>Microcytosis</td><td>Small cells (MCV&lt;80fl)</td><td>Iron deficiency, thalassaemia, anaemia of chronic disorders, hyperthyroidism, childhood.</td></tr><tr><td>Nucleated red cells</td><td>Erythrocytes with nuclei</td><td>Any severe anaemia (except aplastic), leukaemia, severe heart failure, haemolytic disease of the newborn.</td></tr><tr><td>Poikilocytosis</td><td>Abnormal shape</td><td>Any anaemia, more prominent if severe</td></tr><tr><td>Polychromasia</td><td>Cells stain bluish grey; slightly larger cells than normal (reticulocytosis)</td><td>Response to blood loss, haemolysis</td></tr><tr><td>Rouleaux</td><td>"Aggregated" red cells, arranged side by side into columns like stacks of coins</td><td>Chronic inflammatory and malignant disease, myeloma, macroglobulinaemia</td></tr><tr><td>Schistocytes</td><td>Fragmented; irregularly contracted cells</td><td>Carcinoma, uraemia, disseminated intravascular coagulation, mechanical damage to cells; drugs and toxins.</td></tr><tr><td>Sickle cells</td><td>Crescent shape</td><td>Sickle cell anaemia</td></tr><tr><td>Spherocytosis</td><td>A spherical hyperchromic cell with no central pallor</td><td>Hereditary spherocytosis; haemolytic anaemia due to antibody</td></tr><tr><td>Burr cells</td><td>Cells with long, irregularly spaced, sharp projections</td><td>Liver disease, normal infants, uraemia, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, carcinoma, pyruvate kinase deficiency</td></tr><tr><td>Target cells</td><td>Cells with a dark centre and periphery and a clear ring in between</td><td>Liver disease, thalassaemia, haemoglobinopathies, post-splenectomy</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="7-artefacts-in-red-cells">7. Artefacts in Red Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#7-artefacts-in-red-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Platelets on top of a red cell, punched-out red cell or stain deposits may appear as variations in red cell morphology. They should not be confused with red cell abnormalities.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 5</p>
<p>Anaemia</p>
<p>Anaemia is not a specific disease. It is a condition in which oxygen carrying capacity of blood is reduced. Anaemia is always a sign of an underlying disease, and never a diagnosis. A red cell count of less than 4.0 million/cu.mm (μl) in males and 3.5 million/cu.mm (μl) in females, or haemoglobin content of less than 10.8 g per 100 ml (108g/L) in males and 9.5 g/100 ml (95 g/L) in females is an indication of anaemia. Patients with anaemia have similar clinical symptoms irrespective of the cause. Fatigue, breathlessness, dizziness and headache are some of the common complaints.</p>
<p>Anaemia may be caused due to the following factors</p>
<p>(i) Increased haemolysis.
(ii) Diminished erythropoiesis.
(iii) Blood loss</p>
<p>Increased haemolysis may be due to hereditary defects such as spherocytosis, or sickle cells, which reduce the life span of the red cell; or may be acquired by the action of haemolytic agents.</p>
<p>Diminished erythropoiesis is either due to a nutritional deficiency or due to the marrow failure. The nutritional factors essential for erythropoiesis are iron, cobalt, copper, vitamin B₁₂, folic acid, pyridoxine, riboflavin, nicotinic acid, Vit C, proteins and some hormones. The deficiency of these factors may be dietetic, due to defective absorption or due to increased demands, (e.g., during pregnancy or period of growth).</p>
<p>Failure of marrow may be endogenous or due to extraneous toxic factors such as chemicals and drugs.</p>
<p>Blood loss may be brought about by trauma or disease and may be acute or chronic in nature.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-anaemia">CLASSIFICATION OF ANAEMIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Generally, anaemias are classified on the basis of the appearance of the red cells (morphological classification) or depending on the physiological cause (aetiological classification).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="morphological-classification-of-anaemia">MORPHOLOGICAL CLASSIFICATION OF ANAEMIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#morphological-classification-of-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Morphological classification of anaemia depends on the examination of blood which includes the determination of haemoglobin, enumeration of red cells, red cell indices and the examination of the peripheral blood smear. The levels of haemoglobin and red cell count determine the severity of anaemia while the examination of smear will give information about the size of the red cells, their haemoglobin content and presence of abnormal red cells. The red cell indices provide important guidelines for morphological classification of anaemia.</p>
<p>Scanned by CamScanner</p>
<p>304 Haematology</p>
<p><img src="assets/images/image-20251218-7ccf89c5.jpeg" alt="img-32.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-macrocytic-normochromic-anaemia">1. Macrocytic, normochromic anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-macrocytic-normochromic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>MCV 100 to 160 cu.microns (fL)
MCHC 32 to 36 %</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="causes">Causes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Deficiency of Vitamin B₁₂ or folic acid, hepatic disease, or antimetabolite drugs. The bone marrow shows abnormal red cell maturation, megaloblastic (increased red cell size) changes.
(b) Chronic liver disease, hypothyroidism etc. where bone marrow does not show abnormal megaloblastic changes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-normocytic-normochromic-anaemia">2. Normocytic, Normochromic Anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-normocytic-normochromic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>MCV 80 to 100 cu.μm (fL)
MCHC 32 to 36 %</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="causes">Causes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Sudden blood loss
(b) Haemolytic anaemias
(c) Haemoglobinopathies
(d) Aplastic anaemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-microcytic-normochromic-anaemia">3. Microcytic Normochromic Anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-microcytic-normochromic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>MCV 69 to 80 cu.μm (fL)
MCHC 32 to 36 %</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="causes">Causes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Inflammatory conditions.
(b) Toxic drugs and chemicals
(c) Malignancy
(d) Endocrine disorders</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-microcytic-hypochromic-anaemia">4. Microcytic Hypochromic Anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-microcytic-hypochromic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>MCV 60 to 80 cu. μm (fL)
MCHC 20 to 30 %</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="causes">Causes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Iron deficiency due to blood loss, improper gastrointestinal absorption, excess demand
(b) Miscellaneous, such as lead poisoning, thalassaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-macrocytic-hypochromic-anaemia">5. Macrocytic Hypochromic Anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-macrocytic-hypochromic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>MCV more than 100 cu. μm (fL)
MCHC less than 30 %</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="causes">Causes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Deficiency of iron associated with deficiency of Vitamin B₁₂ or folic acid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="32bbf28b">♦ ETIOLOGICAL CLASSIFICATION OF ANAEMIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#32bbf28b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-anaemia-resulting-from-excessive-destruction-of-red-cells">I. Anaemia Resulting from Excessive Destruction of Red Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-anaemia-resulting-from-excessive-destruction-of-red-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) Due to intracellular defects. Hereditary defects of red cell membrane (e.g. spherocytosis).</p>
<p>Scanned by CamScanner</p>
<p>Anaemia 305</p>
<p>ovalocytosis); reduced globin chain synthesis (e.g. thalassaemia); and abnormal globin chain synthesis (e.g. sickle cell anaemia), fall in this category. Acquired defects of red cells (e.g. paroxysmal nocturnal haemoglobinuria, thermal injury and deficiency diseases) may also lead to anaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="ii-due-to-extracellular-abnormalities">(ii) Due to extracellular abnormalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-due-to-extracellular-abnormalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Immune mechanism with demonstrable antibodies, e.g., naturally acquired immunities against A and B antigens and autoimmune haemolytic anaemia, are responsible for most haemolytic reactions.</p>
<p>(b) Non-immune mechanism without demonstrable antibodies, e.g., infectious agents which parasatise RBCs as in malaria; bacterial toxins or haemolysins as in <em>Clostridium perfringes</em>, and toxic chemicals such as arsenic, lead etc. are responsible for destruction of red cells.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-decreased-production-of-haemoglobin-erythrocyte-mass-ineffective-erythropoiesis">2. Decreased Production of Haemoglobin/Erythrocyte Mass (ineffective Erythropoiesis)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-decreased-production-of-haemoglobin-erythrocyte-mass-ineffective-erythropoiesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-anaemia-resulting-from-specific-deficiency">A. Anaemia resulting from specific deficiency<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-anaemia-resulting-from-specific-deficiency" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>
<p>Vitamin B₁₂ deficiency due to unbalanced diet, deficiency of intrinsic factors or decreased absorption in total or partial gastrostomy. The deficiency can also be due to defective absorption or increased requirement due to pregnancy.</p>
</li>
<li>
<p>Folic acid deficiency due to low consumption of vegetables, defective absorption, defective utilisation or increased requirements.</p>
</li>
<li>
<p>Iron deficiency due to increased loss of iron, increased requirement or decreased intake due to defective diet or chronic malabsorption.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-anaemia-resulting-from-endocrine-abnormality-e-g-in-abnormality-of-thyroid-pituitary-adrenal-glands">B. Anaemia resulting from endocrine abnormality e.g in abnormality of thyroid, pituitary, adrenal glands.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-anaemia-resulting-from-endocrine-abnormality-e-g-in-abnormality-of-thyroid-pituitary-adrenal-glands" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="c-anaemia-resulting-from-inadequate-marrow-function">C. Anaemia resulting from inadequate marrow function<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-anaemia-resulting-from-inadequate-marrow-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>
<p>Anaemia resulting from mechanism interference with marrow function due to inadequate capacity as in new-born or in premature babies; or in conditions like malignancy.</p>
</li>
<li>
<p>Anaemia resulting from relative marrow failure, e.g., due to infection, renal disease, liver disease.</p>
</li>
<li>
<p>Anaemia of bone-marrow failure, resulting from low or no cell production.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-anaemia-resulting-from-blood-loss">3. Anaemia Resulting from Blood Loss<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-anaemia-resulting-from-blood-loss" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In this type of anaemia, a large amount of blood may be lost from the circulation either suddenly (acute haemorrhage) as a result of the opening of a large vessel (e.g. accidental wounds, duodenal ulcer), or by repeated small haemorrhages (chronic haemorrhage).</p>
<p>&gt; <strong>Note</strong>
&gt; Very often, multiple factors are involved in anaemia. The classification in such cases, may not be well-defined.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="physiological-types-of-anaemia">PHYSIOLOGICAL TYPES OF ANAEMIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#physiological-types-of-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-iron-deficiency-and-other-hypochromic-anaemias">1. Iron Deficiency and Other Hypochromic Anaemias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-iron-deficiency-and-other-hypochromic-anaemias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The commonest cause of anaemia is iron deficiency. In this type of anaemia, the red cells appear microcytic and hypochromic, and red cell indices (MCV, MCH, MCHC) are lowered.</p>
<p><strong>Iron Distribution in the body</strong> About 66% of body iron is present in haemoglobin molecules. At the end of the life span of the red cells, they are broken down in the macrophages of the reticuloendothelial (RE) system. The iron from the haemoglobin is released into the plasma and bound to transferrin for its transport. This transferrin-bound iron, along with a small portion of dietary iron absorbed through the gastro-intestinal tract, is incorporated into developing erythroblasts in the bone marrow, and in reticulocytes. The excess iron is stored in the RE cells as hemosiderin and ferritin. A small amount of the iron is also present in muscles and in enzymes.</p>
<p>Scanned by CamScanner</p>
<p>306 Haematology</p>
<p>Iron in food exists in the form of ferric hydroxides, ferric-protein complexes and haem-protein complexes. Meat products, especially liver, have a larger iron content than eggs, dairy products and vegetables. Average daily diet contains about 10–12 mg of iron, out of which about 5–10 % is normally absorbed.</p>
<p>When iron deficiency is developing, the haemosiderin and ferritin stored in RE cells become completely depleted before anaemia occurs. The clinical symptoms include:</p>
<ul>
<li>Brittle, ridged or spoon nails (Koilonychia)</li>
<li>Dysphagia (difficulty in swallowing)</li>
<li>Unusual dietary cravings (pica)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="causes">Causes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Blood loss due to injury, or from the gastrointestinal tract, due to ulcer, malignancy, hookworm infection.</li>
<li>Increased demands</li>
</ol>
<ul>
<li>(i) Premature birth</li>
<li>(ii) Growth</li>
<li>(iii) Pregnancy</li>
</ul>
<ol start="3">
<li>Malabsorption (e.g. gastrectomy, coeliac disease)</li>
<li>Poor diet</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="laboratory-findings-in-iron-deficiency-anaemia">Laboratory findings in iron deficiency anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laboratory-findings-in-iron-deficiency-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Decrease in the concentration of haemoglobin, RBC count, and packed cell volume. MCV, MCH, MCHC are lowered.</li>
<li>Red cell morphology in peripheral blood shows microcytosis and hypochromia, target cells may be present.</li>
<li>Decrease in the reticulocyte count.</li>
<li>Examination of bone marrow indicates erythroid hyperplasia (increase in the number of the red cells series) with delay in haemoglobinisation of normoblasts.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sideroblastic-anaemia">Sideroblastic Anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sideroblastic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A sideroblast is a normal erythroblast containing 2 to 4 randomly distributed iron granules in the cytoplasm. These can be seen when sideroblasts are stained for iron (e.g. with Prussian blue). In sideroblastic anaemia, abnormal erythroblasts containing numerous iron granules arranged in a ring around the nucleus are seen (Fig. 5.1). The cause of this anaemia is probably a defect in the synthesis of haem. Because the iron cannot be incorporated in the haemoglobin molecule, it shows the signs and symptoms of iron deficiency anaemia. The red cells in the peripheral blood smear are microcytic and hypochromic, with low red cell indices.</p>
<p><img src="assets/images/image-20251218-f9efd33e.jpeg" alt="img-33.jpeg">
Fig. 5.1 A normal sideroblast and a ring sideroblast in sideroblastic anaemia</p>
<p>The sideroblastic anaemia may be hereditary (usually in males) or acquired either due to malignant changes or by drugs (e.g. antituberculous drugs), alcohol or lead.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="anaemia-due-to-lead-poisoning">Anaemia Due to Lead Poisoning<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anaemia-due-to-lead-poisoning" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lead poisoning can cause anaemia because lead inhibits synthesis of both haem and globin. The peripheral blood smear shows hypochromic red cells and some show punctate basophilia (basophilic stippling). The bone marrow may show ring sideroblasts.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="anaemia-due-to-chronic-disorders">Anaemia Due to Chronic Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anaemia-due-to-chronic-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Patients suffering from chronic inflammatory diseases or malignancies may show signs of mild anaemia with mildly hypochromic red cell morphology and low indices. The causes of this type of anaemia are:</p>
<ul>
<li>(i) Decreased release of iron from the RE macrophages to plasma.</li>
<li>(ii) Reduced red cell life span.</li>
<li>(iii) Inadequate erythropoietin response to anaemia.</li>
</ul>
<p>This anaemia is corrected by successful treatment of the underlying disease.</p>
<p>Scanned by CamScanner</p>
<p>Anaemia 307</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-megaloblastic-anaemia-and-other-macrocytic-anaemias">2. Megaloblastic Anaemia and Other Macrocytic Anaemias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-megaloblastic-anaemia-and-other-macrocytic-anaemias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This group of anaemias is a result of defective DNA synthesis leading to delayed maturation of the nucleus of erythroblasts as compared to the maturation of their cytoplasm. The bone marrow shows large erythroblasts (megaloblasts) with immature nucleus and normal haemoglobinisation of the cytoplasm. The defect in DNA synthesis is most commonly due to deficiency of vitamin B₁₂ or folic acid, or sometimes due to abnormalities of metabolism of these substances. Both the vitamin B₁₂ and folic acid play an essential role in cell metabolism. They act as coenzymes in the synthesis of DNA.</p>
<p><strong>Vitamin B₁₂</strong> A normal human diet contains a large excess of vitamin B₁₂ than is necessary. This vitamin is found in foods of animal origin such as fish, liver and dairy products. It does not occur in vegetables, fruit or cereals unless they are acted upon by bacteria which synthesise it in nature. After consumption, vitamin B₁₂ is absorbed in blood only if it combines with a glycoprotein called intrinsic factor (IF) produced by the parietal cells in the gastric mucosa.</p>
<p><strong>Folic acid</strong> This is a yellow, water soluble compound present in green vegetables, liver and yeast. Human body is unable to synthesise it. Bacteria can synthesise it in the presence of para-amino benzoic acid (PABA). Sulphonamides block the incorporation of PABA and thus inhibit the synthesis of folic acid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pernicious-anaemia">Pernicious anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pernicious-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is a type of megaloblastic anaemia caused due to malabsorption of vitamin B₁₂ from the gastric mucosa. The causes for this malabsorption can be:</p>
<p>(i) Absence of or decrease in intrinsic factor (IF) secreted by the gastric parietal cells.
(ii) An auto-immune mechanism which produces antibodies either against the parietal cells which secrete IF, or against the IF itself.</p>
<p>Both these causes affect the absorption of vitamin B₁₂ into the blood stream, leading to megaloblastic anaemia. This type of anaemia is also called Addisonian pernicious anaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-features-of-megaloblastic-anaemia">Clinical features of megaloblastic anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-features-of-megaloblastic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Insidious onset with gradually progressive symptoms of anaemia.</li>
<li>Mild jaundice.</li>
<li>Glossitis (a beefy, red, sore tongue).</li>
<li>Loss of weight.</li>
<li>Sometimes purpura and widespread melanin pigmentation.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="laboratory-findings-in-megaloblastic-anaemia">Laboratory findings in megaloblastic anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laboratory-findings-in-megaloblastic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Decrease in haemoglobin concentration, red cell count and PCV.</li>
<li>MCV and MCH are increased, MCHC is normal.</li>
<li>Peripheral blood smear examination shows:
(i) Macrocytosis
(ii) Red cell inclusions such as Howell-Jolly bodies and Cabot rings
(iii) Hypersegmented neutrophils</li>
<li>Decreased white cell count, platelet count and reticulocyte count.</li>
<li>Mild increase in unconjugated serum bilirubin level.</li>
<li>Bone marrow examination reveals erythroid hyperplasia with a large number of megaloblasts.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-haemolytic-anaemias">3. Haemolytic Anaemias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-haemolytic-anaemias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Haemolytic anaemias are those anaemias which result from increased destruction of blood cells. In severe haemolytic anaemias the red cells survive only for a few days instead of a normal life span of 120 days. The causes of this increased haemolysis can be varied and may be summarised as in Table 5.1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="general-features-of-haemolytic-anaemia">General features of haemolytic anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-features-of-haemolytic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In addition to general symptoms of anaemia, haemolytic anaemia is symptomised by:</p>
<ol>
<li>Pallor of the mucous membranes</li>
<li>Mild fluctuating jaundice</li>
<li>Splenomegaly</li>
</ol>
<p>Scanned by CamScanner</p>
<p>308 Haematology</p>
<p>Table 5.1 Causes of haemolytic anaemia</p>
<table><thead><tr><th>Defect</th><th>Disease</th></tr></thead><tbody><tr><td>Hereditary</td><td></td></tr><tr><td>Membrane</td><td>e.g., Hereditary spherocytosis, hereditary elliptocytosis</td></tr><tr><td>Metabolism</td><td>e.g., G6PD deficiency, pyruvate kinase deficiency</td></tr><tr><td>Haemoglobin</td><td>1. Abnormal (HbS, HbC, unstable, etc)</td></tr><tr><td></td><td>2. Defective synthesis (thalssaeimias)</td></tr><tr><td>Acquired</td><td></td></tr><tr><td>Immune</td><td>e.g., Haemolytic disease of the new born, haemolytic transfusion reaction</td></tr><tr><td>Secondary</td><td>e.g., Renal disease, liver disease, Paroxysmal nocturnal haemoglobinuria</td></tr><tr><td>Miscellaneous causes: Infections, chemicals, toxins and drugs</td><td></td></tr></tbody></table>
<p>Laboratory findings Laboratory findings in haemolytic anaemia depend on the cause and may include:</p>
<ol>
<li>Spherocytes, elliptocytes or red cell fragments in the peripheral blood smear.</li>
<li>Reticulocytosis</li>
<li>Bone marrow erythroid hyperplasia</li>
<li>Increased osmotic fragility, autohaemolysis</li>
<li>Increased serum unconjugated bilirubin</li>
<li>Increased urine urobilinogen</li>
<li>Increased faecal stercobilinogen</li>
</ol>
<p>Haemolytic anaemias due to membrane defects</p>
<ol>
<li>Hereditary spherocytosis This type of haemolytic anaemia may present itself at any time from infancy to old age. Hereditary spherocytosis is usually due to a defect in the main structural protein called spectrin of the red cell membrane. The marrow produces cells of normal biconcave shape, but the membrane is lost during their circulation through the RE system, especially the spleen. As a result, they lose the biconcave shape and become spherical. These spherical cells, called spherocytes, are unable to pass through the splenic circulation and die prematurely.</li>
</ol>
<p>In vitro, glucose helps to reduce haemolysis by preventing sodium from leaking out of the cell.</p>
<p>Laboratory findings</p>
<p>(i) Reticulocytosis
(ii) The peripheral blood smear shows spherocytes
(iii) Osmotic fragility is increased after 24 hours incubation at 37°C
(iv) Autohaemolysis is increased which can be corrected with glucose
(v) Direct Coomb's test (antiglobulin test) is negative</p>
<ol start="2">
<li>Hereditary elliptocytosis This is similar to hereditary spherocytosis except that the peripheral blood smear shows elliptocytes. It is a mild form of haemolytic anaemia.</li>
</ol>
<p>Haemolytic anaemias due to defective red cell metabolism</p>
<ol>
<li>Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency G6PD is an enzyme in the hexose monophosphate pathway in which glycolysis occurs oxidatively. Persons deficient in G6PD are extremely susceptible to oxidant stresses. The main syndrome which occurs in response to an oxidant stress is acute haemolytic anaemia. The agents which may cause haemolytic anaemia in G6PD deficient persons are listed in Table 5.2.</li>
</ol>
<p>Inheritance of G6PD deficiency is sex-linked and mainly affects males. The main geographical</p>
<p>Scanned by CamScanner</p>
<p>Anaemia 309</p>
<p>areas where this deficiency is noticed are West Africa, South-East Asia, Mediterranean and the Middle East. They vary in their degree of severity.</p>
<p><strong>Clinical features</strong> Rapidly developing intravascular haemolysis is precipitated by some of the agents summarised in Table 5.2.</p>
<p><strong>Specific laboratory findings</strong></p>
<ol>
<li>
<p>Special screening test or direct enzyme assay for G6PD reveals deficiency of the enzyme.</p>
</li>
<li>
<p>Peripheral blood film shows contracted and fragmented red cells, and blister cells in which haemoglobin appears to have separated away from the cell membrane.</p>
</li>
<li>
<p>Heinz bodies may be seen in reticulocyte preparation.</p>
</li>
<li>
<p>Pyruvate kinase (PK) deficiency PK is an enzyme in Embden-Meyerhof pathway in which glucose is metabolised to lactic acid with liberation of energy-rich phosphate bonds. Red cells deficient in PK become rigid due to reduced formation of ATP, and undergo autohaemolysis.</p>
</li>
</ol>
<p><strong>Clinical features</strong> Evidence of mild haemolytic anaemia. The deficiency is hereditary.</p>
<p><strong>Specific laboratory findings</strong></p>
<ol>
<li>Special test for PK deficiency is positive.</li>
<li>Autohaemolysis test is positive, and is not corrected by glucose as in hereditary spherocytosis</li>
<li>Peripheral blood smear shows poikilocytes and distorted cells.</li>
</ol>
<p><strong>Haemolytic anaemias due to abnormalities in haemoglobin</strong></p>
<p>Hereditary haemoglobin abnormalities are divided into two main groups.</p>
<p><strong>A. Synthesis of an abnormal haemoglobin</strong> Abnormal haemoglobin is produced due to an amino acid substitution in either alpha or beta globin chain. Variants of the normal adult haemoglobin HbA are produced depending on the type and site of substitution. Some of these abnormalities may be completely asymptomatic, some may produce a mild haemolytic anaemia, but the most important of these is the sickle-cell anaemia due to formation of HbS.</p>
<p>&gt; <strong>Note</strong>
&gt; Abnormal haemoglobin can also cause symptoms other than haemolytic anaemia e.g. polycythaemia (increased Hb, RBC and PCV) and cyanosis (methaemoglobinaemia).</p>
<p><strong>B. Reduced synthesis of normal globin chain</strong> Production of either alpha or beta globin chain may be reduced, leading to alpha or beta thalassaemias.</p>
<p><strong>Sickle-cell anaemia</strong></p>
<p>In sickle-cell anaemia, the abnormal haemoglobin S (HbS) is formed by substitution of valine for glutamic acid in position 6 of the beta chain of the haemoglobin molecule (Fig. 5.2). HbS is insoluble and readily oxidises under reduced oxygen tension. As a result, the red cells become distorted into</p>
<p>Table 5.2 Agents which can cause haemolytic anaemia in G6PD deficiency</p>
<table><thead><tr><th>1. Infections and other acute illnesses, e.g. diabetic ketoacidosis</th></tr></thead><tbody><tr><td>2. Drugs:</td></tr><tr><td>(a) anti-malarials, e.g., primaquine, quinine, chloroquine</td></tr><tr><td>(b) analgesics, e.g., acetylsalicylic acid, paracetamol</td></tr><tr><td>(c) anti-bacterial, e.g., sulphonamides, nitrofurones, penicillin, isoniazid.</td></tr><tr><td>(d) miscellaneous, e.g. vitamin K, probenecid, dapsone</td></tr><tr><td>3. Fava beans (possibly other vegetables)</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>310 Haematology</p>
<p><img src="assets/images/image-20251218-1d15d648.jpeg" alt="img-34.jpeg"></p>
<p>(Key: glu-glutamic acid, pro-proline, val-valine, G-guanine, A-adenine, C-cytosine, T-thymine)
Adenine is replaced by thymine in the DNA base composition of the normal β chain. This leads to the formation of HbS molecule by replacement of amino acid glutamic acid with valine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fig-5-2-synthesis-of-hbs">Fig. 5.2 Synthesis of Hbs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fig-5-2-synthesis-of-hbs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>sickle or holly leaf shapes (Fig. 5.3). The term sickle cell anaemia is derived from this appearance of the red cells. This condition exists in two forms:</p>
<p><img src="assets/images/image-20251218-aa0efdcf.jpeg" alt="img-35.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fig-5-3-peripheral-blood-smear-in-sickle-cell-anaemia">Fig. 5.3 Peripheral blood smear in sickle cell anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fig-5-3-peripheral-blood-smear-in-sickle-cell-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Sickle cell disease (homozygous) In sickle cell anaemia, the gene for HbS synthesis is inherited from both the parents. Clinically, this presents as a severe haemolytic anaemia, punctuated by crises, mostly painful. These crises are precipitated by factors such as infection, dehydration or deoxygenation (e.g. altitude, violent exercise, exposure to cold, surgery, etc.). The 'crises' affect a variety of organs including bones, spleen and lungs. Individuals with sickle cell disease are particularly predisposed to Salmonella infections, while they are immune to plasmodium falciparum malaria.</p>
<p>Sickle cell disease is the most common disease caused by an abnormal haemoglobin. The term sickle cell disease applies to two conditions, namely (i) homozygous sickle cell anaemia (HbSS) and (ii) mixed syndromes in which sickling occurs due to HbS in combination with another Hb. The most frequent of such combinations are with HbC, HbD, HbE, HbO and beta thalassaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="specific-laboratory-findings">Specific laboratory findings<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specific-laboratory-findings" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Peripheral blood smear shows sickle cells and target cells (Fig. 5.3). Howell-Jolly bodies, nucleated red cells and polychromasia are also present.</li>
<li>Screening test for sickling is positive.</li>
<li>Haemoglobin electrophoresis (Fig. 5.4) shows HbS and variable levels of HbF. HbA is not detected.</li>
</ol>
<p>(ii) Sickle cell trait (heterozygous) In sickle cell trait, the HbS synthesis gene is inherited from only one parent, and a benign condition with no obvious anaemia is present.</p>
<p>Laboratory diagnosis is by sickle cell test and Hb electrophoresis which shows bands of both HbS and HbA (Fig. 5.4).</p>
<p>Scanned by CamScanner</p>
<p>Anaemia 311</p>
<p><img src="assets/images/image-20251218-f7df9cd4.jpeg" alt="img-36.jpeg">
Fig. 5.4 Electrophoresis of normal and abnormal haemoglobin</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="thalassaemias">Thalassaemias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thalassaemias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Thalassaemia is a disease in which there is failure or reduced capacity to produce one type of chain in the globin portion of the haemoglobin molecule. Decreased synthesis of alpha-chain is called alpha-thalassaemia, while decreased beta-chain synthesis is designated as beta-thalassaemia. The seriousness of any condition depends on whether it is inherited from both parents (homozygous), in which case the symptoms are more severe, or from one parent (heterozygous) where there may be no detectable symptoms.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="alpha-thalassaemia-syndromes">Alpha-thalassaemia syndromes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alpha-thalassaemia-syndromes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Alpha-thalassaemia traits are often not associated with anaemia, but all the red cell indices are low. Haemoglobin electrophoresis is usually normal. However, the alpha/beta chain synthesis ratio, which is 1:1 under normal conditions, is reduced.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="beta-thalassaemia-syndromes">Beta-thalassaemia syndromes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta-thalassaemia-syndromes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Homozygous beta-thalassaemia (beta-thalassaemia major, or Mediterranean anaemia or Cooley's anaemia) presents clinically as:</p>
<p>(i) Severe anaemia 3–6 months after birth.
(ii) Enlargement of the liver and spleen due to excessive red cell destruction and iron overload.</p>
<p>(iii) Intense hyperplasia of the bone marrow causes expansion of bones and gives rise to a typical facial appearance (prominent frontal and parietal bones, enlarged maxilla).
(iv) Iron overload due to repeated transfusions causes damage to the liver and endocrine organs resulting in failure of growth, delayed or absent puberty, diabetes mellitus with ultimate death. These abnormalities usually appear after 100 units of blood transfusion (each unit of 500 ml contains about 250 mg of iron) unless the excess iron is removed by chelation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specific-laboratory-findings">Specific laboratory findings<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specific-laboratory-findings" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Severe microcytic hypochromic anaemia with peripheral blood film showing target cells, basophilic stippling and normoblasts.
(ii) Reticulocytes are increased.
(iii) Haemoglobin electrophoresis shows total or almost total absence of HbA. Most of the haemoglobin is in the form of HbF (Fig. 5.4).</p>
<p>Scanned by CamScanner</p>
<p>312 Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="autoimmune-haemolytic-anaemias-aiha">Autoimmune haemolytic anaemias (AIHA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#autoimmune-haemolytic-anaemias-aiha" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In AIHA, the defect is extracorpuscular. These anaemias occur because of the production of antibodies against the patient's own red cells. The classification of their causes is shown in Table 5.3. The warm antibodies react better at 37°C while cold antibodies are active at 4°C.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="warm-aiha">Warm AIHA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#warm-aiha" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Clinical features</strong> It is a haemolytic anaemia of varying severity occurring at any age. The spleen is enlarged. Warm AIHA is frequently associated with other autoimmune disorders such as systemic lupus erythematosus (SLE).</p>
<p><strong>Laboratory findings</strong></p>
<ol>
<li>Peripheral blood smear is typical of haemolytic anaemia and shows prominent spherocytosis.</li>
<li>Direct Coomb's test is positive.</li>
<li>Antibodies are best detected at 37°C.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cold-aiha">Cold AIHA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cold-aiha" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Clinical features</strong> The patients have chronic haemolytic anaemia which increases in cold weather. Peripheral circulation (tip of the nose, ears, fingers, toes) may be affected due to agglutination of red cells in small vessels. Infections such as infectious mononucleosis or mycoplasma pneumonia may precipitate cold AIHA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iso-immune-haemolytic-anaemia">Iso-immune haemolytic anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iso-immune-haemolytic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In this type of anaemia, antibodies produced by one person react with the red cells of another. This can occur in:</p>
<p>(i) Transfusion of ABO incompatible blood
(ii) Haemolytic disease of the new-born (HDN)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-induced-immune-haemolytic-anaemia">Drug-induced immune haemolytic anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-induced-immune-haemolytic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Many drugs can induce the formation of antibodies, either against the drug itself or against red cell antigens. These antibodies, in the presence of complement, can bring about lysis of red cells. Drugs which are known to cause haemolytic anaemia include penicillin, cephalothin, phenacetin and methyl DOPA. Haemolytic anaemia gradually disappears when the drug is discontinued.</p>
<p><strong>Paroxysmal nocturnal haemoglobinuria (PNH)</strong> This occurs due to an acquired defect of the red cell membrane that makes it susceptible to complement mediated lysis of red cells. The defect is rare, haemolysis is intravascular and usually occurs at night (nocturnal). PNH is diagnosed by Ham's serum acid test (demonstration of red cell lysis at low pH). White cell, platelet and reticulocyte counts are low.</p>
<p><strong>Paroxysmal cold haemoglobinuria (PCH)</strong></p>
<p>This is similar to PNH but haemolysis occurs after exposure to cold. The patient's blood contains an antibody called Donath-Landsteiner antibody which binds red cells in the cold. The lysis with complement occurs at 37°C. Syphilis and viral infections are predisposing factors.</p>
<p>Table 5.3 Classification of autoimmune haemolytic anaemias (AIHA)</p>
<table><thead><tr><th>Warm antibody</th><th>Cold antibody</th></tr></thead><tbody><tr><td>1. Idiopathic</td><td>1. Idiopathic</td></tr><tr><td>2. Secondary to</td><td></td></tr><tr><td>(i) Systemic lupus erythematosus (SLE)</td><td></td></tr><tr><td>(ii) Other auto-immune diseases</td><td></td></tr><tr><td>(iii) Chronic lymphocytic leukaemia (CLL)</td><td></td></tr><tr><td>(iv) Lymphoma</td><td></td></tr><tr><td>(v) Drugs such as methyl DOPA</td><td>2. Secondary to</td></tr><tr><td>(i) Infectious mononucleosis</td><td></td></tr><tr><td>(ii) Mycoplasma pneumoniae infection</td><td></td></tr><tr><td>(iii) Lymphoma</td><td></td></tr><tr><td>(iv) Paroxysmal cold haemoglobinuria (rare)</td><td></td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Anaemia 313</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-haemolytic-anaemias">Miscellaneous haemolytic anaemias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-haemolytic-anaemias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Various causes other than those mentioned earlier can give rise to haemolysis and haemolytic anaemia. These include:</p>
<p>(i) Malaria.
(ii) Bacterial infections
(iii) Extensive burns.
(iv) Overdose with oxidising drugs.
(v) Chemical poisoning
(vi) Snake and spider bites.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="4-aplastic-anaemia">4. Aplastic Anaemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-aplastic-anaemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Aplastic anaemia results from aplasia of bone marrow. Haemopoiesis is affected causing reduction in the counts of all blood cell series (anaemia, leucopenia, thrombocytopenia, collectively called pancytopenia). The causes of aplastic anaemia are divided into two groups:</p>
<p>(i) Primary causes</p>
<p>(a) Congenital.
(b) Idiopathic—without any obvious precipitating cause.</p>
<p>(ii) Secondary causes</p>
<p>(a) Exposure to radiation such as radiotherapy, radioactive isotopes.
(b) Chemicals: Organic solvents like benzene, hair dyes.
(c) Drugs: Such as cyclophosphamide, 6-mercaptopurine, chloramphenicol.
(d) Infections: Viral hepatitis caused by hepatitis A virus and other related viruses.</p>
<p>Clinical features It can occur at any age, but is more common around 30 years of age. Infections, either localised (e.g. of the mouth and throat) or generalised, are very common. The lymph nodes, liver and spleen are not enlarged.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="laboratory-findings">Laboratory findings<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laboratory-findings" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Peripheral blood smear shows normocytic or macrocytic (MCV increased) and normochromic red cells. The reticulocyte count is low.</li>
<li>Leucopenia: There is a marked decrease in granulocytes, though their morphology is normal.</li>
<li>Platelet count is very low (thrombocytopenia).</li>
<li>Peripheral blood smear shows no abnormal cells.</li>
<li>Bone marrow shows hypoplasia. There is a fatty degeneration of the haemopoietic tissue. The main cell types seen are lymphocytes and plasma cells.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="5-anaemia-in-systemic-disease">5. Anaemia in Systemic Disease<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-anaemia-in-systemic-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Anaemia may appear as one of the symptoms in various systemic diseases of organs other than bone marrow. These include:</p>
<p>(i) Malignant disease.
(ii) Rheumatoid arthritis, SLE and other connective tissue disorders.
(iii) Chronic renal failure.
(iv) Liver disease.
(v) Alcoholism.
(vi) Hypothyroidism.
(vii) Tuberculosis.</p>
<p>Scanned by CamScanner</p>
<p><img src="assets/images/image-20251218-646d03a4.jpeg" alt="img-37.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-investigations-in-haematology">Miscellaneous Investigations in Haematology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-investigations-in-haematology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>S ome investigations other than those already described may be necessary to diagnose a haematological disease or disorder. Some of these tests are described in this section.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reticulocyte-count">RETICULOCYTE COUNT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reticulocyte-count" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Reticulocytes, the young red cells that have lost their nuclei but not the cytoplasmic RNA, appear in the peripheral blood as polychromatic red cells when stained with a Romanowsky stain. However, reticulocytes are demonstrated with a supra-vital stain, when the RNA appears as a network of strands or granules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="staining-solution-for-supra-vital-staining">Staining Solution for Supra-vital staining<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staining-solution-for-supra-vital-staining" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Brilliant cresyl blue</strong></p>
<p>Brilliant cresyl blue 1 g</p>
<p>3 % sodium citrate 20 ml</p>
<p>0.9 % sodium chloride 80 ml</p>
<p>Mix to dissolve and filter before use. OR</p>
<p><strong>New methylene blue</strong></p>
<p>New methylene blue 1 g</p>
<p>3 % sodium citrate 20 ml</p>
<p>0.9 % sodium chloride 80 ml</p>
<p>Mix to dissolve</p>
<p><strong>Note</strong></p>
<p>Sodium citrate in the staining solution prevents coagulation when capillary specimen is used, and sodium chloride provides an isotonicity to preserve the red cells.</p>
<p><strong>Specimen</strong> Capillary blood, or anticoagulated venous blood taken into EDTA or sodium citrate.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Mix two drops of blood and two drops of the staining solution in a test tube.</li>
<li>Allow to stand at room temperature for 15-20 minutes or at 37°C for 10 minutes.</li>
<li>Gently tap the tube to remix the contents.</li>
<li>With a drop of the mixture, prepare a blood film in the same manner as for peripheral smear.</li>
<li>Allow the film to dry completely.</li>
<li>Examine under the oil-immersion objective (X 100). The reticular material (RNA) is precipitated by the dye and is stained blue-black. Mature red cells appear pale green (Fig. 6.1).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="counting">Counting<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#counting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Select an area on the smear where the red cells do not overlap. Count the number of red cells and reticulocytes in each field. At least 10 successive fields should be counted, preferably with a total of 1000 red cells. To minimise the difficulty of counting 1000 red cells in a large field, the microscopic field can be reduced by inserting an adjustable diaphragm or a circular piece of paper with a small square cut in the centre.</p>
<p>Scanned by CamScanner</p>
<p>Miscellaneous Investigations in Haematology 315</p>
<p><img src="assets/images/image-20251218-3d3f7c15.jpeg" alt="img-38.jpeg">
Fig. 6.1 Reticulocytes stained with brilliant cresyl blue</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="calculation">Calculation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calculation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi mathvariant="normal">%</mi><mtext>Reticulocytes</mtext><mo>=</mo><mfrac><mtext>Number&nbsp;of&nbsp;reticulocytes&nbsp;counted</mtext><mtext>Number&nbsp;of&nbsp;red&nbsp;cells&nbsp;+&nbsp;reticulocytes&nbsp;counted</mtext></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\% \text{Reticulocytes} = \frac{\text{Number of reticulocytes counted}}{\text{Number of red cells + reticulocytes counted}} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">%</span><span class="mord text"><span class="mord">Reticulocytes</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;red&nbsp;cells&nbsp;+&nbsp;reticulocytes&nbsp;counted</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;reticulocytes&nbsp;counted</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="miller-eyepiece-method-for-counting">Miller-eyepiece Method for Counting<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miller-eyepiece-method-for-counting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Alternatively, a special eyepiece, called Miller eyepiece can be used (Fig 6.2). The small square occupies one-ninth of the large square. Count the red cells in the small square and reticulocytes in the whole area of the large square. Count 10–20 fields showing an even distribution of cells.</p>
<p><img src="assets/images/image-20251218-0bf47204.jpeg" alt="img-39.jpeg">
Fig. 6.2 Miller eyepiece for reticulocyte count</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi mathvariant="normal">%</mi><mtext>Reticulocytes</mtext><mo>=</mo><mfrac><mtext>Number&nbsp;of&nbsp;reticulocytes</mtext><mrow><mtext>Number&nbsp;of&nbsp;reticulocytes&nbsp;+&nbsp;(Red&nbsp;cells&nbsp;</mtext><mstyle mathcolor="#cc0000"><mtext>\times</mtext></mstyle><mtext>9)</mtext></mrow></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\% \text{Reticulocytes} = \frac{\text{Number of reticulocytes}}{\text{Number of reticulocytes + (Red cells \times 9)}} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">%</span><span class="mord text"><span class="mord">Reticulocytes</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.3074em; vertical-align: -0.936em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;reticulocytes&nbsp;+&nbsp;(Red&nbsp;cells&nbsp;</span><span class="mord text" style="color: rgb(204, 0, 0);"><span class="mord" style="color: rgb(204, 0, 0);">\times</span></span><span class="mord">9)</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Number&nbsp;of&nbsp;reticulocytes</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p><strong>Interpretation</strong> Normal reticulocyte count in adults is 0.2–2 %. Counts are higher in new born babies (2.5–6 %). Presence of anaemia and low reticulocyte count indicate hypoplastic bone marrow. Increase in reticulocytes is seen in conditions such as haemolysis or blood loss.</p>
<p><strong>Note</strong> For anaemic blood, add half the volume of stain.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="staining-of-heinz-bodies">STAINING OF HEINZ BODIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staining-of-heinz-bodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Heinz bodies are denatured molecules of haemoglobin. They can be stained supravitally with methyl violet or crystal violet.</p>
<p><strong>Specimen</strong> Fresh blood anticoagulated with EDTA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="staining-solution">Staining solution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staining-solution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<table><thead><tr><th>Methyl violet</th><th>0.5 g</th></tr></thead><tbody><tr><td>0.9 % sodium chloride</td><td>100 ml</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) Mix equal volumes of blood and stain.
(ii) Incubate at 37°C for 20 min.
(iii) Mix and prepare a thin film.
(iv) Dry and examine under the oil-immersion objective.</p>
<p>Heinz bodies are seen as intense purple granules, 1–3 microns in size, situated close to the periphery of the red cells. One large or several small Heinz bodies may be seen in one red cell (Fig. 4.4).</p>
<p><strong>Interpretation</strong> Heinz bodies are absent in a normal blood specimen. They may appear after splenectomy, in hyposplenism or in haemolytic anaemias e.g. due to G6PD deficiency.</p>
<p>Scanned by CamScanner</p>
<p>316 Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="6d8988fb">♦ STAINING OF SIDEROCYTES (DEMONSTRATION OF PAPPENHEIMER BODIES)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6d8988fb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Siderocytes are red cells containing Pappenheimer bodies. Pappenheimer bodies are small, dense bodies of free iron, which can be demonstrated by a positive 'Prussian blue reaction'. Ferricyanide, under acidic conditions, reacts with iron to produce a blue colour.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="staining-solutions">Staining solutions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staining-solutions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>A. 1 % potassium ferricyanide
B. 0.2 N HCl
Mix equal volumes of A and B just before use.</li>
<li>0.1 % aqueous safranin or eosin.</li>
</ol>
<p><strong>Specimen</strong> Capillary blood or venous blood anticoagulated with EDTA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) Prepare a thin blood smear.
(ii) Fix it in methanol for 10 minutes.
(iii) Dry the smear and keep it in the ferricyanide-HCl mixture for 10 minutes.
(iv) Wash the smear in running tap water for 10 minutes and counterstain with aqueous safranin or eosin for 10–15 seconds.
(v) Wash and dry.
(vi) Examine under oil-immersion objective.</p>
<p><strong>Interpretation</strong> The Pappenheimer bodies stain deep blue-black. They are less than 2 microns in diameter, unevenly distributed in the red cell (Fig. 4.4).</p>
<p>They are rarely seen in a normal blood specimen. They are found in disorders associated with impaired haemoglobin synthesis (e.g. thalassaemia), in lead poisoning, in some haemolytic conditions, or after splenectomy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="9e24d798">♦ PEROXIDASE STAINING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#9e24d798" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This staining reaction is used to differentiate between the cells of lymphoid series and those of myeloid and monocyte series. The granules in both the latter series of cells contain peroxidase which liberates oxygen from hydrogen peroxide and oxidises benzidine. A blue colour indicates a positive reaction.</p>
<p><strong>Specimen</strong> A thin peripheral blood film or bone-marrow smear.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>
<p>Fixative
95 % ethyl alcohol 9 parts
Formaldehyde 1 part</p>
</li>
<li>
<p>Staining solution
Benzidine dihydrochloride 0.3 g
Methanol 30 ml
Dissolve benzidine dihydrochloride in methanol.
Add distilled water 70 ml
3.8 % Zinc sulphate 1.0 ml
Sodium acetate 1.0 g
1 N Sodium hydroxide 1.5 ml
Add 0.7 ml of 10 vol hydrogen peroxide just before use.</p>
</li>
</ol>
<p>&gt; <strong>Note</strong> Benzidine is carcinogenic, and therefore, must be handled with utmost care.</p>
<ol start="3">
<li>Giemsa counterstain
Dilute the stock Giemsa solution (commercially available) 1:10 in 0.066 M phosphate buffer, pH 6.4.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) Fix the dried smear in the fixative for 60 seconds.
(ii) Wash under tap water for 15 seconds. Immerse in the benzidine staining solution for 30 seconds.
(iii) Wash under tap water for 5–10 seconds.
(iv) Counterstain with Giemsa for 10 minutes.
(v) Wash, dry and examine under the oil-immersion objective.</p>
<p><strong>Interpretation</strong> A positive peroxidase reaction is indicated by the presence of blue-back granules in the cytoplasm. Early granulocyte precursors show a weak, localised reaction, becoming stronger and more generalised with increasing cell maturity. Monocytes may be negative, but sometimes show a weak positive reaction. Normal lymphoid and erythroid cells are invariably negative. Auer bodies</p>
<p>Scanned by CamScanner</p>
<p>Miscellaneous Investigations in Haematology 317</p>
<p>can be demonstrated by peroxidase reaction in myeloblasts and promyelocytes. The peroxidase reaction is most useful for differentiation between leukaemias of myeloid and lymphoid series.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="periodic-acid-schiff-pas-reaction">PERIODIC-ACID SCHIFF (PAS) REACTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#periodic-acid-schiff-pas-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This reaction depends on the liberation of carbohydrate radicals from compounds, such as glycogen; and their oxidisation to aldehydes by the Schiff reagent. Polysaccharides, mucopolysaccharides, glycoproteins and mucoproteins are PAS positive. A positive reaction is indicated by a bright red colour. In blood cells a positive reaction usually denotes the presence of glycogen. Developing granulocytes react positively at all stages of development. Mature polymorphonuclear neutrophils react most strongly showing large amounts of magenta coloured granules in their cytoplasm. Myelocytes contain fewer positively staining granules with a pale pink cytoplasm. In eosinophils the background cytoplasm is positive but the large specific granules show a negative reaction.</p>
<p>Lymphocytes show a few fine or coarse PAS positive granules while monocytes contain a small amount of fine, scattered positively staining material. The cytoplasm of normoblast does not normally stain at any stage of development. Platelets are positive and megakaryocytes also show a strong positivity. The positive granules are enormous in lymphoblasts in acute lymphocytic leukaemia.</p>
<p>The erythroblasts react positively in diseases like erythroleukaemia, thalassaemia, iron deficiency anaemia, sideroblastic anaemia, myelosclerosis.</p>
<p><strong>Specimen</strong> Thin film prepared with peripheral blood or bone marrow.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Periodic acid 10 g per litre.</li>
<li>Schiff’s reagent</li>
</ol>
<p>Dissolve 1 gm basic fuchsin in boiling water and dilute up to 400 ml. Cool the solution to 50°C and filter. To the filtrate add 1 ml of thionyl chloride and allow to stand in the dark for 12 hours.</p>
<p>Add 2 g of activated charcoal, shake for 1 minute and filter. Store the solution in the dark at 0 to 4°C. Filter before use.</p>
<ol start="3">
<li>Aqueous haematoxylin: Dissolve 2 g haematoxylin in 100 ml distilled water.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Fix the blood film in methanol for 5 to 15 minutes.
(ii) Wash in running tap water for 15 minutes.
(iii) Allow it to stand in periodic acid solution for 10 minutes and immerse in Schiff’s reagent in a coplin jar for 30 minutes.
(iv) Rinse the slide in tap water and then in distilled water for five minutes. Counterstain with aqueous haematoxylin for 10–15 minutes.
(v) Dry the film in the air, mount in a neutral mountant such as DPX, and examine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="neutrophil-leucocyte-alkaline-phosphatase">NEUTROPHIL (LEUCOCYTE) ALKALINE PHOSPHATASE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neutrophil-leucocyte-alkaline-phosphatase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Leucocyte alkaline phosphatase (LAP) activity reflects intracellular metabolic activity. The enzyme is located in cytoplasmic granules. This enzyme activity is greatly increased in leucocytosis; and is mainly associated with bacterial infections. It is particularly useful in differentiating leukaemias from leukaemoid reactions.</p>
<p><strong>Principle</strong> The alkaline phosphatase activity is demonstrated by the hydrolysis of alpha-naphthol phosphate by the enzyme to liberate naphthol. This, in turn, unites with a diazotised amine to form an insoluble coloured precipitate. The intensity of the colour is proportional to the concentration of the enzyme.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-fixative">1. Fixative<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-fixative" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>10 % Formalin-methanol: Add 10 ml of formalin to 90 ml of absolute methanol. The reagent is stable for 2–4 weeks if stored at –20°C.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-buffer">2. Buffer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-buffer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Stock solution 0.2 M Propanediol
2-amino-2-methyl-1,3 propanediol 21 g
Distilled water 1 L</p>
<p>Scanned by CamScanner</p>
<p>318 Haematology</p>
<p>Store at 4°C.</p>
<p>Working buffer 0.05 M Propanediol, pH 9.4-9.6</p>
<p>Stock buffer 250 ml
2N Hydrochloric acid 3.5 ml
Distilled water up to 1 L</p>
<p>Store at 4°C.</p>
<ol start="3">
<li>Substrate</li>
</ol>
<p>Sodium salt of
Naphthol AS-B1 phosphate 0.5 g
Fast violet B 0.04 g
Working buffer 60 ml</p>
<p>Prepare just before use. Shake well to dissolve and filter</p>
<ol start="4">
<li>Mayer's haematoxylin</li>
</ol>
<p>Haematoxylin 1 g
Distilled water 500 ml
Heat to boiling point.
Add distilled water 500 ml
Sodium iodate 0.2 g
Aluminium potassium sulphate 50g</p>
<p>Shake well to dissolve, filter and store in a brown bottle.</p>
<p>Specimen</p>
<p>Prepare blood smears from freshly withdrawn blood without anticoagulant. Fix immediately. If the blood sample is collected in EDTA, the blood smears should be made in less than one hour and fixed immediately.</p>
<p>Once fixed, the smear can be stored at 4°C for 24 hours or at -20°C for 3-4 weeks.</p>
<p>Prepare positive control smears from normal healthy individuals or from pregnant women and store as above.</p>
<p>Technique</p>
<p>(i) Fix the test and control smears in the cold fixative at 0 to 5°C for 30 seconds.
(ii) Wash gently in tap water and air dry.
(iii) Place in the freshly prepared substrate for 15 minutes.
(iv) Rinse in tap water.
(v) Stain with Mayer's haematoxylin for 6-8 minutes.
(vi) Rinse in tap water and air dry. Mount in aqueous mounting medium.
(vii) Examine under the oil immersion objective.</p>
<p>Alkaline phosphatase activity is indicated by the presence of bright blue granules in the cytoplasm of mature neutrophils. Count at least 100, preferably 200, neutrophils. Each cell is rated 0-4 on the basis of intensity of the stain as shown in Table 6.1. [After examination, remove the coverglass and dry the smear for re-examination at a later date, if required.]</p>
<p>Eosinophils, basophils, lymphocytes and monocytes should not be counted.</p>
<p>Results A rating in a total of 100 cells is counted. The sum of the ratings in 100 cells is the smear score. A normal score is 14 to 100 per 100 neutrophils. A score of 200 is considered normal in pregnancy and in children. Elevated alkaline phosphatase activity is observed in infections, in non-leukaemic myeloproliferative disorders such as polycythaemia, in Hodgkin's disease, aplastic anaemia, Down's syndrome, cirrhosis and in pregnancy. Low scores are found in chronic myeloid leukaemia, paroxysmal nocturnal haemoglobinuria and infectious mononucleosis.</p>
<p>Table 6.1 Scoring criteria in the LAP reaction</p>
<table><thead><tr><th>Cell Rating</th><th>Precipitated Azo Dye in the Cytoplasm</th><th></th><th></th><th>Cytoplasm Background</th></tr></thead><tbody><tr><td></td><td>Amount (%)</td><td>Granule size</td><td>Stain Intensity</td><td></td></tr><tr><td>0</td><td>—</td><td>—</td><td>—</td><td>Unstained</td></tr><tr><td>1+</td><td>20-50</td><td>Small</td><td>Faint to moderate</td><td>Unstained to Pale pink</td></tr><tr><td>2+</td><td>40-80</td><td>Small/medium</td><td>Moderate/strong</td><td>Unstained to pale pink</td></tr><tr><td>3+</td><td>80-100</td><td>Medium/large</td><td>Strong</td><td>Pink</td></tr><tr><td>4+</td><td>100</td><td>Medium/large</td><td>Brilliant</td><td>Cytoplasm not visible</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Miscellaneous Investigations in Haematology 319</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="examination-of-bone-marrow">EXAMINATION OF BONE MARROW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#examination-of-bone-marrow" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bone marrow examination is useful in the assessment of composition, cellularity and maturation of haemopoietic cells. It is necessary when peripheral blood examination fails to provide a clue for the diagnosis of a haematological disorder, or when further information is needed on a diagnosis reached by peripheral blood smear examination. Bone marrow examination is a must when there is an unexplained pancytopenia or cytopenia of a blood cell series. It is useful in the follow up of patients undergoing therapy for malignancies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="site-of-aspiration">Site of Aspiration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#site-of-aspiration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The bone marrow is aspirated from the medullary cavity by penetrating the cortical bone. The sternum and the iliac crest are the most common sites. Spinuous processes of vertebrae may be used. In infants and young children the medial aspect of the upper end of the tibia may be used.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="materials">Materials<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#materials" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>2% lignocaine without adrenaline (2–5 ml)</p>
<ul>
<li>Syringes: 2 ml and 5 ml.</li>
<li>Needles: 21, 22 and 25 gauge.</li>
</ul>
<p>Marrow aspiration needle with a sliding or screw guard.</p>
<ul>
<li>10–12 clean microscope slides.</li>
<li>EDTA bottle.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Select a site and position the patient appropriately.</p>
</li>
<li>
<p>Cleanse the skin with 70% ethanol or 0.5% chlorhexidine.</p>
</li>
<li>
<p>Infiltrate the skin with 2% lignocaine with the syringe at a right angle to the skin surface. Continue to inject the local anaesthetic till the needle touches the bone. Inject in all directions to cover about 1 cm² area. Withdraw the syringe and needle and cover with a gauze swab.</p>
</li>
<li>
<p>Wait for about one minute to allow the anaesthetic to act. Check that the aspiration equipment is functioning properly.</p>
</li>
<li>
<p>With the bevel uppermost, and stylet in, insert the marrow needle at right angle to the bone surface, and advance till the bone is touched. Lower the guard to 1 cm above the skin surface. With a firm pressure, push and rotate the needle through the cortex. The resistance suddenly ends when the needle reaches the medullary cavity. Continue advancing until the guard touches the skin.</p>
</li>
<li>
<p>Withdraw stylet and attach a 20 ml syringe. Aspirate the marrow quickly applying continuous suction. Remove the syringe and the needle, keep the area of aspiration under pressure with a gauze swab and apply an adhesive dressing.</p>
</li>
<li>
<p>After disconnecting the needle from the syringe, quickly prepare 10–12 smears of the aspirated bone marrow. The contents of the syringe are emptied into a glass petri dish. With a glass spreader pick up the yellowish particles of marrow and spread them on clean glass slides. Work quickly to avoid marrow clotting. The preparation should not be diluted with sinusoidal blood. A good bone marrow smear should contain marrow particles, leaving their trails behind while spreading the film.</p>
</li>
<li>
<p>Transfer the left over marrow to the EDTA tube and mix.</p>
</li>
</ol>
<p><strong>Staining</strong> Stain two bone-marrow films using any one of Romanowsky group of stains.</p>
<p>Preserve the other slides for special staining procedures if necessary.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="differential-cell-count-on-bone-marrow-myelogram">Differential Cell Count on Bone Marrow (Myelogram)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#differential-cell-count-on-bone-marrow-myelogram" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Many workers perform counts on marrow films by presenting the data in the form of a myelogram, and expressing the various cell types as a percentage. Because of the naturally renegated pattern of the bone marrow and the irregular distribution of the marrow cells, differential cell counts on marrow aspirated from normal subjects show a very wide range of normality. It is necessary to choose a proper area for differential count. The cellular trails of the fragments are considered to be ideal.</p>
<p>Scanned by CamScanner</p>
<p>320 Haematology</p>
<p>sites. The examination should commence from the marrow fragments working back towards the head of the films. The particles should be examined with a low power objective with particular reference to their cellularity. Estimate whether the marrow is hypocellular, normocellular or hyperplastic.</p>
<p>Select a highly cellular area of the film where the nucleated cells are well stained and well spread. The cells in the cellular areas should be examined with the oil-immersion objective. Observe the stages of maturation of myeloid and erythroid components. Count a total number of 500 cells and record each cell type as a percentage. The normal ratio of myeloid/erythroid cells ranges from 2.5:1 to 5:1. Any abnormality in maturation, e.g. megaloblastosis, should be recorded.</p>
<p>In adults, about 10 % of nucleated cells are lymphocytes. Their number may be higher in children. Megakaryocytes, monocytes and plasma cells should be examined for both their number and morphology, and any abnormality should be noted.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="normal-ranges-for-differential-counts-on-aspirated-bone-marrow">Normal Ranges for Differential Counts on Aspirated Bone Marrow<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#normal-ranges-for-differential-counts-on-aspirated-bone-marrow" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th>Undifferentiated blast cells</th><th>0.1</th><th>-</th><th>2 %</th></tr></thead><tbody><tr><td>Myeloblast</td><td>0.1</td><td>-</td><td>1 %</td></tr><tr><td>Promyelocytes</td><td>0.5</td><td>-</td><td>5 %</td></tr><tr><td>Myelocytes</td><td></td><td></td><td></td></tr><tr><td>(a) Neutrophil</td><td>5</td><td>-</td><td>20 %</td></tr><tr><td>(b) Eosinophil</td><td>0.1</td><td>-</td><td>3 %</td></tr><tr><td>(c) Basophil</td><td>0</td><td>-</td><td>0.5 %</td></tr><tr><td>Metamyelocytes</td><td>10</td><td>-</td><td>30 %</td></tr><tr><td>Granulocytes</td><td></td><td></td><td></td></tr><tr><td>(a) Neutrophil</td><td>7</td><td>-</td><td>25 %</td></tr><tr><td>(b) Eosinophil</td><td>0.2</td><td>-</td><td>3 %</td></tr><tr><td>(c) Basophil</td><td>0</td><td>-</td><td>0.5 %</td></tr><tr><td>Lymphocytes</td><td>5</td><td>-</td><td>20 %</td></tr><tr><td>Monocytes</td><td>0</td><td>-</td><td>0.2 %</td></tr><tr><td>Megakaryocytes</td><td>0.1</td><td>-</td><td>0.5 %</td></tr><tr><td>Plasma cells</td><td>0.1</td><td>-</td><td>3.5 %</td></tr><tr><td>Proerythroblasts</td><td>0.5</td><td>-</td><td>5 %</td></tr><tr><td>Normoblasts</td><td>2</td><td>-</td><td>20 %</td></tr><tr><td>Myeloid/Erythroid ratio</td><td>2.5</td><td>-</td><td>5.0:1</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-for-sickle-cells">TEST FOR SICKLE CELLS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-for-sickle-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In homozygous sickle cell anaemia, the sickle cells may be seen in the peripheral blood smear, and the diagnosis can be made from the clinical and haematological picture. However, in heterozygous sickle cell trait, these changes are not apparent and diagnosis is difficult. In such cases, if the whole blood is exposed to reduced oxygen tension with the help of a reducing agent, sickling can be demonstrated.</p>
<p><strong>Specimen</strong> A fresh anticoagulated blood sample. A normal blood specimen should be used as a control.</p>
<p><strong>Reagent</strong> A freshly prepared solution of 2 % sodium metabisulphite. Dissolve 0.2 g in 10ml distilled water.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Add 0.5 ml of whole blood to 0.5 ml of 2% sodium metabisulphite in a test tube.</p>
<p>(ii) Mix thoroughly and place a drop on a glass slide, cover with a coverslip. Seal all the four edges with vaseline.</p>
<p>(iii) Leave at room temperature for one hour.</p>
<p>(iv) Observe the red cell morphology under the microscope.</p>
<p>(v) Proceed with the control in the same way.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation">Interpretation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The control shows normal red cells which retain their biconcave discoid shape in the presence of sodium metabisulphite.</p>
<p>In sickle cell trait, the red cells lose their characteristic morphology due to reduced oxygen tension in the presence of sodium metabisulphite and some cells may appear crescent-shaped (Fig. 5.3).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="demonstration-of-le-cells">DEMONSTRATION OF LE CELLS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#demonstration-of-le-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>An LE cell is a neutrophil which contains a basophilic, opaque, homogeneous mass in its cytoplasm. The nucleus is pushed towards the periphery and appears crescent shaped around the ingested mass. An LE cell is formed when the LE</p>
<p>Scanned by CamScanner</p>
<p>Miscellaneous Investigations in Haematology 321</p>
<p>factor combines with nuclear protein in the presence of phagocytic leucocytes. The LE factor is the IgG antibody to nucleoprotein derived either from granulocytes or lymphocytes. LE cells can be found in about 60 to 75 % of patients with systemic lupus erythematosus (SLE). They are also produced in response to various drugs such as procainamide and hydralazine.</p>
<p>The test consists of incubation of patient's plasma containing LE factor with patient's leucocytes. The smears are prepared for the presence of LE cells.</p>
<p><strong>Specimen</strong> Collect about 10 ml of blood in heparinised tube containing 10 glass beads. The LE factor does not act on leucocytes unless they are slightly damaged. This is achieved by rotating the whole blood with glass beads.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Rotate the blood sample with the beads in the tube for 30 minutes either manually or on a rotator.
(ii) Incubate at 37°C for 30 minutes to 1 hour, shaking intermittently.</p>
<p>(iii) Transfer the blood to a Wintrobe tube using a pasteur pipette and centrifuge at 1,500 rpm for 15 to 20 minutes.
(iv) Discard the layer of plasma at the top. Carefully withdraw the cells from the buffy coat and prepare thin smears.
(v) Examine under oil immersion objective for LE cells which are indicated by bluish purple mass in the cytoplasm of a neutrophil.</p>
<p>&gt; <strong>Note</strong> The LE cell test is neither completely specific, nor very sensitive for the diagnosis of SLE. More specific and sensitive tests, such as immunofluorescence and latex agglutination for the detection of antinuclear antibody (LE factor) are available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="latex-agglutination-test-for-the-detection-of-le-factor">Latex Agglutination Test for the Detection of LE Factor<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#latex-agglutination-test-for-the-detection-of-le-factor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The test employs agglutination of latex particles coated with deoxyribonucleoprotein (DNP) by LE factor, which is an antibody to DNP.</p>
<ol>
<li>Decreased saline concentration (Hypotonic solution)</li>
</ol>
<p><img src="assets/images/image-20251218-0658a99f.jpeg" alt="img-40.jpeg"></p>
<p>Cell takes in water, enlarges and bursts liberating haemoglobin</p>
<p>Haemolysis</p>
<ol start="2">
<li>Increased saline concentration (Hypertonic solution)</li>
</ol>
<p><img src="assets/images/image-20251218-9e2fa550.jpeg" alt="img-41.jpeg"></p>
<p>Cell loses water and becomes wrinkled or crenated</p>
<p>The osmotic fragility is altered when the cell shape is abnormal. The initial shape of the cell influences the amount of water it can take before it bursts e.g. spherocytes have increased fragility i.e. they can absorb very little water before lysis.</p>
<p>Fig. 6.3 Principle of osmotic fragility test</p>
<p>Scanned by CamScanner</p>
<p>322 Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specimen-serum-technique">Specimen Serum Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen-serum-technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Mix one drop of patient’s serum with one drop of well mixed latex suspension coated with DNP, on a slide.
(ii) Rotate for one minute and examine for agglutination.
(iii) Run a known positive control in the same way along with the test.</p>
<p><strong>Result</strong> Agglutination appearing within one minute indicates a positive test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cf4b48aa">♦ OSMOTIC FRAGILITY TEST<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cf4b48aa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This test may be required to investigate haemolytic anaemias due to red cell membrane defect, e.g. spherocytosis.</p>
<p><strong>Principle</strong> The test determines the resistance of red cells to haemolysis in various concentrations of hypotonic saline solutions (Fig. 6.3). The ability of erythrocytes to absorb water without lysis depends on the ratio of volume to surface area of the cells. In the normal red cells, the volume may increase up to 70 % before lysis can occur. Spherocytes have reduced surface to volume ratio and therefore absorb less water.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>The stock solution of sodium chloride osmotically equivalent to 10 % is prepared as follows.</li>
</ol>
<table><thead><tr><th>Sodium chloride</th><th>90 g</th></tr></thead><tbody><tr><td>Disodium hydrogen phosphate</td><td>13.65 g</td></tr><tr><td>Sodium dihydrogen phosphate</td><td>2.34 g</td></tr><tr><td>Distilled water</td><td>1 litre</td></tr></tbody></table>
<p><strong>Specimen</strong> Heparinised venous blood or defibrinated blood should be used. Oxalated, citrated or EDTA blood should be avoided because additional salts may interfere with the test. The test should be carried out immediately. If delay is expected, the blood should be preserved at 4°C and the test performed within six hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Dilute the stock solution of sodium chloride 1 : 10 with distilled water to obtain a 1 % solution.
(ii) Take 12 tubes and prepare dilutions as follows:</p>
<table><thead><tr><th>Table No.</th><th>1 % NaCl (ml)</th><th>Distilled Water (ml)</th><th>Final concentration of NaCl (%)</th></tr></thead><tbody><tr><td>1</td><td>4.5</td><td>0.5</td><td>0.9</td></tr><tr><td>2</td><td>3.75</td><td>1.25</td><td>0.75</td></tr><tr><td>3</td><td>3.25</td><td>1.75</td><td>0.65</td></tr><tr><td>4</td><td>3</td><td>2</td><td>0.6</td></tr><tr><td>5</td><td>2.75</td><td>2.25</td><td>0.55</td></tr><tr><td>6</td><td>2.5</td><td>2.5</td><td>0.5</td></tr><tr><td>7</td><td>2.25</td><td>2.75</td><td>0.45</td></tr><tr><td>8</td><td>2</td><td>3</td><td>0.4</td></tr><tr><td>9</td><td>1.75</td><td>3.25</td><td>0.35</td></tr><tr><td>10</td><td>1.5</td><td>3.5</td><td>0.3</td></tr><tr><td>11</td><td>1</td><td>4</td><td>0.2</td></tr><tr><td>12</td><td>0.5</td><td>4.5</td><td>0.1</td></tr></tbody></table>
<p>(iii) Add 0.05 ml of the blood to each of the tubes and mix immediately by gently inverting several times.
(iv) A blood sample from a normal individual is run in parallel as a control.
(v) Stand at room temperature (18–20°C) for 30 minutes.
(vi) Remix and centrifuge.
(vii) The amount of lysis in each tube is determined colorimetrically using a green filter, at 540 nm. The first tube in the series serves as a blank (0 % lysis) as it contains 0.9 % isotonic saline. The 12th tube containing 0.1 % saline serves as 100 % lysis since this gives complete lysis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="calculation">Calculation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calculation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>Percentage&nbsp;haemolysis</mtext><mo>=</mo><mfrac><mtext>Absorbance&nbsp;of&nbsp;test</mtext><mtext>Absorbance&nbsp;of&nbsp;100&nbsp;%&nbsp;lysis&nbsp;type</mtext></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\text{Percentage haemolysis} = \frac{\text{Absorbance of test}}{\text{Absorbance of 100 \% lysis type}} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">Percentage&nbsp;haemolysis</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Absorbance&nbsp;of&nbsp;100&nbsp;%&nbsp;lysis&nbsp;type</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Absorbance&nbsp;of&nbsp;test</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p>Plot a graph of % lysis against concentration of sodium chloride (Fig 6.4). Record the results as:</p>
<ol>
<li>Complete lysis or maximum resistance as the highest concentration of saline shows complete lysis.</li>
</ol>
<p>Scanned by CamScanner</p>
<p>Miscellaneous Investigations in Haematology 323</p>
<ol start="2">
<li>Initial lysis or minimum resistance as highest concentration of saline in which lysis appears to be just detectable.</li>
</ol>
<p>Normal range of osmotic fragility is indicated as shown below:</p>
<table><thead><tr><th>Concentration of sodium chloride</th><th>% Lysis</th></tr></thead><tbody><tr><td>0.1 %</td><td>100</td></tr><tr><td>0.2 %</td><td>100</td></tr><tr><td>0.3 %</td><td>97–100</td></tr><tr><td>0.35 %</td><td>90–99</td></tr><tr><td>0.45 %</td><td>50–95</td></tr><tr><td>0.5 %</td><td>5–45</td></tr><tr><td>0.55 %</td><td>0–6</td></tr><tr><td></td><td>Contd.*</td></tr></tbody></table>
<p>(Contd.)*</p>
<table><thead><tr><th>* Conc. of NaCl</th><th>% Lysis</th></tr></thead><tbody><tr><td>0.6 %</td><td>0</td></tr><tr><td>0.65 %</td><td>0</td></tr><tr><td>0.7 %</td><td>0</td></tr><tr><td>0.75 %</td><td>0</td></tr><tr><td>0.8 %</td><td>0</td></tr><tr><td>0.85 %</td><td>0</td></tr></tbody></table>
<p>The normal fragility curve should fall in the shaded area shown in the graph (Fig. 6.4).</p>
<p>Alternatively, the osmotic fragility may be expressed as the concentration of NaCl causing 50 % haemolysis. Mean Corpuscular Fragility (MCF), from the graph. The normal range for MCF is 0.4 to 0.45 g/100 ml.</p>
<p><img src="assets/images/image-20251218-c6afe420.jpeg" alt="img-42.jpeg"></p>
<p>Interpretation:</p>
<table><thead><tr><th>Osmotic fragility</th><th>Haemolysis begins at % NaCl</th><th>100% lysis at % NaCl</th><th>Medium Corpuscular Fragility (MCF) at % NaCl</th><th>Clinical Condition</th></tr></thead><tbody><tr><td>Normal —</td><td></td><td></td><td></td><td></td></tr><tr><td>Increased —</td><td></td><td></td><td></td><td></td></tr><tr><td>Decreased —</td><td>0.5 - 0.55</td><td></td><td></td><td></td></tr></tbody></table>
<blockquote>
<p>0.55 (e.g. 0.75)
&lt; 0.5 (e.g. 0.45) | 0.3 - 0.35
0.35 (e.g. 0.5)
&lt; 0.3 (e.g. 0.2) | 0.4-0.45
0.45 (e.g. 0.6)
&lt; 0.4 (e.g. 0.3) | -
Spherocytosis
Thalassaemia, iron deficiency anaemia  |</p>
</blockquote>
<p>Fig. 6.4 Osmotic fragility graph</p>
<p>Scanned by CamScanner</p>
<p>324 Haematology</p>
<p><strong>Note</strong> The osmotic fragility is increased when the lysis starts at a concentration higher than 0.5 % and is decreased when 100 % lysis starts at a concentration lower than 0.3 %.</p>
<p><strong>Interpretation</strong> Various haematological disorders show characteristic changes in osmotic fragility. Osmotic fragility is increased (i.e. resistance reduced) in hereditary spherocytosis, in ABO haemolytic disease, and haemolytic disease of the new-born. It is reduced (i.e. resistance increased) in thalassaemia, iron deficiency anaemia, liver disease and splenomegaly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="estimation-of-haemoglobin-f-foetal-haemoglobin-by-alkali-denaturation-method">ESTIMATION OF HAEMOGLOBIN F (Foetal Haemoglobin) BY ALKALI DENATURATION METHOD<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#estimation-of-haemoglobin-f-foetal-haemoglobin-by-alkali-denaturation-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Foetal haemoglobin (HbF) constitutes 70 to 90 % of the total haemoglobin at birth, but is replaced by the adult haemoglobin (HbA) during the first few months after birth. HbF consists of two alpha (α) and two gamma (γ) chains in its globin molecule, and each chain is linked with a haem group. When HbF is converted to HbA, an amino acid in the gamma chain is replaced, and the resulting chain is called a beta (β) chain. Thus</p>
<ul>
<li>Globin chains in Hb A 2 α and 2 β</li>
<li>Globin chains in Hb F 2 α and 2 γ</li>
</ul>
<p>In beta-thalassaemia, there is a decrease in the synthesis of beta chains, and therefore, an increase in HbF.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principle">Principle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>HbF is more resistant to denaturation by alkali than HbA. This property is used to estimate the amount of HbF in a blood sample. A haemolysate is prepared. A measured quantity of the haemolysate is exposed to the action of an alkaline reagent for a defined period of time. Denaturation process is interrupted by adding a solution which simultaneously lowers the pH and precipitates the denatured haemoglobin. After filtration, the unaltered haemoglobin (HbF) is determined by reading the absorbance of the filtrate. This is expressed as a percentage of total initial amount of haemoglobin present in the specimen of blood.</p>
<p><strong>Specimen</strong> Blood anticoagulated with EDTA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Sodium or potassium hydroxide (0.083 N) Dilute before use, 1 N NaOH or KOH 1:12 (8.1 ml of 1 N solution to 100 ml with distilled water).</li>
<li>Precipitating agent: Add 2 ml of concentrated hydrochloric acid to 500 ml of half saturated ammonium sulphate solution. Prepare saturated ammonium sulphate solution by adding about 500 g of the salt to 500 ml water. Allow it to stand for 1-2 hours. Dilute the supernatant 1:2 to obtain a half-saturated solution.</li>
<li>Sodium chloride 0.85 % solution.</li>
<li>Chloroform</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Step 1 Preparation of haemolysate</strong> Centrifuge the specimen of blood.</p>
<p>Wash the cells three times with the sodium chloride solution.</p>
<p>For lysing the cells, shake each volume of packed cells (0.4 ml) vigorously with equal volume of distilled water (0.4 ml) and half volume of chloroform (0.2 ml) for two minutes.</p>
<p>Centrifuge at 3000 rpm for 20 minutes.</p>
<p>Remove the upper layer of haemoglobin. Filter to clear if necessary.</p>
<p>Determine the haemoglobin concentration of the haemolysate by one of the standard methods in use. e.g. cyanmethaemoglobin method.</p>
<p>Adjust the haemoglobin concentration of the haemolysate to approximately 10 g%. For example, if haemoglobin content of the haemolysate is 13 g%, add 0.3 ml of distilled water to 1.0 ml of the haemolysate to obtain the concentration equal to 10 g%.</p>
<p><strong>Step 11 Alkali denaturation</strong> Place 3.0 ml of 0.083 N hydroxide solution in a test tube.</p>
<p>Add 0.2 ml of the haemolysate quickly from a pipette and gently shake the tube for 10 seconds. Start a stop watch at the time of adding the haemolysate.</p>
<p>Scanned by CamScanner</p>
<p>Miscellaneous Investigations in Haematology 325</p>
<p>At the end of exactly 1 minute, add 6.8 ml precipitating agent.</p>
<p>Mix by inverting several times and filter through two layers of Whatman No. 1 filter paper. With normal adult haemoglobin, the filtrate is colourless whereas in the presence haemoglobin F, the filtrate may be light brown to deep red in colour.</p>
<p>Prepare a standard haemoglobin solution by diluting 0.2 ml of the haemolysate prepared in Step 1 to 200 ml with 0.04 % ammonia solution. This corresponds to 5 % alkali resistant haemoglobin.</p>
<p>Read the absorbance of the standard and test against a water blank using a blue filter (415 nm).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="calculations">Calculations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calculations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) The amount of foetal haemoglobin (HbF) is expressed as a percentage of total haemoglobin (HbF + HbA).</p>
<p>(ii) During alkali denaturation, 0.2 ml of the haemolysate is diluted to 10 ml (1:50 dilution).</p>
<p>(iii) If all the haemoglobin is in the form of alkali resistant haemoglobin (HbF), the absorbance of 1:50 dilution should be equivalent to 100 % HbF.</p>
<p>(iv) Therefore, 0.2 ml of the haemolysate diluted to 200 ml (1:1000 dilution) is equivalent to 5 % HbF.</p>
<p>Alkali resistant haemoglobin (%)</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mo>=</mo><mfrac><mtext>Reading&nbsp;of&nbsp;test</mtext><mtext>Reading&nbsp;of&nbsp;standard</mtext></mfrac><mo>×</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">= \frac{\text{Reading of test}}{\text{Reading of standard}} \times 5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Reading&nbsp;of&nbsp;standard</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Reading&nbsp;of&nbsp;test</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span></div>
<p><strong>Normal range</strong> In the normal adult blood, only 0.5 to 1.7 % of the total haemoglobin is alkali resistant (HbF).</p>
<p><strong>Interpretation</strong> Increased levels of upto 5 % HbF are found in various genetic and acquired disorders. In addition to beta thalassaemia, high HbF may be seen in leukaemias, aplastic anaemia and sickle cell anaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="haemoglobin-electrophoresis">HAEMOGLOBIN ELECTROPHORESIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemoglobin-electrophoresis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Electrophoresis is the movement of charged particles in an electric field. The speed of movement depends on the electrical charge on each particle and hydrogen ion concentration (pH) of the medium. At an alkaline pH of 8.4 to 8.6, haemoglobin is negatively charged and migrates towards the anode. Due to structural variations in their molecules, different haemoglobins possess different electrical charges and therefore, separate during electrophoresis. Presence of abnormal haemoglobins can be detected by this method. Various support media such as paper, agar gel or cellulose acetate can be used for haemoglobin electrophoresis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="requirements">Requirements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#requirements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Electrophoresis chamber with power pack</li>
<li>Cellulose acetate medium</li>
<li>TRIS buffer, pH 8.4</li>
</ol>
<ul>
<li>TRIS 10.2 g</li>
<li>EDTA 0.68 g</li>
<li>Boric acid 3.2 g</li>
<li>Distilled water 1 Litre</li>
</ul>
<ol start="4">
<li>Ponceau stain (0.5 %)</li>
</ol>
<ul>
<li>Ponceau S 0.5 g</li>
<li>Trichloroacetic acid 5.0 g</li>
<li>Distilled water 100 ml</li>
</ul>
<ol start="5">
<li>Destaining and clearing agents</li>
</ol>
<ul>
<li>5 % acetic acid</li>
<li>Methyl alcohol</li>
<li>20 % acetic acid in absolute methyl alcohol</li>
</ul>
<ol start="6">
<li>Normal saline</li>
<li>Abnormal haemoglobin control specimens.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specimen">Specimen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>EDTA anticoagulated blood</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Step 1: Preparation of haemolysate</strong></p>
<p>(i) Centrifuge the anticoagulated blood at 2500 rpm for five minutes.</p>
<p>(ii) Remove the plasma and wash the packed cells with large volumes of saline three times.</p>
<p>(iii) After the final washing, lyse the red cells by adding equal volume of distilled water, one-quarter volume of toluene and one drop of 3 % potassium cyanide. Mix by inversion and centrifuge to remove the cell debris.</p>
<p>(iv) Transfer the haemolysate to a clean tube.</p>
<p><strong>Step II: Electrophoresis</strong></p>
<p>(i) Pour the buffer into the electrophoresis chamber, soak the wicks and position them. Pre-soak the cellulose acetate plate for 20–30 minutes in the buffer. Remove the excess buffer by keeping the plate between absorbent papers.</p>
<p>Scanned by CamScanner</p>
<p>326 Haematology</p>
<p>(ii) Using an applicator, apply 0.5 to 0.6 ml of the specimen approximately 3 cm from the cathode. Also apply at least two abnormal controls on each plate.</p>
<p>(iii) Place the plate in the electrophoresis chamber. Place a microscope slide over it.</p>
<p>(iv) Run the electrophoresis at 450 volts for 20 minutes.</p>
<p>(v) Remove the cellulose acetate plate and stain with Ponceau S for three minutes.</p>
<p>(vi) Wash in three changes of 5 % acetic acid.</p>
<p>(vii) Fix in absolute methyl alcohol for five minutes.</p>
<p>(viii) Clear in 20 % acetic acid in absolute methyl alcohol for 10 minutes.</p>
<p>(ix) Dry in oven at 65°C for 10 minutes.</p>
<p>(x) Scan the cellulose acetate plate with a scanning densitometer.</p>
<p><strong>Interpretation</strong> Compare the relative mobility of abnormal haemoglobins in the control samples with those of the test sample both visually and with scanning densitometer. Identify the abnormal haemoglobins present in the test sample (Fig. 5.4).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="detection-of-glucose-6-phosphate-dehydrogenase-g-6-pd-deficiency">DETECTION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G-6-PD) DEFICIENCY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#detection-of-glucose-6-phosphate-dehydrogenase-g-6-pd-deficiency" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>G-6-PD deficiency is one of the most commonly inherited disorders. The inheritance is sex-linked, affecting males, while females act as carriers. Most individuals are symptom free, but acute haemolytic anaemia may occur by exposure to certain haemolytic agents listed in Table 5.2. It is necessary to detect the deficiency so that the haemolytic agents can be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="g-6-pd-screening-test">G-6-PD Screening Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#g-6-pd-screening-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When whole blood or haemolysate is incubated with an excess of glucose-6-phosphate (the substrate) and nicotinamide adenosine diphosphate (NADP), the enzyme G-6-PD converts NADP to the reduced form of NADP (NADPH). The NADPH reduces the dye nitro blue tetrazolium (NBT) in presence of phenazine methosulphate (PMS), to a brown coloured compound. The reduction of NBT in a defined period of time indicates normal G-6-PD activity.</p>
<p><strong>Specimen</strong> Capillary blood or venous blood anticoagulated with EDTA.</p>
<p>A control specimen from a known normal individual should also be collected.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Tris (2-amino-hydroxy-methyl propane 1-3 diol) buffer, pH 8.5 (0.07M) Dissolve 8.95g of tris in about 90 ml distilled water. Adjust the pH to 8.5 with 0.1 N hydrochloric acid and make the volume upto 100ml with distilled water.</p>
</li>
<li>
<p>Buffer-substrate solution</p>
</li>
</ol>
<table><thead><tr><th>Glucose-6-phosphate</th><th>40 mg</th></tr></thead><tbody><tr><td>NADP</td><td>25 mg</td></tr><tr><td>Nitro blue tetrazolium</td><td>25 mg</td></tr><tr><td>Distilled water</td><td>20 ml</td></tr><tr><td>Tris buffer</td><td>5 ml</td></tr></tbody></table>
<p>This reagent is stable for one month at 4°C.</p>
<ol start="3">
<li>Phenazine methosulphate (PMS) Prepare freshly before use by dissolving 1mg per ml distilled water.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Into a test-tube, pipette 0.9 ml of the buffer-substrate solution.</p>
<p>(2) Add 0.01ml whole blood.</p>
<p>(3) Add 0.05 ml PMS solution</p>
<p>(4) Mix well and allow to stand at room temperature for 30 minutes, away from direct sunlight.</p>
<p>(5) Read the colour change macroscopically.</p>
<p>(6) Prepare a control tube in the same way as above using the control specimen.</p>
<p>(7) Prepare a reagent blank using distilled water instead of whole blood.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reading-results">Reading results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reading-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Dark brown colour with or without a blue precipitate Normal G-6-PD level</p>
<p>No change in colour G-6-PD deficient males or homozygous females</p>
<p>Tan colour or brown colour Heterozygous females</p>
<p>Scanned by CamScanner</p>
<p>Miscellaneous Investigations in Haematology 327</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ham-s-test-acidified-serum-test">HAM'S TEST (Acidified Serum Test)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ham-s-test-acidified-serum-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In paroxysmal nocturnal haemoglobinuria (PNH), haemolytic anaemia occurs due to the lysis of some red cells in the presence of complement. In vitro, these red cells can be detected by exposing them to complement at an acidic pH, using complement in patient’s own serum or any other compatible serum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principle">Principle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The patient’s red cells are exposed to complement in his or her own acidified serum and incubated. The amount of lysis produced in this way is compared with that produced by serum heated at 56°C for 20–30 minutes to inactivate the complement. Haemolysis does not occur in inactivated serum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specimen">Specimen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Venous blood divided into two parts, one part collected in anticoagulant and the other in a plain tube.</li>
<li>Venous blood from a group ‘O’ individual collected as for the test sample.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>0.2 N HCl</li>
<li>Sodium chloride, 0.9 %</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Place 0.5 ml of serum in a test tube and inactivate at 56°C for 20 minutes.</li>
<li>Wash patient’s red cells from the anticoagulated blood three times in saline and make a 20 % suspension in saline.</li>
<li>Prepare a 20 % suspension in the same way from the normal blood sample (group O).</li>
<li>Set up four tubes as follows:</li>
</ol>
<table><thead><tr><th>Tube No.</th><th>1</th><th>2</th><th>3</th><th>4</th></tr></thead><tbody><tr><td>Fresh normal serum</td><td>0.5 ml</td><td>0.5 ml</td><td>–</td><td>0.5 ml</td></tr><tr><td>Heat inactivated serum</td><td>–</td><td>–</td><td>0.5 ml</td><td>–</td></tr><tr><td>0.2 N HCl</td><td>–</td><td>0.05 ml</td><td>0.05 ml</td><td>–</td></tr><tr><td>Patient’s red cells</td><td>0.05 ml</td><td>0.05 ml</td><td>0.05 ml</td><td>–</td></tr><tr><td>Group ‘O’ red cells</td><td>–</td><td>–</td><td>–</td><td>0.05 ml</td></tr></tbody></table>
<p>Mix well and incubate at 37°C for 1 hour.</p>
<ol start="5">
<li>Mix and centrifuge.</li>
<li>Examine for haemolysis.</li>
</ol>
<p><strong>Results</strong> PNH abnormality is detected by strong haemolysis in tube 2, trace or no haemolysis in tube 1, and no haemolysis in tubes 3 and 4. Haemolysis in tubes 3 and 4 shows a false positive test or some rare congenital conditions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="donath-landsteiner-d-l-antibody-test">DONATH-LANDSTEINER (D-L) ANTIBODY TEST<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#donath-landsteiner-d-l-antibody-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Paroxysmal cold haemoglobinuria (PCH), is caused by a ‘biphasic’ auto antibody which is IgG in nature. When incubated with red cells at 0°C this antibody binds to the red cells. Lysis occurs when this antibody-red cell complex is incubated at 37°C in the presence of complement.</p>
<p><strong>Specimen</strong> Collect 5 ml blood in each of two plain tubes. Immediately place both the tubes at 37°C.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Place one tube in crushed ice for 30 minutes (Tube 1).</li>
<li>At the same time, place the second tube at 37°C for 1 hour (Tube 2).</li>
<li>At the end of 30 minutes, transfer the tube from the ice-bath to the incubator at 37°C, and incubate for 30 minutes.</li>
<li>Centrifuge both tubes at 200 g for one minute and compare the supernatant in both the tubes.</li>
</ol>
<p><strong>Results</strong> The test is positive if the tube 1 shows haemolysis. The other tube incubated at 37°C serves as a control and should show no evidence of haemolysis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="detection-of-drug-induced-antibody">DETECTION OF DRUG-INDUCED ANTIBODY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#detection-of-drug-induced-antibody" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antibodies to certain drugs, such as penicillin, react with red cells on which the drug is adsorbed. These antibodies may cause haemolytic anaemia.</p>
<p><strong>Specimen</strong> Serum.</p>
<p>Scanned by CamScanner</p>
<p>328 Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>One million units of penicillin or a daily dose of the drug under investigation.</li>
<li>Phosphate buffered saline, (PBS) pH 7.0</li>
<li>Barbital buffer (0.1 M) pH 9.6</li>
<li>Washed group ‘O’ red cells</li>
<li>Anti-human globulin serum (AHGS).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="step-i-adsorption-of-the-drug-on-red-cells">Step I: Adsorption of the drug on red cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#step-i-adsorption-of-the-drug-on-red-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Dissolve 1 million units of penicillin in 15 ml of barbital buffer.</li>
<li>Place 0.5 ml of washed group ‘O’ red cells in a test tube and add 7.5 ml of the penicillin solution.</li>
<li>Mix and incubate at room temperature for one hour. Gently mix the tube intermittently throughout incubation.</li>
<li>Wash the red cells three times in PBS.</li>
<li>Prepare a 5 % suspension of the cells.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="step-ii-indirect-antiglobulin-test-on-drug-coated-red-cells">Step II: Indirect antiglobulin test on drug-coated red cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#step-ii-indirect-antiglobulin-test-on-drug-coated-red-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>In a tube, mix 0.6 ml of patients serum and 0.2 ml of drug-coated red cell suspension.</li>
<li>Incubate at 37°C for 1 hour.</li>
<li>Examine for agglutination or haemolysis. If positive, report and do not proceed further.</li>
<li>If there is no agglutination, wash the cells-serum mixture three times in PBS, resuspending the cells after completely removing the supernatant each time.</li>
<li>After the third washing, add two drops of anti-human globulin serum (AHGS). Mix and stand for five minutes.</li>
<li>Centrifuge at 1000 g for 15 seconds.</li>
<li>Examine the tube for agglutination macroscopically by tapping the tube. Examine under the microscope by streaking a small drop on a slide with a pasteur pipette.</li>
</ol>
<p><strong>Results</strong> Agglutination of red cells indicates the presence of antibodies to the drug.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="31d1ce20">DIRECT ANTIGLOBULIN TEST (Direct Coomb’s Test)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#31d1ce20" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Anti-human globulin serum (AHGS) can detect the presence of antibody on the red cells formed due to sensitisation <em>in vivo</em>. Sensitisation of red cells can occur <em>in vivo</em> by</p>
<p>(i) Auto-antibodies, e.g., in auto-immune haemolytic anaemia.
(ii) Allo-antibodies, e.g., in haemolytic transfusion reaction or in haemolytic disease of the newborn (HDN).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specimen">Specimen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Anticoagulated whole blood.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Wash patient’s red cells three times with saline, and prepare a 5 % suspension.</li>
<li>Add 0.2 ml of washed red cells to 0.4 ml of AHGS in a test tube.</li>
<li>Allow it to stand for five minutes and centrifuge at 1000 g for 15 seconds.</li>
<li>Examine the tube for agglutination macroscopically and microscopically.</li>
</ol>
<p><strong>Results</strong> Agglutination indicates the presence of <em>in vivo</em> sensitisation of red cells by an antibody showing that, the direct Coomb’s test is positive.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="autohaemolysis-test">AUTOHAEMOLYSIS TEST<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#autohaemolysis-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If the metabolic activity of the red cells and their cell membrane is defective, it may lead to haemolytic anaemia. In some haemolytic anaemias, the amount of lysis of red cells is reduced by glucose, while in others it is unaffected by glucose. This test is used for the differential diagnosis of hereditary spherocytosis and pyruvate kinase deficiency. When fresh normal blood is incubated for 24 to 48 hours in the presence of sterile glucose, the amount of lysis is markedly reduced.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specimen">Specimen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Fresh venous blood, either defibronated or anticoagulated with heparin.</p>
<p>A specimen from a known normal individual should be used as a control.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Sterile Glucose Solution (10%)</strong> Dissolve 10 g of glucose in 100 ml distilled water and sterilise by steaming.</p>
<p><strong>Aqueous ammonia solution (0.04%)</strong> Dilute 0.1 ml (100 μl) of ammonia to 250 ml with distilled water.</p>
<p>Scanned by CamScanner</p>
<p>Miscellaneous Investigations in Haematology 329</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="method">Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Keep 1 ml of whole blood at 4°C to be used as a control for 100% lysis.</li>
<li>Centrifuge 1 ml of blood, separate the plasma and store it at 4°C to be used as a blank.</li>
<li>Place 1 ml of blood in each of the four sterile tubes (1, 2, 3 and 4).</li>
<li>To two tubes (labelled 1 and 2), add 0.1 ml of the glucose solution under aseptic conditions to avoid bacterial contamination.</li>
<li>Place all the four tubes at 37°C in an incubator.</li>
<li>Gently shake each tube after 24 hours to mix the contents thoroughly.</li>
<li>After 48 hours, check macroscopically for bacterial contamination, which may be indicated by turbidity or offensive odour. If not contaminated, pool the contents of two tubes with glucose (1, 2) and the contents of two tubes without glucose (3, 4).</li>
<li>Estimate the PCV (haematocrit L/L) of blood in each tube either by Wintrobe’s or by microhaematocrit method.</li>
<li>Centrifuge the remaining blood in the two tubes to separate the plasma.</li>
<li>Dilute the pre-incubation plasma (from step 2) and post-incubation plasma with and without glucose (from step 9) 1:10 with 0.04% ammonia.</li>
<li>Dilute the blood sample (from step 1) 1:200 with 0.04% ammonia for 100% lysis.</li>
<li>Read the optical densities of diluted post-incubation plasma. Use diluted pre-incubation plasma (from step 10) as a blank.</li>
<li>Read the optical density of the 100% lysis control.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="calculation-to-summarise">Calculation To summarise,<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calculation-to-summarise" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Tubes 1 and 2 contain plasma after 48 hours incubation with glucose. Dilute 1:10 with 0.04% ammonia.</li>
<li>Tubes 3 and 4 contain plasma after 48 hours incubation without glucose. Dilute 1:10 with 0.04% ammonia.</li>
<li>Pre-incubation plasma from step 2 acts as blank. Dilute 1:10 with 0.04% ammonia.</li>
<li>Blood at 4°C from step 1 acts as 100% lysis standard. Dilute 1:200 with 0.04% ammonia.</li>
</ol>
<p>Calculate per cent haemolysis with and without glucose as:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi mathvariant="normal">%</mi><mtext>haemolysis</mtext><mo>=</mo><mfrac><mtext>OD&nbsp;of&nbsp;diluted&nbsp;plasma&nbsp;after&nbsp;48&nbsp;hrs</mtext><mtext>OD&nbsp;of&nbsp;100%&nbsp;lysis</mtext></mfrac><mo>×</mo><mfrac><mtext>Dilution&nbsp;of&nbsp;blood</mtext><mtext>Dilution&nbsp;of&nbsp;plasma</mtext></mfrac><mo>×</mo><mo stretchy="false">(</mo><mn>1</mn><mo>−</mo><mtext>PCV</mtext><mo stretchy="false">)</mo><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\% \text{haemolysis} = \frac{\text{OD of diluted plasma after 48 hrs}}{\text{OD of 100\% lysis}} \times \frac{\text{Dilution of blood}}{\text{Dilution of plasma}} \times (1 - \text{PCV}) \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">%</span><span class="mord text"><span class="mord">haemolysis</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">OD&nbsp;of&nbsp;100%&nbsp;lysis</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">OD&nbsp;of&nbsp;diluted&nbsp;plasma&nbsp;after&nbsp;48&nbsp;hrs</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Dilution&nbsp;of&nbsp;plasma</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Dilution&nbsp;of&nbsp;blood</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord text"><span class="mord">PCV</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="normal-range">Normal range<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#normal-range" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lysis after 48 hours at 37°C</p>
<p>without glucose 1.0–2.5%
with glucose 0.25–0.75%</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="interpretation">Interpretation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The autohaemolysis test is positive when haemolysis without glucose is more than 2.5%. In hereditary spherocytosis, the autohaemolysis test is positive, and is corrected with glucose, showing results within the normal range. In pyruvate kinase deficiency, the autohaemolysis test is positive, but is not corrected with glucose.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="spectroscopic-examination-of-blood-for-the-detection-of-abnormal-haemoglobin-pigments">SPECTROSCOPIC EXAMINATION OF BLOOD FOR THE DETECTION OF ABNORMAL HAEMOGLOBIN PIGMENTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#spectroscopic-examination-of-blood-for-the-detection-of-abnormal-haemoglobin-pigments" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Certain chemicals and drugs may react with haemoglobin to form abnormal pigments which affect its capacity to bring about gaseous exchange. Three such pigments, methaemoglobin, sulphhaemoglobin and carboxyhaemoglobin, can be differentiated from each other with the help of a spectroscope.</p>
<p>The spectroscope splits white light into its component colours with the help of a prism or a diffraction grating. Some substances absorb light at various wavelengths. When viewed through the eyepiece of the spectroscope, this absorbed light appears as a dark band at that particular wavelength. Such absorption bands are specific for each compound and is called an absorption spectrum of that substance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Dilute the sample of blood 1:10 or 1:20 with distilled water and view it through a spectroscope. Absorption bands appear either in the green or the red part of the spectrum, depending on the type of the pigment present (Fig. 6.5)</p>
<p>Scanned by CamScanner</p>
<p>330 Haematology</p>
<p><img src="assets/images/image-20251218-4dce274a.jpeg" alt="img-43.jpeg"></p>
<p>Fig. 6.5 Absorption spectra produced by haemoglobin pigments</p>
<p>Oxyhaemoglobin (normal Hb) shows a narrow band at 575 nm (yellow region) and a wider band at 540 nm (green region).</p>
<p>Methaemoglobin shows three bands which may not be very well defined, at 630 nm, 575 nm and 538 nm.</p>
<p>Sulphhaemoglobin also shows three absorption bands at 618 nm, 575 nm and 538 nm.</p>
<p>Carboxyhaemoglobin has an absorption spectrum very similar to that of oxyhaemoglobin, with bands at 570 nm, 534 nm and a weak band at 418 nm.</p>
<p><strong>Note</strong></p>
<p>Simple chemical tests help in the differentiation of haemoglobin pigments if the absorption bands are not very clear. For example,</p>
<p>i. Dilute the blood sample 1:500. The normal oxyhaemoglobin will show a yellowish red colour. If, however,</p>
<p>carboxyhaemoglobin is present in it, a purplish tint will be observed.</p>
<p>ii. To one drop of blood on a slide, add two drops of sodium hydroxide (NaOH, 250g/L) solution. A normal specimen of blood will change to a brownish red colour whereas that containing carboxyhaemoglobin will remain red.</p>
<p>iii. The absorption bands of methaemoglobin and sulphhaemoglobin are very similar. To differentiate between them, add 2–3 drops of sodium cyanide solution (50g/L) to a solution of haemoglobin. The cyanide will convert methaemoglobin into cyanate, a thin solution of haemoglobin which does not show any absorption band at the red region (630 nm). Absorption spectrum of sulphhaemoglobin remains unchanged.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 7</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="haemostasis-and-fibrinolysis">Haemostasis and Fibrinolysis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemostasis-and-fibrinolysis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="haemostasis">HAEMOSTASIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemostasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hemostasis is the arrest of blood flow and control of haemorrhage from an injured blood vessel. It is the process by which the blood is retained within the vascular system. Haemostasis is initiated when a blood vessel is injured. The mechanism of haemostasis is very complex and involves platelets, the coagulation factors and fibrinolytic system.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-haemostasis">MECHANISM OF HAEMOSTASIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-haemostasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Haemostasis involves a series of delicately balanced physical and biochemical changes following an injury to a blood vessel (Fig. 7.1(a)). As the most immediate response, the blood vessel constricts reducing the volume of blood flowing out. The platelets aggregate at the site of the injury and form a plug which further reduces the bleeding. These activated platelets secrete substances that initiate the coagulation factors. The factors interact serially, forming a fibrin-network or clot in which white cells, red cells and platelets are enmeshed and form a solid plug of blood (coagulation) which seals off the injury completely. Slow lysis of the clot, fibrinolysis, then begins and the site of injury is finally repaired (Fig. 7.1(b)).</p>
<p>The entire mechanism of haemostasis can be divided into three parts:</p>
<ol>
<li>Extravascular effects</li>
<li>Vascular effects</li>
<li>Intravascular effects.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="extravascular-effects">Extravascular Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#extravascular-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The extravascular effects can be physical or biochemical. The physical effects include the attempts of the tissue surrounding the injury site (muscle, skin etc) to mechanically close the break in the blood vessel. Certain substances are released from the tissues which react with the plasma and platelet factors in the process of coagulation. These substances are responsible for the extravascular biochemical effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vascular-effects">Vascular Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vascular-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The blood vessels themselves participate in haemostasis in two ways.</p>
<p><strong>Vasoconstriction</strong> Blood vessels constrict almost instantaneously when injured. This spontaneous response is then prolonged by serotonin, a substance secreted by platelets.</p>
<p><strong>Platelet plug</strong> Blood vessels are internally lined by a single layer of epithelial cells, called endothelium. If this endothelium is disrupted due to trauma, the underlying basement membrane containing collagen fibres is exposed. When platelets circulating in the blood come in contact with the collagen, they immediately adhere to the wall at the site of injury. The platelets then release adenosine diphosphate (ADP) which promotes the adhesion</p>
<p>Scanned by CamScanner</p>
<p>332 Haematology</p>
<p><img src="assets/images/image-20251218-d293d9e3.jpeg" alt="img-44.jpeg"></p>
<p>Fig. 7.1(a) Haemostasis</p>
<p><img src="assets/images/image-20251218-3bde7667.jpeg" alt="img-45.jpeg"></p>
<p>Fig. 7.1(b) Coagulation in equilibrium with fibrinolysis</p>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 333</p>
<p>and aggregation of platelets until a haemostatic plug covers the site of injury. Platelets also produce serotinin for vasoconstriction and platelets factor 3 (PF3) which participates in coagulation.</p>
<p>Intravascular effects In an extremely complex sequence of reactions, intravascular factors produce a firm clot from liquid blood. This process, initiated by platelets, is followed by activation of the intrinsic system of coagulation from the substances present within the blood. A fibrin clot is then formed as a result of coagulation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="function-of-platelets-in-haemostasis-and-coagulation">FUNCTION OF PLATELETS IN HAEMOSTASIS AND COAGULATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#function-of-platelets-in-haemostasis-and-coagulation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Platelets are disc shaped particles produced by cytoplasmic fragmentation of megakaryocytes in the bone marrow. They are non-nucleated and are surrounded by a layer of proteins and carbohydrates which participate in coagulation and fibrinolysis. The platelets also contain granules which are rich in adenosine triphosphate (ATP) and other substances.</p>
<p>Platelets perform three important functions:</p>
<ol>
<li>
<p>Form a platelet plug which offers a physical obstruction to blood loss: Adhesion of platelets to the exposed collagen fibres of the blood vessels starts activation of platelets. Activated platelets change their form and become spherical with long projections. In this way, the surface area of platelets is increased and enhances interaction with other platelets and coagulation factors. The changes on their outer coats also enhances the tendency to aggregate to form a plug.</p>
</li>
<li>
<p>Help in activation of coagulation factors and participate in the process of coagulation: The platelets serve as a barrier in extensive blood loss by participating in blood coagulation in various ways. Platelets produce a phospholipoprotein on their plasma membrane called platelet factor 3 (PF3) which is necessary for the activation of certain coagulation factors. Many coagulation proteins such as factors II, V, VIII, IX, XII and XIII are found in or on the platelets.</p>
</li>
<li>
<p>Maintain the endothelial lining of the blood vessels: Platelets also secrete certain products which help to maintain and repair the endothelium of the blood vessels. Platelets plug the gaps in the endothelial lining and prevent leakage of red cells in the surrounding tissues.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="role-of-blood-vessels">Role of Blood Vessels<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#role-of-blood-vessels" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The vascular system is a closed system of tubules which serves to regulate the flow of blood to and from the heart and the tissues. The entire system is internally lined by a single layer of endothelium. In larger vessels, the endothelium is surrounded by smooth muscle which helps in regulation of blood flow. The thickness of this muscle varies with the size of the vessels. The capillaries are much smaller and are lined by a single layer of endothelial cells without any muscular tissue. This allows the passage of molecules across the endothelium. The endothelium is supported by a basement membrane and collagen.</p>
<p>The vascular endothelium monitors the integrity of the vessel wall in two ways.</p>
<p>(i) It synthesises and releases substances such as prostaglandins which inhibit aggregation and adhesion of platelets to the vessel wall.</p>
<p>(ii) It stores substances such as plasminogen activator. When stimulated, this activator activates plasminogen which gets converted to plasmin. The plasmin, in turn, dissolves fibrin clots within the vessel, thus allowing a free flow of blood (Fig. 7.1b).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="coagulation">COAGULATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#coagulation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Haemostasis involves a series of related and overlapping events. It results in coagulation of blood to prevent blood loss from an injured or ruptured vessel. The entire process of haemostasis is initiated by a vessel injury involving the platelets, the endothelium and the surrounding tissues leading to the formation of a clot.</p>
<p>Coagulation of blood occurs by conversion of a soluble protein, fibrinogen, into cross-linked fibrin strands by the action of the enzyme, thrombin. This transformation occurs in a cascade of enzymatic</p>
<p>Scanned by CamScanner</p>
<p>334 Haematology</p>
<p>reactions by 'activated' clotting factors along with other non-enzymatic cofactors. If any of these factors and cofactors are deficient, severe trauma from an injury can result in the collapse of the coagulation mechanism, leading to severe haemorrhage. Thus, coagulation is a delicately controlled process which continues the maintenance of blood circulation and responds to injury when necessary. In a series of biochemical reactions, inactive proenzymes are converted into active enzyme forms. These, in turn, activate other proenzymes. The coagulation process is thus a cascade of factor activities, initiated by:</p>
<p>(i) Interaction of certain clotting factors with the collagen fibres beneath the endothelium (intrinsic pathway),</p>
<p>or</p>
<p>(ii) Release of a lipoprotein tissue factor (extrinsic pathway).</p>
<p>Both the pathways ultimately activate factor X on the surface of the platelets and finally lead to the formation of fibrin strands.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="coagulation-factors">COAGULATION FACTORS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#coagulation-factors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>With the exception of calcium and the phospholipid in platelets, all the coagulation factors are protein in nature which become active enzymes after some changes in their structure. In order to standardise the complex nomenclature, twelve coagulation factors are designated by Roman numerals I to XIII (there is no factor VI). In addition to the Roman numerals, the other substances which participate in the coagulation process are the phospholipoprotein of platelets (PF3); prekallikrein (the active form of kallikrein); kininogen and protein C (Table 7.1). When factors have been activated, they have 'a' added after the numeral, e.g., Xa.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factor-i-fibrinogen">Factor I (Fibrinogen)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-i-fibrinogen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Fibrinogen or factor I is a plasma protein having a molecular weight of 340,000 daltons. It is synthesised in the liver, but does not depend on vitamin K for its production. Fibrinogen is precipitated at 56°C, and the half life is 3–4 days.</p>
<p>By the action of the enzyme thrombin, fibrinogen is converted into a monomer of fibrin, which then polymerises and aggregates to form polymer (fibrin strands). The normal range of plasma fibrinogen is 200–400 mg/dl.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factor-ii-prothrombin">Factor II (Prothrombin)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-ii-prothrombin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Prothrombin is a protein with a molecular weight of about 69,000 daltons. It is synthesised in the</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="table-7-1-coagulation-factors">Table 7.1 Coagulation factors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-7-1-coagulation-factors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<table><thead><tr><th>Factor</th><th>Name</th></tr></thead><tbody><tr><td>I</td><td>Fibrinogen</td></tr><tr><td>II</td><td>Prothrombin</td></tr><tr><td>III</td><td>Tissue thromboplastin</td></tr><tr><td>IV</td><td>Calcium</td></tr><tr><td>V</td><td>Proaccelerin</td></tr><tr><td>VII</td><td>Proconvertin</td></tr><tr><td>VIII</td><td>Antihapemophilic factor (AHF)</td></tr><tr><td>IX</td><td>Plasma thromboplastin component (PTC)</td></tr><tr><td>X</td><td>Stuart-Prower factor</td></tr><tr><td>XI</td><td>Plasma thromboplastin antecedent (PTA)</td></tr><tr><td>XII</td><td>Hageman factor</td></tr><tr><td>XIII</td><td>Fibrinase</td></tr><tr><td></td><td>Prekallikrein (PK)</td></tr><tr><td></td><td>High-molecular-weight kininogen (HMWK)</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 335</p>
<p>liver through the action of vitamin K. Prothrombin is heat stable and the half-life is of 3–5 days.</p>
<p>Prothrombin is a precursor of thrombin. It is converted to thrombin in the presence of calcium ions by some enzymes which act on fibrinogen to produce fibrin. Concentration of prothrombin is about 10 mg/dl. It is consumed in the process of coagulation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factor-iii-tissue-thromboplastin">Factor III (Tissue Thromboplastin)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-iii-tissue-thromboplastin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tissue thromboplastin is a high molecular weight lipoprotein that is found in almost all body tissues, but is present in higher concentrations in the lungs and the brain. Its molecular weight depends on its source and ranges from 45,000 to 1 million daltons.</p>
<p>Thromboplastin can bring about conversion of prothrombin to thrombin. All injured tissues possess a potential thromboplastic activity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factor-iv-calcium">Factor IV (Calcium)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-iv-calcium" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The term factor IV is used for calcium in its ionic state when it participates in the process of coagulation. It appears to function as a bridge between the platelets and other clotting factors.</p>
<p>Because coagulation cannot occur without calcium, the substances that bind calcium can be used as anticoagulants. For example, ethylene diamine tetra acetic acid (EDTA).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factor-v-proaccelerin">Factor V (Proaccelerin)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-v-proaccelerin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Factor V is a globulin with a molecular weight of about 330,000 daltons. It is synthesised in the liver. It is labile, and deteriorates rapidly in oxalated plasma, even when it is frozen. It is the most unstable of the coagulation factors, and therefore, is called labile factor. It does not require vitamin K for its synthesis.</p>
<p>Factor V is essential for the prompt conversion of prothrombin to thrombin in both the intrinsic and extrinsic pathways. It is fully consumed in coagulation. The half-life is 12–36 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factor-vii-proconvertin">Factor VII (Proconvertin)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-vii-proconvertin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is a beta-globulin with a molecular weight of 48,000 daltons. It is synthesized in the liver and is dependent on vitamin K. It is neither consumed nor destroyed in the process of coagulation. It has a very short half-life of about 4–6 hours. In contrast to its short half-life in vivo, factor VII is stable in citrated plasma for up to 2 weeks at 4°C. It takes part in the extrinsic pathway of coagulation by activating the tissue thromboplastin.</p>
<p>Factor VII converts factor X to factor Xa.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factor-viii-antihaemophilic-factor">Factor VIII (Antihaemophilic Factor)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-viii-antihaemophilic-factor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is a high molecular weight (1.2 million daltons) beta globulin. The site of its synthesis is not yet clearly identified, but it is not dependant on vitamin K. It has a short half-life of 6–10 hours. In circulation, factor VIII has two functional subunits:</p>
<p>(i) Factor VIII: C is a coagulation factor. The term Haemophilia A indicates a hereditary disease with a deficiency of factor VIII: C subunit. Haemophilia is a sex-linked inherited coagulation disorder, also called ‘bleeder’s disease’.</p>
<p>(ii) Factor VIII: vWF (von-Willebrand’s Factor) is not necessary for the coagulation mechanism, but facilitates adhesion of platelets to the sub-endothelial surfaces. This subunit forms the larger part of the whole factor VIII, and is strongly antigenic in nature.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factor-ix-plasma-thromboplastin-component">Factor IX (Plasma Thromboplastin Component)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-ix-plasma-thromboplastin-component" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is a beta-globulin with a molecular weight of about 57,000 daltons. It is synthesised in the liver and requires vitamin K for its production. It is not consumed during clotting. It is stable at 4°C for up to 2 weeks. The half-life is about 20 hours.</p>
<p>Factor IX is required in the intrinsic thromboplastic generation system. It helps in the conversion of factor X to Xa. Its deficiency may result in a sex-linked hereditary bleeding disorder called haemophilia B. The clinical symptoms are similar to those of haemophilia A.</p>
<p>Scanned by CamScanner</p>
<p>336 Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factor-x-stuart-prower-factor">Factor X (Stuart-Prower Factor)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-x-stuart-prower-factor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is an alpha globulin having a molecular weight of 59,000 daltons. It is synthesised in the liver and is dependent on vitamin K. It is a stable factor which can remain unaltered for about 2 months at 4°C. It has a half-life of 24 to 65 hours.</p>
<p>Factor X is partially consumed in the process of coagulation. It is activated by both the intrinsic and the extrinsic pathways to form the final common pathway.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factor-xi-plasma-thromboplastin-antecedent">Factor XI (Plasma Thromboplastin Antecedent)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-xi-plasma-thromboplastin-antecedent" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is a beta globulin with a molecular weight of about 160,000 to 200,000 daltons. Its synthesis in the liver is independent of vitamin K. Factor XI has a half life of 60 hours and is stable at room temperature.</p>
<p>Factor XII is necessary for the thromboplastin generating mechanism. It circulates as a complex with another protein called kininogen or HMWK. Only a small fraction of factor XI is used in coagulation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factor-xii-hageman-factor">Factor XII (Hageman Factor)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-xii-hageman-factor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is a gamma globulin with a molecular weight of about 80,000 daltons. It is synthesised in the liver and does not depend on vitamin K. Factor XII can resist heating at 60°C for 30 minutes. It can be stored at 4°C for about three months in oxalated plasma.</p>
<p>Factor XII takes part in the initial phase of the intrinsic pathway. This factor is activated when it comes in contact with glass. Platelets or injured endothelium can also activate it. It is not consumed during the coagulation process.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factor-xiii-fibrinase">Factor XIII (Fibrinase)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factor-xiii-fibrinase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is a high molecular weight alpha-globulin. The site of its synthesis is not definitely known. Factor XIII circulates in the blood as two pairs of subunits of dissociable complexes (a₂b₂). It is an enzyme which, when activated by thrombin, catalyses polymerisation of fibrin. Most of factor XIII is used up in this process. It also helps in tissue growth and repair. Factor XIII is inhibited by EDTA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prekallikrein-pk-flatcher-factor">Prekallikrein (PK, Flatcher Factor)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prekallikrein-pk-flatcher-factor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Prekallikrein is synthesised in the liver and is not dependent on vitamin K. Prekallikrein activates plasminogen, and is also a precursor for kallikrein, the chemotactic factor for phagocytes. PK is present in the plasma with HMWK.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="high-molecular-weight-kininogen-hmwk-fitzgerald-factor">High-molecular-weight Kininogen (HMWK, Fitzgerald Factor)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#high-molecular-weight-kininogen-hmwk-fitzgerald-factor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HMWK is produced in the liver and does not depend on vitamin K for its synthesis. It is a cofactor in the activation of factor VII.</p>
<p>Table 7.2 summarizes the properties of coagulation factors.</p>
<table><thead><tr><th>Table 7.2 Properties of coagulation factors</th></tr></thead><tbody><tr><td><strong>Fibrinogen Group:</strong> Factors I, V, VIII, XIII</td></tr><tr><td>Thrombin interacts with them all</td></tr><tr><td>Activity lost in coagulation process (not present in serum)</td></tr><tr><td>Increase during inflammation, in pregnancy and women on oral contraceptives</td></tr><tr><td>V and VIII lose activity in stored plasma</td></tr><tr><td><strong>Prothrombin Group:</strong> Factors II, VII, IX, X</td></tr><tr><td>Dependent on vitamin K for synthesis, require Ca++ for activation</td></tr><tr><td>All except prothrombin (II) are not consumed during coagulation (present in serum)</td></tr><tr><td>Stable, well preserved in stored plasma</td></tr><tr><td><strong>Contact group:</strong> Factors XI, XII, prekallikrein</td></tr><tr><td>Not dependent on vitamin K for synthesis, not calcium dependent, stable, well preserved in stored plasma</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 337</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pathways-for-the-coagulation-process">PATHWAYS FOR THE COAGULATION PROCESS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathways-for-the-coagulation-process" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The final product in the coagulation process is the fibrin clot formed by activation of prothrombin to form thrombin, which in turn converts fibrinogen to fibrin. There are two pathways leading to the activation of prothrombin, the intrinsic pathway and the extrinsic pathway. Both lead to a common pathway. The various factors, their precursors and other reacting substances respond in an orderly, controlled process called the coagulation cascade.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="intrinsic-pathway">Intrinsic Pathway<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#intrinsic-pathway" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In this pathway, all the necessary components are found within the circulating blood. When blood comes in contact with a foreign surface, for example exposed collagen fibres in the wall of the blood vessel or a glass surface, a series of reactions, mediated by enzymes, start. On contact with a foreign surface, prekallikrein and HMWK participate in the activation of factor XII to XIIa. XIIa in turn activates factor XI to form XIa. This process continues further, involving factors IX, VIII and X. Factor X is converted to Xa by the action of calcium ions and phospholipid on the platelets. (Fig 7.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="extrinsic-pathway">Extrinsic Pathway<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#extrinsic-pathway" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The extrinsic system is initiated when there is tissue damage together with an injured blood vessel. The damaged tissue releases thromboplastin which is not normally present in the blood. This thromboplastin, along with factor VII in the presence of calcium, activates factor X to produce Xa. The extrinsic pathway is much shorter and quicker than the intrinsic pathway (Fig. 7.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="common-pathway">Common Pathway<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#common-pathway" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The common pathway involves the activation of factor X to Xa via the extrinsic or intrinsic pathway. Factor Xa, in the presence of calcium ions, platelet factor 3 and factor V, converts factor II (prothrombin) to the active enzyme thrombin.</p>
<p>Thrombin acts on factor I (fibrinogen) to convert it to fibrin. Factor XIII helps in the formation of stabilised, stronger clot. Figure 7.3 shows the relationship between the extrinsic, intrinsic and common pathways.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="control-of-coagulation">Control of Coagulation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#control-of-coagulation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In health there is a balance between the clot inhibiting and clot promoting activities of the coagulation system so that harmful intravascular clotting is prevented. Endothelial cells play a major role and has both clot promoting and clot inhibiting functions.</p>
<p>There are three mechanisms by which coagulation is controlled.</p>
<p>(i) Physical control The continuous flow of circulating blood in the blood vessel is maintained by dilution of activated products.</p>
<p>(ii) Physiological control Physiological inhibitors of coagulation act on the activated coagulation factors and inhibit their action, thus bringing the coagulation process to a halt. Antithrombin III and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-macroglobulin are the two major inhibitors. Antithrombin III reacts mainly with factor Xa and thrombin. It also inhibits other factors such as IXa, XIa, XIIa and VII. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-macroglobulin is particularly active against thrombin, kallikrein and plasmin. Other inhibitors of coagulation include <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-antitrypsin, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-antiplasmin, protein C and S inhibitors.</p>
<p>(iii) Cellular control Haemostasis is partially regulated by the removal of active materials by the reticulo-endothelial (RE) system. The RE system and the liver actively clear away fibrinogen and fibrin degradation products.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fibrinolysis">FIBRINOLYSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fibrinolysis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The process of removing unwanted, insoluble deposits formed as a result of coagulation is called fibrinolysis. It is a physiological process in which a fibrin clot is broken down by enzymes into soluble fragments. The fibrinolytic system involves conversion of a plasma proenzyme plasminogen</p>
<p>Scanned by CamScanner</p>
<p>338 Haematology</p>
<p><img src="assets/images/image-20251218-ba93cd66.jpeg" alt="img-46.jpeg"></p>
<p>Fig. 7.2 Coagulation cascade</p>
<p>into plasmin. Plasmin digests fibrin and breaks it into soluble fragments.</p>
<p>Plasminogen <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mtext>Activators</mtext></mpadded></mover></mrow><annotation encoding="application/x-tex">\xrightarrow{\text{Activators}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1113em; vertical-align: -0.011em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.1003em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Activators</span></span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span></span></span></span></span> Plasmin
Fibrin polymer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mtext>Plasmin</mtext></mpadded></mover></mrow><annotation encoding="application/x-tex">\xrightarrow{\text{Plasmin}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1191em; vertical-align: -0.011em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.1081em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Plasmin</span></span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span></span></span></span></span> soluble fragments</p>
<p>Plasmin is also capable of breaking down fibrinogen, factor V and factor VII in the presence of plasminogen activators. These activators are present in the largest quantities in the endothelial cells of capillaries. They are also found in small amounts in plasma and in lysosomes of most body</p>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 339</p>
<p><img src="assets/images/image-20251218-e4d34151.jpeg" alt="img-47.jpeg">
Fig. 7.3 Relationship between the extrinsic, intrinsic and common pathways</p>
<p>cells. The endothelial cells also secrete another important plasminogen activator called tissue-type plasminogen activator (t-PA). The t-PA does not circulate in an inactive form like other activators. It is secreted in large amounts in an active form by the endothelial cells in response to various stimuli. When released, it continuously interacts with plasminogen activator inhibitor (PAI) forming an inactive complex. High levels of t-PA are associated with bleeding disorders. PAI is present in small amounts in plasma and in much larger amounts in platelets. High PAI levels are seen in sepsis, in pregnancy and are associated with thrombotic activity.</p>
<p>Increased levels of plasminogen are observed in acute bacterial infections, inflammatory conditions, myocardial infarction, thrombophlebitis, pregnancy and after long term use of oral contraceptives.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="disorders-of-blood-coagulation">DISORDERS OF BLOOD COAGULATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#disorders-of-blood-coagulation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The common causes of coagulation disorders include deficiencies of coagulation factors, inhibitors of coagulation factors and defects in platelet function. The disorders may be hereditary or acquired. Some commonly occurring disorders are mentioned below.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-inherited-disorders">I Inherited Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-inherited-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-haemophilia-a-classical-haemophilia">1. Haemophilia A (classical haemophilia)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-haemophilia-a-classical-haemophilia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Haemophilia A is the most commonly inherited disorder of the coagulation factors. The frequency of the disease is approximately 1:25,000 and males are primarily affected. This disorder occurs due to the deficiency of a small subunit of the factor VIII molecule called factor VIII antigen (VIII:Ag). This deficiency is carried on the X-</p>
<p>Scanned by CamScanner</p>
<p>340 Haematology</p>
<p>chromosome. Therefore, haemophilia A occurs almost exclusively in males and is very rare in females. Clinically, classical haemophilia occurs along with haemorrhage. Such haemorrhages can occur both internally and externally. Bleeding into joints and muscles is typical. Other symptoms include excessive bleeding after surgery or major trauma, and even after superficial abrasions. Bleeding may also occur through the nose, mouth, eyes and gastrointestinal tract. Severe bleeding may lead to a rapidly progressive normocytic anaemia. Intracranial haemorrhage is the most common cause of death.</p>
<p><strong>Laboratory findings</strong> Partial thromboplastin time (PTT) is an effective screening test for classical haemophilia. It gives abnormal results when factor VIII is about 25% of the normal value. Platelet count and platelet function tests such as bleeding time and thrombin time are normal. Thromboplastin generation test (TGT) and prothrombin consumption test (PCT) are too sensitive and give abnormal results even in very mild haemophilia.</p>
<p>Assay of factor VIII is the diagnostic test. Inhibitors of factor VIII are detected in severely affected young patients. These are specific IgG antibodies to factor VIII.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-haemophilia-b-factor-ix-deficiency">2. Haemophilia B (Factor IX deficiency)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-haemophilia-b-factor-ix-deficiency" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Haemophilia B is an inherited deficiency of factor IX and is an X-chromosome linked disorder like haemophilia A. Haemophilia B is five times less frequent than haemophilia A. Clinically, haemophilia B is indistinguishable from the classical haemophilia but is generally a milder form. The therapy for both the haemophilias being different, it is necessary to differentiate between the two disorders.</p>
<p><strong>Laboratory findings</strong> As in haemophilia A, a prolonged PTT, normal thrombin time and normal bleeding time is observed in haemophilia B patients. Prothrombin time is normal in most cases. Factor VIII level is normal whereas factor IX is deficient and is diagnostic.</p>
<p>Antibodies to factor IX may be seen only in patients undergoing long term therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-haemophilia-c-factor-xi-deficiency">3. Haemophilia C (Factor XI deficiency)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-haemophilia-c-factor-xi-deficiency" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is a rarely inherited bleeding disorder. The symptoms are similar to those of the other haemophilias. The severity of the disease is not related to the level of factor XI.</p>
<p><strong>Laboratory findings</strong> These are similar to the other haemophilias, and the diagnosis depends on the assay of factor XI.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-von-willebrand-syndrome">4. von Willebrand syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-von-willebrand-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>von Willebrand syndrome (vWS) is one of the commonly occurring inherited coagulation disorders. Like haemophilia A, vWS is also related to the abnormality or the deficiency of factor VIII. Factor VIII is a complex of two molecules: VIII:C and VIII:Ag.</p>
<p>(i) A small active molecule is the factor VIII coagulant-antigen (VIII:Ag). Deficiency of this fraction leads to haemophilia A.</p>
<p>(ii) A larger fragment is called von Willebrand factor (vWF), which is synthesized by endothelial cells and megakaryocytes. The vWF circulating in the blood binds with factor VIII:Ag. It plays a carrier role for the smaller active fraction and protects it from proteolytic destruction. The main role of vWF is in the adhesion of platelets to foreign surfaces such as glass, especially after vessel injury.</p>
<p>Clinically, the patients with vWS characteristically bleed from mucous membranes and cutaneous sites. Easy bruising and excessive bleeding following dental extractions and tonsillectomy is common. Unlike classical haemophilia, bleeding in the joints and deep muscles is not observed in vWS except in severe cases. Gastrointestinal bleeding and menorrhagia are also common.</p>
<p><strong>Laboratory findings</strong> The diagnosis of vWS is difficult. The routine laboratory screening tests are of limited value. Generally, bleeding time and PTT are abnormal. The PCT (prothrombin consumption test) is usually abnormal. Platelet adhesion and</p>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 341</p>
<p>aggregation tests are more consistently abnormal. Factor VIII:Ag is often reduced. For more specific diagnosis, rocket immunoelectrophoresis is performed using an antibody to vWF.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-other-inherited-deficiencies">5. Other Inherited deficiencies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-other-inherited-deficiencies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Inherited deficiencies of coagulation factors other than those described above are very rare.</p>
<p>(a) Deficiency of factor VII may be associated with the tendency of severe bleeding. A prolonged prothrombin time with normal PTT and thrombin time is suggestive. Specific factor VII assay should confirm the diagnosis.</p>
<p>(b) Deficiencies of factor XII, HMWK or prekallikrein show very mild bleeding tendencies. The laboratory tests show a prolonged activated PTT, normal prothrombin time and normal thrombin time. If factors VIII and IX are suspected, then specific assays of these factors should be performed.</p>
<p>(c) Deficiency of factor X is not clinically distinguishable from that of factor VII. The severity of the disease may vary. In most cases activated PTT and prothrombin time are prolonged. Stypven time test should be performed to differentiate between the two deficiencies. The test involves use of venom of the snake Vipera russelli (Russell’s viper). It acts directly on factor X to convert it to factor Xa in the absence of other clotting factors. A prolonged Stypven time in the presence of a prolonged prothrombin time is indicative of factor X deficiency.</p>
<p>(d) Deficiency of factor V is quite rare. The laboratory tests show prolonged prothrombin time, PTT and TGT. Coagulation time may be abnormal.</p>
<p>(e) In factor XIII deficiency, the laboratory results are almost normal. The diagnostic test is based on solubility of the unstabilised fibrin clot in a five molar urea solution or 1% mono-chloroacetic acid.</p>
<p>(f) Fibrinogen deficiency is a rare inherited disorder but may lead to severe bleeding. Laboratory results show abnormality in all the tests which have a fibrin clot as the end point, e.g., prothrombin time, thrombin time and PTT. The PCT and TGT are normal except in severe cases.</p>
<p>(g) Prothrombin deficiency is quite rare. The laboratory findings show prolonged prothrombin time and PTT. Bleeding time, platelet count, clot retraction and thrombin time are normal. Diagnosis is made by the specific assay for prothrombin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-acquired-disorders">II. Acquired Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-acquired-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-vitamin-k-deficiency">1. Vitamin K deficiency<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-vitamin-k-deficiency" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Deficiency of vitamin K leads to defects in the synthesis of coagulation factors VII, IX, X and prothrombin, all of which are dependent on vitamin K for their synthesis. Vitamin K is normally obtained in two ways; through the dietary intake of the vitamin produced by plants, and the vitamin synthesised by the intestinal bacteria. Vitamin K deficiency may result from inadequate diet, intestinal malabsorption, biliary obstruction or gut sterilisation. Haemorrhagic disease of the new-born may occur in neonates. Vitamin K deficiency may be intentionally induced by the administration of anticoagulant drugs such as coumarin. These drugs are administered orally and are absorbed in the blood through the gastrointestinal tract. The level of the anticoagulant in the blood is regulated in such a way that the prothrombin time ratio is maintained at 1.5 (For example, prothrombin time of patient’s plasma is 15 seconds when that of the control is 10 seconds).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-heparin-therapy">2. Heparin therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-heparin-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Heparin is a fast-acting mucopolysaccharide which interferes with coagulation by inhibiting the action of factors IIa, XIa, XIIa and XIII by blocking the conversion of fibrinogen to fibrin. It also inhibits platelet aggregation. Heparin therapy is used in the treatment of thrombosis so that the coagulation is extended with minimum of bleeding. The anticoagulant activity of the heparin treated plasma is best monitored with the help of activated partial thromboplastin time (APTT). The desired range of APTT is similar to that in the oral anticoagulant therapy i.e. 1.5 times that of the control.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="3-diffuse-intravascular-coagulation-dic">3. Diffuse intravascular coagulation (DIC)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-diffuse-intravascular-coagulation-dic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>DIC syndrome may result from a wide variety of pathological processes which lead to activation of</p>
<p>Scanned by CamScanner</p>
<p>342 Haematology</p>
<p>the coagulation system. Intravascular fibrin deposits may be produced with excessive consumption of coagulation factors. Reduction in the level of coagulation factors in turn leads to imbalance in the haemostatic mechanism and uncontrolled bleeding may start. This process is often accompanied by fibrinolysis which increases the bleeding tendency. The aetiological agents of DIC include sepsis, neoplasms, autoimmune diseases, haematological diseases, obstetric problems and intravascular haemolysis.</p>
<p>Laboratory findings in DIC vary widely and depend on the cause and its severity. Generally, prothrombin time, thrombin time and PTT are increased. Most cases of DIC are associated with thrombocytopenia with leucocytosis. Schistocytes (fragmented red cells) may be seen in the peripheral blood smear.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-lupus-type-anticoagulants">4. Lupus-type anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-lupus-type-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Some patients with systemic lupus erythematosus and other wide variety of disorders and those undergoing therapy with drugs such as phenothiazine, develop coagulation inhibitors known as lupus-type anticoagulants. These substances inhibit the conversion of factor X to factor Xa. The lupus-type anticoagulants produced under various conditions may not be identical, but they are antibodies of either IgG or IgM type. The peculiar feature of these anticoagulants is that they rarely show a clinical bleeding tendency unless there is another pre-existing or additional haemostatic abnormality. The laboratory result show abnormal prothrombin time, thrombin time and PTT.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-inherited-disorders-of-platelet-function">III. Inherited Disorders of Platelet Function<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-inherited-disorders-of-platelet-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-glanzmann-s-thrombasthenia">1. Glanzmann's thrombasthenia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-glanzmann-s-thrombasthenia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>In this disorder, the platelet count and individual platelet morphology is normal, but they show a characteristic tendency to resist clumping together. This results in inadequate platelet plug formation and is due to an abnormality in the surface membrane glycoproteins. Clinically, the bleeding can be very severe. The laboratory tests show abnormal bleeding time, prothrombin consumption, and clot retraction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-bernard-soulier-syndrome">2. Bernard-Soulier syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-bernard-soulier-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This inherited disorder is due to the absence of some membrane glycoproteins which are essential for platelet adhesion. The laboratory findings include abnormally large (74 μm) platelet forms, prolonged bleeding time and reduced platelet adhesion to glass. The clot retraction is normal.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="3-storage-granule-abnormalities">3. Storage granule abnormalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-storage-granule-abnormalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Some platelet disorders involve a deficiency or abnormality of one or more types of storage granules. In most cases, platelet release function after stimulation and platelet aggregation are affected.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-acquired-disorders-of-platelet-function">IV. Acquired Disorders of Platelet Function<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-acquired-disorders-of-platelet-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-drug-induced-disorders">1. Drug induced disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-drug-induced-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A large number of drugs influence platelet function. Aspirin and its derivatives are the principle causes of such disorders. Other examples include antibiotics such as penicillins and cephalosporins; analgesics and anti-inflammatory agents like ibuprofen; and other miscellaneous drugs such as heparin. The platelet function usually returns to normal when administration of causative agent is discontinued.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-other-factors">2. Other factors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-other-factors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A number of other disease states adversely affect platelet function. They include acute and chronic leukaemias, haemorrhagic thrombocythaemia, myelofibrosis, autoimmune diseases, systemic lupus erythematosus and anaemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v-quantitative-platelet-disorders">V. Quantitative Platelet Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-quantitative-platelet-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-thrombocytopenia">1. Thrombocytopenia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-thrombocytopenia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A reduced number of circulating platelets (thrombocytopenia) can result from:</p>
<p>(1) Decreased production of platelets. Decreased production of megakaryocytes or ineffec</p>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 343</p>
<p>tive platelet production due to vitamin B₁₂ deficiency can lead to thrombocytopenia.</p>
<p>(II) Disorders of distribution This can occur due to conditions such as hypothermia or transfusion of stored blood.</p>
<p>(III) Platelet destruction A wide variety of conditions can lead to platelet destruction. Infection, tissue injury, snake bite, thrombotic thrombocytopenic purpura, autoimmune diseases, liver disease and malignancies are some of the conditions that can cause platelet destruction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-thrombocytosis">2. Thrombocytosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-thrombocytosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Increased platelet counts or thrombocytosis may result from a benign, reactive process or may be associated with a myeloproliferative disorder. In most cases, platelet stimulation and aggregation is affected.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="de83e586">♦ TESTS FOR COAGULATION FUNCTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#de83e586" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="bleeding-time">Bleeding Time<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bleeding-time" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Bleeding time measures the time required for the blood to stop flowing after a standardised capillary puncture. This depends on the number and function of platelets and capillary integrity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="method-1-ivy-bleeding-time-test">Method 1: Ivy Bleeding Time Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-1-ivy-bleeding-time-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(1) Place a blood pressure cuff on the upper arm and inflate it to 40 mm Hg.
(2) Clean the area of the fore arm below the anticubital fossa with 70% alcohol. There should be no superficial veins in the area selected.
(3) Make two skin punctures in rapid succession, each 3 mm deep, using disposable lancets.
(4) Start the stop-watch as soon as bleeding starts. Wipe off the blood at 15 seconds intervals by touching lightly with a blotting paper.
(5) Record the time taken for the blood to stop flowing in both the punctures and determine the mean time. Remove the blood pressure cuff and cover the puncture sites with plaster.</p>
<p>Normal range 2–6 minutes. Values between 6 and 10 minutes are considered borderline and the test should be repeated. However, owing to variations in techniques and patients population, each laboratory should establish its own normal range.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="method-2-duke-method">Method 2: Duke Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-2-duke-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(1) Clean an ear lobe or a finger tip (or heel, in an infant) with 70% alcohol.
(2) Make a 3 mm deep puncture using a disposable lancet.
(3) Start the stop-watch as soon as bleeding starts.
(4) Blot the drops of blood in the same way as in method 1.
(5) Record time at which bleeding stops.</p>
<p>Normal range 0–6 minutes is considered normal.</p>
<p><strong>Interpretation</strong> Conditions associated with prolonged bleeding time include:
(i) Thrombocytopenia
(ii) Inherited or acquired platelet function defects.
(iii) Inherited plasma defects (e.g. von Willebrand’s disease, factor V deficiency)
(iv) Vascular abnormalities.
(v) Drugs, e.g. aspirin and antihistamine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="afafc608">♦ CLOTTING TIME (Lee-White method)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#afafc608" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This test is a qualitative measurement of factors involved in the intrinsic pathway. Therefore, deficiency in the factors of intrinsic pathway (I, II, V, VIII, IX, X, XI, XII) will affect the result.</p>
<p><strong>Principle</strong> The test is based on the fact that whole blood, when added to a foreign surface such as glass, will form a clot. The time required for the formation of a clot is a rough indication of the efficiency of the coagulation factors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(1) Make a clean venepuncture with minimum trauma to the connective tissue (to avoid contamination with tissue thromboplastin).</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p>(2) Start a stop-watch as soon as the blood enters the glass syringe. Draw <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4.0</mn><mtext> </mtext><mtext>ml</mtext></mrow><annotation encoding="application/x-tex">4.0 \, \text{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">4.0</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord text"><span class="mord">ml</span></span></span></span></span></span> of blood and deliver <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mtext> </mtext><mtext>ml</mtext></mrow><annotation encoding="application/x-tex">1 \, \text{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord text"><span class="mord">ml</span></span></span></span></span></span> each into 4 glass test tubes previously warmed to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>37</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mtext>C</mtext></mrow><annotation encoding="application/x-tex">37^{\circ} \text{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord text"><span class="mord">C</span></span></span></span></span></span>.
(3) Place the tubes immediately at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>37</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mtext>C</mtext></mrow><annotation encoding="application/x-tex">37^{\circ} \text{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord text"><span class="mord">C</span></span></span></span></span></span> water bath.
(4) At the end of 1 minute, gently tilt one tube to see if the blood is clotted.
(5) Continue tilting the tubes one after the other at one minute intervals till one of them can be tilted at an angle of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>90</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mtext>C</mtext></mrow><annotation encoding="application/x-tex">90^{\circ}\text{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">9</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord text"><span class="mord">C</span></span></span></span></span></span> without the blood flowing out.
(6) Note the time.
(7) Continue with the remaining tubes and take the average of the clotting time in all the four tubes.</p>
<p><strong>Note.</strong> If plastic or silconated syringe is used, the stop watch is started after adding blood to the glass tubes.</p>
<p><strong>Normal range</strong> 5–10 minutes.</p>
<p><strong>Interpretation</strong> The clotting time is prolonged if there is a marked deficiency in one of the coagulation factors of the intrinsic pathway.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clot-retraction">CLOT RETRACTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clot-retraction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Normal blood clots completely in 5–10 minutes. The clot begins to retract in one hour, and the clot retraction should be complete within four hours, separating itself from serum. Normal clot retraction is indicative of normal platelet function.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="qualitative-method-for-clot-retraction">Qualitative Method for Clot Retraction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#qualitative-method-for-clot-retraction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Collect 5–10 ml of blood directly into a clean glass test tube.
(2) Place the tube in a water bath at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>37</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mtext>C</mtext></mrow><annotation encoding="application/x-tex">37^{\circ} \text{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord text"><span class="mord">C</span></span></span></span></span></span>.
(3) Observe the clot retraction periodically for up to 24 hours.</p>
<p>In case of normal individuals, the clot retraction is completed in four hours.</p>
<p>In patients with abnormal platelet function, the clot retraction is delayed and may be poor or absent after 24 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="quantitative-method-for-clot-retraction">Quantitative Method for Clot Retraction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quantitative-method-for-clot-retraction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Specimen</strong> Collect 10 ml of blood in a graduated centrifuge tube and 2 ml in an EDTA tube.</p>
<p><strong>Technique</strong></p>
<p>(1) Place an applicator stick into the blood in the centrifuge tube before it clots.
(2) As soon as it clots, place it in a water bath at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>37</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mtext>C</mtext></mrow><annotation encoding="application/x-tex">37^{\circ} \text{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord text"><span class="mord">C</span></span></span></span></span></span> for exactly one hour.
(3) Withdraw the clot by gently removing the applicator stick, leaving the serum and some free cells in the tube.
(4) Note the characteristics of the clot if it is firm or friable; and also note the clot retraction is complete or poor.</p>
<p>Measure the volume of the serum and cells in the tube, expressed from 10 ml of blood:</p>
<p>Determine the haematocrit value of the blood sample either by Wintrobe’s or microhaematocrit method using the EDTA anticoagulated blood.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="calculation">Calculation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calculation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clot retraction (%)</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>Volume&nbsp;of&nbsp;serum&nbsp;expressed</mtext><mo>=</mo><mfrac><mtext>from&nbsp;100&nbsp;ml&nbsp;blood</mtext><mrow><mn>100</mn><mo>−</mo><mtext>Haematocrit&nbsp;%</mtext></mrow></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\text{Volume of serum expressed} = \frac{\text{from 100 ml blood}}{100 - \text{Haematocrit \%}} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">Volume&nbsp;of&nbsp;serum&nbsp;expressed</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.1408em; vertical-align: -0.7693em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">Haematocrit&nbsp;%</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">from&nbsp;100&nbsp;ml&nbsp;blood</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.7693em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>Volume&nbsp;of&nbsp;serum&nbsp;expressed</mtext><mo>=</mo><mfrac><mrow><mtext>from&nbsp;10&nbsp;ml&nbsp;blood</mtext><mo>×</mo><mn>10</mn></mrow><mrow><mn>100</mn><mo>−</mo><mtext>Haematocrit&nbsp;%</mtext></mrow></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\text{Volume of serum expressed} = \frac{\text{from 10 ml blood} \times 10}{100 - \text{Haematocrit \%}} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">Volume&nbsp;of&nbsp;serum&nbsp;expressed</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.1408em; vertical-align: -0.7693em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">Haematocrit&nbsp;%</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">from&nbsp;10&nbsp;ml&nbsp;blood</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.7693em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p><strong>Normal range</strong> 58–97% in one hour</p>
<p><strong>Interpretation</strong> Decreased clot retraction may be observed in a number of platelet defects. It is lowered in thrombocytopenia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-to-measure-the-extrinsic-system-one-stage-prothrombin-time-pt">TEST TO MEASURE THE EXTRINSIC SYSTEM: ONE-STAGE PROTHROMBIN TIME (PT)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-to-measure-the-extrinsic-system-one-stage-prothrombin-time-pt" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This test measures the extrinsic pathway of coagulation. When tissue thromboplastin and calcium ions are added to plasma, extrinsic clotting factors are activated, resulting in the generation of</p>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 345</p>
<p>thrombin and the formation of fibrin clot. Thus, the test indicates functions of factors II, V, VII and X.</p>
<p>A tissue extract serves as a source of thromboplastin. The reagent most popularly employed is the saline extract of human brain.</p>
<p><strong>Note:</strong> Rabbit brain is now used instead of human brain because of the risk of HIV infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Thromboplastin Remove the meninges, cerebellum and blood vessels from a fresh human (or rabbit) brain removed at post mortem. Wash thoroughly in running water, drain and blot dry. Cut into small pieces and emulsify in saline using a pestle and mortar or in a blending machine at a low speed. Centrifuge the emulsion at 70g for 20 min. Decant the supernatant in a separate container. Prepare dilutions (from 1:2 to 1:10) and determine prothrombin time of a normal plasma, using each dilution. Select the dilution which gives a clotting time of 12 seconds. Dilute the bulk in 0.5% phenol saline (0.5 g phenol in 100ml saline) to the desired concentration, distribute in suitable aliquots and store at 4°C.</li>
</ol>
<p><strong>Note:</strong> Brain thromboplastin is commercially available.</p>
<ol start="2">
<li>0.025M Calcium chloride Dissolve 2.7g of calcium chloride in distilled water and make up to one litre.</li>
</ol>
<p>Specimen Collect blood into a tube containing 3.8% sodium citrate in the ratio of 9:1. Plastic tube and syringes should be used wherever possible. Mix the blood gently with citrate by inverting it several times. The test should be performed within 2-3 hours of blood collection since the labile factor (factor V) is destroyed on standing at room temperature.</p>
<p>Collect a control blood sample in the same way.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Centrifuge both the test and the control blood samples at 1000 g for 15 minutes to obtain platelet-poor plasma
(2) Add 0.1 ml thromboplastin in two glass tubes and place them at 37°C water bath.</p>
<p>(3) Add 0.1 ml of normal control plasma to each tube and incubate for one minute.
(4) Add 0.1 ml of calcium chloride to one tube, and start a stop watch.
(5) Tilt the tube repeatedly until a clot forms. Note the time.
(6) Repeat with the second control tube and take the average time as: The reading for the control.
(7) Repeat the procedure with the test sample. Express the prothrombin time in seconds as the mean of the two readings.</p>
<p>Normal range Control time should be 13-15 seconds, though each laboratory should establish its own range.</p>
<p>The test sample should form a clot within two seconds of the control.</p>
<p>Calculation Prothrombin time results may be expressed as</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>Prothrombin&nbsp;ratio</mtext><mo>=</mo><mfrac><mtext>Patients&nbsp;clotting&nbsp;time</mtext><mtext>Control&nbsp;clotting&nbsp;time</mtext></mfrac></mrow><annotation encoding="application/x-tex">\text{Prothrombin ratio} = \frac{\text{Patients clotting time}}{\text{Control clotting time}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord text"><span class="mord">Prothrombin&nbsp;ratio</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Control&nbsp;clotting&nbsp;time</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Patients&nbsp;clotting&nbsp;time</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>or</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>Prothrombin&nbsp;index</mtext><mo>=</mo><mfrac><mtext>Control&nbsp;clotting&nbsp;time</mtext><mtext>Patient’s&nbsp;clotting&nbsp;time</mtext></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\text{Prothrombin index} = \frac{\text{Control clotting time}}{\text{Patient's clotting time}} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord text"><span class="mord">Prothrombin&nbsp;index</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Patient’s&nbsp;clotting&nbsp;time</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Control&nbsp;clotting&nbsp;time</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p>Interpretation Prolongation of prothrombin time occurs in liver disease, congenital deficiencies of coagulation factors in the extrinsic pathway and in oral anticoagulant therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-for-prothrombin-consumption-index-pci">TEST FOR PROTHROMBIN CONSUMPTION INDEX (PCI)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-for-prothrombin-consumption-index-pci" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>About 95% of prothrombin is utilised by activation to thrombin when whole blood clots. Citrated plasma is clotted in the absence of platelets and much less prothrombin is consumed. Thus, by comparing the clotting time of serum and plasma in the presence of fibrinogen, the contribution of platelets to the coagulation process can be determined.</p>
<p>Specimens Collect 1.8 ml of blood in a tube containing 0.2 ml of 3.8% sodium citrate and 2.0 ml blood in a plain tube. Keep the plain tube at 37°C for one hour and centrifuge to separate the</p>
<p>Scanned by CamScanner</p>
<p>346 Haematology</p>
<p>serum. Centrifuge the citrated blood as for prothrombin time (1000 g for 15 minutes).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Brain thromboplastin</li>
<li>0.025 M Calcium chloride</li>
<li>Fibrinogen: Human fibrinogen, 150–200 mg in 100 ml saline.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Add 0.1 ml of serum to two glass tubes and keep at 37°C.
(2) Add 0.1 ml of brain thromboplastin to one tube, start a stop watch.
(3) At the end of one minute, add 0.1 ml calcium chloride and mix.
(4) After two minutes, remove any fibrin formed with an applicator stick; and add 0.2 ml fibrinogen. Note the time required for clot formation at 37°C.
(5) Repeat the same procedure with the second tube, record average time.
(6) Repeat the same procedure with citrated plasma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="calculation">Calculation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calculation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Prothrombin Consumption Index =</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mtext>Plasma&nbsp;clotting&nbsp;time</mtext><mtext>Serum&nbsp;clotting&nbsp;time</mtext></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\frac{\text{Plasma clotting time}}{\text{Serum clotting time}} \times 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Serum&nbsp;clotting&nbsp;time</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Plasma&nbsp;clotting&nbsp;time</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p>Normal range &lt;30%</p>
<p>Interpretation PCI may be prolonged due to</p>
<ol>
<li>Thrombocytopenia</li>
<li>Platelet coagulation defects</li>
<li>Platelet aggregation defects</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-for-intrinsic-system">TEST FOR INTRINSIC SYSTEM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-for-intrinsic-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Such as kaolin or glass, is used to trigger the intrinsic system.</p>
<p>Specimen The citrated plasma is centrifuged at 1500–2000 g for 15 minutes to remove platelets. The plasma sample used for prothrombin time can also be used.</p>
<p>Plasma from a healthy person should be used as control.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Kaolin Suspend 0.5 g kaolin in 100 ml saline.</li>
<li>Phospholipid (brain extract or partial thromboplastin)</li>
</ol>
<p>Place about 100 g washed brain in a large mortar and cover with acetone. Mash with a pestle for about two minutes. When acetone becomes turbid, decant and replace with fresh acetone. Continue until the residual brain is granular. Spread it on a filter paper and allow it to dry at room temperature. This is the acetone-dried brain. Store in perforated containers in a dessicator.</p>
<p>Weigh 1 g acetone dried brain and add 20 ml acetone. Mix continuously for two hours. Centrifuge for five minutes at 1500 g. Discard the supernatant and add 20 ml chloroform. Mix again for two hours. Filter through a Whatman No.1 filter paper. Evaporate the chloroform in the filtrate using a stream of warm air. Emulsify the residue in 10 ml normal saline by mixing for up to 48 hours.</p>
<p>Standardise the partial thromboplastin thus obtained by selecting a dilution (e.g. 1:100) which gives optimum clotting time (e.g. 35–43 seconds) with control plasma.</p>
<p>This reagent is commercially available.</p>
<ol start="3">
<li>0.025M calcium chloride Dissolve 2.77 g in one litre distilled water.</li>
</ol>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 347</p>
<p>(5) Leave the tube for 30 seconds, and then remove.
(6) Check for clotting by tilting the tube.
(7) Record the time taken to clot.
(8) Repeat the same procedure with the test plasma.</p>
<p>Normal range Control plasma should clot between 35–43 seconds.</p>
<p>Prolongation of the clotting time by seven seconds or more than that of the control is significant.</p>
<p>Interpretation The activated partial thromboplastin time may be prolonged due to</p>
<ol>
<li>Defects in the intrinsic system: e.g. factors VIII: c, IX, XI, XII etc.</li>
<li>Defects in the common pathway e.g. factors X, V, II, I.</li>
<li>Inhibitory action of heparin, specific inhibitors of factors etc.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="af9f7193">♦ ASSAYS OF COAGULATION FACTORS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#af9f7193" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-fibrinogen">1. Fibrinogen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-fibrinogen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Principle During the process of coagulation, the enzyme thrombin converts soluble fibrinogen into insoluble fibrin. The time required for this conversion is proportional to the concentration of fibrinogen in plasma. By plotting a graph of known concentrations of fibrinogen and their clotting time, the concentration of fibrinogen in the test sample can be determined.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h4 level="4" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h4></div>
<p>(i) Veronal buffer (pH 7.35) Dissolve 5.9 g of sodium barbital and 7.1 g of sodium chloride in 2.5 ml of 0.1 N hydrochloric acid and 785 ml of distilled water. It is stable for a long time at 4°C.
(ii) Thrombin 100 NIH (Nilhydril) units/ml
(iii) Standard fibrinogen A lyophilised fibrinogen with a known concentration is commercially available.</p>
<p>Specimen Collect 4.5 ml of whole blood in 0.5 ml of 3.8% sodium citrate.</p>
<p>Collect a normal control blood in the same way.</p>
<p>Separate the plasma by centrifuging at 1000 g for 15 minutes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h4 level="4" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h4></div>
<p>Step I: To obtain a calibration curve using the fibrinogen standard (1) Set up three tubes and prepare 1:5, 1:15 and 1:40 dilutions of the fibrinogen standard as follows:</p>
<table><thead><tr><th>Tube No.</th><th>1</th><th>2</th><th>3</th></tr></thead><tbody><tr><td>Veronal buffer (ml)</td><td>1.6</td><td>0.8</td><td>2.8</td></tr><tr><td>Fibrinogen</td><td></td><td>↓</td><td>↑</td></tr><tr><td>standard (ml)</td><td>0.4</td><td>0.4</td><td>0.4</td></tr><tr><td>Final dilution</td><td>1:5</td><td>1:15</td><td>1:40</td></tr></tbody></table>
<p>(2) Dispense each dilution in two tubes in 0.1 ml amounts and incubate at 37°C for two minutes.
(3) Add 0.1 ml of the thrombin solution to tube 1. Start the stop watch.
(4) Determine the clotting time at the first sign of clot when a fibrin strand is observed with a hooked nichrome wire.
(5) Repeat the test with the second tube of the same dilution and record the average as the clotting time.
(6) Determine the clotting time for tubes 2 and 3 in the same way.
(7) Plot the clotting time of each dilution against the fibrinogen concentration.</p>
<p>Step II: To determine the clotting time for the test and control plasma (1) Dilute the test and control plasma 1:10 with the veronal buffer.
(2) Determine the clotting time of each in duplicate in the same way as in step I.
(3) Read the concentration of fibrinogen in the 1:10 dilution of the test sample and the control from the calibration curve.
(4) Multiply by 10 to get the actual concentration.</p>
<p>Normal range 200 to 400 mg/dl</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-factor-assays-based-on-the-prothrombin-time-assay-of-factor-v-vii-x-and-ii">2. Factor Assays Based on the Prothrombin Time (Assay of factor V, VII, X and II)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-factor-assays-based-on-the-prothrombin-time-assay-of-factor-v-vii-x-and-ii" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>In the assay of these factors, substrate plasmas deficient in the factors to be assayed are used. The factor</p>
<p>Scanned by CamScanner</p>
<p>348 Haematology</p>
<p>deficient substrate plasma is mixed with serial dilutions of pooled normal plasma. Prothrombin time (PT) of each dilution is determined to plot a calibration curve. The same procedure is repeated with the test plasma. The percentage of the factor is then read from the normal curve.</p>
<p>This basic assay can be used for all factors, except fibrinogen, which is involved in the prothrombin time test. A plasma substrate deficient for the factor should be used, all other reagents are constant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Thromboplastin prepared as for the prothrombin time test or obtained commercially.
(ii) Calcium chloride (0.025M) : 2.77g of calcium chloride is dissolved in one litre of distilled water.
(iii) Normal pooled plasma, prepared at least from five normal specimens. The concentration of the factor under assay is considered to be 100% in this plasma.
(iv) Factor-deficient substrate plasma
(v) Veronal buffer, pH 7.35 as for fibrinogen assay.</p>
<p><strong>Specimen</strong> Citrated blood collected as for prothrombin time (9 parts whole blood + 1 part 3.8% sodium citrate)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Step I: To prepare a normal activity curve using normal pooled plasma with factor deficient plasma:</strong> (1) Prepare serial dilutions of the normal pooled plasma ranging from 1:10 to 1:320 as follows:</p>
<p>(2) Mix 0.1 ml of 1:10 dilution of the normal plasma with 0.1 ml of the factor deficient substrate plasma. Keep at 37°C for two minutes.
(3) Add 0.2 ml of pre-warmed thromboplastin solution and 0.1 ml of 0.025 M calcium chloride solution. Start the stop watch and record the clotting time.
(4) Repeat the test with the same dilution and record the average clotting time.
(5) Determine the clotting time for each dilution of the normal plasma in the same way.
(6) Plot the dilutions against the clotting time (seconds) on a graph paper. The graph should be a straight line.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="step-ii-to-determine-the-pt-of-test-plasma">Step II: To determine the PT of test plasma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#step-ii-to-determine-the-pt-of-test-plasma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Dilute the test plasma 1:10 and 1:20 with the veronal buffer.
(2) Determine the clotting time for each dilution in the same way as in step I.
(3) The percentage factor activity of the test plasma is indicated by the point at which the clotting time of 1:10 dilution intercepts the normal i.e. 100% concentration curve. The results obtained with 1:20 dilution are multiplied by 2 to obtain the percentage deficiency. The average of the two values should be reported.</p>
<p><strong>Normal Range</strong> 50–150%.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-factor-assays-based-on-the-partial-thromboplastin-time-assay-of-factors-viii-ix-and-xii">3. Factor Assays Based on the Partial Thromboplastin Time (Assay of Factors VIII, IX and XII)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-factor-assays-based-on-the-partial-thromboplastin-time-assay-of-factors-viii-ix-and-xii" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> This test detects deficiencies of factors in the intrinsic pathway using the APTT method and substrate deficient plasma.</p>
<table><thead><tr><th>Tube No.</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th><th>6</th></tr></thead><tbody><tr><td>Veronal buffer (ml)</td><td>1.8</td><td>1.0</td><td>1.0</td><td>1.0</td><td>1.0</td><td>1.0</td></tr><tr><td>Normal plasma (ml)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Factor conc. 100%)</td><td>0.2</td><td>1.0</td><td>1.0</td><td>1.0</td><td>1.0</td><td>1.0</td></tr><tr><td>Final dilution</td><td>1:10</td><td>1:20</td><td>1:40</td><td>1:80</td><td>1:160</td><td>1:320</td></tr><tr><td>Concentration of</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>the factor (%)</td><td>100</td><td>50</td><td>25</td><td>12.5</td><td>6.25</td><td>3.12</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Haemostasis and Fibrinolysis 349</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Phospholipid reagent (brain extract), as for APTT.
(ii) Factor-deficient substrate plasma for the factor under investigation.
(iii) Calcium chloride, 0.025M-Dissolve 2.77 g per litre distilled water.
(iv) Veronal buffer, pH 7.35.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specimen">Specimen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Citrated blood sample (9 parts whole blood + 1 part 3.8% sodium citrate).</p>
<p>Collect a pooled control plasma in the same way.</p>
<p><strong>Note</strong></p>
<p>(i) For factors VIII and IX assays, it is essential to keep the test and control plasmas frozen if any delay is expected in carrying out the test. Moreover, while carrying out the test the diluted plasma specimens should be kept at 4°C or on crushed ice until required for the test.
(ii) For the assay of factor XI, only fresh test samples should be used. Storage in the refrigerator may increase factor XI activity.
(iii) For factors XI and XII assays, the test plasma must not come in contact with any glass surface during collection and testing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Step I: To prepare a normal activity curve using control plasma with factor deficient plasma:</strong></p>
<p>(1) Dilute the control plasma 1:5, 1:10, 1:20 and 1:40 with veronal buffer as follows:</p>
<table><thead><tr><th>Tube No.</th><th>1</th><th>2</th><th>3</th><th>4</th></tr></thead><tbody><tr><td>Venoral buffer (ml)</td><td>0.4</td><td>0.9</td><td>1.9</td><td>3.9</td></tr><tr><td>Control plasma (ml)</td><td>0.1</td><td>0.1</td><td>0.1</td><td>0.1</td></tr><tr><td>Final dilution</td><td>1:5</td><td>1:10</td><td>1:20</td><td>1:40</td></tr><tr><td>Factor concentration (%)</td><td>100</td><td>50</td><td>25</td><td>12.5</td></tr></tbody></table>
<p>(2) In a 37°C water bath, mix 0.1 ml volumes of phospholipid reagent, factor deficient plasma and diluted control plasma from tube 1. Start the stop watch as soon as the control plasma is added.
(3) Exactly at the end of three minutes, add 0.1 ml of 0.025 M calcium chloride solution to the mixture.
(4) Mix and start another stop watch or start counting the time freshly at this point.
(5) Leave the tube undisturbed at 37°C for 40 seconds.
(6) Remove the tube and tilt back and fourth quickly till the clot is formed. Record the time.
(7) Repeat the test for the same dilution. Record the average clotting time.
(8) Repeat the same procedure for tubes 2, 3 and 4.
(9) Plot a curve of factor concentration against clotting time in seconds.</p>
<p><strong>Step II: To determine the partial thromboplastin time of the test plasma with factor-deficient plasma</strong></p>
<p>Repeat the same technique as in step I using the test plasma instead of the control plasma. Draw a separate curve for the test plasma plotting the expected factor concentration at each dilution against clotting time.</p>
<p>The degree of correction can be determined by finding out the concentration in the control plasma at the clotting time of 1:5 dilution of the test plasma. For example, clotting time for tube 1 of test plasma is 70 seconds whereas the control plasma curve shows a factor concentration of 30% at 70 seconds clotting time, the factor activity of the test plasma is said to be 30%.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="normal-range">Normal range<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#normal-range" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Factors VIII, IX and XI 50–150 %
Factor XII 40–150 %</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-tests-for-coagulation-disorders">Other Tests for Coagulation Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-tests-for-coagulation-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In a specialised coagulation laboratory other tests are performed such as Russell viper venom time, reptilase time, assays of other factors not described above and the assays for inhibitors.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 8</p>
<p><img src="assets/images/image-20251218-162636e1.jpeg" alt="img-48.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="blood-group-serology-immunohaematology">Blood Group Serology (Immunohaematology)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blood-group-serology-immunohaematology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Each species of animals, including humans, has certain inherited antigens on the surface of the red cells which are unique for that species. These are known as isoantigens. Similarly, certain antigens, the alloantigens are common to some, but not all, members of that particular species. Blood group serology involves the detection of these antigens and their antibodies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="blood-group-genetics">BLOOD GROUP GENETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blood-group-genetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>All the antigenic substances present on the red cells of an individual are inherited. The unit of inheritance is a gene and each antigen is controlled by a gene for that antigen. Genes are made up of deoxyribonucleic acid (DNA) which, when organised in a linear form, make up a chromosome. Humans have 23 pairs of chromosomes in each nucleated cell. The genes responsible for a particular character always occupy the same position on a particular chromosome. The position of each gene on a chromosome is called its locus. Genes are always arranged in the same sequence on a chromosome.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="some-terms-commonly-used-in-genetics">Some Terms Commonly Used in Genetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#some-terms-commonly-used-in-genetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Allele or allelomorph</strong> Two or more genes responsible for the same characteristic occupying the same position on the chromosomes.</p>
<p><strong>Homozygous</strong> A person who has inherited same allelic genes from both parents e.g. having both blue eyed colour genes.</p>
<p><strong>Heterozygous</strong> A person who has inherited different allelic genes for a trait e.g. having a blue and brown- eye colour genes.</p>
<p><strong>Dominant gene</strong> Certain alleles are stronger than other alleles. For example, brown eye genes mask the presence of blue eye genes, and are therefore dominant over blue eye genes. A dominant gene expresses itself in both homozygous and heterozygous states.</p>
<p><strong>Recessive gene</strong> The recessive genes are expressed only when their dominant allele is absent e.g. only in the homozygous state. That is, the colour of the eye will be blue if both the alleles are for blue eyes.</p>
<p><strong>Co-dominant gene</strong> In a co-dominant gene, various alleles for the same character are equally dominant e.g. alleles for a particular blood group system.</p>
<p><strong>Genotype</strong> The genetic make up of an individual or a cell is called its genotype.</p>
<p><strong>Phenotype</strong> It is the observable characteristics of an individual or a cell. e.g. an individual of group BO genotype would be expressed as group B because O gene is recessive.</p>
<p>Scanned by CamScanner</p>
<p>Blood Group Serology (Immunohaematology) 351</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="blood-group-antigens">BLOOD GROUP ANTIGENS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blood-group-antigens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The blood group antigens include substances on the red blood cells and on other blood constituents such as leucocytes, platelets and plasma. The blood constituent antigens, which are governed by a single gene or a group of genes, are inherited as 'groups'. Blood groups controlled by a set of genes are called a blood group system. Most blood group antigens follow the laws of inheritance. Chemically, blood group antigens are usually glycoproteins, lipoproteins or glycolipids in nature.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="blood-group-antibodies">BLOOD GROUP ANTIBODIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blood-group-antibodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Specific blood group antibodies develop in response to the antigenic stimulation by a particular blood group antigen. The level of antibody activity depends on the immunogenicity of the corresponding antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="alloantibodies">Alloantibodies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alloantibodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Alloantibodies are antibodies which are present in some members of a species, but not all. For example, anti-A antibodies are present in all human beings belonging to blood group B and O. Due to the presence of alloantibodies, it is necessary to select a blood donor who is negative for the corresponding antigen i.e. if a recipient has anti-A antibodies, he cannot receive blood which contains group A antigen. Alloantibodies to red cell may be of three types:</p>
<p>(i) Naturally occurring i.e. the antigenic stimulus is unknown. ABO antibodies belong to this type.</p>
<p>(ii) As a result of immunisation through transfusion, some red cell antigens which are absent in the recipient may be introduced and induce antibody production.</p>
<p>(iii) Induced by exposure to foetal erythrocytes either during pregnancy or during delivery. These antibodies are similar to those produced by blood transfusion. Development of Rh antibodies in a Rh negative mother by a Rh positive foetus is a good example.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="autoantibodies">Autoantibodies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#autoantibodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>An autoantibody is the antibody which is induced by an antigen in the same individual. It also reacts with the same antigen if it is present in other individuals. In some cases, the reaction of the antigen and its autoantibody may not show any demonstrable clinical symptoms, whereas sometimes such a reaction may lead to haemolytic anaemia, leucopenia or thrombocytopenia.</p>
<p>Autoantibodies are divided into two general categories depending on their optimum reacting temperature.</p>
<p>(i) Warm autoantibodies These constitute about 85% of the autoantibodies. Their optimal reacting temperature is 37°C. Warm autoantibodies are generally IgG in nature and can be detected with the direct antibody test (DAT).</p>
<p>(ii) Cold autoantibodies About 15% of the autoantibodies are of this type. They are generally IgM in nature and agglutinate red blood cells strongly at 4°C, weakly at 24°C and not at all at 37°C. Most of autoantibodies are present in normal individuals, very few are associated with diseases. It is important to be aware of cold antibodies when the patients body temperature needs to be lowered for procedures such as cardiopulmonary bypass.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="main-blood-group-systems">MAIN BLOOD GROUP SYSTEMS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#main-blood-group-systems" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Approximately 600 blood group antigens have been described so far. These are inherited stable characteristics and therefore are useful in paternity testing. The knowledge of blood group antigens is important in blood transfusion. If a recipient lacks a particular blood group antigen, he may produce antibodies against that antigen leading to a transfusion reaction. Different blood group antigens have varying degrees of antigenicity. The ABO and Rhesus groups are of major clinical significance. There are many other systems of less importance.</p>
<p>Scanned by CamScanner</p>
<p>352 Haematology</p>
<p>Table 8.1 ABO blood group system</p>
<table><thead><tr><th>Phenotype</th><th>Genotype</th><th>Antigens</th><th>Naturally-occurring antibodies</th></tr></thead><tbody><tr><td>O</td><td>OO</td><td>None</td><td>Anti-A, B</td></tr><tr><td>A</td><td>AA or AO</td><td>A</td><td>Anti-B</td></tr><tr><td>B</td><td>BB or BO</td><td>B</td><td>Anti-A</td></tr><tr><td>AB</td><td>AB</td><td>AB</td><td>None</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="abo-blood-group-system">ABO BLOOD GROUP SYSTEM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#abo-blood-group-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The ABO system is the most important blood group system in blood transfusion and organ transplantation because of two unique features.</p>
<p>(i) Strongly reactive antibodies are present in the serum of individuals who lack the corresponding antigens.</p>
<p>(ii) A and B antigens are present on many tissue cells in addition to the red cells.</p>
<p>The ABO system consists of four blood groups or phenotypes: A, B, AB and O. The two antigen, A and B are responsible for these four groups. If A antigen is present on the red cell, the individual is said to belong to group A, those having B antigen are group B persons. Group AB individuals have both A and B antigens while group O persons have neither A nor B antigen on their red cells. (Table 8.1). Three allelic genes, A, B and O, can be inherited in the ABO system. The following combinations of alleles is possible: AA, AO, AB, BB, BO, OO; resulting in A, A, AB, B, B, and O group individuals respectively. This is so because A and B genes are dominant and O gene is recessive.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="laws-of-inheritance-of-abo-groups">Laws of Inheritance of ABO Groups<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laws-of-inheritance-of-abo-groups" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>According to Bernstein’s theory, two laws of inheritance have been proved.</p>
<ol>
<li>It is not possible that an offspring can possess antigen A, B or both unless it is inherited from one or both parents (Fig 8.1).</li>
</ol>
<p><img src="assets/images/image-20251218-2c02eaa4.jpeg" alt="img-49.jpeg">
Fig. 8.1 Possible ABO phenotypes of offspring</p>
<ol start="2">
<li>A parent of blood group AB cannot produce an offspring of group O. Similarly, a parent of blood group O can not produce AB offspring. The reason for this law is that group AB is heterozygous, and therefore A and B genes must come from two parents. Table 8.2 shows the possible ABO phenotypes of offsprings.</li>
</ol>
<p>Table 8.2 Possible ABO phenotypes of offsprings</p>
<table><thead><tr><th>Phenotypes of parents</th><th>Possible phenotypes of offspring</th></tr></thead><tbody><tr><td>O X O</td><td>O</td></tr><tr><td>O X A</td><td>O or A</td></tr><tr><td>O X B</td><td>O or B</td></tr><tr><td>O X AB</td><td>A or B</td></tr><tr><td>A X A</td><td>A or O</td></tr><tr><td>A X B</td><td>A, B, AB or O</td></tr><tr><td>A X AB</td><td>A, B, or AB</td></tr><tr><td>B X B</td><td>B or O</td></tr><tr><td>B X AB</td><td>A, B, or AB</td></tr><tr><td>AB X AB</td><td>A, B or AB</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Blood Group Serology (Immunohaematology) 353</p>
<p>Group O individuals have an antigen called H antigen on the surface of their red cells which is a precursor of A and B antigen. The original classification of the ABO system was made by Karl Landsteiner in 1900. Although other cells in the body have ABO antigens, only ABO antigens on red cells play an important role in blood transfusion reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="subgroups-of-abo">Subgroups of ABO<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#subgroups-of-abo" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Both groups A and B can be further subdivided. The most important of these subgroups are A₁ and A₂. Both A₁ and A₂ cells react with anti-A antiserum. Approximately 20% of group A and AB persons belong to subgroup A₂ and 80% to A₁. There are some more subgroups of A, but they are rare and produce weak reactions. Several subgroups of B have been identified but they are very rare.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="h-substance-and-bombay-group">H Substance and Bombay Group<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#h-substance-and-bombay-group" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Another gene, H, is inherited independently of ABO. The H substance produced by the H gene is a precursor for A and B antigens. Therefore, this gene is necessary for the synthesis of AB antigens, and is present in 99.9% of the population. The H gene may have a silent-allele, h. In an homozygous hh individual, even if ABO genes are present, the precursor for the synthesis of these antigens is not produced in the absence of H gene. (Fig 8.2). This rare blood group is called Bombay group (Oh) as it was discovered in this city. The Bombay group is only a phenotypic expression because these individuals do possess ABO genes. If offsprings of a Bombay individual (hh) receive an H gene from the other parent, they will exhibit normal AB antigens.</p>
<p>Because A and B antigens are absent in Bombay group individuals, they are typed as group O persons with anti-A and anti-B sera. Only anti-H can detect the Bombay blood group. While other groups will give a positive reaction with anti-H serum, the Bombay group will give a negative reaction.</p>
<p><strong>Se gene</strong> Se is another independent gene involved in ABO expression. Individuals possessing Se gene have respective A, B and H antigens (according to their genotype) in their secretion and body fluids such as saliva, tears, milk and urine. These persons are called ‘secretors’ and form about 80% of the population. The non-secretor status is due to the presence of the silent allele se (genotype sese) on both the chromosomes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="natural-antibodies-of-abo-system">Natural Antibodies of ABO System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#natural-antibodies-of-abo-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Individuals whose red cells lack A, B or both antigens have the respective antibody in their sera</p>
<p><img src="assets/images/image-20251218-b178c972.jpeg" alt="img-50.jpeg">
Fig. 8.2 The H substance and the Bombay group</p>
<p>Scanned by CamScanner</p>
<p>354 Haematology</p>
<p>(Table 8.1). This is known as Landsteiner's rule. These antibodies are not present at birth. Infants start producing them after 3–6 months of age. Anti-A and anti-B reach peak levels between 5 to 10 years and then the titre gradually declines. The ABO antibodies are absent in infants, elderly persons, and in pathological conditions which affect antibody production.</p>
<p>ABO antibodies are the most important of all other blood group antibodies. Transfusion of an incompatible blood can cause a severe transfusion reaction. These antibodies are potent haemolysins and can bring about intravascular haemolysis. The antibodies are of both IgG and IgM types, and can bind to complement.</p>
<p>As ABO antigens are also present on the tissue cells, their antibodies can cause rapid organ rejection in the transplantation of highly vascularised organs. ABO IgG antibodies can cross the placenta during pregnancy and may cause haemolytic disease of the new-born (HDN) in an antigen positive foetus. However, HDN due to ABO antibodies is rarely severe because the development of antigens in the new-born is incomplete and the infant’s soluble antigens have a neutralising effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immune-response-to-blood-group-antigens">Immune Response to Blood Group Antigens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immune-response-to-blood-group-antigens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Exposure to non-self (foreign) red cell antigens may not always result in the production of antibodies. Antibody production depends on a number of factors:</p>
<ol>
<li>Immunogenic potential of the antigen. Some antigens are more immunogenic than others e.g. Rhesus (Rh) antigen is a very potent immunogen.</li>
<li>Dose of the antigen. At the initial exposure to the antigen, a large dose of antigen is necessary to stimulate antibody production.</li>
<li>Immunocompetence of the individual. Individuals vary in their ability to respond to antigenic stimulation. Some disease states may depress or amplify immune function.</li>
</ol>
<p>Primary response to blood group antigens after the first exposure requires several weeks, if the concentration of the antibody is low, and the time declines within a short period. These antibodies are predominantly IgM type.</p>
<p>Secondary response upon the next exposure to the same antigen, on the other hand, is more rapid, requires a much lower dose, results in the production of larger amounts of antibody, and a higher titre is maintained for a much longer period. These antibodies are IgG in nature.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="8bad84ee">♦ ABO GROUPING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#8bad84ee" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Determination of ABO group is necessary both for the donor as well as the recipient, preliminary to blood transfusion. The blood group may be determined by</p>
<ol>
<li>Detecting the antigens on the red cells. If an individual has A antigen on his red cells, he is said to belong to group A, those having B antigen on red cells belong to group B, those having both the antigens belong to group AB and those who have neither A nor B antigen on their red cells belong to group O. This process of grouping is known as cell grouping.</li>
<li>Detecting antibodies in the serum. According to Landsteiner’s rule, corresponding antigens and antibodies cannot co-exist in the same person’s blood. For example, persons who are blood group A cannot have antibodies to antigen A (anti-A) in their blood, and group B persons cannot have anti-B in their blood. However, for ABO system, natural antibodies are present in the blood of every individual. Therefore, group A person will not have anti-A in his serum, but will possess anti-B because B antigen is absent on his red cells. This process of grouping is known as serum grouping.</li>
</ol>
<p>This can be summarised thus:</p>
<table><thead><tr><th>Blood group</th><th>Antigen on red cells</th><th>Antibodies in serum</th></tr></thead><tbody><tr><td>A</td><td>A</td><td>Anti-B</td></tr><tr><td>B</td><td>B</td><td>Anti-A</td></tr><tr><td>AB</td><td>AB</td><td>None</td></tr><tr><td>O</td><td>None</td><td>Anti-A, Anti-B</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Blood Group Serology (Immunohaematology) 355</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="abo-grouping-sera">ABO Grouping Sera<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#abo-grouping-sera" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="selection-and-preparation">Selection and preparation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#selection-and-preparation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>ABO grouping sera are usually obtained from selected donors whose antibody levels are suitable for use as a laboratory reagent. A satisfactory antiserum must have:</p>
<ol>
<li>
<p><strong>Specificity</strong> It must be specific for the antigen to be detected, under the test conditions. The specificity of the antiserum can be established by testing equal volumes of serum against 2–5% suspensions of red cells of ABO groups. Agglutination should occur only with appropriate cells.</p>
</li>
<li>
<p><strong>Sufficient titre</strong> A serum to be used for grouping should have an anti-A titre of 512 and anti-B titre of 256 when titrated against A and B cells respectively.</p>
</li>
</ol>
<p>To find the titre, prepare serial doubling dilutions of the antiserum (e.g. 1:2 to 1:1024) in saline and add cells of the appropriate group. The titre is the reciprocal of the highest dilution showing agglutination.</p>
<ol start="3">
<li><strong>Avidity</strong> It is the power of antibody to agglutinate quickly and strongly. A suitable serum should produce complete agglutination in 30 seconds when mixed with a 2–5% suspension of appropriate cells. Avidity of the antiserum to A antigens is essential to detect weak subgroups of A.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sources-of-antisera">Sources of antisera<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-antisera" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Animals are inoculated with antigen. After an appropriate period, the serum containing the antibody is collected, purified, tested and standardised.</p>
</li>
<li>
<p>Humans can be sensitised with an antigen through transfusion, pregnancy or intramuscular injection. Blood can be collected after the appropriate immune response. Sometimes blood donors having an antiserum of required qualities can be directly bled without a prior dose of antigen.</p>
</li>
<li>
<p>Monoclonal antibodies (antisera) can be produced by hybridisation when an antibody producing cell is fused with sensitized splenic lymphocytes obtained from mice.</p>
</li>
</ol>
<p>The antisera obtained from the above sources should be purified to remove unwanted fractions, distributed into small amounts under aseptic conditions, labelled and stored at 4°C.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lectins">Lectins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lectins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Extracts of seeds of some plants contain certain substances that can agglutinate red cells. In most plants, the extracts do not seem to exhibit antigen specificity and bring about agglutination irrespective of the blood group antigen. However, there are two extracts from seeds which can be used in blood grouping.</p>
<ol>
<li>
<p><em>Dolichos bifloris</em> (commonly known as horse gram): If diluted appropriately, this extract reacts specifically with A₁ antigen and does not react with A₂.</p>
</li>
<li>
<p><em>Ulex europaeus</em> (common gorse): This reacts specifically with H-substance and agglutinates A₂, A₂B and O cells more strongly than A₁B or B cells.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparation-of-red-cell-suspensions">Preparation of Red Cell Suspensions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparation-of-red-cell-suspensions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Suspensions of washed red cells having known and unknown antigens on their surface are required for various tests in the laboratory. The washing of cells is necessary to remove plasma, which may interfere with the reaction of the cells. In addition, blood group substances in plasma may neutralise the antiserum leading to false negative results. It is also necessary to use a red cell suspension of appropriate strength for optimum reaction with antibody molecules. The red cells are suspended in an isotonic solution of sodium chloride. (0.15 mol/L or 8.5 g/L), pH adjusted to 7.0.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Place 0.2 to 0.5 ml of blood in a test tube.</p>
<p>(2) Fill the tube with saline to 1 cm from the top.</p>
<p>(3) Centrifuge at 200 g for 1–2 minutes to obtain packed red cells.</p>
<p>(4) Remove the supernatant by pouring off the saline in one quick, continuous movement or by using a pasteur pipette.</p>
<p>(5) Tap the tube to re-suspend the cells in the residual fluid. This constitutes one wash.</p>
<p>Scanned by CamScanner</p>
<p>356 Haematology</p>
<p>(6) Repeat the procedure with the same cells at least twice. The last wash should show clear, colourless supernatant with no signs of haemolysis.
(7) To make a 2% cell suspension, add 1 volume of packed red cells to 49 volumes of saline (e.g. 0.1 ml cells and 4.9 ml saline).
(8) To make a 5% cell suspension, add 1 volume of packed cells to 19 volumes of saline.
(9) To make a 10% cell suspension, add 1 volume of packed cells to 9 volumes of saline.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reaction-of-antisera-with-red-cells">Reaction of Antisera with Red Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reaction-of-antisera-with-red-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The reaction between the antiserum and red cells can occur in various ways:</p>
<p><strong>Agglutination</strong> If the red cells and the antiserum contain corresponding antigen and antibody, they will react to bring about agglutination (clumping) of the red cells. If either antigen or antibody is absent, there will be no agglutination.</p>
<p><strong>Haemolysis</strong> Sometimes, the antigen-antibody reaction may result in haemolysis due to activation of the complement system. Complement, if present in the antiserum, can bind to the antigen-antibody complex, and lyse the red cells. Complement can be easily inactivated by heating at 56°C for 30 minutes.</p>
<p><strong>Rouleaux formation</strong> A high concentration of globulin in patient’s serum can hold the red cells together to appear like a stack of coins. This is rouleaux formation and can be mistaken for agglutination.</p>
<p>&gt; <strong>Note</strong>
&gt; The speed and strength of antigen-antibody reactions are affected by many factors. It is necessary to use optimum concentrations of antigen and antibody. Similarly, the physical conditions, such as the pH and temperature, should be maintained at an optimal level for the test. Most blood group antibodies show optimum activity at pH 6.5–7.5 and at 37°C.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a45a44db">♦ ABO GROUPING METHODS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a45a44db" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="method-1-the-tile-method">Method 1: The Tile Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-1-the-tile-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h4 level="4" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h4></div>
<ol>
<li>ABO grouping antisera: Anti-A, anti-B and Anti-AB.</li>
<li>ABO control cells (10% suspension): A₂ cells, B cells, O cells.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h4 level="4" id="specimen">Specimen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h4></div>
<ol>
<li>10% suspension of patient’s cells in saline.</li>
<li>Patient’s serum.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h4 level="4" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h4></div>
<p>(1) Mark a clean white tile with 16 wells shown in Fig. 8.3.</p>
<table><thead><tr><th>Patient’s cells</th><th>Anti-A</th><th>Anti-B</th><th>Patient’s serum</th></tr></thead><tbody><tr><td></td><td>Patient’s cells</td><td>Patient’s cells</td><td>Patient’s cells</td></tr><tr><td>A₂ cells</td><td>A₂ cells</td><td>A₂ cells</td><td>A₂ cells</td></tr><tr><td>B cells</td><td>B cells</td><td>B cells</td><td>B cells</td></tr><tr><td>O cells</td><td>O cells</td><td>O cells</td><td>O cells</td></tr></tbody></table>
<p>&gt; <strong>Fig. 8.3 ABO Grouping—Tile method</strong></p>
<p>(2) Place one drop of anti-A serum in all the wells of row 1, one drop of anti-B serum in row 2, one drop of anti-AB serum in row 3 and one drop of patient’s serum in row 4.
(3) Place one drop of 10% suspension of patient’s cells in all the wells of the horizontal row 1, 10% A₂ cells in row 2, 10% B cells in row 3 and 10% O cells in row 4.
(4) Mix the cells and the serum in each well using a separate applicator stick.
(5) Allow to stand at room temperature for five minutes.
(6) Rock the tile gently and read the results in the control and test wells macroscopically.</p>
<p>Scanned by CamScanner</p>
<p>Blood Group Serology (Immunohaematology) 357</p>
<p>Results For the reactions of the control and the test serum, refer to Table 8.3.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="method-2-the-tube-method">Method 2: The Tube Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-2-the-tube-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Control blood grouping sera: anti-A, anti-B, anti-AB</li>
<li>Control red cells: 2% suspension of A cells, B cells and O cells.</li>
</ol>
<p><strong>Specimen</strong> 1. 2% suspension of patient’s red cells
<strong>Patient’s serum</strong></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(1) Arrange and label six tubes from one to six in a rack.
(2) Add 1 drop of anti-A serum in tube 1, one drop of anti-B serum in tube 2 and one drop of anti-AB serum in tube 3.
(3) Add one drop each of 2% red cell suspension of patient’s cells in tubes 1, 2 and 3.
(4) Add two drops of patient’s serum in each of the tubes 4, 5 and 6.
(5) To tube 4, add 1 drop of 2% suspension of group A red cells, in tube 5, add 1 drop of 2% group B cells and in tube 6, add 1 drop of 2% group O cells.
(6) Mix the contents of all the tubes by shaking the rack.
(7) Allow the tubes to stand at room temperature for two hours.</p>
<p>Alternatively, centrifuge the tubes at 200g for 2-3 minutes after five minutes incubation.
(8) After incubation or centrifugation, re-suspend the cells by tapping the tubes.
(9) Read the results microscopically.</p>
<p><strong>Caution</strong> It is important to rinse the pasteur pipette used in transferring the cells on to the slides after each transfer.</p>
<p><strong>Results</strong> The findings in the first three tubes with known antisera must agree with those in tubes 4, 5 and 6 with known red cell antigens. The reactions of the ABO groups are as shown in Fig. 8.4. The patient’s blood group should be interpreted accordingly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rhesus-rh-grouping-system">Rhesus (Rh) Grouping System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rhesus-rh-grouping-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The discovery of the Rh system is based on the work by Landsteiner and Wiener in 1940 and by Levine and Stetson in 1939. A woman who delivered a still-born foetus was transfused with her husband’s blood. Although both the husband and wife belonged to group O, the woman experienced a severe haemolytic reaction. Levine and Stetson proposed a theory that the woman’s red cells were lacking in an antigen. This antigen was called new antigen, which, the child had inherited from the father. The antigen on the foetal cells stimulated the production of antibodies in the mother’s blood. When she was transfused with husband’s blood, these antibodies brought about the haemolytic reaction.</p>
<p>In 1940, Landsteiner and Wiener inoculated red cells of Rhesus monkeys into rabbits and guinea pigs. The resulting antibodies agglutinated the red cells of the monkeys and also of about 85% of the population. These 85% were called Rh (Rhesus) positive because they possessed the same antigen</p>
<p>|  Group | Anti-A | Anti-B | Anti-A + B
(Group O serum)  |
| --- | --- | --- | --- |
|  A | + | - | +  |
|  B | - | + | +  |
|  AB | + | + | +  |
|  O | - | - | -  |</p>
<p>Scanned by CamScanner</p>
<p>358 Haematology</p>
<table><thead><tr><th></th><th>Patient's red cells + Known antiserum</th><th></th><th></th><th>Patient's serum + Known red cells</th><th></th><th></th><th></th></tr></thead><tbody><tr><td></td><td>Anti-A Serum</td><td>Anti-B Serum</td><td>Anti-AB Serum</td><td>A cells</td><td>B cells</td><td>O cells</td><td>Blood group</td></tr><tr><td>Tube No</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td></td></tr><tr><td>REA DI NG</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>-</td><td>O</td></tr><tr><td></td><td>+</td><td>-</td><td>+</td><td>-</td><td>+</td><td>-</td><td>A</td></tr><tr><td></td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>B</td></tr><tr><td></td><td>+</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td><td>AB</td></tr></tbody></table>
<p>Key: Agglutination → +
No agglutination → -</p>
<p>Fig. 8.4 ABO grouping: Tube method</p>
<p>that was present on the red cells of Rhesus monkeys. The rest of the population were called Rh-negative. It was found that the antibodies to the same antigen can cause a haemolytic reaction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rh-antigens">Rh Antigens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rh-antigens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The Rh blood group system is much more complex than the ABO system. More than 40 antibodies have been described. Basically, there are six related blood group factors C, D, E, c, d and e; and the corresponding antibodies (except anti-d). Like ABO antigens, the Rh factors are also inherited traits. There are six Rhesus genes, C, D and E and their alleles c, d, and e. There are only eight possible combinations in which chromosomes can carry these genes. They are: CDe, cDE, CDE, cDe, Cde, cdE, CdE and cde. A shorthand system has been devised for easy identification of these combinations. The three pairs of genes are carried on the same chromosome and have three closely linked loci. Every individual has loci for six Rh genes.</p>
<p>The factors C, D, E, c and e (except d) are antigenic. They are capable of stimulating the production of antibodies if introduced into the body of an individual whose red cells lack them. However, the Rh antigens vary in their degree of antigenicity. The D antigen is the most immunogenic of them. The first transfusion of the Rh (D) antigen into an Rh(D) negative person will stimulate the production of anti-D antibodies. Subsequent transfusion with the Rh (D) antigen will result in a haemolytic transfusion reaction, similar to that of Levine and Stetson's patient in 1939. Therefore, it is necessary to test the blood of both the donor and the recipient for Rh (D) antigen before blood transfusion. If the blood sample shows the presence of Rh (D) antigen, the individual is termed as Rh Positive; if it is absent, as Rh negative.</p>
<p>Scanned by CamScanner</p>
<p>Blood Group Serology (Immunohaematology) 359</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="3bedafad">The D⁰ Antigen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3bedafad" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Some D antigens react weakly with the anti-D sera. This weak reactivity with anti-D sera is due to D⁰ antigen. Some workers believe that the presence of this antigen can be the result of some genetic variation. One theory to explain D⁰ antigen suggests that the D antigen is made up of four fractions. An Rh-D positive individual possesses all the four, while none is present in an Rh-D negative person. Some persons may lack one or more of these fractions and therefore their red cells are agglutinated by only some of the anti-D antisera. Such an incomplete D antigen is termed as D⁰. It does not usually react with complete anti-D, but it does react with incomplete anti-D antisera with a varying degree of reactivity.</p>
<p>While typing a blood sample for the Rh antigen, the anti-D serum will not produce agglutination with D⁰ antigen, but will produce sensitised cells i.e. the red cells will be coated with the antibody. The presence of sensitised cells can be detected by the antiglobulin test. If a D⁰ person is given Rh-D positive blood, he is likely to produce anti-D antibodies, therefore, he is considered as an Rh-negative recipient. Similarly, a D⁰ blood given to a Rh negative person will stimulate anti-D antibodies. Therefore D⁰ blood is given only to Rh positive persons.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="rh-antibodies">Rh Antibodies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rh-antibodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Unlike ABO antibodies, there are no naturally occurring Rh antibodies. All Rh-antibodies are 'immune' antibodies resulting from specific antigenic stimulation, e.g. transfusion, pregnancy or by injection of the antigen. Because there are no natural Rh-antibodies, antibody typing is not possible in the Rh system. Therefore, all Rh-typing methods depend upon antigen typing using known antiserum.</p>
<p>Some Rh-antibodies cannot be detected in saline suspensions of red cells. However, if a protein rich medium, such as serum or albumin is used, the antibodies can agglutinate the respective red cells. Such antibodies are called incomplete or albumin active antibodies.</p>
<p>The Rh-antibodies which can react even in saline solution are called complete or saline-active antibodies. There is still another class of antibodies which can be demonstrated only by means of antihuman globulin or Coomb's reagent. Such antibodies are known as incomplete univalent antibodies.</p>
<p>The size of the antibody molecule is largely responsible for the differences in their reactivities. The saline-active antibody molecules are of the IgM type and are the largest. The length of the IgM molecule is sufficient to cause bridging of adjacent red cells in suspension. When in suspension, red cells carry an electrical charge called the zeta potential, which causes repulsion among two adjacent red cells. The IgM antibody molecules extend beyond the range of the zeta potential and agglutinate the red cells by binding onto their antigenic sites. The IgG molecules are smaller in size and cannot reach beyond the minimum distance between the cells, and are unable to agglutinate them. The zeta potential can be reduced by suspending the cells in a high protein medium e.g. patient's own serum or 22% albumin solution. Similarly, the antihuman globulin can detect incomplete univalent antibodies by bringing them together along with red cells to which they are attached (Fig. 8.5).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="rh-typing-methods">Rh Typing Methods<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rh-typing-methods" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>As there are no naturally occurring Rh-antibodies, Rh typing methods involve typing of red cells using known antisera against various Rh-antigens. Commercial antisera are available for C, D, E, c and e factors. Since anti-d antibody is not known to be present, it is not possible to test for Rh-d factor. Routine testing for Rh-antigens other than Rh-D is not recommended unless it is specifically indicated. All blood samples which do not give a positive reaction for Rh-D should be tested for D⁰ antigen before reporting them as Rh-D negative. The method used for Rh-D typing depends upon the type of antibody used.</p>
<p>Scanned by CamScanner</p>
<p>360 Haematology</p>
<p><img src="assets/images/image-20251218-569132bd.jpeg" alt="img-51.jpeg">
Fig. 8.5 Antiglobulin Reaction</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="50396b52"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋄</mo></mrow><annotation encoding="application/x-tex">\diamond</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋄</span></span></span></span></span> METHOD 1: SALINE METHOD FOR Rh-D TYPING USING COMPLETE ANTI-D<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#50396b52" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-slide-test">A. Slide Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-slide-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Specimen</strong> Whole blood or 50% red cell suspension prepared from clotted blood in patient’s own serum.</p>
<p><strong>Reagents</strong> Anti-D antiserum (complete)</p>
<p><strong>Method</strong>
(1) Place a drop of antiserum on a labelled white tile.
(2) Add two drops of the specimen (whole blood or 50% red cell suspension).
(3) Mix well and place the slide on a warm viewing box, to bring the temperature of the mixture to about 37°C.
(4) Gently rock the tile back and forth for a maximum of two minutes.
(5) Examine microscopically for agglutination by transferring a small volume on a slide with a clean pasteur pipette.
(6) Test a positive and a negative control in the same way.</p>
<p><strong>Results</strong>
Agglutination: Rh-D positive
No agglutination: Rh-D negative</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-tube-test">B. Tube Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-tube-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Specimen</strong> Washed 5% red cell suspension of patient’s blood.</p>
<p><strong>Reagent</strong> Anti-D antiserum (complete)</p>
<p><strong>Method</strong>
(1) In an appropriately labelled test tube, add one drop of anti-D antiserum.
(2) Add one drop of 5% red cell suspension.
(3) Mix well and incubate at 37°C in a water bath for 30 minutes.
(4) Roll the tube gently to redisperse the cells.
(5) Check for agglutination microscopically.</p>
<p>If no agglutination occurs, centrifuge at 200 g for 1–2 minutes and check again.</p>
<p>Run known positive and negative controls simultaneously with the test.</p>
<p><strong>Results</strong>
Agglutination: Rh positive
No agglutination: Rh negative.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="38353839"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋄</mo></mrow><annotation encoding="application/x-tex">\diamond</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋄</span></span></span></span></span> METHOD 2: ALBUMIN DISPLACEMENT TECHNIQUE FOR Rh TYPING USING INCOMPLETE ANTI-D<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#38353839" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A 22% bovine albumin solution used in this method reduces the zeta potential (repellent electric charge), thus bringing the red cells closer, so that IgG antibody molecules can agglutinate them.</p>
<p><strong>Specimen</strong> 5% washed red cell suspension of patient’s blood.</p>
<p><strong>Reagents</strong></p>
<ol>
<li>Incomplete anti-D antiserum.</li>
<li>22% bovine albumin.</li>
</ol>
<p><strong>Method</strong>
(1) In an appropriately labelled test tube, add one drop of incomplete anti-D and one drop of 5% red cell suspension.
(2) Mix well and incubate at 37°C water bath for 60 minutes.
(3) Without disturbing the cell button, run down one drop of 22% bovine albumin along the side of the tube onto the cells. Do not mix.
(4) Incubate further at 37°C for 30 minutes.</p>
<p>Scanned by CamScanner</p>
<p>Blood Group Serology (Immunohaematology) 361</p>
<p>(5) Read microscopically for agglutination.
(6) Run positive and negative controls simultaneously with the test.</p>
<p><strong>Results</strong></p>
<p>Agglutination Rh-D positive
No agglutination Rh-D negative.</p>
<p><strong>♦ METHOD 3: ENZYME TECHNIQUES</strong></p>
<p>Some antibodies agglutinate or lyse red cells which have been treated with proteolytic enzymes such as papain, trypsin or bromeline. These enzymes remove some negatively charged molecules from the red cell surface, allowing them to come closer for IgG molecules to agglutinate them. These proteolytic enzymes also enhance agglutination by removing a part of the hydration layer surrounding the red cell.</p>
<p>&gt; <strong>Note</strong>
&gt; The enzyme techniques can be used for cell typing, detection of incomplete antibodies, screening for antibodies before transfusion, and for detection of antibodies in the post-transfusion reactions.</p>
<p><strong>Two-stage Papain Technique (Using Papain Treated Cells)</strong></p>
<p><strong>Specimen</strong> Packed red cells for cell typing.</p>
<p><strong>Reagents</strong> 1. Known antiserum (e.g. incomplete anti-D for Rh-D typing). 2. 0.1% solution of papain in saline.</p>
<p><strong>Technique</strong></p>
<p><strong>Step 1: Preparation of papain-treated cells</strong> Mix 4 drops of 0.1% papain and 1 drop of packed red cells in a labelled test-tube.</p>
<p>Incubate at 37°C in a water bath for 15 minutes. (The time may vary with the batch of papain and should be standardised.)</p>
<p>Wash the cells twice in saline.</p>
<p>Make a 5% suspension in saline (These cells can be used for up to 48 hours if stored at 4°C).</p>
<p><strong>Step 11: Antigen detection</strong> (1) Mix 1 drop of papain treated cells from step I and 1 drop of known antiserum in a test tube.
(2) Incubate at 37°C for 20 minutes.
(3) Centrifuge at 200 g for 1 minute, or continue incubation up to 60 minutes.
(4) After centrifugation or incubation, examine macroscopically over a source of light for evidence of haemolysis in the supernatant. Then examine for agglutination by gently tapping the tube. Do not examine microscopically.</p>
<p>Record the presence of lysis and/or agglutination, which indicates a positive reaction.</p>
<p>&gt; <strong>Note</strong>
&gt; 1. A similar technique can be used with ficin instead of papain.
&gt; 2. The same technique can also be used for the detection of unknown antibodies in patient’s serum using known control red cells.</p>
<p><strong>♦ ANTIGLOBULIN TECHNIQUES</strong></p>
<p>Antiglobulin techniques are used for the detection of incomplete univalent antibodies which cannot be detected by the other methods described above. These antibodies react with the red cells, but the reaction is not observable as agglutination or haemolysis. Such red cells are called sensitised red cells. The antibody binds with one antigen site on one red cell, but is unable to reach the adjacent red cell with the other binding site because the distance between two cells is greater than the size of the antibody molecule. Thus, bridging and subsequent agglutination of red cells does not occur. However, in vivo, these incomplete antibodies are capable of bringing about severe reactions.</p>
<p>To demonstrate the presence of these antibodies in vitro, a reagent was developed by Coombs which is an antibody to human globulin. This antiglobulin antibody is IgM in nature and can agglutinate the incomplete antibody coating the adjacent red cells. (Fig. 8.5).</p>
<p>Scanned by CamScanner</p>
<p>362 Haematology</p>
<p>The antihuman globulin (AHG) reagent is prepared by inoculating laboratory animals, usually rabbits, with human serum (globulin) or purified globulin. The animals produce an antibody to this human globulin, AHG. The serum of the animal is purified till it reacts specifically only with human globulin. This AHG is monospecific. Some AHG reagents can combine both with globulin and with complement. These are called polyspecific AHG. The monospecific AHG are produced by injecting purified fractions of human serum into rabbits where as the polyspecific reagent can be prepared by pooling the required monospecific reagents together.</p>
<p>The antiglobulin techniques can be used for cell typing with incomplete antibodies, for antibody screening before transfusion, for antibody detection in post-transfusion reactions and other reactions such as the haemolytic disease of the newborn (HDN), haemolytic anaemias etc.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="d80092c8">♦ ANTIHUMAN GLOBULIN TESTS (Coombs’ Tests)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d80092c8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are two types of antiglobulin tests:</p>
<p>(i) Direct test is used to detect <em>in vivo</em> sensitisation of red cells by an incomplete antibody.</p>
<p>(ii) Indirect test detects the presence of incomplete antibody in the patient’s serum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ea674dda">Direct Antihuman Globulin Test (DAT, Direct Coombs’ Test)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ea674dda" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>DAT is performed on red cells which are suspected of being coated with an antibody <em>in vivo</em> as in haemolytic disease of the new-born (HDN) and autoimmune haemolytic anaemia. These sensitised red cells are washed and mixed with the AHG which binds the incomplete antibody on the red cell surface and brings about agglutination of red cells.</p>
<p>&gt; <strong>Note</strong>
&gt; It is essential to remove all traces of serum globulins by thoroughly washing the cells.</p>
<p><strong>Specimen</strong> Whole blood or 5% washed red cells suspension in saline.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Monospecific or polyspecific AHG serum.</li>
<li>O Rh-positive red cells.</li>
<li>Anti-D serum (incomplete antibody, IgG).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><em>Preparation of IgG coated red cells</em></p>
<ol>
<li>Wash O Rh-positive red cells three times in saline.</li>
<li>To the packed red cells, add equal volume of anti-D serum.</li>
<li>Incubate at 37°C for 30 minutes.</li>
<li>Wash the red cells four times in saline, and prepare a 5% suspension.</li>
<li>Take one volume of the 5% cell suspension and add two volumes of AHG to it.</li>
<li>Centrifuge at 1000 g for 15–20 seconds and examine for agglutination. Strong agglutination with AHG indicates that the cells are properly coated with IgG.</li>
</ol>
<p>The IgG coated red cells can be stored at 4°C for 48 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="d0028ec1">Direct Coombs’ Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d0028ec1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Prepare a 5% suspension of patient’s red cells.</li>
<li>To one volume (e.g. 0.1 ml) of the red cell suspension, add two volumes of AHG.</li>
<li>Mix gently and centrifuge at 1000g for 15–20 seconds.</li>
<li>Read the tubes microscopically for agglutination.</li>
<li>Use the IgG coated cells as positive control and repeat steps 1–4.</li>
</ol>
<p><strong>Result</strong> Agglutination of patient’s red cells with AHG indicates a positive direct Coombs’ test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="5d159a06">Indirect Antihuman Globulin Test (IAT, Indirect Coombs’ Test)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5d159a06" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This test is useful for the detection of antibodies in patient’s serum that may have formed as a result of sensitisation by transfusion or pregnancy. In autoimmune haemolytic anaemia, the patient may</p>
<p>Scanned by CamScanner</p>
<p>Blood Group Serology (Immunohaematology) 363</p>
<p>have free circulating antibodies in addition to those sensitising the red cells. The IAT technique can also be used for the detection of antigens e.g. for cell typing, using a known incomplete antibody and AHG serum.</p>
<p>The indirect Coombs' test is performed in four stages as follows:</p>
<ol>
<li>Incubation of control red cells and test serum (for antibody detection) at 37°C: This step will result in sensitisation of red cells because antibodies in serum will bind to the antigen sites on red cells.</li>
<li>Washing of the red cells to remove excess of free antibodies in the suspension: This step should ensure that there are no free reacting antibodies or interfering proteins in the suspension to give false results.</li>
<li>Addition of antihuman globulin serum: A positive test will be indicated by agglutination in this step.</li>
<li>Checking of negative results with sensitised red cells: If the test is negative, add sensitised red cells to the test. The presence of agglutination indicates that the AHG is active and is not neutralised by any other antigen in the preparation.</li>
</ol>
<p><strong>Note</strong> This technique can be adapted for the detection of antigen on red cells by using a known positive antiserum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>5% washed red cell suspension in saline. For example, O-Rh positive cells for the detection of anti-Rh antibodies.</li>
<li>Patient's serum</li>
<li>Antihuman globulin serum.</li>
<li>IgG coated red cells prepared as for the direct Coomb's test.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Mix one volume of 5% cell suspension with 3-4 volumes of patient's serum.</li>
<li>Incubate at 37°C for 45-60 minutes.</li>
<li>Centrifuge at 1000 g for 15-20 seconds, and examine for haemolysis or agglutination. If agglutination is observed, do not proceed further. The agglutination at this stage cannot be due to IgG. If partial haemolysis is observed, record and proceed further.</li>
<li>Wash the cells at least three times, taking care to remove as much supernatant as possible after each wash. Resuspend the cells in saline by tapping before centrifugation.</li>
<li>Resuspend the cells by tapping and add two drops of antihuman globulin serum.</li>
<li>Mix and centrifuge the tubes at 1000 g for 15-20 seconds.</li>
<li>Read the tubes macroscopically and microscopically for agglutination. Record results.</li>
<li>If there is no agglutination in step 7, leave the tubes at room temperature for 5 minutes, recentrifuge and examine for agglutination.</li>
<li>If the test is still negative, add 1 drop of IgG coated red cells, centrifuge and examine again.</li>
<li>It is necessary to run a positive control, using known antibody in parallel with the test.</li>
</ol>
<p><strong>Note</strong> For the detection of antigens on red cells, follow the same technique using known positive antiserum</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A positive reaction in step 8 indicates that the negative reaction in step 7 is valid; and the test should be recorded as positive indirect Coombs' test.</p>
<p>A positive reaction in step 9 indicates a negative indirect Coombs' test.</p>
<p>A negative reaction in steps 7, 8 and 9 indicates that the test is invalid and must be repeated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="applications-of-antihuman-globulin-tests-coombs-tests">Applications of Antihuman Globulin Tests (Coombs' Tests)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#applications-of-antihuman-globulin-tests-coombs-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Direct Coomb's test is positive in:</p>
<ol>
<li>Haemolytic disease of the new-born (HDN).</li>
<li>Autoimmune haemolytic anaemia.</li>
<li>Recipients of incompatible blood transfusion.</li>
</ol>
<p>Scanned by CamScanner</p>
<p>364 Haematology</p>
<ol start="4">
<li>Drug induced haemolytic anaemia e.g. due to penicillin, methyldopa, caphalothin.</li>
</ol>
<p>Indirect Coombs' test is used for the detection of:</p>
<ol>
<li>Certain blood factors e.g. some blood group antigens of systems such as Duffy, Kell, Kidd.</li>
<li>Antibodies to the above blood factors.</li>
<li>Incompatibility in the donor's and recipient's blood samples.</li>
<li>Antibodies which are destroyed by proteolytic enzymes.</li>
<li>Complement fixing antibodies on the red cells.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="haemolytic-disease-of-the-new-born-hdn">Haemolytic Disease of the New-born (HDN)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemolytic-disease-of-the-new-born-hdn" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Haemolytic disease of the new-born, also known as erythroblastosis foetalis, occurs when a child inherits an antigen from the father which is absent in the mother. It may result from incompatibilities of any blood group system, but the most commonly involved factors are those of the Rh and ABO systems. For HDN to occur, the child must be positive for a particular antigen, and the mother must be negative for the same antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="mechanism">Mechanism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The mechanism of HDN involves sensitisation of the mother to the foreign antigen present on the child's red cells. Normally, while the foetus is in the uterus, mixing of the mother's and foetus blood does not occur because only small molecules can pass through the placenta, and the circulatory systems of the mother and the foetus are separate. However, a small amount of the child's blood can enter the mother's circulation during childbirth, and the antibody is produced by the mother subsequently. This antibody, which is of the IgG type, may then cross the placenta in the next pregnancy, resulting in the destruction of the red cells of the foetus.</p>
<p>HDN most often involves D antigen of the Rh system, the mother being Rhesus negative, and the father positive. Only the children who are Rh-D positive can be affected by the disease. However, the first child is rarely affected, and less than 20% of Rh-negative mothers are sensitised during childbirth. Once sensitised, all the other Rh-D positive foetuses will suffer from HDN.</p>
<p>Other antibodies causing HDN include anti-Anti-E, anti-K (Kell) and antibodies produced due to incompatibilities of the ABO system. The incidence of HDN has been dramatically reduced after the introduction of Rh immune globulin (RMG). RMG is given to an Rh-D negative mother within 72 hours of delivery of an Rh-D positive child, the production of anti-D antibodies is suppressed. When HDN does occur, the destruction of child's red cells by mother's antibody results in clinical jaundice. If the serum bilirubin level is high, it may lead to brain damage and mental retardation. The treatment for HDN is 'exchange blood transfusion', in which the child's blood is replaced with blood without the antigen responsible for HDN e.g. Rh-D negative blood.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinically-less-significant-blood-group-systems">CLINICALLY LESS SIGNIFICANT BLOOD GROUP SYSTEMS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinically-less-significant-blood-group-systems" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Besides the ABO and Rh systems, there are a large number of other antigens detectable on a human red cell. Some of these antigens have been identified to form distinct systems similar to ABO and Rh systems, but they are clinically much less significant. Some of such blood group systems most commonly encountered in clinical situations are described below.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lewis-blood-group-system-le">Lewis Blood Group System (Le)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lewis-blood-group-system-le" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The Lewis blood group is determined by the productive allele, called Le. A silent Le may be present at the same locus in the absence of Le. There are two main Le antigens, Le⁴ and Le⁵, with phenotypes Le (a+b-), Le (a-b+) and Le (a-b-), Le (a-b-) individuals have no Le gene, but they</p>
<p>Scanned by CamScanner</p>
<p>Blood Group Serology (Immunohaematology) 365</p>
<p>produce antigens which are similar to a and b. These are called Le(a) and Le(b). Another Le antigen Le (α) is present on all adult cells which are Le (a+b-) or Le(a-b+). Antigens Le(a) and Le(c) are found in non-secretors and Le(b) and Le(d) are found in secretor individuals.</p>
<p>Usually, anti-Le(a) and anti-Le(b) are produced by Le(a-b-) individuals i.e. those lacking both the antigens a and b. Occasionally, Le (a+b-) individual may produce anti-Le(b), but Le (a-b+) individuals never produce anti-Le(a). Lewis antibodies are IgM in nature and therefore, do not cross through the placenta. They react better at lower temperatures. However, transfusions with a Lewis incompatible blood group rarely results in a severe transfusion reaction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-blood-group-system">II Blood Group System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-blood-group-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I antigen is present on all red cells of all human adults, but only a small amount is present at birth. Conversely, its allele i is present in the red cells at birth, and changes from i to I during the first 18 months. Thus adult cells show a very small amount of i antigen. The i antigen also serves as a marker for maturation of red cells. If a large number of immature red cells are being released into circulation, the i activity is enhanced.</p>
<p>As a rare exception, the maturation of i antigen to I does not take place and such i adult individuals remain strongly positive for i throughout life and show only traces of I. Such individuals may produce anti-I. Anti-I is produced as an auto-antibody in low titres (&lt; 64) in the serum of many healthy individuals. The titre is increased (&gt; 64) in Mycoplasma and some viral infections. Autoantibody to i antigen occurs rarely. It is found to be associated with infectious mononucleosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="p-blood-group-system">P Blood Group System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#p-blood-group-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Most of the red cells have two closely related antigens on their surfaces, P and Pk. Occasionally some lack P and have only Pk antigen. Approximately 80–90% individuals also have on their red cells an antigen called P1. The red cells lacking P1 are called P2. Anti-P1 occurs very commonly in the sera of P2 individuals, and is detectable at low temperature. The p phenotype results from the absence of P antigen.</p>
<p>'p' individuals therefore lack P, P1 and Pk antigens. They contain an anti-P, P1, Pk antibody. The serum of Pk individuals contains anti-P antibody. These two antibodies can produce haemolysis. The biphasic haemolysis in paroxysmal cold haemoglobinuria (PCH) is often found to be due to anti-P antibodies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mnss-blood-group-systems">MNSs Blood Group Systems<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mnss-blood-group-systems" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This system contains two sets of antigens, MN and Ss. Both the genes responsible for their production are closely linked and are inherited together as a complex. Anti-M and Anti-N occur in human serum as natural antibodies if the respective antigen is absent on red cells. They are IgM in nature and are active below 37°C. Anti-S and anti-s are often of an immune origin and can be detected by antihuman globulin serum. Antibodies of this system are destroyed by enzymes and therefore can not be detected by the enzyme technique.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="kell-blood-group-system">Kell Blood Group System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#kell-blood-group-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This system includes at least 22 antigens such as K1, K2, K3, etc. There are other less frequent antigens also found to belong to this group. The K antigen is considered to be next in immunogenicity to the D antigen of the Rh system, but it is relatively much less frequent. There is a rare Ko group which does not possess any of the K antigens, but is rich in their precursor Kx.</p>
<p>Kell antibodies are capable of mediating immune haemolysis. They have high titres and high affinity for their antigens. Most Kell antibodies are IgG and can be detected by antihuman globulin serum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="duffy-blood-group-system">Duffy Blood Group System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#duffy-blood-group-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This system consists of at least three allelic genes Fya and Fyb, which produce antigens Fya and Fyb respectively. The third gene Fy does not produce</p>
<p>Scanned by CamScanner</p>
<p>366 Haematology</p>
<p>either Fya or Fyb. An antibody, anti-Fy3 was first detected in the serum of an individual of the phenotypeFy(a-b-). Anti-Fy3 is directed against the cells other than Fy(a-b-) phenotype.</p>
<p>Anti-Fya and anti-Fyb are present in serum invariably as a result of immune response. They can be detected by the antihuman globulin test. They are inactivated by proteolytic enzymes, and cannot be detected by the enzyme method.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="kidd-blood-group-system">Kidd Blood Group System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#kidd-blood-group-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Two antigens have been detected which belong to this system and are called Jka and Jkb. A phenotype Jk (a-b-) has an antibody which reacts with both Jka and Jkb antigens. A peculiar property of Jk (a-b-) phenotype is that these red cells resist lysis by 2M urea solution. This can be used as a screening method for the detection of Jk (a-b-) phenotype.</p>
<p>Anti-Jka and anti-Jkb can be detected by the antihuman globulin test. They react better with the antihuman globulin reagent with anti-complement component (polyspecific reagent). However, the antibodies are lost quickly on storage. They can cause delayed haemolytic transfusion reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lw-blood-group-system">LW Blood Group System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lw-blood-group-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Both Rh-D positive and Rh-D negative red cells carry LW antigen, but it is present in much lesser amounts on Rh-D negative cells. The LW blood group has two alleles, LWa and LWb. The LW negative individuals lack the antigen LWa. Some LW positive persons are known to produce autoantibodies to the LW antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lutheran-blood-group-system">Lutheran Blood Group System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lutheran-blood-group-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The Lutheran system has two allelic genes producing Luᵃ and Luᵇ antigens. An Lu(a-b-) phenotype exists due to an inhibitor gene, InLu. This inhibitor gene is also known to suppress some other antigens such as the i, and P1. The Lutheran system has about 15 antigens, but the antibodies are not clinically important. They can be detected by the antihuman globulin serum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-sex-linked-antigen">The Sex-Linked Antigen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-sex-linked-antigen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This sex-linked (x-chromosome) antigen, Xg has a unique feature that it is more likely to be present in women than in men, because women have two X chromosomes, while men have only one. Men never inherit it from their fathers, because the single X chromosome they possess is inherited from their mothers. On the other hand, daughters of men who are positive for this antigen (Xgᵃ) always inherit it from the fathers. Anti-Xgᵃ is a rare antibody. It can be detected by the antihuman globulin technique but is destroyed in the enzyme technique.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 9</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="blood-banking-blood-transfusion-and-compatibility-testing">Blood Banking, Blood Transfusion and Compatibility Testing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blood-banking-blood-transfusion-and-compatibility-testing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Therapeutic administration of blood and blood products is indicated in many diseases and other health problems. Loss of blood from the body impairs the ability of the circulatory system to supply adequate amounts of oxygen to body tissues and upsets the delicate water and acid-base balance of the body fluids. This can lead to severe illness and death. Loss of blood may be due to haemorrhage, excessive destruction of red cells or inability of the body to replenish its own blood cells.</p>
<p>The technique of replacing a patient's whole blood or its components is known as blood transfusion. The blood used for transfusion should be such that it should not have any harmful effect on the patient. The tests carried out for this purpose are called compatibility tests and are performed on a blood sample of a willing, normal, healthy individual, the donor. The procedures involved in collecting, storing, processing and distributing the blood of potential donors is called blood banking.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="selection-of-a-donor">SELECTION OF A DONOR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#selection-of-a-donor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Most healthy individuals can donate blood without any ill-effects. However, selection and proper identification of a donor is essential so that the blood collected for transfusion is safe and beneficial to the patient (recipient). Most blood donations are voluntary.</p>
<p>Two basic principles must be kept in mind when the donor is selected:</p>
<ol>
<li>The blood collection procedure should not be harmful to the donor.</li>
<li>The donor's blood should not be harmful to the recipient.</li>
</ol>
<p>The selection of the blood donor involves a medical history and simple physical examination (pulse rate, blood pressure), and later, screening for transfusion-transmissible diseases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pre-transfusion-tests-on-donor-s-blood">PRE-TRANSFUSION TESTS ON DONOR'S BLOOD<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pre-transfusion-tests-on-donor-s-blood" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>While collecting donor's blood, a small sample of blood should be collected separately for testing before it can be safely transfused into any recipient. The following screening tests must be performed on the donor's blood sample.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="haemoglobin-concentration">Haemoglobin Concentration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemoglobin-concentration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The concentration of haemoglobin may be determined by any method described in this book. It is best to disqualify persons with haemoglobin of less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">12\mathrm{g}/100\mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mord">/100</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. This rule may be relaxed to permit individuals with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10\mathrm{g}/100\mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mord">/100</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> haemoglobin to donate blood in emergencies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="parasites">Parasites<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#parasites" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Blood should be screened for blood parasites such as malaria, microfilaria and trypanosomes, especially in endemic areas.</p>
<p>Scanned by CamScanner</p>
<p>368 Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="tests-for-syphilis">Tests for Syphilis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tests-for-syphilis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A blood sample positive for syphilis may transmit live spirochaetes of <em>Treponema pallidum</em> to the recipient. Therefore, screening tests such as VDRL or RPR should be performed on the donor’s sample. The blood should be discarded if found positive. However, <em>T. pallidum</em> cannot survive for more than 48–72 hours at 4°C. Hence, the blood stored for more than 72 hours at 4°C has no risk of transmitting syphilis to the recipient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-for-hepatitis-b">Test for Hepatitis B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-for-hepatitis-b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Transfusion of blood from a hepatitis B carrier can result in the transmission of the disease to the recipient. Therefore the blood sample of the donor must be screened for the presence of hepatitis B antigen (HBsAg) by one of the various methods available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-for-human-immunodeficiency-virus-hiv">Test for Human Immunodeficiency Virus (HIV)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-for-human-immunodeficiency-virus-hiv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS) poses the highest risk of transmission through blood transfusion, and can lead to the fatal disease. Therefore, every blood donor must be screened for HIV by ELISA or other screening tests.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="collection-of-blood">COLLECTION OF BLOOD<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#collection-of-blood" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Blood for transfusion must be collected and handled under strictly sterile conditions to prevent contamination. Plastic blood collection bags are used which contain an anticoagulant sufficient for the amount of blood to be collected. Generally, a combination of citrate and dextrose is used as an anticoagulant. Citrate binds with calcium and prevents activation of the coagulation cascade. Dextrose provides energy for the red blood cells. The anticoagulant also contains inorganic phosphate buffer to increase the production of energy-rich adenosine triphosphate (ATP) which increases red cell viability. If adenine is added, it increases the survival period of red cells. The two commonly used anticoagulants are citrate phosphate dextrose (CPD) and citrate phosphate dextrose adenine-1 (CPDA-1). When stored at 1–6°C, CPD anticoagulated blood is approved for 21 days storage while with CPDA-1, blood can be stored for up to 35 days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="blood-containers">Blood Containers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blood-containers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Plastic containers of blood have replaced the glass bottles. The plastic bags are more compact and lighter in storage. They are more flexible and can avoid the hazard of air embolism. Two or three bags can be connected to each other aseptically so that components can be separated without contaminating the primary container.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="method-of-collecting-blood">Method of Collecting Blood<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-of-collecting-blood" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>While collecting blood, the donor should lie down, and a blood pressure cuff should be used on the arm above the venepuncture site. Under aseptic conditions, make a venepuncture using an 18 gauge needle to obtain a faster flow. The collection bag with anticoagulant should be kept below the level of the arm for gravity flow. Swirl the bag intermittently to bring about mixing of blood with the anticoagulant. The donor should gently flex the fingers or clench and unclench the fist to assist the flow of blood from the vein. About 420–450 ml of blood can be collected from a donor at a time. When the full amount of blood has been collected, collect the blood into 2 tubes in 5 ml amounts for various screening tests. Seal the venepuncture site on the donor’s arm with a plaster to stop the flow of blood. The donor should be allowed to rest for a while and offered a nourishing drink to adjust for the loss of blood.</p>
<p>Proper labelling of the collecting container is of utmost importance. The label should contain the following information:</p>
<p>Scanned by CamScanner</p>
<p>Blood Banking, Blood Transfusion and Compatibility Testing 369</p>
<p>(i) Donor identification number
(ii) ABO and Rh type
(iii) The type and volume of anticoagulant.
(iv) Volume and name of the product (e.g., whole blood, red cells.)
(v) Temperature for storage.
(vi) Date of expiry.</p>
<p>The blood must be stored in a refrigerator with a constant temperature of 1–6°C. An alarm should sound if the temperature exceeds the limit. The stored blood should be inspected daily for colour, turbidity, haemolysis and clot formation, and should be discarded if there is any evidence of bacterial contamination.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="anticoagulants-and-preservatives-used-for-blood-collection">Anticoagulants and Preservatives Used for Blood Collection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticoagulants-and-preservatives-used-for-blood-collection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The most important factor that affects recovery of red cells after blood storage is the anticoagulant solution used. The changes in blood on storage are directly related to the storage time and the type of anticoagulant used. The solutions commonly in use are both anticoagulants and red cell preservatives, but are referred to as anticoagulants.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="anticoagulant-citrate-dextrose-acd">Anticoagulant Citrate Dextrose (ACD)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticoagulant-citrate-dextrose-acd" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This solution has been in use and modified for a number of years since 1918. The anticoagulant contains 100 ml of 2% sodium citrate and 20 ml of 15% glucose for the preservation of 420 ml of blood. This anticoagulant is now replaced by CPD and CPDA-1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="citrate-phosphate-dextrose-cpd">Citrate Phosphate Dextrose (CPD)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#citrate-phosphate-dextrose-cpd" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This anticoagulant has a pH higher than that of ACD and is more isotonic. With CPD, the survival rate of red cells is as good or better than that of ACD, but there is a remarkable improvement in the red cell function. Therefore, CPD has replaced ACD as the anticoagulant of choice.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="citrate-phosphate-dextrose-adenine-1-cpda-1">Citrate Phosphate Dextrose Adenine-1 (CPDA-1)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#citrate-phosphate-dextrose-adenine-1-cpda-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Because the red cell needs ATP as a source of energy, addition of adenine to CPD helps in the maintenance of high ATP levels. Adenine is non-toxic and well tolerated by recipients.</p>
<p>The composition of CPD and CPDA-1 is shown in Table 9.1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-additives-and-anticoagulants">Other Additives and Anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-additives-and-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Synthetic enzyme inhibitors are sometimes added to the anticoagulant to inhibit some enzymes produced by leucocytes which may cause haemolysis. Ion exchange resins are sometimes used to remove all cations, including calcium from blood, thus preventing coagulation. Such blood is useful for plasma production and sometimes for research.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="compatibility-testing">COMPATIBILITY TESTING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#compatibility-testing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Before a donor’s blood is transfused into a recipient, there should be no antigens or antibodies in</p>
<p>Table 9.1 Composition of CPD and CPDA-1 solution (for 450 ml of blood)</p>
<table><thead><tr><th>Ingredient</th><th>CPD</th><th>CPDA-1</th></tr></thead><tbody><tr><td>Trisodium citrate (g)</td><td>1.66</td><td>1.66</td></tr><tr><td>Citric acid (mg)</td><td>206</td><td>206</td></tr><tr><td>Dextrose (g)</td><td>1.61</td><td>2.01</td></tr><tr><td>Monobasic sodium phosphate (mg)</td><td>140</td><td>140</td></tr><tr><td>Adenine (mg)</td><td>-</td><td>17.3</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>370 Haematology</p>
<p>both the donor's blood and recipient's blood that would react with each other, resulting in the destruction of red cells. In other words, there should be no transfusion reaction. The donor's blood should be compatible with recipient's blood and should give maximum benefit to the recipient.</p>
<p>Compatibility testing involves the following:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-abo-and-rh-typing-of-the-donor-and-the-recipient">I. ABO and Rh Typing of the Donor and the Recipient<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-abo-and-rh-typing-of-the-donor-and-the-recipient" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>ABO and Rh D grouping of the donor and the recipient blood should be done. Both should belong to the same ABO group and Rh-D type to be compatible. The methods of grouping have been discussed in Chapter 8.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-crossmatching">II. Crossmatching<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-crossmatching" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Crossmatching is divided into two parts:</p>
<ol>
<li>Major cross match: It involves testing donor's red cells with recipient's serum to detect unexpected antibodies in recipient's serum that will destroy donor's red cells.</li>
<li>Minor cross match: It tests recipient's red cells with donor's serum in the same way as the major cross match. These antibodies can also be detected by antibody screening tests.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="327c6aa5">♦ METHODS OF CROSSMATCHING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#327c6aa5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="method-i-saline-method">Method I: Saline Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-i-saline-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h4 level="4" id="a-slide-method">A. Slide method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-slide-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h4></div>
<ol>
<li>Prepare 5% washed red cell suspensions of the donor and recipient red cells in saline in properly labelled tubes.</li>
<li>Divide the slide in two parts, major and minor, as shown below.</li>
</ol>
<table><thead><tr><th>Major</th><th>Minor</th></tr></thead><tbody><tr><td>Donor cells</td><td>Recipient cells</td></tr><tr><td>+</td><td>+</td></tr><tr><td>Recipient serum</td><td>Donor serum</td></tr></tbody></table>
<ol start="3">
<li>To the 'major' part of the slide, add one drop of recipient's serum and one drop of donor's red cell suspension. Mix with an applicator stick.</li>
<li>To the 'minor' part of the slide, add one drop of donor's serum and one drop of recipient's red cells. Mix.</li>
<li>Allow to stand at room temperature for 5-10 minutes in a moist chamber.</li>
<li>Examine both macroscopically and microscopically for agglutination.</li>
</ol>
<p>&gt; <strong>Note</strong>: The results should be read as soon as possible because drying of the suspension may show false agglutination.</p>
<p><strong>Interpretation</strong> Compatible donor and recipient blood should show no agglutination in both the major and the minor crossmatch.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h4 level="4" id="b-tube-method">B. Tube method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-tube-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h4></div>
<ol>
<li>Prepare 5% washed red cell suspensions of donor's and recipient's red cells in appropriately labelled tubes.</li>
<li>In a test tube labelled 'major', mix one drop of donor's red cells and two drops of recipient's serum.</li>
<li>In another tube labelled 'minor', mix one drop of recipient's cells and two drops of donor's serum.</li>
<li>Allow the tubes to stand at room temperature for five minutes. Centrifuge at 1000 g for 15-20 seconds.</li>
<li>Examine macroscopically and microscopically for agglutination.</li>
<li>If agglutination is observed in any tube, it indicates incompatibility of blood of the donor and the recipient.</li>
<li>If there is no agglutination, incubate the tubes at 37°C for 60 minutes.</li>
<li>Centrifuge again and examine for agglutination as before.</li>
<li>If there is no agglutination, proceed with the albumin or antihuman globulin (AHG) serum technique.</li>
</ol>
<p>Scanned by CamScanner</p>
<p>Blood Banking, Blood Transfusion and Compatibility Testing 371</p>
<p><strong>Note</strong>
Incubation at 37°C in step 7 may detect some warm antibodies reacting in saline which might have been missed at room temperature. For example antibodies of the P, MNSs or Kell systems sometimes react this way.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="method-2-albumin-tube-method">Method 2: Albumin tube method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-2-albumin-tube-method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Label the tubes and mix the red cells and sera for major and minor crossmatch as for the saline method.</li>
<li>Incubate both the tubes at 37°C for 60 minutes.</li>
<li>Gently allow a drop of 22% bovine albumin solution to run down the sides of the tube so that it forms a layer between the cells and the serum. Do not shake.</li>
<li>Incubate at 37°C for 30 minutes.</li>
<li>Tap the tubes gently to disperse the cells and look for agglutination microscopically.</li>
</ol>
<p>This albumin technique can detect some incompatibilities due to incomplete immune antibodies such as Rh-antibodies which may not be detected by the saline method.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="method-3-antihuman-globulin-ahg-crossmatch-coomb-s-crossmatch">Method 3: Antihuman Globulin(AHG) Crossmatch (Coomb's Crossmatch)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method-3-antihuman-globulin-ahg-crossmatch-coomb-s-crossmatch" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Prepare a major crossmatch tube by mixing one drop of donor's washed red cell suspension and two drops of recipient's serum.</li>
<li>Prepare a minor crossmatch tube by mixing one drop of recipient's washed red cell suspension and two drops of donor's serum.</li>
<li>Incubate at 37°C for 60 minutes.</li>
<li>Centrifuge at 1000g for 15–20 seconds, decant the serum completely and wash the cells three times in saline.</li>
<li>Add two drops of AHG to each tube, stand at room temperature for five minutes, and centrifuge again as above.</li>
<li>Examine macroscopically and microscopically for agglutination.</li>
</ol>
<p>This test is very sensitive for the detection of incomplete, immune antibodies such as Rh antibodies, and antibodies of Duffy, Kidd and Kell systems.</p>
<p><strong>Interpretation</strong> Blood which shows incompatibility in major crossmatch should never be transfused, because the large plasma volume of the recipient blood containing antibodies can destroy the donor's red cells easily. The minor incompatibility is less important because the donor's serum which contains antibodies is diluted in the recipient's own plasma, making the antibodies very dilute and ineffective.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="9cd49f37">♦ UNEXPECTED ANTIBODY SCREENING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#9cd49f37" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is done by testing recipient's serum with a series of group O red cells coated with antigens to some clinically significant antibodies. These group O red cells contain antigens such as C, c, D, E, e, Le⁶, M, S, s, K, k, Fya, Fyb, Jka, Jkb. They are commercially available.</p>
<p>The techniques used for the detection of antibodies include papain technique and indirect antiglobulin technique. If antibodies are detected with the screening tests, they should be identified using individual red cell antigens.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="f77b8962">♦ BLOOD TRANSFUSION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#f77b8962" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are clinical conditions in which therapeutic replacement of blood is indicated. The potential benefits of transfusion must always be greater than any potential harm to the patient. The indications for blood transfusion may be divided into four major categories:</p>
<ol>
<li>Restoration of oxygen carrying capacity Blood transfusion may be necessary to restore or maintain the oxygen carrying capacity of blood. The best results are achieved by transfusion of red blood cells after removing the plasma. If the plasma is not removed, the increase in total blood volume may result in circulatory overload.</li>
</ol>
<p>Scanned by CamScanner</p>
<p>372 Haematology</p>
<ol start="2">
<li>
<p>Maintenance of blood volume In cases of acute blood loss (e.g., post-operative massive bleeding or bleeding after injury); transfusion of whole blood or plasma gives good results. However, the best results are obtained by replacing the lost volume of blood with an electrolyte solution, followed by packed red cells later.</p>
</li>
<li>
<p>Maintenance of haemostasis It is sometimes necessary to replace coagulation factors to maintain haemostasis. Various blood components or derivatives may be transfused as the situation demands. Examples of such transfusions include platelet concentrates, fresh frozen plasma, cryoprecipitates and factor VIII and IX concentrates.</p>
</li>
<li>
<p>Restoration of leucocyte function The clinical conditions demanding transfusion of leucocytes do not arise very often, but may be necessary in a granulocytopenic patient with infection.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="autologous-transfusion">Autologous Transfusion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#autologous-transfusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Transfusion of blood or blood products previously collected from the same person is called autologous transfusion. Usually such a person expects to undergo a surgical procedure which may involve loss of blood. The patient’s own blood is preferred because the hazards of immunisation by foreign material and transmission of disease do not arise. Autologous transfusion may also be necessary when a person is immunised to some antigens. However, autologous transfusion is not a common practice.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="directed-transfusion">Directed Transfusion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#directed-transfusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is elective transfusion of blood to a patient with the blood donated by his family member or a friend. Recently, directed transfusions have become more common due to the fear of transmission of HIV.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ae31094f">♦ USE OF BLOOD COMPONENTS, FRACTIONS AND DERIVATIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ae31094f" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Each component of whole blood such as the formed elements, proteins and electrolytes, has a different and important function to perform. Therefore, in-discriminate use of whole blood is not justified when most patients can be effectively treated with one or more of the components. Optimum use of every blood donation is achieved when each donor serves more than one patient. It can be accomplished by skilful and intelligent use of proper blood component or derivative for each indication.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="blood-components">Blood Components<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blood-components" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Blood components are prepared from a single blood donation by simple physical separation methods e.g. by centrifugation. The use of plastic bags instead of glass bottles has facilitated separation of blood components. The separated components can then be transferred aseptically into other container bags, stored and transfused individually, avoiding the hazard of contamination of components.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="blood-fractions-or-derivatives">Blood Fractions or Derivatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blood-fractions-or-derivatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Blood fractions or derivatives are prepared by pooling the plasma from many donors which is then subjected to more complex physical and chemical processes. Unlike blood components, which can be prepared in any well equipped blood blank, blood fractionation is still a very complex manufacturing process usually undertaken by the pharmaceutical industry.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="transfusion-by-haemapheresis">Transfusion by Haemapheresis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#transfusion-by-haemapheresis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Haemapheresis is a process in which whole blood is taken from a person, the required component separated and retained, and the remainder returned to the individual’s blood stream. The whole process is done in one sitting. This procedure is useful for two purposes: to obtain certain blood components from a donor for transfusion, and to remove harmful components from patient’s blood (therapeutic apheresis or plasma exchange).</p>
<p>Table 9.2 shows some blood components and fractions, and their uses.</p>
<p>Scanned by CamScanner</p>
<p>Blood Banking, Blood Transfusion and Compatibility Testing 373</p>
<p>Table 9.2 Some blood components and derivatives in common use</p>
<table><thead><tr><th>Blood component or Derivative</th><th>Use</th></tr></thead><tbody><tr><td>Whole blood</td><td>Acute blood loss where both red cells and volume are desired: rarely indicated</td></tr><tr><td>Red blood cells</td><td>To increase red cell mass (e.g. therapy for anaemia); use with colloids or crystalloids in active bleeding or massive transfusion</td></tr><tr><td>Red blood cells</td><td></td></tr><tr><td>Additive solution added</td><td></td></tr><tr><td>Leukocytes removed by centrifugation, washing or filtration</td><td>Packed red cells or whole blood</td></tr><tr><td>To increase red cell mass and avoid ferbrile and allergic reactions from leukocytes or plasma proteins and to prevent anaphylactic reactions</td><td></td></tr><tr><td>Deglyceralised blood</td><td>To extend storage of red cells with rare blood types and autologous transfusion or to prevent HLA sensitisation</td></tr><tr><td>Platelets (platelet concentrates, platelet-rich plasma from random or single donor by apheresis from Granulocytes, apheresis</td><td>Functional or quantitative platelet defects</td></tr><tr><td>Rare; for septic, severely granulocytopenic patients who do not respond to antibiotic therapy after 48 hrs of treatment</td><td></td></tr><tr><td>Fresh frozen plasma</td><td>In bleeding patients with multiple coagulation defects; also for treatment of factor V or XI deficiency</td></tr><tr><td>Cryoprecipitate</td><td>For treatment of von Willebrand's disease, factor XIII deficiency or hypofibrinogenemia</td></tr><tr><td>Factor VIII concentrate</td><td></td></tr><tr><td>Factor IX concentrate</td><td>For haemophilia A</td></tr><tr><td>For hereditary deficiency of factors II, VII, IX or X</td><td></td></tr><tr><td>Albumin/plasma protein fraction (plasma substitutes)</td><td>For volume expansion and colloid replacement without risk of hepatitis or AIDS</td></tr><tr><td>Immune serum globulin</td><td>For treatment or prophylaxis of hypogammaglobulinemia and to prevent or modify hepatitis A and C.</td></tr><tr><td>Rh immune globulin</td><td>To prevent haemolytic disease of the newborn in Rh-negative women exposed to Rh-positive red cells</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>374 Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="transfusion-reactions">TRANSFUSION REACTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#transfusion-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The term transfusion reaction means an obviously adverse response to transfusion, usually during, or immediately after, the transfusion. The transfusion reactions can be of four main types: haemolytic, febrile, allergic or those due to circulatory overload. However, poor survival of the transfused blood, or failure to achieve the desired clinical effect in the patient, should also be considered as mild forms of transfusion reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="haemolytic-transfusion-reactions">Haemolytic Transfusion Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#haemolytic-transfusion-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The true haemolytic transfusion reaction is caused by the <em>in vivo</em> combination of an antibody with red cells possessing the corresponding antigen. In most severe reactions, the antibody is in the recipient's plasma and the antigen on the donor's red cells (major incompatibility). Minor incompatibility occurs when the antibody is in the donor's plasma and the antigen on the recipient's red cells. Antibodies which are readily haemolytic <em>in vitro</em> are most likely to cause haemolytic transfusion reactions e.g. complement binding IgM type of antibodies. Anti-A and anti-B antibodies is the major cause of this type of reactions, and the incompatible red cells are lysed intravascularly within a few minutes.</p>
<p>Antibodies which are not haemolytic <em>in vitro</em> such as IgG antibodies to Rh-antigens usually cause extravascular instead of intravascular haemolysis. Antibodies of this type usually coat the red cells resulting in their removal from circulation by the spleen. This results in raised bilirubin levels in the serum, and may be associated with haemoglobinaemia and haemoglobinuria. Most antibodies other than anti-A and anti-B produce this type of transfusion reactions.</p>
<p>Delayed haemolytic transfusion reactions may be seen in patients who are already immunised to certain blood group antigens. Anti-E or anti-c Rh antibodies, and antibodies of the Kidd system are likely to cause such delayed type of haemolytic reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="febrile-transfusion-reactions">Febrile Transfusion Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#febrile-transfusion-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Febrile reactions are manifested as chills and varying degrees of fever. The almost universal use of disposable blood containers and tubing has eliminated those febrile reactions due to pyrogenic products of bacterial growth. Many febrile reactions are caused by the recipient antibodies directed against donor leukocyte antigens, or due to some plasma proteins.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="allergic-transfusion-reactions">Allergic Transfusion Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#allergic-transfusion-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Allergic reactions usually appear as urticaria appearing during the transfusion. The skin lesions are pale, irregular, slightly raised patches. More serious reactions may result in facial or glottal oedema or asthma, or pulmonary oedema. Such allergic reactions may be caused by passive transfer of donor allergens to the recipient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="transfusion-reactions-due-to-circulatory-overload">Transfusion Reactions Due to Circulatory Overload<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#transfusion-reactions-due-to-circulatory-overload" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Patients who already have increased plasma volumes or incipient heart failure, may feel tightness in the chest and dry cough after transfusion of whole blood. It may also lead to pulmonary oedema.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-causes-of-transfusion-reactions">Other Causes of Transfusion Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-causes-of-transfusion-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These include various forms of embolism (e.g. air embolism), transfusion of ice-cold blood, contaminated blood components, citrate toxicity and graft-versus-host disease (GVHD).</p>
<p>Common forms of transfusion reactions are summarised in Table 9.3.</p>
<p>Scanned by CamScanner</p>
<p>Blood Banking, Blood Transfusion and Compatibility Testing 375</p>
<p>Table 9.3 Common forms of transfusion reactions</p>
<table><thead><tr><th>Reaction</th><th>Cause</th></tr></thead><tbody><tr><td>Haemolytic, immediate</td><td>Major incompatibility</td></tr><tr><td></td><td>Minor incompatibility</td></tr><tr><td></td><td>Interdonor incompatibility</td></tr><tr><td></td><td>Nonimmune factors</td></tr><tr><td>Haemolytic, delayed</td><td>Secondary antibody response</td></tr><tr><td>Allergic</td><td>Allergen in donor plasma</td></tr><tr><td>Anaphylaxis</td><td>Idiosyncratic response (e.g., anti-IgA)</td></tr><tr><td>Febrile</td><td>Antibodies to donor WBC, platelets, plasma</td></tr><tr><td>Overload</td><td>Excess volume infusion</td></tr><tr><td>Embolism</td><td>Usually air in transfusion set</td></tr><tr><td>Cardiac arrhythmia</td><td>Cold blood or citrate effect (rapid massive transfusion)</td></tr><tr><td>Respiratory</td><td>Leukocyte antibodies</td></tr><tr><td>Bleeding tendency</td><td>Massive transfusion (thrombocytopenia)</td></tr><tr><td>Electrolyte toxicity</td><td>Excess K or NH_{3} in older stored blood</td></tr><tr><td>Graft-vs-host</td><td>Donor lymphocytes, immunocompromised recipient</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="investigation-of-suspected-transfusion-reaction">INVESTIGATION OF SUSPECTED TRANSFUSION REACTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#investigation-of-suspected-transfusion-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A standardised investigational procedure should be used for all suspected transfusion reactions. The most important immediate step is to check the clerical records that the patient has received the blood intended for him. A laboratory schedule for the investigation of a transfusion reaction is shown in Table 9.4.</p>
<p>Table 9.4 Schedule for investigations of transfusion reactions</p>
<table><thead><tr><th>A. All reported reactions</th></tr></thead><tbody><tr><td>1. Specimens needed</td></tr><tr><td>(a) Pretransfusion blood of recipient</td></tr><tr><td>(b) Posttransfusion blood of recipient</td></tr><tr><td>2. Investigation (letters refer to specimens listed above)</td></tr><tr><td>Check donor and patient identification and crossmatch report Repeat ABO and Rh typing</td></tr><tr><td>(b and donor bag, if indicated)</td></tr><tr><td>Direct antiglobulin test (b, if indicated)</td></tr><tr><td>Examine for visible hemolysis (b): if necessary, compare (b) with (a)</td></tr><tr><td>If these procedures reveal no evidence of incompatibility or haemolysis, and there is no additional information to arouse suspicion, no further investigation is needed. Otherwise, proceed as follows:</td></tr></tbody></table>
<p>(Contd)</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-9-4-contd">Table 9.4 (Contd.)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-9-4-contd" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>B. If there is evidence of haemolysis or incompatible transfusion</p>
<ol>
<li>
<p>Specimen needed
(a) Pre-transfusion blood of recipient
(b) Post-transfusion blood of recipient
(c) Pilot samples of donor blood
(d) Blood from container implicated in reaction (if available)
(e) Post-transfusion urine</p>
</li>
<li>
<p>Immunological investigation
Repeat ABO, Rh and direct antiglobulin test (a,c,d)
Repeat crossmatch (a, b, c, d if indicated) (major; minor only if indicated)
Repeat antibody screen (a,b,c) (special, sensitive techniques if necessary)
Identification of any unexpected antibody or incompatibility</p>
</li>
<li>
<p>Other procedures as indicated
Serum haptoglobin (a,b)
Bacteriological smear and culture (d)
Serum urea and bilirubin (a,b)
Urine haemoglobin (e)
Urine haemosiderin (e)</p>
</li>
<li>
<p>Investigation of nonimmune causes of haemolysis</p>
</li>
</ol>
<p>Scanned by CamScanner</p>
<p>Chapter 10</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-major-histocompatibility-complex-mhc-and-the-hla-system">The Major Histocompatibility Complex (MHC) and the HLA System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-major-histocompatibility-complex-mhc-and-the-hla-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Most of the blood group antigens belong exclusively to red cells except the ABO antigens which are present on almost all body cells. There are some other antigens which are specific for granulocytes and some others which are present only on platelets. However, a single highly complex antigenic system called HLA is responsible for most of the antigens possessed by tissue cells, leucocytes and platelets. This HLA system, originally called Human leucocyte Locus A, is now known as Human Leucocyte Antigen system.</p>
<p>The HLA system is controlled by a supergene called Major Histocompatibility Complex (MHC) which includes several closely linked loci on the human chromosome 6. The antigens controlled by alleles on these loci are found on all nucleated cells in the body, and also on some non-nucleated cells and in some body fluids.</p>
<p>The antigens of the HLA system are proteins which are involved in various aspects of immunological recognition and reaction. In addition, these antigens play a major role in organ transplantation and in blood transfusion</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="proteins-of-the-hla-system">PROTEINS OF THE HLA SYSTEM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#proteins-of-the-hla-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The MHC genes encode proteins of the HLA system. These genes have six main subregions: HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP. Each subregion encodes at least one glycoprotein.</p>
<p>On the basis of structure, genetic origin and function, these proteins of the MHC genes are grouped into three classes: Class I, Class II and Class III (Fig. 10.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="class-i-molecules">Class I Molecules<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#class-i-molecules" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are three Class I molecules in the human MHC. They are HLA-A, HLA-B and HLA-C (Fig. 10.1). Each Class I molecule is made up of two polypeptide chains of unequal size (Fig. 10.2). The</p>
<p><img src="assets/images/image-20251218-c1a2cbb0.jpeg" alt="img-52.jpeg">
Fig. 10.1 Subregions of MHC</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p>heavy chain (α-chain) is a glycoprotein which spans across the cell membrane with its amino-terminus outside the cell. The smaller chain is a β-microglobulin and is associated with extracellular region of the heavy glycoprotein chain. The β-microglobulin is necessary for the cell surface expression. The Class I molecules are highly polymorphic. This polymorphism is due to the variable region at the amino-terminus of the heavy chain. The heavy chains are encoded within the HLA complex on chromosome 6 whereas β-microglobulin chains are encoded on chromosome 15.</p>
<p><img src="assets/images/image-20251218-6c36d88b.jpeg" alt="img-53.jpeg">
Fig. 10.2 Class I molecule of the MHC</p>
<p>The Class I molecules are expressed on almost all nucleated cells in the body and also on platelets. They play a major role in the immune mechanism of the body. They recognise and eliminate tumour cells or cells infected with virus. Some antigens such as the viral antigens are expressed on the cell surface in association with Class I molecules. The immunocompetent cytotoxic T lymphocytes can recognise the antigen only in conjunction with the</p>
<p>Class I molecule. Following this interaction, the T lymphocytes are able to trigger the cellular and humoral immune responses. A similar interaction occurs between the T-lymphocytes and the foreign histocompatibility antigens during an organ or tissue transplant (alloantigens) or the self-antigens in an autoimmune disease (autoantigens). As a general rule, Class I molecules are involved with the recognition of endogenous antigens synthesised within the cell.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="class-ii-molecules">Class II Molecules<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#class-ii-molecules" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The Class II molecules include the proteins of the HLA-DR, HLA-DQ and HLA-DP regions. They are glycoproteins consisting of two chains, an α-chain and a β-chain (Fig. 10.3). Unlike Class I molecules, both the chains are encoded within the MHC on the chromosome 6. Both the α and the β chains extend beyond the cell membrane. Because of these variable regions, the Class II molecules are also very polymorphic like the Class I molecules.</p>
<p><img src="assets/images/image-20251218-391f87cd.jpeg" alt="img-54.jpeg">
Fig. 10.3 Class II molecule of the MHC</p>
<p>Scanned by CamScanner</p>
<p>The Major Histocompatibility Complex (MHC) and the HLA System 379</p>
<p>The Class II molecules are expressed on the cells of the immune system except on the resting T lymphocytes. They appear on T lymphocyte only when they are activated. The function of the Class II molecules is similar to that of the Class I molecules. They bind to the antigens and present them on the surface of the cell to be recognised by the cytotoxic T lymphocytes. However, the Class II molecules bind to the soluble and particulate exogenous antigens unlike class I molecules which are bound to the endogenous antigens.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="class-iii-molecules">Class III Molecules<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#class-iii-molecules" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Class III molecules include the MHC linked complement components, namely C2, C4 (C4A and C4B) and BF; 21-hydroxylase (21A and B) and tumour necrosis factor (TNF) (Fig. 10.1). This is a heterogeneous group of molecules without any common features and can be more appropriately described as 'non-I non-II' molecules.</p>
<p>The proteins C2 and C4 belong to the classical pathway of complement activation whereas factor BF is of the alternative pathway. These proteins are encoded on entirely different chromosomes from MHC. The 21-hydroxylase (21OH) is an adrenal steroid cytochrome. TNF has other biological functions. The genes for TNF are closer to the HLA-B region. The proteins C2, C4 and factor B participate in processes such as inflammation and facilitate opsonisation of foreign substances. They also mediate antibody-directed cytotoxicity against microorganisms and various cells. The 21OH is an enzyme for the synthesis of cortisol whereas TNF is cytotoxic for tumour cells and helps in the regulation of cellular growth and activity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="inheritance-of-mhc">Inheritance of MHC<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inheritance-of-mhc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The inheritance of MHC genes follows Mendel's laws. The MHC loci are closely linked. Therefore the haplotype, that is, a single strand of chromosome with MHC loci, is inherited by an offspring from each parent. Thus, each individual receives two haplotypes of the MHC with two alleles for each gene. The two alleles are co-dominant and their characteristics are equally expressed in the offspring. If the haplotypes from the father are named ab and those from the mother cd, there are four possible MHC genotypes in the offspring - ac, ad, bc and bd.</p>
<p><img src="assets/images/image-20251218-ad529c0c.jpeg" alt="img-55.jpeg"></p>
<p>If there are five children in a family, at least two siblings will possess identical HLA. Sometimes, however, there are chances of crossing over between two linked loci. It has also been observed that some HLA alleles are found more frequently in some ethnic subpopulations than others, whereas some HLA alleles are confined only to some ethnic groups.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="techniques-for-hla-typing">TECHNIQUES FOR HLA TYPING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#techniques-for-hla-typing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Specialised complex procedures and reagents are required for typing and compatibility testing of HLA. Usually institutions that undertake organ transplants have histocompatibility laboratories with necessary expertise. Some commonly employed techniques are described briefly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-lymphocyte-microcytotoxicity-assay-for-class-i-and-class-ii-molecules">I. Lymphocyte Microcytotoxicity Assay for Class I and Class II Molecules<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-lymphocyte-microcytotoxicity-assay-for-class-i-and-class-ii-molecules" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Principle</strong> The microtoxicity method of HLA typing involves complement mediated lysis and ultimate death of the cell. A living lymphocyte suspension prepared from the peripheral blood or lymphatic tissue of the patient is exposed to antisera to Class I and Class II antigens in the presence of complement. The antigens present on the patient's lymphocytes bind with the respective antibodies. The complement is fixed by this antigen-antibody</p>
<p>Scanned by CamScanner</p>
<p>380 Haematology</p>
<p>complex which results in the death of the cells. The dead cells are detected microscopically by using vital stains such as trypan blue which stain only the dead cells (Fig. 10.4).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="requirements">Requirements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#requirements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Lymphocytes</strong> The lymphocyte can be separated from the peripheral whole blood by layering it over Ficoll-Hypaque density gradient. On centrifugation, mononuclear cells separate at the junction of blood and Ficoll-Hypaque. Both T and B lymphocytes can be used for typing the HLA-A, B and C.</p>
<p>Enriched B lymphocytes are required for HLA-DQ and DR typing. They can be separated from T lymphocytes by incubating the mixture on a nylon-wool column. T lymphocytes attached to the nylon wool are relatively non-adherent to the nylon wool and get washed off the column while the B lymphocytes, firmly attached to the nylon wool are removed by vigorous agitation. Monocytes also remain on the nylon-wool.</p>
<p>Other methods of lymphocyte separation include the use of magnetic beads coated with monoclonal antibodies to B lymphocytes, or antihuman globulin specific for B lymphocytes.</p>
<p><strong>Typing sera</strong> During pregnancy, the mother mounts an immune response against the antigen received by the foetus from the father. Therefore, sera of women with multiple childbirths is a rich source of HLA typing sera. Similarly, individuals who have received multiple blood transfusions or have undergone organ transplantation develop antibodies to foreign HLA types. Such sera are collected, typed and standardised against known antigens.</p>
<p>Trays containing wells coated with about 140 to 210 antisera are commercially available.</p>
<p><img src="assets/images/image-20251218-fc9b23db.jpeg" alt="img-56.jpeg"></p>
<p>Scanned by CamScanner</p>
<p>The Major Histocompatibility Complex (MHC) and the HLA System 381</p>
<p>Complement Rabbit serum can be used as a source of complement. It is also commercially available in lyophilised form.</p>
<p>Technique (1) Mix appropriate lymphocyte suspension (2000 cells/ml) and the antiserum.
(2) Incubate at 22–24°C for 30 minutes.
(3) Wash the sensitised lymphocytes in buffered saline to remove excess of serum.
(4) Add complement in excess and incubate further for 60 minutes. If the lymphocytes carry a Class I or Class II molecule, it will be recognised by the complement fixing antibody in the serum. This will result in the death of the cells.
(5) Terminate the assay by addition of vital dye such as trypan blue with EDTA or eosin and formalin. The stains can penetrate only the dead cells. Fluorescent indicators may also be used.</p>
<p>The results can be graded microscopically as:</p>
<ol>
<li>Negative, less than 20% dead cells</li>
<li>Doubtful, 20–39% dead cells</li>
<li>Weak positive 40–59% dead cells</li>
<li>Positive, 60–84% dead cells</li>
<li>Strong positive, more than 85% dead cells. Class I and class II antigens on the lymphocytes can thus be identified.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-mixed-lymphocytes-culture-mlc-technique">II. Mixed Lymphocytes Culture (MLC) Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-mixed-lymphocytes-culture-mlc-technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Principle T lymphocytes in the peripheral blood are capable of recognising an antigen even <em>in vitro</em>. They respond by undergoing cell division which is proportional to the antigenic stimulus. The degree of DNA replication during cell division can be measured by using radioactive thymidine. The radioactive thymidine gets incorporated into the dividing cells. Thus increase in the radioactivity of the lymphocyte suspension indicates the degree of antigenic stimulus.</p>
<p>This property of T lymphocytes is employed to determine the degree of compatibility between the donor and the recipient before an organ transplant. The response of lymphocytes of one individual in tissue culture to the alloantigens on the surface of lymphocytes of another individual is called the mixed lymphocyte culture (MLC) or mixed lymphocyte reaction (Fig. 10.5). The differences in the Class II molecules of two individuals can thus be measured by MLC. To observe a unidirectional response, the lymphocytes of either the donor or the recipient are prevented from replicating either by irradiation or by treatment with mitomycin before mixing the two cultures.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="requirements">Requirements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#requirements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Lymphocytes of the donor and the recipient</strong> The lymphocytes can be separated from the whole blood by the same technique using Ficoll-Hypaque as described for the microcytotoxicity technique. This technique is useful because it removes the granulocytes which may interfere with <em>in vitro</em> replication of lymphocytes.</p>
<p><strong>Mitomycin-C</strong> It is used at a concentration of 25 to 50 µg/ml.</p>
<p><strong>Tissue culture medium</strong> An appropriate medium supplemented with serum and antibiotics should be used.</p>
<p><strong>Radioactive thymidine</strong> The tritiated ³H thymidine is used.</p>
<p><strong>Fibreglass filters</strong></p>
<p><strong>Scintillation counter</strong></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Treat the lymphocytes from the donor (i.e. the stimulator cells), with mitomycin-C.
(2) Mix the responder cells (i.e. the recipient’s lymphocytes) and the stimulator cells in a U-well microtitre plate to which the tissue culture medium has been added.
(3) Incubate the plate in humid atmosphere at 37°C for 5 to 6 days.
(4) Add ³H-thymidine of known radioactivity to each well.</p>
<p>The replication of lymphocytes begins and continues till about eighth day of the culture, incorporating the thymidine during replication.</p>
<p>(5) After 8 days, filter the MLC onto small fibreglass filters to separate the non-incorporated thymidine.
(6) Measure the radioactivity of the unused thymidine on the filters using a scintillation counter. Thus, the amount of thymidine incorporated into the cells can be measured. A higher degree of histocompatibility is indicated by a smaller amount of thymidine absorbed by the MLC.</p>
<p>Scanned by CamScanner</p>
<p>382 Haematology</p>
<p><img src="assets/images/image-20251218-311bf8d8.jpeg" alt="img-57.jpeg">
Fig. 10.5 Mixed lymphocyte culture technique</p>
<p><strong>Note</strong>
Although MLC is a sensitive technique, it requires several days to complete, and therefore, is not useful for cadaver transplants. It is useful however, for the selection of donors among patient's relatives.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="f3cadd9e">♦ ROLE OF HLA SYSTEM IN TRANSPLANTATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#f3cadd9e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A successful tissue or organ transplantation is long-term survival of the tissue such as bone marrow or organ such as kidney of one individual (donor) into another (recipient). The major obstacle to such a transplant or graft is the immunological rejection of the graft. Survival of any individual depends upon the ability of the immune system to recognise and respond to foreign antigens such as bacteria, viruses and tumour cells. The foreign antigens, however, also include alloantigens of the HLA system from another individual of the same species. Such an immune response results in the rejection of the transplanted tissue or organ. This immune reaction can be bypassed in two ways to achieve a successful transplant.</p>
<p>Scanned by CamScanner</p>
<p>The Major Histocompatibility Complex (MHC) and the HLA System 383</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-immunosuppressive-therapy">1. Immunosuppressive Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-immunosuppressive-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs such as prednisone, azathioprine and cyclosporin A suppress the immune response and can be carefully administered till the allograft is accepted.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-histocompatibility-matching">2. Histocompatibility Matching<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-histocompatibility-matching" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>By selecting a donor who has HLA matching optimally with the recipient, the chances of allograft survival are greatly increased. Grafts between HLA identical siblings have the highest survival rates.</p>
<p>The importance of Class I antigens in transplantation is that they are attacked by the recipient's humoral antibody response, especially when cytotoxic antibodies to these antigens are already present in the host. To avoid this, the transplanted organ must be serologically compatible and should lack the corresponding antigen to which the host has antibodies. It is only then that the rejection of the transplanted organ can be prevented. On the other hand, the Class II antigens of the donor are responsible for stimulating a cellular immune response in the host if the host does not have the same antigens and considers these new class II antigens as foreign. Therefore, several series of HLA antigens have a different significance in the transplantation of various organs.</p>
<p>In case of kidney transplantation, the best results are seen when the donor and the recipient have identical AB and DR antigens. The C antigen seems to have very little significance. In case of living kidney donors, compatibility of donor's lymphocytes with the host's cellular immune system is determined by using mixed lymphocyte culture (MLC) technique. However, it is difficult to find a compatible kidney if the recipient (host) has pre-existing cytotoxic antibodies.</p>
<p>For bone marrow transplantation, the transplants are made from HLA-identical or related donors, usually siblings of the patient compatible by both cytotoxicity and MLC techniques. For heart and liver transplants, the donor and the recipient are HLA typed but the antibody screening test is the major decisive factor. If the antibody screening test is negative, it is usually considered safe to transplant without awaiting the results of a compatibility test.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 11
Automation in Haematology</p>
<p>Automation has found its way into the haematology laboratory in various fields. There are analysers available to count, size and classify cells. Semiautomated and fully automated instruments are available for coagulation studies and in blood group serology. However, considerable thought should be given to the selection of the type of instrumentation best suited to the needs of the laboratory concerned.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="automated-cell-counting-methods">AUTOMATED CELL COUNTING METHODS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#automated-cell-counting-methods" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A wide range of automated and semiautomated devices are available for measuring different haematological parameters, using different analytical technologies.</p>
<p>There are two methods used by automated cell counters in haematology.</p>
<ol>
<li>Impedance methods utilised by the Coulter principle (voltage pulse counting).</li>
<li>Optical methods using focused laser beams.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cell-counts-using-the-coulter">Cell Counts Using the Coulter<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cell-counts-using-the-coulter" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> Impedance counting was developed by Wallace Coulter in 1956. The Coulter counter system is based on the principle that the red or white cell is a poor conductor of electricity compared to the diluent such as saline. When the diluent is displaced by a cell, it causes a measurable change in resistance. In the basic Coulter counter, the cells are allowed to pass through an aperture through which an electric current is flowing. Cells passing through the aperture displace the diluent; and being bad conductors of electricity, increase the resistance which is counted as a voltage pulse. The cell suspension is drawn through the aperture with the help of a vacuum pump into a system of tubing.</p>
<p>The instrument consists of a glass aperture tube that can be filled with the conducting fluid such as saline. It has a small orifice, 100 microns in diameter, in its wall. An electrode is immersed inside the fluid in the aperture tube and is called internal electrode. The aperture tube is closed at the top by a stopcock valve. Below the stopcock, the aperture tube is connected to a U-shaped glass tube which is partly filled with mercury. The U-tube has two electrical contacts, an activating counter and a deactivating counter which leads to a vacuum pump. The aperture tube is immersed in a container which contains the cell suspension in saline and an electrode, the external electrode. Thus an electric current can flow through the aperture between the internal and the external electrodes (Fig. 11.1).</p>
<p>As the vacuum pump draws the mercury up the tube, the cell suspension flows through the aperture into the aperture tube. When a cell passes</p>
<p>Scanned by CamScanner</p>
<p>Automation in Haematology 385</p>
<p><img src="assets/images/image-20251218-a13fdf27.jpeg" alt="img-58.jpeg">
Fig. 11.1 Schematic diagram of Coulter counter</p>
<p>through the aperture, it displaces an equal volume of the conducting solution and increases the electrical resistance, creating a voltage pulse. The height of the pulse (impedance) is proportional to the volume of the cell. The number of pulses indicate the cell count. The section of the tubing between the activating and deactivating counters is calibrated to contain a known volume, e.g. 0.5 ml, of fluid. The counting mechanism starts when the mercury reaches the activating counter and stops when it reaches the deactivating counter. Thus variations of the current measured across the aperture can determine the cell count, the cell volume and the particle size in a known volume.</p>
<p>Coulter counter Model S Coulter counter model S provides seven haematological parameters: the red cell count, the white cell count, haemoglobin and red cell indices (PCV, MCV, MCH, MCHC). Haemoglobin is determined photometrically by passing a beam of light through the lysed solution and measuring the absorbance by a photosensitive device.</p>
<p>Coulter counter Model S-plus Coulter counter model S-plus is more compact, less complicated and more computerized than model S. In addition to the seven parameters, it also counts platelets and detects the degree of anisocytosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="optical-methods-using-focused-laser-beams">Optical Methods Using Focused Laser Beams<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#optical-methods-using-focused-laser-beams" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This method is also known as flow cytometry. The blood is diluted in isotonic saline and passed through a laser beam as a stream of single cells. Light is scattered at an angle proportional to the structural details of the cell. There are two types of light sensors: a light sensor that detects forward scatter of the beam, i.e., at 180 degrees from the light source, which correlates with the cell volume and density, and another that detects the right an</p>
<p>Scanned by CamScanner</p>
<p>Haematology</p>
<p>gle or 90 degrees scatter, which depends on the cellular contents such as the granularity of the cytoplasm. These light signals are converted by photodetectors into electrical impulses which are then processed by a computer. It provides data such as the cell counts, MCV and simple differential counts (granulocytes, non-granulocytes).</p>
<p>Cell identification can be enhanced by using a fluorochrome dye in the cell suspension. This dye can directly stain or tag certain cell components such as a granule or an enzyme. It can also be used to detect antigens on cell surfaces by labelling the corresponding antibody with a fluorochrome dye. Different types of fluorochrome dyes can be used. These are excited by different wavelengths of light, so that different tags can be counted separately. Thus differential leucocyte count or reticulocyte count can be done using various laser detection systems in sequence (Fig. 11.2). Modifications of flow cytometry can be used to identify specific cells by specific markers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="advantages-and-disadvantages-of-automated-cell-counter">Advantages and Disadvantages of Automated Cell Counter<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advantages-and-disadvantages-of-automated-cell-counter" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The autoanalysers produce the data with much greater precision, accuracy and speed. Multiple analyses can be performed on a very small volume of specimen. This is particularly useful when analyzing samples from neonates. In general, these autoanalysers provide more economical use of laboratory resources such as reagents, personnel and time.</p>
<p>On the other hand, maintenance of the autoanalysers is a high-quality job. Well-trained personnel should be available to ensure proper functioning and maintenance of the instrument. Also, the staff members which operate the autoanalysers should be aware of the indicators that monitor functioning of the machine. Strict quality control measures should be observed.</p>
<p>Another problem arising from automation is the generation of a large amount of data within a short</p>
<p><img src="assets/images/image-20251218-f7116757.jpeg" alt="img-59.jpeg">
Fig. 11.2 Flow cytometry: Laser based system</p>
<p>Scanned by CamScanner</p>
<p>Automation in Haematology 387</p>
<p>period of time. There should be a proper system for collection, storage and retrieval of the data. Use of computers provides a solution to the overall effectiveness of the service.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="autoanalysers-in-coagulation-studies">AUTOANALYSERS IN COAGULATION STUDIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#autoanalysers-in-coagulation-studies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are three types of autoanalysers used in coagulation studies:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-optical-density-detection">1. Optical Density Detection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-optical-density-detection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>In this instrument, the clot formation is detected by the change in the optical density of plasma. About 50–60 plasma specimens are placed in cuvettes on a turn table. The reagent e.g. factor deficient plasma, is delivered at a preset interval from a secondary pump. Samples move on to the incubation block at 37°C. The final reagent is delivered from the primary pump which initiates clot formation and triggers the timing mechanism. When a clot is formed, there is a change in the optical density which is detected by a photo device and the clotting time is recorded on a print-out.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-electromechanical-detection-of-a-fibrin-thread-fibrinometer">2. Electromechanical Detection of a Fibrin Thread (Fibrinometer)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-electromechanical-detection-of-a-fibrin-thread-fibrinometer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This is a semi-automated instrument where the specimens and the reagents are manually added. A hook-type electrode is placed in the incubating mixture as soon as the final reagent is added. The electrode moves in and out of the incubating mixture. When the first fibrin thread formed across the electrode completes the electrical circuit, the timer stops and clotting time is displayed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="3-impedance-revolving-steel-ball-displacement-by-the-fibrin-thread">3. Impedance Revolving Steel Ball Displacement by the Fibrin Thread<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-impedance-revolving-steel-ball-displacement-by-the-fibrin-thread" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>In this semi-automated system, the plasma specimens and reagents are added to cuvettes containing a steel ball. The timer starts after the addition of the reagent. The incubating mixture is rotated in an inclined position around its long axis. The steel ball runs on a given point in the mixture. As coagulation occurs, the ball is displaced by the fibrin filament and trips a magnetic sensor which records the time of clot formation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="automation-in-blood-group-serology">AUTOMATION IN BLOOD GROUP SEROLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#automation-in-blood-group-serology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are two types of automated blood group systems.</p>
<ol>
<li>Photometric reading system</li>
<li>Continuous flow system</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-photometric-system">1. Photometric System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-photometric-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>In this system, patient’s cells and serum are mixed with appropriate reagents in cuvettes. The cuvettes are centrifuged to accelerate the agglutination process. The next step involves agitation of cuvettes to resuspend and disperse all unagglutinated red blood cells. The agglutinated red cells remain in the central area of the cuvette. Each cuvette is then read photometrically twice. One reading is for the central position and the other for the peripheral portion. No variation in both readings indicates absence of agglutination whereas a significant variation denotes a positive result. The machine can compare, interpret and print out the results. Specimens have barcoded labels and are identified by a laser scanner.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="2-continuous-flow-system">2. Continuous Flow System<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-continuous-flow-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This system of blood grouping is adapted from autoanalysers used in Clinical Chemistry. Patient’s red cells and plasma are aspirated separately and carried through a system of tubings. Two specimens are separated by air bubbles. Reagents are drawn in by another system of tubings. The volume of each reagent is controlled by the diameter of the tubes. After the reaction, the free red cells are dispersed by a jet of saline, leaving the agglutinated red cells behind. The dispersed free cells are then lysed and the degree of lysis is determined colorimetrically. A higher degree of lysis denotes absence of agglutination.</p>
<p>Scanned by CamScanner</p></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>